<SEC-DOCUMENT>0001387131-15-003188.txt : 20151109
<SEC-HEADER>0001387131-15-003188.hdr.sgml : 20151109
<ACCEPTANCE-DATETIME>20151105161549
ACCESSION NUMBER:		0001387131-15-003188
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151105
DATE AS OF CHANGE:		20151105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		151200838

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_093015.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT"><div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 14pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 14pt Times New Roman, Times, Serif"><b>UNITED
STATES&nbsp;</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>
<p style="margin: 0; text-align: center; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>WASHINGTON,
D.C. 20549</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: center; font: 18pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>FORM
10-Q</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">(Mark
One)</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 7%;"><font style="font: 12pt Times New Roman, Times, Serif"><b>&#9746;</b></font></td>
<td style="width: 93%;"><font style="font: 12pt Times New Roman, Times, Serif"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">For
the quarterly period ended September 30, 2015</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 7%;"><font style="font: 12pt Times New Roman, Times, Serif"><b>&nbsp;&#9744;</b></font></td>
<td style="width: 93%;"><font style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">For
the transition period from________ to ___________</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Commission
File No. <b><u>001-00100</u></b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 24pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b><u>THERAPEUTICSMD,
INC.</u>&nbsp;</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">(Exact
Name of Registrant as Specified in Its Charter)</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="border-bottom: Black 1pt solid; width: 45%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>Nevada</b></font></td>
<td style="padding-bottom: 1pt; width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>87-0233535</b></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(State or Other Jurisdiction of Incorporation
or Organization)</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="border-bottom: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>6800
Broken Sound Parkway NW, Third Floor, Boca Raton, FL 33487</b></font></td>
<td style="padding-bottom: 1pt; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center;"><font style="font-family: Times New Roman, Times, Serif"><b>(561)
961-1900</b></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices)</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(Issuer&rsquo;s Telephone Number)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b><u>N/A</u></b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;&#9744;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;&#9744;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act (Check one):</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="padding-left: 20pt; width: 55%;"><font style="font-family: Times New Roman, Times, Serif">Large accelerated filer&nbsp;&nbsp;&#9744;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 40%;"><font style="font-family: Times New Roman, Times, Serif">Accelerated filer&nbsp;&nbsp;&#9746;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="padding-left: 20pt;"><font style="font-family: Times New Roman, Times, Serif">Non-accelerated filer&nbsp;&nbsp;&#9744;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Smaller reporting company&nbsp;&nbsp;&#9744;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">(Do not check if a smaller reporting company)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;&#9746;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">The
number of shares outstanding of the registrant&rsquo;s common stock, par value $0.001 per share, as of November 2, 2015 was <font style="background-color: white">177,848,041</font>.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font><font style="font-family: Times New Roman, Times, Serif"><br></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="5"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="5"><font style="font: 10pt Times New Roman, Times, Serif"><b>INDEX</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 0.5pt solid; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">Page</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-decoration: underline; font-weight: bold;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif"><b>PART
I - FINANCIAL INFORMATION</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-decoration: underline; font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 1.</b></font></td>
<td style="text-decoration: underline; font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Financial
Statements</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 2%;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 12%;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 72%;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_002"><font style="font-size: 10pt">Consolidated
Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014</font></a></font></td>
<td style="width: 4%;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif"><a href="#a_003"><font style="font-size: 10pt">Consolidated Statements
of Operations for the Three and Nine Months Ended September 30, 2015 (Unaudited) and 2014 (Unaudited)</font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif"><a href="#a_004"><font style="font-size: 10pt">Consolidated Statements
of Cash Flows for the Nine Months Ended September 30, 2015 (Unaudited) and 2014 (Unaudited)</font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif"><a href="#a_005"><font style="font-size: 10pt">Notes to Consolidated
Financial Statements (Unaudited)</font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr>
<td style="vertical-align: bottom;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: top; font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 2.</b></font></td>
<td style="vertical-align: bottom; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_006"><font style="font-size: 10pt"><b>Management's
Discussion and Analysis of Financial Condition and Results of Operations</b></font></a></font></td>
<td style="vertical-align: bottom;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">19</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 3.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_007"><font style="font-size: 10pt"><b>Quantitative
and Qualitative Disclosures about Market Risk</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">30</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 4.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_008"><font style="font-size: 10pt"><b>Controls
and Procedures</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">31</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;" colspan="3"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_009"><font style="font-size: 10pt"><b>Part
II - OTHER INFORMATION</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">31</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 1.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_010"><font style="font-size: 10pt"><b>Legal
Proceedings</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">31</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 1A.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_011"><font style="font-size: 10pt"><b>Risk
Factors</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">31</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 2.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_012"><font style="font-size: 10pt"><b>Unregistered
Sales of Equity Securities and Use of Proceeds</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">32</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item 6.</b></font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif"><a href="#a_013"><font style="font-size: 10pt"><b>Exhibits</b></font></a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">32</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom">
<td colspan="2"><font style="font-size: 10pt"><b><a href="#a_031">Signatures</a></b></font></td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: center"><font style="font-size: 10pt">33</font></td></tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;<b>PART
I - FINANCIAL INFORMATION</b></font><font style="font-family: Times New Roman, Times, Serif"><br></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;Item
1.&nbsp; Financial Statements</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="5"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="5"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="5"><font style="font-family: Times New Roman, Times, Serif"><a name="a_002"></a><font style="font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></font></font></td>
</tr>
</table>
<p style="margin: 0;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="13"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif">September
30, 2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif">December
31, 2014</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">ASSETS</font></td>
<td style="text-align: center;" colspan="10"></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Current Assets:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 56%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td>
<td style="width: 8%;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">81,123,988</font></td>
<td style="width: 1%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">51,361,607</font></td>
<td style="width: 1%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable,
net of allowance for doubtful accounts</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;of $96,916
and $59,753, respectively</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">3,666,586</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">2,154,217</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt;"><font style="font: 10pt Times New Roman, Times, Serif">Inventory</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">870,059</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,182,113</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets</font></td>
<td style="padding-bottom: 1pt; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,120,805</font></td>
<td style="padding-bottom: 1pt; text-align: left; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,537,407</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
current assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">87,781,438</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">56,235,344</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Fixed assets, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">56,748</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">63,293</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Other Assets:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expense</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,172,051</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,427,263</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets, net</font></td>
<td style="font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,324,284</font></td>
<td style="text-align: left; font-family: Calibri, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,228,588</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Security
deposit</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
other assets</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">2,621,335</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">2,780,851</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
assets</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">90,459,521</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">59,079,488</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;LIABILITIES AND STOCKHOLDERS' EQUITY</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Current Liabilities:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">5,301,625</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">6,327,129</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Other current liabilities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">6,386,777</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">3,840,639</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Deferred
revenue</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">522,613</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
current liabilities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">11,688,402</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">10,690,381</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">Long-Term Liabilities:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Accrued
expenses</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1,213,874</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
liabilities</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">12,902,276</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">10,690,381</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Commitments and Contingencies - See Note
15</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Stockholders' Equity:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt;"><font style="font: 10pt Times New Roman, Times, Serif">Preferred stock - par value $0.001; 10,000,000
shares authorized;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;no shares
issued and outstanding</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt;"><font style="font: 10pt Times New Roman, Times, Serif">Common stock - par value $0.001; 350,000,000
and 250,000,000 shares</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;authorized;&nbsp;&nbsp;177,787,927
and 156,097,019 issued and outstanding, respectively</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">177,788</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">156,097</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Additional paid-in capital</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">279,723,640</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">182,982,846</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated
deficit</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">(202,344,183</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">(134,749,836</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
stockholders' equity</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">77,557,245</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">48,389,107</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
liabilities and stockholders' equity</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">90,459,521</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">59,079,488</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="text-align: center;"><font style="font-family: Times New Roman, Times, Serif">The accompanying footnotes are an integral
part of these consolidated financial statements.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 3 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="19"><font style="font-family: Times New Roman, Times, Serif">THERAPEUTICSMD,
INC. AND SUBSIDIARIES</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-weight: bold;" colspan="19"><font style="font-family: Times New Roman, Times, Serif"><a name="a_003"></a>CONSOLIDATED
STATEMENTS OF OPERATIONS</font></td>
</tr>
</table>
<p style="margin: 0;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Three
Months Ended</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Nine
Months Ended</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">September
30,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">September
30</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 40%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Revenues, net</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">5,190,175</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4,186,261</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14,513,158</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">10,768,572</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Cost of goods sold</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,193,965</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,068,605</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,270,695</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,792,268</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Gross profit</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,996,210</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,117,656</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">11,242,463</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">7,976,304</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Operating expenses:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Sales, general, and
administration</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">7,060,944</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6,043,354</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">20,089,998</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,610,015</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Research and development</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,421,753</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14,909,430</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">58,789,302</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">29,052,149</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Depreciation
and amortization</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,548</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">12,747</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">44,400</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">39,909</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
operating expenses</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">23,499,245</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">20,965,531</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">78,923,700</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">45,702,073</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Operating loss</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,503,035</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,847,875</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,681,237</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,725,769</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Other income (expense):</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Miscellaneous income</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">27,630</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6,260</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">71,728</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">43,411</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Interest income</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,760</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">9,364</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">15,162</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">27,756</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Financing
costs</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(260,027</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
other income (expense)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">30,390</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">15,624</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">86,890</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(188,860</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Loss before income taxes</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,472,645</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,832,251</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,594,347</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,914,629</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Provision for income
taxes</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Net loss</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,472,645</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,832,251</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,594,347</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,914,629</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Loss&nbsp;per share, basic and diluted:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Net loss per share,
basic and diluted</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(0.11</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(0.12</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(0.39</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(0.26</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">Weighted average number of common</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;shares
outstanding, basic and diluted</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">177,206,168</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">152,200,455</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">171,589,595</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">147,594,810</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_004"></a><font style="font-size: 10pt"><b>(Unaudited)</b></font></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Nine
Months Ended</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">September
30, 2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">September
30, 2014</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom">
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING
ACTIVITIES</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; width: 56%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Net
loss</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,594,347</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,914,629</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments
to reconcile net loss to net cash used in</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;operating
activities:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">22,104</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">22,713</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization
of intangible assets</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">22,296</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">17,196</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision
for doubtful accounts</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">37,163</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,594</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based
compensation</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4,740,906</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,934,836</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization
of deferred financing costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">260,027</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in operating assets and liabilities:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
receivable</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(1,549,532</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(460,565</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">312,054</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">31,673</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
current assets</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(621,923</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">197,569</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
assets</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(15,162</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,069</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
payable</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(1,025,504</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,534,462</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
revenue</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(522,613</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(754,431</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
current liabilities</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,546,138</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">909,890</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long
term accrued expenses</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,213,874</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(62,434,546</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(30,235,734</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING
ACTIVITIES</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Patent
costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(117,992</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(193,349</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Purchase
of property and equipment</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(15,559</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(30,962</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Net
cash used in investing activities</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(133,551</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(224,311</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING
ACTIVITIES</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Proceeds
from sale of common stock, net of costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">91,374,649</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">42,771,353</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Proceeds from exercise of
options</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">589,829</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">315,546</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Proceeds
from exercise of warrants</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">366,000</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">181,000</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">92,330,478</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">43,267,899</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Increase in cash</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">29,762,381</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">12,807,854</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-bottom: 1pt; padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">Cash, beginning
of period</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">51,361,607</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">54,191,260</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-bottom: 2.5pt; padding-left: 10pt;"><font style="font-family: Times New Roman, Times, Serif">Cash, end of period</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">81,123,988</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">66,999,114</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 5 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_005"></a><font style="font-size: 10pt">&nbsp;<b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
1 &ndash; THE COMPANY</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed, BocaGreenMD, Inc., a Nevada corporation, or BocaGreen, and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as "our company," "we," "our," or "us."</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Nature
of Business</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
are a women&rsquo;s health care product company focused on creating and commercializing products targeted exclusively for women.
As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary
for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used
in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related
hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug
candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical
efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates
are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone
or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter,
or OTC, vitamins.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &ndash; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Interim
Financial Statements</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2014. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance </font><font style="font: 10pt Times New Roman, Times, Serif">with accounting
principles generally accepted in the United States of America, or GAAP<font style="color: #252525">, for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying
unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete
financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting
of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for
the interim periods presented. Interim results are not necessarily indicative of results for a full year, or any other interim
period.</font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 6 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &ndash; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Continued)</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, the Financial Accounting Standards Board, or FASB, issued final guidance that requires entities to measure
inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance
applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail
inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does
not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM
guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable
costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate
other measures of &ldquo;market.&rdquo; The guidance is effective for public business entities for fiscal years beginning
after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently
evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-10, Technical Corrections and Improvements, to correct
differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references
and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for
fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The other amendments are effective
immediately. We do not expect the adoption of ASU 2015-10 to have a material effect on our consolidated financial statements and
disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">In
August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure
of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether
there are conditions and events that raise substantial doubt about </font><font style="font: 10pt Times New Roman, Times, Serif">the
entity&rsquo;s ability to continue as a going concern within one year after the financial statements are issued (or available
to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December
15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or
interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of
ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with
Customers (Topic 606). The standard&rsquo;s core principle is that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous
guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration
to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,
the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after
December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,
2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements
and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently
issued, but not yet effective, accounting standards been adopted in the current period.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 7 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment
of Long-Lived Assets</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes
in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets
during the three and nine months ended September 30, 2015 and 2014.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of
accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of
such instruments.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements. </i> The fair value hierarchy gives the highest priority to quoted prices in
active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and
liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 0.5in;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1in;"><font style="font-family: Times New Roman, Times, Serif"><b>Level 1</b></font></td>
<td><font style="font-family: Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or
liabilities;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif"><b>Level 2</b></font></td>
<td><font style="font-family: Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets
or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially
the full term of the financial instrument; and</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif"><b>Level 3</b></font></td>
<td><font style="font-family: Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable
inputs (Level 3) in connection with any required impairment test.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is
fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support
team utilizing similar marketing techniques.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>
<p style="background-color: white; margin: 0; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues,
net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our customers pay for our
products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize
accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept
product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of estimated returns, sales
discounts, and eCommerce fees.</font></p>

<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif">&nbsp;</p>
<!-- Field: Page; Sequence: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>
<p style="background-color: white; margin: 0; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue
from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following
product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January
1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve
as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return
no longer existed.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we
send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages,
which is reviewed, and adjusted if necessary, on a quarterly basis.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>
<p style="margin: 0; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was
included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance
sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of
which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying
consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other
activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants
that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff
with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing
experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside
legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters.
These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical
trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We
make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable
advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or
when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study
expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided
by CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study costs as long term Accrued Expenses
related to the costs that will be paid at the completion of one of our clinical trials. Estimated accrued CRO costs are subject
to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise
to the revision become known.</font></p>

<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 9 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
4 &ndash; INVENTORY</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">December
31,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Finished
product</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">787,232</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">874,294</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Raw material</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">82,827</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">155,341</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Deferred
costs</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">152,478</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL
INVENTORY</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">870,059</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,182,113</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
5 &ndash; OTHER CURRENT ASSETS</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">December
31,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Prepaid
insurance</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">870,949</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">394,878</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Prepaid research
and development costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">381,813</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">299,498</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Prepaid consulting</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">373,339</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">411,864</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Other receivables-related
party (Note 13)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">249,981</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">249,981</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Other prepaid costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">219,086</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">181,186</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Prepaid
vendor deposits</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">25,637</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL
OTHER CURRENT ASSETS</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,120,805</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,537,407</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
6 &ndash; FIXED ASSETS, NET</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">December 31,</font></p>
<p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">2014</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Equipment</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">132,150</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">132,150</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Furniture
and fixtures</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">69,454</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">53,895</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">201,604</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">186,045</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accumulated
depreciation</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(144,856</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(122,752</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL
FIXED ASSETS, NET</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">56,748</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">63,293</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended September 30, 2015 and 2014 was $7,856 and $7,122, respectively, and $22,104 and $22,713 for
the nine months ended September 30, 2015 and 2014, respectively.</font></p>

<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 10 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
7 &ndash; PREPAID EXPENSE</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid
expense (long-term) consists of the following:</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">December 31,</font></p>
<p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">2014</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Prepaid
manufacturing costs</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">978,704</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">963,543</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Prepaid
research and development costs</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">193,347</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">463,720</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL
PREPAID EXPENSE</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,172,051</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,427,263</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
8 &ndash; INTANGIBLE ASSETS, NET</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2015 and December 31, 2014:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="15"><font style="font-family: Times New Roman, Times, Serif">September
30, 2015</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Gross
Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated
Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;Net</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Weighted-
Average Amortization Period (yrs.)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Amortizing intangible
assets:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 40%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;OPERA<sup>&reg;
</sup>software patent</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">31,951</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(3,994</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">27,957</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Development costs
of</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporate
website</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(91,743</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Approved
hormone</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;therapy
drug</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;candidate
patents</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">605,502</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(40,199</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">565,303</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">17.25</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">Non-amortizing intangible</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;assets:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Hormone
therapy drug</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;candidate
patents</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(pending)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">585,241</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">585,241</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Multiple
trademarks for</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vitamins/supplements</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">145,783</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">145,783</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,460,220</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(135,936</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,324,284</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>

<p style="margin: 0; font: 11pt Times New Roman, Times, Serif">&nbsp;</p>
<!-- Field: Page; Sequence: 11 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-size: 11pt;" colspan="15"><p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;December
31, 2014</font></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Gross
Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated
Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;Net</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Weighted-
Average Amortization Period (yrs.)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Amortizing intangible
assets:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 40%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;OPERA<sup>&reg;
</sup>software patent</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">31,951</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(2,496</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">29,455</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14.75</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Development costs
of</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporate
website</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(91,743</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Approved
hormone</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;therapy
drug</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;candidate
patents</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">439,184</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,401</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">419,783</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">18</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">Non-amortizing intangible</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;assets:</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Hormone
therapy drug</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;candidate
patents</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(pending)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">675,982</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">675,982</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Multiple
trademarks for</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vitamins/supplements</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">103,368</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">103,368</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,342,228</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(113,640</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,228,588</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If
the patent is not granted, we write-off any capitalized patent costs at that time.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">Trademarks
are perpetual and are not amortized. As of September 30, 2015, the remaining life related to OPERA&reg; patent was approximately
14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years. During
the three and nine months ended September 30, 2015 and 2014, there was no impairment recognized.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
addition to numerous pending patent applications, as of September 30, 2015, we had </font><font style="font: 10pt Times New Roman, Times, Serif">13
issued patents,<font style="background-color: white"> including:</font></font></p>
<table style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">&bull;</td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">one method patent that relates to our
OPERA&reg; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in
2029;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&bull;</font></td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">twelve utility patents that relate to
our combination progesterone and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration
dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Canada, the
European Union, Israel, Mexico, Brazil, Japan, Russia, South Africa and South Korea.</font></td>
</tr>
</table>
<p style="margin: 0 0 0 0.5in; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $8,692 and $5,625 for the three months ended September 30, 2015 and 2014, respectively and $22,296 and $17,196 for
the nine months ended September 30, 2015 and 2014, respectively. Estimated amortization expense for the next five years is as
follows:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Year
Ending December 31,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Estimated
Amortization</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 43%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">2015 (3 months)</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 43%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">8,692</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2016</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">34,768</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2017</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">34,768</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2018</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">34,768</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2019</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">34,768</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif;"></p>
<!-- Field: Page; Sequence: 12 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;<font style="font-size: 10pt"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
9 &ndash; OTHER CURRENT LIABILITIES</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">December 31,</font></p>
<p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">2014</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued
clinical trial costs</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,528,061</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,706,542</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued payroll,
bonuses and commission costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">930,913</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">814,205</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued legal and
accounting expense</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">615,946</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">276,470</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued compensated
absences</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">490,170</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">442,430</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Other accrued expenses</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">388,268</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">185,965</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Allowance for coupons
and returns</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">208,361</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">90,446</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Allowance for wholesale
distributor fees</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">96,440</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">160,503</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued rent</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">86,998</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">91,368</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Accrued
royalties</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">41,620</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">72,710</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL
OTHER CURRENT LIABILITIES</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6,386,777</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,840,639</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
10 &ndash; NET LOSS PER SHARE</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of
common stock, par value $0.001 per share, or Common Stock outstanding during the period, less any shares subject to repurchase
or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three and nine
months ended September 30, 2015 and 2014.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Since
we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as
warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.</font></p>
<p style="color: #252525; margin: 0; text-align: justify; font: 11pt/14.4pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss
per share allocable to common stockholders if they were not antidilutive for the periods presented.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">As
of September 30,</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Stock
options</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">17,414,242</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,851,943</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Warrants</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">12,722,431</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">13,927,916</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">30,136,673</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">30,779,859</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
11 &ndash; STOCKHOLDERS&rsquo; EQUITY</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Preferred
Stock</u></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2015, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares
of Preferred Stock were issued or outstanding.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<!-- Field: Page; Sequence: 13 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Common
Stock</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2015, we had 350,000,000 shares of Common Stock authorized, of which 177,787,927 shares of Common Stock were issued
and outstanding.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
July&nbsp;9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim
Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public
offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting
agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common
Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting
underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&nbsp;15,
2015 and we issued 4,423,077 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative
of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common
Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters
a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full.
The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and
other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our
Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &amp; Co, or Goldman Sachs, as the representative
of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310
shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement,
we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On
July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock.
Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other
offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Exercises
During 2015</u></i></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2015, certain individuals exercised stock options to purchase 95,000 shares of Common Stock
for $98,478 in cash. During the nine months ended September 30, 2015, certain individuals exercised stock options to purchase
472,867 shares of Common Stock for $589,829 in cash.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Exercises
During 2014</u></i></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, certain individuals exercised stock options to purchase 793,800 shares of Common Stock.
Stock options to purchase shares of Common Stock were exercised as follows: (i) 674,193 options for $315,546 in cash and (ii)
<font style="letter-spacing: -0.15pt">119,607 options, pursuant to the stock options&rsquo; cashless provision, wherein 113,837
shares of Common Stock were issued. Also during the nine months ended September 30, 2014, we issued 50,000 shares of Common Stock
to an employee upon the vesting of restricted stock units that were granted in December 2013.</font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Warrants
to Purchase Common Stock </u></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, we had warrants outstanding to purchase an aggregate of 12,772,431 shares of Common Stock with a weighted-average
contractual remaining life of 1.92 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average
exercise price of $1.93 per share.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 14 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes
Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free
interest rate and the term of the warrant.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
January 2013, we granted warrants to purchase 1,250,000 shares of Common Stock in connection with the issuance of a Revolving
Credit Note to Plato and Associates, LLC, or the Plato Warrant. The Plato Warrant has an exercise price of $3.20 per share. The
Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant,
with a fair value of $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free
rate of 0.88%; and a dividend yield of 0%. For the nine months ended September 30, 2015 and 2014, $0 and $260,027, respectively,
was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial
statements.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2013, we entered into a consulting agreement with Sancilio &amp; Company, Inc., or SCI, to develop drug technology to be used
in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and
Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and
vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000
shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration
under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has
vested or will vest, as applicable, as follows:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 24px; text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares were earned on May 11,
2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel
vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest
until June 30, 2013. &nbsp;The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes
Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield
of 0%. &nbsp;We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 24px; text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares vested on June 30, 2013.&nbsp;&nbsp;The
fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term
of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%.&nbsp;&nbsp;As of September 30, 2015,
we recorded $115,543 in other current assets in the accompanying consolidated financial statements with respect to such shares.&nbsp;&nbsp;During
the three and nine month periods ended September 30, 2015 and 2014, we recorded $38,517 and $115,551, respectively, as non-cash
compensation in the accompanying consolidated financial statements with respect to such shares; and</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 24px;"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">283,334 shares will vest upon the receipt
by us of any final FDA approval of a drug candidate that SCI helped us design. &nbsp;It is anticipated that this event will not
occur before December 2016.</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $567,000
and will be recognized over a period of 1.75 years.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant
at an exercise price of $6.35 and the expiration date of April 6, 2020. The total non-cash compensation expense related to this
warrant was $42,266 and $86,008, respectively, for the three and nine months ended September 30, 2015.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 15 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Warrant
exercises</u></i></font></p>
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 310,000 shares of
Common Stock<font style="letter-spacing: -0.15pt"> pursuant to the warrants&rsquo; cashless exercise provisions, wherein 232,197
shares of Common Stock were issued.</font> During the nine months ended September 30, 2015, certain individuals and an entity
exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for
$366,000 in cash and (ii) warrants to purchase 310,000<font style="letter-spacing: -0.15pt"> shares of Common Stock were exercised
pursuant to the warrants&rsquo; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued. </font></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for
$181,000 in cash.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Options
to Purchase Common Stock </u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009
Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder.
During the nine months ended September 30, 2015, we granted 1,231,000 non-qualified stock options under the 2009 Plan. As of September
30, 2015, there were non-qualified stock options to purchase 15,445,768 shares of Common Stock outstanding under the 2009 Plan.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of
September 30, 2015, there were non-qualified stock options to purchase 1,968,474 shares of Common Stock outstanding under the
2012 Plan.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including estimated volatility of the stock price, the risk-free interest rate, and the expected
life of the stock options. The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and
2014 are set forth in the table below.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Nine
Months Ended September 30,</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Risk-free interest
rate</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1.47-1.54</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">1.68-1.77</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">Volatility</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">58.77-62.94</font></td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">69.15-70.93</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Term (in years)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">Dividend
yield</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
</table>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period
is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is
expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility
of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is
based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer
entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual
terms of the stock option using the simplified method.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 16 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 12pt Arial, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">A summary
of activity under the 2009 and 2012 Plans and related information follows:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Number
of Shares Underlying Stock Options</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
Average Exercise Price</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
Average</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Life
in Years</font></p>
</td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="3"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
Intrinsic Value</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 40%;"><font style="font-family: Times New Roman, Times, Serif">Balance at December 31,
2014</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,792,443</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1.88</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6.92</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">43,996,311</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Granted</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,231,000</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6.38</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Exercised</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(472,867</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1.25</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Expired/Forfeited</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(136,334</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3.01</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="font-family: Times New Roman, Times, Serif">Balance at September
30, 2015</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">17,414,242</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2.21</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6.09</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">64,265,785</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: 10pt;"><p style="margin-bottom: 0; margin-top: 0;"><font style="font-family: Times New Roman, Times, Serif">Vested and Exercisable at
September 30, 2015</font></p>
</td>
<td style="padding-bottom: 2.5pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">13,848,923</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">1.59</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">5.49</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">59,095,453</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white"></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">At
September 30, 2015, our outstanding stock options had exercise prices ranging from $0.10 to $7.72 per share.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">Share-based
compensation expense for options recognized in our results of operations (based on vested awards) for the three and nine months
ended September 30, 2015 were $1,626,862 and $4,328,964, respectively, and $1,047,493 and $3,341,604, respectively, for the same
periods in 2014. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual
forfeitures differ from the estimates. At September 30, 2015, total unrecognized estimated compensation expense related to unvested
options granted prior to that date was approximately $5,593,000 which may be adjusted for future changes in forfeitures. This
cost is expected to be recognized over a weighted-average period of 2.3 years. No tax benefit was realized due to a continued
pattern of operating losses.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
12 &ndash; INCOME TAXES</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of (i) the losses recorded
during the nine months ended September 30, 2015, (ii) additional losses expected for the remainder of 2015, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is "more likely than not" that some component or all of the benefits of deferred tax assets will not be realized.
As of September 30, 2015, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no
provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting
period.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
13 &ndash; RELATED PARTIES</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was
elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course
of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent
directors of our company.</font></p>

<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 17 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>

<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015 and 2014, we did not engage in any transactions with Pernix. At September 30, 2015 and
December 31, 2014, there were amounts due Pernix of approximately $46,000.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Additionally,
there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and
supply agreement in the amounts of approximately $250,000 at both September 30, 2015 and December 31, 2014.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
14 - BUSINESS CONCENTRATIONS</u></b></font></p>
<p style="margin: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
purchase our products from several suppliers with approximately 54% and 77% of our purchases supplied from one vendor for the
nine months ended September 30, 2015 and 2014, respectively.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain
drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated
from four major customers accounted for approximately 90% and 95% of our recognized revenue for the nine months ended September
30, 2015 and 2014, respectively.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Customers
that generated more than 10% of our sales are designated as customers &ldquo;A&rdquo;, &ldquo;B&rdquo;, &ldquo;C&rdquo; and &ldquo;D&rdquo;.&nbsp;
During the nine months ended September 30, 2015, two customers generated more than 10% of revenues and during the nine months
ended September 30, 2014, four customers generated more than 10% of revenues. During the nine months ended September 30, 2015,
customer A generated approximately $6,930,000 in revenues and customer B generated approximately $3,005,000 in revenues. During
the nine months ended September 30, 2014, customers A, B, C and D generated approximately $3,930,000, $1,846,000, $1,590,000 and
$1,555,000 in sales, respectively.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
15 &ndash; COMMITMENTS AND CONTINGENCIES</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced
on July 1, 2013 and expires on September 30, 2018. On February 18, 2015, we entered into an agreement to lease additional administrative
office space in Boca Raton, Florida, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015
and will expire with the original lease term on September 30, 2018.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 12pt Arial, Helvetica, Sans-Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
straight line rental expense related to our current lease totaled approximately $119,000 and $90,000 for the three months ended
September 30, 2015 and 2014, respectively, and approximately $328,000 and $271,000 for the nine months ended September 30, 2015
and 2014, respectively. The 2014 amounts were partially offset by the rent income of approximately $6,000 and $42,000, respectively,
for sublet space. We did not sublet any space during the nine months ended September 30, 2015.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, future minimum rental payments are as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Years
Ending December 31,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 43%; vertical-align: bottom; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">2015
(3 months)</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 10%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 43%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">121,698</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">2016</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">493,790</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">2017</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">507,087</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">2018</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">388,976</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">Minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,511,551</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
16 &ndash; SUBSEQUENT EVENTS</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
October 2015, we completed enrollment in the REPLENISH trial, a phase 3 study of TX-001HR in postmenopausal women with an intact
uterus. The trial was designed to enroll approximately 1,750 patients at approximately 100 sites.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_006"></a><font style="font-size: 10pt"><b>Item
2. Management's Discussion and Analysis of Financial Condition and Results of Operations</b></font></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>General</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our
results of operations and financial condition for the periods described. This discussion should be read together with our consolidated
financial statements and the notes to the consolidated financial statements, which are included in this Quarterly Report on Form
10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for
the year ended December 31, 2014 filed with the Securities and Exchange Commission, or the Commission or the SEC, on March 12,
2015, or the Annual Report, including the audited financial statements and notes included therein. The reported results will not
necessarily reflect future results of operations or financial condition.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.
Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as
well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project,
believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &ldquo;believes,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo;
and similar expressions and are based on assumptions and assessments made in light of management&rsquo;s experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such
statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties, many of which are outside of our control. Important factors
that could cause actual results, developments and business decisions to differ materially from forward-looking statements are
described in the sections titled &ldquo;Risk Factors&rdquo; in our Annual Report, and include the following: our ability to maintain
or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of our clinical trials; the potential of adverse side effects
or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to
conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities
and health insurance companies for our products; the impact of product liability lawsuits; and the influence of extensive and
costly government regulation.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">Throughout
this Quarterly Report on Form 10-Q, the terms "we," "us," "our," "TherapeuticsMD," or "our company" refer to TherapeuticsMD, Inc.,
a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited
liability company, or VitaMed, BocaGreenMD, Inc., a Nevada corporation, or BocaGreen, and VitaCare Prescription Services, Inc.,
a Florida corporation, or VitaCare.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
June 30, 2015, we exceeded the $750 million public float threshold to trigger &ldquo;large accelerated filer&rdquo; reporting
status with the SEC beginning in fiscal year 2016. Consequently, as of January 1, 2016, we will no longer be an &ldquo;accelerated
filed&rdquo; as such term is defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and we will need to comply
with the large accelerated filer reporting deadlines for our Annual Report on Form 10-K for the fiscal year ending December 31,
2015, and our Quaterly Reports on Form 10-Q beginning with the quarter ending March 31, 2016.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Overview</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
are a women&rsquo;s health care company focused on creating and commercializing products targeted exclusively for women. Currently,
we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy
pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and
reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal
discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination,
with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared
with competing products. Our drug candidates are created from hormone technology that enables the administration of hormones with
high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal
vitamins, as well as over-the-counter, or OTC, vitamins.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 19 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
common stock, par value $0.001 per share, or Common Stock, is traded on the NYSE MKT under the symbol &ldquo;TXMD&rdquo;. We maintain
the following websites at www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com, and www.bocagreenmd.com. The information
contained on our websites or that can be accessed through our websites does not constitute part of this Quarterly Report on Form
10-Q.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&nbsp;</i></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Research
and Development</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Overview</i></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
have obtained the U.S. Food and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications
to conduct clinical trials for four of our hormone therapy drug candidates: TX-001HR, our oral combination of progesterone and
estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our vaginal estradiol softgel
with estradiol alone.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
are currently conducting phase 3 clinical trials for TX-001HR and TX-004HR. In July 2014, we temporarily suspended enrollment
in the phase 3 clinical trial for TX-002HR, and in October 2014 we temporarily stopped the trial in order to update the phase
3 protocol based on discussions with the FDA. We have no current plans to conduct clinical trials for TX-003HR.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">TX-001HR,
our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe
vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort for post-menopausal
women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in
a woman&rsquo;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination
of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent
the first time a combination product of estradiol and progesterone (bioidentical to the estradiol and progesterone produced by
the ovaries), would be approved for use in a single combined product.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
September 5, 2013, we began enrollment of the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, phase 3 study
of TX-001HR in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the
treatment of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned
to one of five treatment arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for
the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined
by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of frequency
and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the number and
severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flushes at screening
are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial hyperplasia analysis. The
secondary endpoints include reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal
dryness, measured at 12 weeks, six months and 12 months. The trial is designed to enroll approximately 1,750 patients at approximately
100 sites. We completed enrollment in the REPLENISH Trial in October 2015 and we currently anticipate that results of the trial
will be reported in the fourth quarter of 2016 or the first quarter of 2017. Based on such timeline and successful reports of
the trial, we would anticipate filing an NDA for TX-001HR during the fourth quarter of 2016 or the first quarter of 2017 and assuming
an FDA review period of ten months from the receipt date to the Prescription Drug User Fee Act, or PDUFA, date for a non-new molecular
entity, the NDA for TX-001HR could be approved by the FDA during the fourth quarter of 2017 or the first quarter of 2018.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 20 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">TX-002HR
is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of
peanut oil. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s
body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January
2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness
of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment
challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In
July 2014, we temporarily suspended enrollment and in October 2014 we temporarily stopped the SPRY Trial in order to update the
phase 3 protocol based on discussions with the FDA. We intend to update the phase 3 protocol to, among other things, target only
those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe
that the updated phase 3 protocol, if approved by the FDA, will allow us to mitigate the enrollment challenges in, and shorten
the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol that
we intend to propose.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">TX-004HR
is a vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women
with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as
the traditional treatments for VVA because of an early onset of action with less systemic exposure inferring a greater probability
of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form
versus traditional VVA treatments. We initiated the REJOICE Trial, a multicenter, double-blind, placebo-controlled phase 3 clinical
trial during the third quarter of 2014 to assess the safety and efficacy of TX-004HR for the treatment of moderate to severe dyspareunia,
or painful intercourse, as a symptom of VVA due to menopause. We are conducting a single 12 week study, evaluating three different
doses of estradiol: 4 mcg, 10 mcg and 25 mcg versus placebo. The FDA has noted that a single, large, well-controlled clinical
trial to support safety and efficacy should be sufficient to submit an NDA for TX-004HR for the proposed indication and that to
support the indication in a single trial, evidence of efficacy for a given dose would need to show statistical significance of
at a 0.01 level. The study has been designed to include four primary endpoints: the reduction of vaginal pH levels to less than
5.0, an increase in superficial cells, a decrease in parabasal cells and the improvement of dyspareunia. If approved, the 4 mcg
formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA. The trial is
designed to enroll approximately 700 patients across approximately 100 sites. The last patient was enrolled in the REJOICE Trial
in June 2015, and we have completed the last patient visit in the trial.&nbsp; We currently anticipate that the topline results
of the trial will be reported during the fourth quarter of 2015. Based on such timeline and successful reports of the trial, we
would anticipate filing an NDA for TX-004HR as soon as the first half of 2016 and that such NDA could be approved by the FDA as
soon as the first quarter of 2017, assuming an FDA review period of ten months from the receipt date to the PDUFA date for a non-new
molecular entity.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, we had 13 issued patents, which included 11 utility patents that relate to our combination progesterone
and estradiol formulations, one utility patent that relates to TX-004HR, which establishes an important intellectual property
foundation for TX-004HR, and one method patent that relates to our OPERA&reg; information technology platform.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">A
significant portion of our operating expenses to date have been incurred in research and development activities. Research and
development expenses relate primarily to the discovery and development of our drug products. Our business model is dependent upon
our company continuing to conduct a significant amount of research and development. Our research and development expenses consist
primarily of expenses incurred under agreements with contract research organizations, or CROs, investigative sites and consultants
that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which include
salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls
capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 21 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="background-color: white; margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable
advance payments for goods and services that will be used in future research and development activities are expensed when the
activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be
expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was included in
Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance sheets. Advance
payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of which $711,362
was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying consolidated balance
sheets.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
following table indicates our research and development expense by project/category for the periods indicated (in 000s):</font></p>
<p style="background-color: white; margin: 0; font: 9pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Three
months ended September 30,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7"><font style="font-family: Times New Roman, Times, Serif">Nine
months ended September 30,</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 40%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">TX-001HR</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">8,175</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">11,518</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">27,504</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 3%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">20,320</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">TX-002HR</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">85</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">18</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,381</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">TX-004HR</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4,581</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">567</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">18,242</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">931</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Other
research and development<sup>(1)</sup></font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,660</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,739</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">13,025</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6,420</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16,422</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14,909</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">58,789</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">29,052</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">____________</font></p>
<p style="background-color: white; margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 8pt Times New Roman, Times, Serif"><sup>(1)
</sup>Product costs are classified as other research and development expenses until one of our drug products receives IND approval
from the FDA.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development expenditures will continue to be significant as we continue development of our pipeline of novel drug candidates.
We expect to incur significant research and development costs as we develop our drug pipeline, complete the ongoing clinical trials
of our drug candidates, conduct our ongoing phase 3 clinical trials, manufacturing, scale-up, and prepare regulatory submissions.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
costs of clinical trials may vary significantly over the life of a project due to factors that include but are not limited to
the following: per patient trial costs, the number of patients that participate in the trials; the number of sites included in
the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out
or discontinuation rates of patients; the amount of time required to recruit patients for the trial, the duration of patient follow-up;
and the efficacy and safety profile of the drug candidate. We base our estimated expenses related to clinical trials on estimates
that are based on our experience and estimates from CROs and other third parties.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0pt"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 22 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0pt"><b><u>Results
of Operations</u></b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Three
months ended September 30, 2015 compared with three months ended September 30, 2014</u></i></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="7"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Three
Months Ended</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Change</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="11"><font style="font-family: Times New Roman, Times, Serif">(000s)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 46%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Revenues,
net</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">5,190</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4,186</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,004</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Cost of goods sold</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,194</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,069</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">125</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Operating
expenses</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">23,499</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">20,965</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,534</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
loss</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,503</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,848</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(1,655</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Total
other income</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">31</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">16</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">15</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Net
loss</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(19,472</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(17,832</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(1,640</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenues
and Cost of Goods Sold</u></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Revenues
for the three months ended September 30, 2015 increased approximately $1,004,000, or 24%, to approximately $5,190,000, compared
with approximately $4,186,000 for the three months ended September 30, 2014. Of this $1,004,000 increase, approximately $825,000,
or 82%, was attributable to an increase in the number of units sold and approximately $179,000, or 18%, was attributable to product
mix and an increase in the average net sales price of our products. Cost of goods sold increased approximately $125,000 or 12%,
to approximately $1,194,000 for the three months ended September 30, 2015, compared with approximately $1,069,000 for the three
months ended September 30, 2014. Cost of goods sold as a percentage of revenue was approximately 23% and 26% for the three months
ended September 30, 2015 and 2014, respectively, which was primarily attributable to a favorable change in product mix.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Operating
Expenses</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items as a percentage of total operating expenses.</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="7"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Three
Months Ended</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 12%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 12%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">2014*</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Research and development
costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">69.9</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">71.1</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Human resource
costs, including salaries, benefits and taxes</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14.7</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">12.8</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Sales and marketing
costs, excluding human resource costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">6.2</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">8.0</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Professional fees
for legal, accounting and consulting</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4.8</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3.5</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify; font-size: 11pt;"><p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
operating expenses</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
</td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4.4</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">4.6</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
</table>
<p style="margin: 0; text-indent: 0.5in; font: 7pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 7pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">*Prior
year numbers have been reclassified to conform to current year&rsquo;s presentation</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Operating
expenses increased by approximately $2,534,000 or 12%, to approximately $23,499,000 for the three months ended September 30, 2015,
from approximately $20,965,000 for the three months ended September 30, 2014 as a result of the following items:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; width: 70%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 10%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 18%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(000s)</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in research
and development costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,513</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in human
resource costs, including salaries, benefits and taxes</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">764</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in professional
fees for legal, accounting and consulting</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">396</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in other
operating expenses</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">82</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Decrease
in sales and marketing, excluding human resource costs</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(221</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,534</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 23 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 10pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development costs for the three months ended September 30, 2015 increased by approximately $1,513,000, or 10%, to approximately
$16,422,000, compared with $14,909,000 for the three months ended September 30, 2014. Research and development costs include costs
related to clinical trials as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and
development activities.&nbsp; The increase in research and development costs was primarily due to an increase in scale-up and
manufacturing activities for our phase 3 hormone therapy drug candidates, partially offset by lower clinical trial costs. Research
and developments costs during the three months ended September 30, 2015 included the following research and development projects.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ending September 30, 2015 and the period from February 2013 (project inception) through September 30, 2015, we
have incurred approximately $8,175,000 and $58,436,000, respectively, in research and development costs with respect to TX-001HR,
our combination estradiol and progesterone drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2015 and the period April 2013 (project inception) through September 30, 2015, we have incurred
approximately $6,000 and $2,520,000, respectively, in research and development costs with respect to TX-002HR, our progesterone
only drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2015 and the period from August 2014 (project inception) through September 30, 2015, we have
incurred approximately $4,581,000 and $22,225,000, respectively, in research and development costs with respect to TX-004HR, our
vaginal estradiol softgel drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts and steps necessary to complete these projects, see &ldquo;Item 1. Business &mdash; Research
and Development&rdquo; in our Annual Report. For a discussion of the risks and uncertainties associated with completing development
of our products, see &ldquo;Item 1A. Risk Factors &mdash; Risks Related to Our Business&rdquo; in our Annual Report. For a discussion
of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient
to complete these projects, see &ldquo;&mdash; Liquidity and Capital Resources.&rdquo; For a discussion as to whether a future
milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory
agency can be reliably determined, see &ldquo;Item 1. Business &mdash; Our Hormone Therapy Drug Candidates,&rdquo; &ldquo;Item
1. Business &mdash; Products in Development&rdquo; and &ldquo;Item 1. Business &mdash; Pharmaceutical Regulation&rdquo; in our
Annual Report. Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent
on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible
subjects for the applicable trials.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Human
resource costs, including salaries, benefits and taxes, for the three months ended September 30, 2015 increased by approximately
$764,000, or 28%, to approximately $3,465,000, compared with $2,701,000 for the three months ended September 30, 2014, primarily
as a result of increases of approximately $520,000 in non-cash compensation related to stock option awards and approximately $244,000
in personnel costs.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Professional
fees for the three months ended September 30, 2015 increased by approximately $396,000, or 54%, to approximately $1,129,000, compared
with $733,000 for the three months ended September 30, 2014, primarily as a result of higher consulting fees.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
operating expense for the three months ended September 30, 2015 increased by approximately $82,000, or 9%, to approximately $1,034,000,
compared with $952,000 for the three months ended September 30, 2014, primarily as a result of increased travel and rent expense.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 24 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs for the three months ended September 30, 2015 decreased by approximately $221,000, or 13%, to approximately
$1,448,000, compared with $1,669,000 for the three months ended September 30, 2014, as a result of decreased costs related to
advertising programs.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Operating
Loss</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $1,655,000, or 9%, to approximately $19,503,000 for the
three months ended September 30, 2015, compared with approximately $17,848,000 for the three months ended September 30, 2014,
primarily as a result of increased research and development costs associated with our continued development of our hormone therapy
drug candidates, partially offset by increased revenue from sales of our prenatal vitamin products.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating
losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there
is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved,
will be successful.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Total
other income</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
income increased by approximately $15,000, or 94%, to approximately $31,000 for the three months ended September 30, 2015 compared
with $16,000 for the comparable period in 2014.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Net
Loss</u></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the net effects of the foregoing, net loss increased approximately $1,640,000, or 9%, to approximately $19,472,000
for the three months ended September 30, 2015, compared with approximately $17,832,000 for the three months ended September 30,
2014. Net loss per share of Common Stock, basic and diluted, was $0.11 for the three months ended September 30, 2015, compared
with $0.12 per share of Common Stock for the three months ended September 30, 2014.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Nine
months ended September 30, 2015 compared with nine months ended September 30, 2014</u></i></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="7"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Nine
Months Ended</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
</td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">Change</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: center;" colspan="11"><font style="font-family: Times New Roman, Times, Serif">(000s)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 46%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Revenues,
net</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">14,513</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">10,769</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 11%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,744</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Cost of goods sold</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3,271</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">2,792</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">479</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Operating
expenses</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">78,923</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">45,703</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">33,220</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
loss</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,681</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,726</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(29,955</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Other
income (expense)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">87</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(189</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">276</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Net
loss</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(67,594</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(37,915</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(29,679</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenues
and Cost of Goods Sold</u></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Revenues
for the nine months ended September 30, 2015 increased approximately $3,744,000, or 35%, to approximately $14,513,000, compared
with approximately $10,769,000 for the nine months ended September 30, 2014. Of this $3,744,000 increase, approximately $2,818,000,
or 75 %, was attributable to an increase in the number of units sold and approximately $926,000, or 25%, was attributable to product
mix and an increase in the average net sales price of our products. Cost of goods sold increased approximately $479,000, or 17%,
to approximately $3,271,000 for the nine months ended September 30, 2015, compared with approximately $2,792,000 for the nine
months ended September 30, 2014. Cost of goods sold as a percentage of revenue was approximately 23% and 26% for the nine months
ended September 30, 2015 and 2014, respectively, which was primarily attributable to a favorable change in product mix.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Operating
Expenses</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items as a percentage of total operating expenses.</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="7"><p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Nine
Months Ended</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 12%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 12%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">2014*</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Research and development
costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">74.5</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">63.6</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Human resource
costs, including salaries, benefits and taxes</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">12.2</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">17.4</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Sales and marketing
costs, excluding human resource costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">5.6</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">9.9</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Professional fees
for legal, accounting and consulting</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3.9</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3.7</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify; font-size: 11pt;"><p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
operating expenses&nbsp;</font></p>
</td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">3.8</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">5.4</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">%</font></td>
</tr>
</table>
<p style="margin: 0; text-indent: 0.5in; font: 7pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">*Prior
year numbers have been reclassified to conform to current year&rsquo;s presentation</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Operating
expenses increased by approximately $33,220,000 or 73%, to approximately $78,923,000 for the nine months ended September 30, 2015,
from approximately $45,703,000 for the nine months ended September 30, 2014 as a result of the following items:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; width: 70%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; width: 10%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 18%; vertical-align: bottom; text-align: center;"><font style="font-family: Times New Roman, Times, Serif">(000s)</font></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in research
and development costs</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">29,737</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in professional
fees for legal, accounting and consulting</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,360</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in human
resource costs, including salaries, benefits and taxes</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">1,674</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Increase in other
operating expenses</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">582</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Decrease
in sales and marketing, excluding human resource costs</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(133</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">33,220</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development costs for the nine months ended September 30, 2015 increased by approximately $29,737,000, or 102%, to approximately
$58,789,000, compared with $29,052,000 for the nine months ended September 30, 2014. Research and development costs include costs
related to clinical trials as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and
development activities. Research and development costs increased as a direct result of the development of our hormone therapy
candidates, related clinical trials and manufacturing, and scale-up. Research and developments costs during the nine months ended
September 30, 2015 included the following research and development projects.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ending September 30, 2015 and the period from February 2013 (project inception) through September 30, 2015, we
have incurred approximately $27,504,000 and $58,436,000, respectively, in research and development costs with respect to TX-001HR,
our combination estradiol and progesterone drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015 and the period April 2013 (project inception) through September 30, 2015, we have incurred
approximately $18,000 and $2,520,000, respectively, in research and development costs with respect to TX-002HR, our progesterone
only drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015 and the period from August 2014 (project inception) through September 30, 2015, we have
incurred approximately $18,242,000 and $22,225,000, respectively, in research and development costs with respect to TX-004HR,
our vaginal estradiol softgel drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 26 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts and steps necessary to complete these projects, see &ldquo;Item 1. Business &mdash; Research
and Development&rdquo; in our Annual Report. For a discussion of the risks and uncertainties associated with completing development
of our products, see &ldquo;Item 1A. Risk Factors &mdash; Risks Related to Our Business&rdquo; in our Annual Report. For a discussion
of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient
to complete these projects, see &ldquo;&mdash; Liquidity and Capital Resources.&rdquo; For a discussion as to whether a future
milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory
agency can be reliably determined, see &ldquo;Item 1. Business &mdash; Our Hormone Therapy Drug Candidates,&rdquo; &ldquo;Item
1. Business &mdash; Products in Development&rdquo; and &ldquo;Item 1. Business &mdash; Pharmaceutical Regulation&rdquo; in our
Annual Report. Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent
on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible
subjects for the applicable trials.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Professional
fees for the nine months ended September 30, 2015 increased by approximately $1,360,000, or 79%, to approximately $3,072,000,
compared with $1,712,000 for the nine months ended September 30, 2014, as a result of higher legal, consulting, accounting and
Board of Director expenses.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Human
resource costs, including salaries, benefits and taxes, for the nine months ended September 30, 2015 increased by approximately
$1,674,000, or 21%, to approximately $9,644,000, compared with $7,970,000 for the nine months ended September 30, 2014, primarily
as a result of an increase of approximately $978,000 in personnel costs, and an increase of approximately $696,000 in non-cash
compensation related to stock option awards.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Other
operating expense for the nine months ended September 30, 2015 increased by approximately $582,000, or 24%, to approximately $3,035,000,
compared with approximately $2,453,000 for the nine months ended September 30, 2014, primarily as a result of increases in data
services and insurance expenses.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs for the nine months ended September 30, 2015 decreased by approximately $133,000, or 3%, to approximately
$4,383,000, compared with $4,516,000 for the nine months ended September 30, 2014, as a result of decreased marketing expense
following the launch of our VitaPearl and Prena1 Pearl products during the first quarter of 2014, partially offset by increased
costs related to sales force incentive programs during the nine months ended September 30, 2015.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Operating
Loss</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $29,955,000, or 79%, to approximately $67,681,000 for the
nine months ended September 30, 2015, compared with approximately $37,726,000 for the nine months ended September 30, 2014, primarily
as a result of increased research and development costs associated with our continued development of our hormone therapy drug
candidates, partially offset by increased revenue from sales of our prenatal vitamin products.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating
losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there
is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved,
will be successful.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Total
other income (expense)</u></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>&nbsp;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Total
other income (expense) changed by approximately $276,000, or 146%, to non-operating income of approximately $87,000 for the nine
months ended September 30, 2015 compared with an expense of approximately $189,000 for the comparable period in 2014. This change
was primarily a result of the elimination of financing costs for the nine months ended September 30, 2015.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 27 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Net
Loss</u></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the net effects of the foregoing, net loss increased approximately $29,679,000, or 78%, to approximately $67,594,000
for the nine months ended September 30, 2015, compared with approximately $37,915,000 for the nine months ended September 30,
2014. Net loss per share of Common Stock, basic and diluted, was $0.39 for the nine months ended September 30, 2015, compared
with $0.26 per share of Common Stock for the nine months ended September 30, 2014.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0pt"><b><u>Liquidity
and Capital Resources</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
have funded our operations primarily through public offerings of our Common Stock and the private placement of equity and debt
securities. For the years ending December 31, 2014 and 2013, we received approximately $43 million and $79 million in net proceeds,
respectively, from the issuance of shares of our Common Stock. During the nine months ended September 30, 2015, we received approximately
$91 million in net proceeds from the issuance of shares of our Common Stock. As of September 30, 2015, we had cash and cash equivalents
totaling approximately $81 million, however, changing circumstances may cause us to consume funds significantly faster than we
currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &amp; Company, Incorporated and Guggenheim Securities,
LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering
of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement,
we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock,
which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting
underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July 15, 2015
and we issued 4,423,077 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0px; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman,Times,serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
February&nbsp;10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the
representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246
shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the
Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option
was exercised in full. The net proceeds to us from the offering were approximately $59.1 million, after deducting underwriting
discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we
issued 15,617,282 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
believe that our existing cash will allow us to fund our operating plan through at least the next 12 months. If our available
cash is insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain
a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing
shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely
affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research
programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be favorable to us.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 28 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">We
need substantial amounts of cash to complete the clinical development of our hormone therapy drug candidates. The following table
sets forth the primary sources and uses of cash for each of the periods set forth below:</font></p>
<p style="margin: 0; font: 11pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 0.7pt 0 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Summary
of (Uses) and Sources of Cash</u></font></p>
<p style="margin: 0 0 1pt 0.25pt; text-indent: 0.5in; font: 12pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt; font-size: 11pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-size: 11pt;" colspan="7"><p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Nine
Months Ended</font></p>
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">September
30,</font></p>
</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="vertical-align: bottom; text-align: center;" colspan="6"><font style="font-family: Times New Roman, Times, Serif">(000)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 56%; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(62,434</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td style="width: 8%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="width: 12%; text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(30,236</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Net cash used in
investing activities</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(134</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">(224</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif">Net cash provided
by financing activities</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">92,330</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif">43,268</font></td>
<td style="text-align: left;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style="margin: 0 0 1pt 0.25pt; font: 11pt/107% Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 1pt 0.25pt; text-align: justify; font: 11pt/107% Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;<font style="font-size: 10pt"><i>Operating
Activities</i></font></font></p>
<p style="margin: 0 0 0 0.25pt; text-align: justify; text-indent: 0.5in; font: 12pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">The
use of cash in both periods resulted primarily from our net loss adjusted for non-cash charges and changes in components of working
capital. The increase of approximately $32,198,000 in cash used in operating activities for the nine months ended September 30,
2015 compared with the comparable period in the prior year was due primarily to increased research and development, and sales,
general, and administrative costs. These were partially offset by an increase of approximately $3,744,000 in revenue over the
same periods.</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>Investing
Activities</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 12pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">A
reduction in spending on patent and trademarks and property and equipment resulted in a minor decrease in cash used in investing
activities for the nine months ended September 30, 2015 compared with the same period in 2014.</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><i>Financing
Activities</i></font></p>
<p style="margin: 0 0 0 0.25pt; text-align: justify; font: 11pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 0.7pt 0 0.5pt; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Financing
activities represent the principal source of our cash flow. Our financing activities for the nine months ended September 30, 2015
consisted of the proceeds from the February 2015 and July 2015 underwritten public offering of our Common Stock and stock option
and warrant exercises.</font></p>
<p style="margin: 0 0.7pt 0 0.5pt; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual
Obligations</b></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
February 18, 2015, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant
to an addendum to our existing 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September
30, 2018. This addendum became effective April 1, 2015 and will expire with the original lease term on September 30, 2018. The
lease addendum stipulates, among other things, average base monthly rents of $9,367 (inclusive of estimated operating expenses)
and sales tax, for total minimum payments over the life of the lease of $393,429.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 29 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>New
Accounting Pronouncements</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>
<p style="margin: 0; text-align: justify; font: 12pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, the Financial Accounting Standards Board, or FASB, issued final guidance that requires entities to measure
inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance
applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail
inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does
not change the calculation of Entities already calculate net realizable value that entities are required to calculate when
applying today&rsquo;s existing LOCOM guidance, and the new guidance doesn&rsquo;t change that calculation. Net realizable
value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion,
disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of
&ldquo;market.&rdquo; The guidance is effective for public business entities for fiscal years beginning after December 15,
2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of
this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2015 the FASB issued Accounting Standards Update, or ASU, Technical Corrections and Improvements, No. 2015-10, to correct
differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references
and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for
fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The other amendments are effective
immediately. We do not expect the adoption of ASU 2015-10 to have a material effect on our consolidated financial statements and
disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">In
August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure
of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether
there are conditions and events that raise substantial doubt about </font><font style="font: 10pt Times New Roman, Times, Serif">the
entity&rsquo;s ability to continue as a going concern within one year after the financial statements are issued (or available
to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December
15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or
interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of
ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with
Customers (Topic 606). The standard&rsquo;s core principle is that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous
guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration
to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,
the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after
December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,
2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements
and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">We
do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently
issued, but not yet effective, accounting standards been adopted in the current period.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0px 0px 9pt; text-align: left; font: 11pt Times New Roman,Times,serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Accounting Policies</b></font></p>
<p style="margin: 0px; text-align: left; text-indent: 0.5in; font: 11pt Times New Roman,Times,serif;"></p>
<p style="text-align: justify; text-indent: 0.5in;"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited
interim consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United
States. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon
the information available. These estimates and assumptions affect the reported amounts of assets and liabilities as of the date
of the financial statements and the reported amounts of revenue and expenses during the reporting period. We routinely evaluate
our estimates based on historical experience and on various other assumptions that management believes are reasonable under the
circumstances. Actual results may differ from these estimates under different assumptions or conditions. During the three months
ended September 30, 2015, we did not experience any significant changes in estimates or judgments inherent in the preparation
of our consolidated financial statements. A summary of our significant accounting policies is contained in Note 2 to our consolidated
financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3 of our unaudited
interim consolidated financial statements included in this Quarterly Report on Form 10-Q for the quarterly period ended September
30, 2015.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>I</b></font><font style="font-family: Times New Roman, Times, Serif"><a name="a_007"></a><font style="font-size: 10pt"><b>tem
3. Quantitative and Qualitative Disclosures about Market Risk</b></font></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
market risk has not changed materially from the interest rate risk disclosed in Item 7A of our Annual Report.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 30 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>I</b><a name="a_008"></a><font style="font-size: 10pt"><b>tem
4. Controls and Procedures</b></font></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Disclosure
Controls and Procedures</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within
the time period specified in the SEC's rules and forms and is accumulated and communicated to our principal executive officer
and principal financial officer, as appropriate, in order to allow timely decisions in connection with required disclosure.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Evaluation
of Disclosure Controls and Procedures</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the
period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on
Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we
file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in
the SEC&rsquo;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented
or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration
of the degree of compliance with policies or procedures.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><u>Changes
in Internal Controls</u></font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2015, there were no changes in our internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_009"></a><font style="font-size: 10pt"><b>PART
II - OTHER INFORMATION</b></font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_010"></a><font style="font-size: 10pt"><b>Item
1. Legal Proceedings</b></font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved
in any legal proceeding that we believe would have a material adverse effect on our business or financial condition.</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_011"></a><font style="font-size: 10pt"><b>Item
1A. Risk Factors</b></font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">There
have been no material changes to the risk factors previously disclosed in our Annual Report.</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 11pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 31 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 12pt; text-align: justify; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_012"></a><font style="font-size: 10pt"><b>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></font></font></p>
<p style="margin: 0; text-align: justify; text-indent: 27.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">On
August 7, 2015, we issued 80,635 shares of Common Stock, pursuant to the warrant cashless exercise provision, upon the exercise
of warrants previously issued to an outside service provider. On July 29, 2015, we issued 151,562 shares of Common Stock, pursuant
to the warrant cashless exercise provision, upon the exercise of warrants previously issued to an outside party. The shares of
Common Stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933,
as amended.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 27.5pt; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><a name="a_013"></a><font style="font-size: 10pt"><b>Item
6. Exhibits</b></font></font></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<table align="center" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; width: 12%; vertical-align: top; text-align: left;"><font style="font-family: Times New Roman, Times, Serif"><b>Exhibit</b></font></td>
<td style="padding-bottom: 1pt; width: 1%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 18%;"><font style="font-family: Times New Roman, Times, Serif"><b>Date</b></font></td>
<td style="padding-bottom: 1pt; width: 2%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="border-bottom: Black 1pt solid; width: 67%;"><font style="font-family: Times New Roman, Times, Serif"><b>Description</b></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font-family: Times New Roman, Times, Serif">1.1</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">July 9, 2015</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Underwriting Agreement, dated July 9, 2015, between the Company and
Stifel, Nicolaus &amp; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters
named in Schedule A thereto (previously filed as Exhibit 1.1 to the Current Report on Form 8-K filed by the Company with the SEC
on July 15, 2015 and incorporated herein by reference).</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">31.1*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">November 5, 2015</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif"><a href="ex31-1.htm"><font style="font-size: 10pt">Certification
of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</font></a></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">31.2*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">November 5, 2015</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif"><a href="ex31-2.htm"><font style="font-size: 10pt">Certification
of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</font></a></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">32.1*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">November 5, 2015</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif"><a href="ex32-1.htm"><font style="font-size: 10pt">Section
1350 Certification of Chief Executive Officer</font></a></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">32.2*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">November 5, 2015</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font-family: Times New Roman, Times, Serif"><a href="ex32-2.htm"><font style="font-size: 10pt">Section
1350 Certification of Chief Financial Officer</font></a></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.INS*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.SCH*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema Document</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.CAL*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation Linkbase
Document</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.DEF*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition Linkbase
Instance Document</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.LAB*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase
Instance Document</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="vertical-align: top; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif">101.PRE*</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation Linkbase
Instance Document</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">____________________________</font></p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</font></p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 32 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: normal 10pt Times New Roman, Times, Serif"><tr><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table style="width: 100%;" cellpadding="0" cellspacing="0"><tr><td style="width: 100%; text-align: center;">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="margin: 0; text-align: center; font: 11pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 11pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><a name="a_031"></a><font style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">DATE:
November 5, 2015</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></font></td>
<td colspan="2"><font style="font-family: Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC.</b></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="width: 50%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 5%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font-family: Times New Roman, Times, Serif"><i>/s/ Robert G. Finizio</i></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Robert G. Finizio</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">(Principal Executive Officer)</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font-family: Times New Roman, Times, Serif">/<i>s/ Daniel A. Cartwright</i></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Daniel A. Cartwright</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td><font style="font-family: Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">33</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;"><div style="border-top: Black 1pt solid; width: 100%; font-size: 1pt;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="txmd-10q_093015.htm">TherapeuticsMD, Inc. 10-Q</A><B>&nbsp;</B></FONT><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Robert G. Finizio, certify that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this quarterly report
    on Form 10-Q of TherapeuticsMD, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report
    does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
    by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial
    statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer
    and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
    13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
    for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such
    disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such
    internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the
    effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
    evaluation; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer
    and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
    auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
<TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">November
5, 2015</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify; padding-bottom: 1pt; width: 17%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-decoration: none; text-align: justify; width: 46%"><FONT STYLE="font-size: 10pt"><I>/s/ Robert G. Finizio</I></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Robert G. Finizio</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">Chief Executive Officer<BR> (Principal Executive Officer)</TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>






<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-10q_093015.htm">TherapeuticsMD, Inc. 10-Q</A>&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF CHIEF FINANCIAL OFFICER</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Daniel A. Cartwright, certify that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this quarterly report
    on Form 10-Q of TherapeuticsMD, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report
    does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
    by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial
    statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer
    and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
    13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
    for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such
    disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such
    internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the
    effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
    evaluation; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant's other certifying officer
    and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
    auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
<TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">November
5, 2015</FONT></TD>
<TD STYLE="vertical-align: bottom; text-align: justify; width: 17%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-decoration: none; text-align: justify; width: 46%"><FONT STYLE="font-size: 10pt"><I>/s/
Daniel A. Cartwright</I></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">Chief Financial Officer<BR> (Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>






<P STYLE="font: 11pt Arial Unicode MS; margin: 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Arial Unicode MS; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Arial Unicode MS; margin: 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="ex32-1.htm">TherapeuticsMD, Inc. 10-Q</A></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE
OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45.8pt">In connection with the
quarterly report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended September 30, 2015
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert G. Finizio, Chief
Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 6%">(1)</TD>
    <TD STYLE="width: 85%">The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a)
or 78o(d)); and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>The
information contained in the Report fairly presents, in all material respects, the financial condition and result of operations
of the Company.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt">November 5<FONT STYLE="background-color: white">,
</FONT>2015</TD>
    <TD STYLE="vertical-align: bottom; width: 19%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 44%; text-decoration: none; text-align: justify; border-bottom: Black 1pt solid"><I>/s/
    Robert G. Finizio</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt">Robert G. Finizio</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this certification has
been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="ex32-2.htm">TherapeuticsMD, Inc. 10-Q</A><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL
OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45.8pt">In connection with the
quarterly report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended September 30, 2015
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Daniel A. Cartwright, Chief
Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 9%"></TD>
    <TD STYLE="width: 6%">(1)</TD>
    <TD STYLE="width: 85%">The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a)
or 78o(d)); and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>The
information contained in the Report fairly presents, in all material respects, the financial condition and result of operations
of the Company.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt">November 5, 2015</TD>
    <TD STYLE="vertical-align: bottom; width: 18%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 45%; text-decoration: none; text-align: justify; border-bottom: Black 1pt solid"><I>/s/
Daniel A. Cartwright</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt">Daniel A. Cartwright</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Chief Financial Officer</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this certification has
been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>txmd-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:txmd="http://therapeuticsmd.com/20150930">
    <link:schemaRef xlink:href="txmd-20150930.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SancilioAndCompanyWarrants3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_NonAmortizingIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:NonAmortizingIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-11-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-28to2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-28</xbrli:startDate>
        <xbrli:endDate>2014-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-28to2014-08-04_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-28</xbrli:startDate>
        <xbrli:endDate>2014-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_Option1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">txmd:Option1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_Option1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">txmd:Option1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_WarrantExercised1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantExercised1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_custom_WarrantExercised2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantExercised2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30_custom_WarrantExercised2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantExercised2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-10-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2015-01-01to2015-09-30">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-01-01to2015-09-30">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2015-01-01to2015-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2015-01-01to2015-09-30">2015-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2015-01-01to2015-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-01-01to2015-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2015-01-01to2015-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2015-01-01to2015-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2015-01-01to2015-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2015-01-01to2015-09-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2015-01-01to2015-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2015-01-01to2015-09-30">2015</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">177787927</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-09-30_custom_Option1Member" unitRef="Shares" decimals="INF">113837</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">177787927</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">13580246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">3846154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">4423077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">15617282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">8565310</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-07-28to2014-08-04_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">9850106</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="AsOf2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USDPShares" decimals="INF">4.05</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-07-09_custom_StifelUnderwritersMember" unitRef="USDPShares" decimals="INF">7.80</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2014-07-29_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">4.67</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-09-30" unitRef="Shares" decimals="INF">472867</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">793800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">2037036</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-07-01to2015-09-30" unitRef="Shares" decimals="INF">95000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">576923</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">1284796</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-09-30_us-gaap_OptionMember" unitRef="Shares" decimals="INF">674800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-09-30_custom_Option1Member" unitRef="Shares" decimals="INF">119607</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USD" decimals="0">59100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="USD" decimals="0">3200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="USD" decimals="0">42800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">589867</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">98478</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-09-30_us-gaap_OptionMember" unitRef="USD" decimals="0">315546</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">12772431</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2015-01-01to2015-09-30_custom_SancilioAndCompanyWarrantsMember">P1Y9M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2015-01-01to2015-09-30_custom_OutsideConsultantMember">P1Y11M1D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">1.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-09-30_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2015-09-30_custom_SancilioAndCompanyWarrants3Member" unitRef="Shares" decimals="INF">283334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2019-01-31</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2015-01-01to2015-09-30_custom_OutsideConsultantMember">2020-04-06</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2013-10-31</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">462196</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1711956</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y3M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MaximumMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-09-30_EmployeeStockOptionMember_MaximumMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.6915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.5877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.7093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-09-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.6294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-09-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-09-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2015-01-01to2015-09-30_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2014-01-01to2014-09-30_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">Black-Scholes Model</txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2015-01-01to2015-09-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">115551</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2014-01-01to2014-09-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">115551</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2015-07-01to2015-09-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">38517</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2014-07-01to2014-09-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">38517</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2015-01-01to2015-09-30_custom_OutsideConsultantMember" unitRef="USD" decimals="0">86008</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2015-07-01to2015-09-30_custom_OutsideConsultantMember" unitRef="USD" decimals="0">42266</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1172051</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1427263</us-gaap:PrepaidExpenseNoncurrent>
    <txmd:UnamortizedCostsOfWarrants contextRef="From2015-01-01to2015-09-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">567000</txmd:UnamortizedCostsOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2015-01-01to2015-09-30_custom_LongTermIncentiveCompensationPlan2009Member">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2015-01-01to2015-09-30_custom_NonQualified2012StockIncentivePlanMember">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2014-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2015-01-01to2015-09-30_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">15445768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2015-01-01to2015-09-30_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">1968474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2015-01-01to2015-09-30_custom_WarrantExercised2Member" unitRef="Shares" decimals="INF">232197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2015-07-01to2015-09-30_custom_WarrantExercised2Member" unitRef="Shares" decimals="INF">232197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">4328964</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">3341604</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">1626862</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1047493</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">17414242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">16792443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-09-30" unitRef="Shares" decimals="INF">1231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-09-30_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">1231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-09-30_custom_OutsideConsultantMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2015-01-01to2015-09-30" unitRef="Shares" decimals="INF">-136334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">13848923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-09-30" unitRef="USDPShares" decimals="INF">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">64265785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43996311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">787232</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">874294</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">82827</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">155341</us-gaap:InventoryRawMaterials>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2015-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">152478</us-gaap:DeferredCostsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">870059</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1182113</us-gaap:InventoryNet>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">373339</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">411864</txmd:PrepaidConsultingCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">870949</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">394878</us-gaap:PrepaidInsurance>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">219086</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">181186</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">2120805</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1537407</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">201604</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-09-30_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">53895</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-09-30_FurnitureAndFixturesMember" unitRef="USD" decimals="0">69454</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">186045</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">144856</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">122752</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">56748</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">63293</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">193347</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">463720</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">439184</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">605502</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">27957</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">29455</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">419783</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">565303</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2015-01-01to2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2015-01-01to2015-09-30_custom_NonAmortizingIntangibleAssetsMember">P17Y2M30D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P14Y9M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P18Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6386777</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">3840639</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">86998</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">91368</us-gaap:AccruedRentCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">208361</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">90446</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">41620</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">72710</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">96440</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">160503</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" id="Foot-00-0" decimals="0">388268</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" id="Foot-00-1" decimals="0">185965</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">615946</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">276470</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">490170</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">442430</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">930913</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">814205</us-gaap:AccruedSalariesCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">3528061</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1706542</txmd:AccruedClinicalTrialCostsCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">90459521</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">77557245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">48389107</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-202344183</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-134749836</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">279723640</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">182982846</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">177788</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">156097</us-gaap:CommonStockValue>
    <us-gaap:Liabilities contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">12902276</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10690381</us-gaap:Liabilities>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">11688402</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10690381</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2015-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">522613</us-gaap:DeferredRevenue>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5301625</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">6327129</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">90459521</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">2621335</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2780851</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1324284</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1228588</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">87781438</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">56235344</us-gaap:AssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">3666586</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2154217</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">81123988</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">51361607</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54191260</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">66999114</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">96916</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59753</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">14513158</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">10768572</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">6930000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">3930000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">3005000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1846000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">1590000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">1555000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">5190175</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">4186261</us-gaap:SalesRevenueNet>
    <us-gaap:PreferredStockValue contextRef="AsOf2015-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:CapitalLeaseObligationsTerm contextRef="From2015-01-01to2015-09-30">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">42000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">6000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">250000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2015-09-30_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">250000</us-gaap:DueFromRelatedParties>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">46000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2015-09-30_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">46000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-09-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.54</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.90</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-09-30" unitRef="Shares" decimals="INF">30136673</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">17414242</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">16851943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12722431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13927916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">30779859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">948499</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1175082</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">585241</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">145783</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">585241</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2015-09-30_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">145783</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1460220</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1342228</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1213874</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">22296</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">17196</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">8692</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">5625</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">22104</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">22713</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">7856</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">7122</us-gaap:Depreciation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">91374649</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">42771353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">381813</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">299498</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:NumberOfPatents contextRef="AsOf2015-09-30" unitRef="Pure" decimals="INF">13</txmd:NumberOfPatents>
    <txmd:NumberOfPatents contextRef="AsOf2015-10-31_us-gaap_SubsequentEventMember" unitRef="Pure" decimals="INF">1750</txmd:NumberOfPatents>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">365583</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2015-01-01to2015-09-30_custom_WarrantExercised1Member" unitRef="Shares" decimals="INF">945485</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2015-01-01to2015-09-30_custom_WarrantExercised2Member" unitRef="Shares" decimals="INF">310000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2015-07-01to2015-09-30_custom_WarrantExercised2Member" unitRef="Shares" decimals="INF">310000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">181000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2015-01-01to2015-09-30_custom_WarrantExercised1Member" unitRef="USD" decimals="0">366000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2015-01-01to2015-09-30">P2Y3M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-09-30" unitRef="USDPShares" decimals="INF">6.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-09-30" unitRef="USDPShares" decimals="INF">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">59095453</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2015-01-01to2015-09-30">P6Y11M1D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="From2015-01-01to2015-09-30">P6Y1M2D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2015-01-01to2015-09-30">P5Y5M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">328000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">271000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">119000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">90000</us-gaap:LeaseAndRentalExpense>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2015-11-02" unitRef="Shares" decimals="INF">177848041</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">11242463</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">7976304</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">3996210</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">3117656</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsSold contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">3270695</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">2792268</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">1193965</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1068605</us-gaap:CostOfGoodsSold>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">78923700</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">45702073</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">23499245</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">20965531</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">44400</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">39909</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">16548</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">12747</us-gaap:DepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">58789302</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">29052149</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">16421753</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">14909430</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">20089998</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">16610015</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">7060944</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">6043354</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-67681237</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-37725769</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-19503035</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-17847875</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">86890</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-188860</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">30390</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">15624</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">15162</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">27756</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">2760</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">9364</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncome contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">71728</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">43411</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">27630</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">6260</us-gaap:OtherNonoperatingIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-67594347</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-37914629</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-19472645</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-17832251</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-67594347</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-37914629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-19472645</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-17832251</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-09-30" unitRef="USDPShares" decimals="INF">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-09-30" unitRef="Shares" decimals="INF">171589595</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">147594810</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-07-01to2015-09-30" unitRef="Shares" decimals="INF">177206168</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">152200455</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">4740906</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">3934836</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">37163</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">2594</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-522613</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-754431</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-1025504</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">3534462</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">15162</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">17069</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">621923</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-197569</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-312054</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-31673</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">1549532</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">460565</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-62434546</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-30235734</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">2546138</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">909890</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">1213874</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">15559</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">30962</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">117992</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">193349</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">-133551</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-224311</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">366000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">181000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">589829</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">315546</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">92330478</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">43267899</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-01-01to2015-09-30" unitRef="USD" decimals="0">29762381</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">12807854</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">193347</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">463720</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">755152</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2015-09-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">115543</us-gaap:OtherAssetsCurrent>
    <txmd:PrepaidVendorDeposits contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">25637</txmd:PrepaidVendorDeposits>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">978704</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">963543</txmd:PrepaidManufacturingCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">8692</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">34768</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">34768</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">34768</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">34768</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5593000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1511551</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">388976</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">507087</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">493790</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">121698</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <txmd:NumberOfSites contextRef="AsOf2015-10-31_us-gaap_SubsequentEventMember" unitRef="Pure" decimals="INF">100</txmd:NumberOfSites>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;1 &amp;#150; THE COMPANY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD,&#13;Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware&#13;limited liability company, or VitaMed, BocaGreenMD, Inc., a Nevada corporation, or BocaGreen, and VitaCare Prescription Services,&#13;Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare&#13;collectively are sometimes referred to as &amp;#34;our company,&amp;#34; &amp;#34;we,&amp;#34; &amp;#34;our,&amp;#34; or &amp;#34;us.&amp;#34;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Nature&#13;of Business&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are a women&amp;#146;s health care product company focused on creating and commercializing products targeted exclusively for women.&#13;As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary&#13;for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used&#13;in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related&#13;hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug&#13;candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical&#13;efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates&#13;are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone&#13;or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter,&#13;or OTC, vitamins.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;2 &amp;#150; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Interim&#13;Financial Statements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #252525"&gt;The&#13;accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,&#13;should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report&#13;on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC, from which&#13;we derived the accompanying consolidated balance sheet as of December 31, 2014. The accompanying unaudited interim consolidated&#13;financial statements have been prepared in accordance &lt;/font&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;with accounting&#13;principles generally accepted in the United States of America, or GAAP&lt;font style="color: #252525"&gt;, for interim financial information&#13;and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying&#13;unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete&#13;financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting&#13;of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for&#13;the interim periods presented. Interim results are not necessarily indicative of results for a full year, or any other interim&#13;period.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2015, the Financial Accounting Standards Board, or FASB, issued final guidance that requires entities to measure&#13;inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance&#13;applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail&#13;inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does&#13;not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM&#13;guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable&#13;costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate&#13;other measures of &amp;#147;market.&amp;#148; The guidance is effective for public business entities for fiscal years beginning after&#13;December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating&#13;the impact of this guidance on our consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-10, Technical Corrections and Improvements, to correct&#13;differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references&#13;and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for&#13;fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The other amendments are effective&#13;immediately. We do not expect the adoption of ASU 2015-10 to have a material effect on our consolidated financial statements and&#13;disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #252525"&gt;In&#13;August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure&#13;of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether&#13;there are conditions and events that raise substantial doubt about &lt;/font&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;the&#13;entity&amp;#146;s ability to continue as a going concern within one year after the financial statements are issued (or available&#13;to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December&#13;15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or&#13;interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of&#13;ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with&#13;Customers (Topic 606). The standard&amp;#146;s core principle is that a company will recognize revenue when it transfers promised&#13;goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange&#13;for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous&#13;guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration&#13;to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,&#13;the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after&#13;December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,&#13;2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements&#13;and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently&#13;issued, but not yet effective, accounting standards been adopted in the current period.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;3 &amp;#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Impairment&#13;of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes&#13;in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets&#13;during the three and nine months ended September 30, 2015 and 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of&#13;accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of&#13;such instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by ASC 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt; The fair value hierarchy gives the highest priority to quoted prices in&#13;active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and&#13;liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,&#13;either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable&#13;inputs (Level 3) in connection with any required impairment test.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is&#13;fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support&#13;team utilizing similar marketing techniques.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; include outbound&#13;shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold.&#13;A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three&#13;banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC&#13;sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue&#13;from prescription product sales, net of sales discounts, chargebacks, and customer rebates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following&#13;product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January&#13;1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve&#13;as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return&#13;no longer existed.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we&#13;send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages,&#13;which is reviewed, and adjusted if necessary, on a quarterly basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal&#13;R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was&#13;included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance&#13;sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of&#13;which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying&#13;consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other&#13;activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants&#13;that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff&#13;with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing&#13;protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing&#13;experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside&#13;legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters.&#13;These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical&#13;trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We&#13;make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable&#13;advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or&#13;when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study&#13;expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided&#13;by&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study&#13;costs as long term Accrued Expenses related to the costs that will be paid at the completion of one of our clinical trials. Estimated&#13;accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in&#13;which the facts that give rise to the revision become known.&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our Company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;4 &amp;#150; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;82,827&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;870,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,182,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;5 &amp;#150; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;870,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;381,813&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;373,339&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 13)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;219,086&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,637&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,120,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;6 &amp;#150; FIXED ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets, net consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;201,604&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(144,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;56,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&#13;expense for the three months ended September 30, 2015 and 2014 was $7,856 and $7,122, respectively, and $22,104 and $22,713 for&#13;the nine months ended September 30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <txmd:PrepaidExpensesDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;7 &amp;#150; PREPAID EXPENSE&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;expense (long-term) consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;978,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;963,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;193,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,172,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,427,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</txmd:PrepaidExpensesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;9 &amp;#150; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,528,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;930,913&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;615,946&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;490,170&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;388,268&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;96,440&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;160,503&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;86,998&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,620&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72,710&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,386,777&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;10 &amp;#150; NET LOSS PER SHARE&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of&#13;common stock, par value $0.001 per share, or Common Stock outstanding during the period, less any shares subject to repurchase&#13;or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three and nine&#13;months ended September 30, 2015 and 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since&#13;we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as&#13;warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/14.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss&#13;per share allocable to common stockholders if they were not antidilutive for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17,414,242&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,851,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,722,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,136,673&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,779,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;12 &amp;#150; INCOME TAXES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred&#13;income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets&#13;and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected&#13;to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of (i) the losses recorded&#13;during the nine months ended September 30, 2015, (ii) additional losses expected for the remainder of 2015, and/or (iii) net operating&#13;loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax&#13;assets if it is &amp;#34;more likely than not&amp;#34; that some component or all of the benefits of deferred tax assets will not be&#13;realized. As of September 30, 2015, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,&#13;no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the&#13;reporting period.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;13 &amp;#150; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was&#13;elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course&#13;of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent&#13;directors of our company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the nine months ended September 30, 2015 and 2014, we did not engage in any transactions with Pernix. At September 30, 2015 and&#13;December 31, 2014, there were amounts due Pernix of approximately $46,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additionally,&#13;there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and&#13;supply agreement in the amounts of approximately $250,000 at both September 30, 2015 and December 31, 2014.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;14 - BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;purchase our products from several suppliers with approximately 54% and 77% of our purchases supplied from one vendor for the&#13;nine months ended September 30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain&#13;drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated&#13;from four major customers accounted for approximately 90% and 95% of our recognized revenue for the nine months ended September&#13;30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customers&#13;that generated more than 10% of our sales are designated as customers &amp;#147;A&amp;#148;, &amp;#147;B&amp;#148;, &amp;#147;C&amp;#148; and &amp;#147;D&amp;#148;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the nine months ended September 30, 2015, two customers generated more than 10% of revenues and during the nine months ended September&#13;30, 2014, four customers generated more than 10% of revenues. During the nine months ended September 30, 2015, customer A generated&#13;approximately $6,930,000 in revenues and customer B generated approximately $3,005,000 in revenues. During the nine months ended&#13;September 30, 2014, customers A, B, C and D generated approximately $3,930,000, $1,846,000, $1,590,000 and $1,555,000 in sales,&#13;respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;16 &amp;#150; SUBSEQUENT EVENTS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;October 2015, we completed enrollment in the REPLENISH trial, a phase 3 study of TX-001HR in postmenopausal women with an intact&#13;uterus. The trial was designed to enroll approximately 1,750 patients at approximately 100 sites.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Impairment&#13;of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes&#13;in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets&#13;during the three and nine months ended September 30, 2015 and 2014.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of&#13;accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of&#13;such instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by ASC 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt; The fair value hierarchy gives the highest priority to quoted prices in&#13;active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and&#13;liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,&#13;either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable&#13;inputs (Level 3) in connection with any required impairment test.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is&#13;fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support&#13;team utilizing similar marketing techniques.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; include outbound&#13;shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold.&#13;A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three&#13;banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC&#13;sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue&#13;from prescription product sales, net of sales discounts, chargebacks, and customer rebates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following&#13;product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January&#13;1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve&#13;as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return&#13;no longer existed.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we&#13;send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages,&#13;which is reviewed, and adjusted if necessary, on a quarterly basis.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal&#13;R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was&#13;included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance&#13;sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of&#13;which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying&#13;consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other&#13;activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants&#13;that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff&#13;with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing&#13;protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing&#13;experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside&#13;legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters.&#13;These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical&#13;trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We&#13;make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable&#13;advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or&#13;when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study&#13;expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided&#13;by&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study&#13;costs as long term Accrued Expenses related to the costs that will be paid at the completion of one of our clinical trials. Estimated&#13;accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in&#13;which the facts that give rise to the revision become known.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our Company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;82,827&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;870,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,182,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;870,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;381,813&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;373,339&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 13)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;219,086&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,637&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,120,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets, net consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;201,604&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(144,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;56,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;expense (long-term) consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;978,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;963,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;193,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,172,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,427,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated amortization expense for the next five years is as&#13;follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Estimated Amortization&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015 (3 months)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8,692&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/p&gt;&#13;                                                                               &lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,528,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;930,913&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;615,946&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;490,170&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;388,268&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;96,440&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;160,503&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;86,998&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,620&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72,710&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,386,777&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss&#13;per share allocable to common stockholders if they were not antidilutive for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17,414,242&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,851,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,722,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,136,673&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,779,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and&#13;2014 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.54&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68-1.77&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.77-62.94&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.15-70.93&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">135936</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">113640</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">3994</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-09-30_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">2496</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">19401</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">40199</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 8 &amp;#150; INTANGIBLE ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Net&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;OPERA&lt;sup&gt;&amp;#174; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(3,994&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,957&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Development costs of&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Approved hormone&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;605,502&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(40,199&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;565,303&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Hormone therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;585,241&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;585,241&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Multiple trademarks for&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145,783&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145,783&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,460,220&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(135,936&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,324,284&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;December 31, 2014&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Net&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;OPERA&lt;sup&gt;&amp;#174; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Development costs of&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Approved hormone&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Hormone therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Multiple trademarks for&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,342,228&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(113,640&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,228,588&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;Trademarks are perpetual and are not amortized. As of September 30, 2015, the remaining life related to OPERA&amp;#174; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years. During the three and nine months ended September 30, 2015 and 2014, there was no impairment recognized.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;In addition to numerous pending patent applications, as of September 30, 2015, we had &lt;/font&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13 issued patents,&lt;font style="background-color: white"&gt; including:&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;one method patent that relates to our OPERA&amp;#174; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;twelve utility patents that relate to our combination progesterone and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Israel, Mexico, Brazil, Japan, Russia, South Africa and South Korea.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0 0 0 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization expense was $8,692 and $5,625 for the three months ended September 30, 2015 and 2014, respectively and $22,296 and $17,196 for the nine months ended September 30, 2015 and 2014, respectively. Estimated amortization expense for the next five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated Amortization&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015 (3 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8,692&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34,768&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Net&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;OPERA&lt;sup&gt;&amp;#174; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(3,994&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,957&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Development costs of&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Approved hormone&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;605,502&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(40,199&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;565,303&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Hormone therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;585,241&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;585,241&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Multiple trademarks for&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145,783&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145,783&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,460,220&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(135,936&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,324,284&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;December 31, 2014&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Net&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;OPERA&lt;sup&gt;&amp;#174; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Development costs of&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Approved hormone&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Hormone therapy drug&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Multiple trademarks for&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,342,228&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(113,640&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,228,588&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 11 &amp;#150; STOCKHOLDERS&amp;#146; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2015, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2015, we had 350,000,000 shares of Common Stock authorized, of which 177,787,927 shares of Common Stock were issued and outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On July&amp;#160;9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&amp;#160;&amp;#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&amp;#160;15, 2015 and we issued 4,423,077 shares of our Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &amp;#38; Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Exercises During 2015&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the three months ended September 30, 2015, certain individuals exercised stock options to purchase 95,000 shares of Common Stock for $98,478 in cash. During the nine months ended September 30, 2015, certain individuals exercised stock options to purchase 472,867 shares of Common Stock for $589,829 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Exercises During 2014&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30, 2014, certain individuals exercised stock options to purchase 793,800 shares of Common Stock. Stock options to purchase shares of Common Stock were exercised as follows: (i) 674,193 options for $315,546 in cash and (ii) &lt;font style="letter-spacing: -0.15pt"&gt;119,607 options, pursuant to the stock options&amp;#146; cashless provision, wherein 113,837 shares of Common Stock were issued. Also during the nine months ended September 30, 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants to Purchase Common Stock &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of September 30, 2015, we had warrants outstanding to purchase an aggregate of 12,772,431 shares of Common Stock with a weighted-average contractual remaining life of 1.92 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In January 2013, we granted warrants to purchase 1,250,000 shares of Common Stock in connection with the issuance of a Revolving Credit Note to Plato and Associates, LLC, or the Plato Warrant. The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the nine months ended September 30, 2015 and 2014, $0 and $260,027, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In May 2013, we entered into a consulting agreement with Sancilio &amp;#38; Company, Inc., or SCI, to develop drug technology to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. &amp;#160;The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. &amp;#160;We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares vested on June 30, 2013.&amp;#160;&amp;#160;The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%.&amp;#160;&amp;#160;As of September 30, 2015, we recorded $115,543 in other current assets in the accompanying consolidated financial statements with respect to such shares.&amp;#160;&amp;#160;During the three and nine month periods ended September 30, 2015 and 2014, we recorded $38,517 and $115,551, respectively, as non-cash compensation in the accompanying consolidated financial statements with respect to such shares; and&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. &amp;#160;It is anticipated that this event will not occur before December 2016.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of September 30, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $567,000 and will be recognized over a period of 1.75 years.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the nine months ended September 30, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant&#13;at an exercise price of $6.35 and the expiration date of April 6, 2020. The total non-cash compensation expense related to this&#13;warrant was $42,266 and $86,008, respectively, for the three and nine months ended September 30, 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Warrant exercises&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the three months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 310,000 shares of Common Stock&lt;font style="letter-spacing: -0.15pt"&gt; pursuant to the warrants&amp;#146; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.&lt;/font&gt; During the nine months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000&lt;font style="letter-spacing: -0.15pt"&gt; shares of Common Stock were exercised pursuant to the warrants&amp;#146; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued. &lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Options to Purchase Common Stock &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. During the nine months ended September 30, 2015, we granted 1,231,000 non-qualified stock options under the 2009 Plan. As of September 30, 2015, there were non-qualified stock options to purchase 15,445,768 shares of Common Stock outstanding under the 2009 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of September 30, 2015, there were non-qualified stock options to purchase 1,968,474 shares of Common Stock outstanding under the 2012 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including estimated volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and 2014 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine Months Ended September 30,&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.54&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68-1.77&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.77-62.94&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69.15-70.93&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&#13;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares Underlying Stock Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life in Years&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.92&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,996,311&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,231,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.38&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(472,867&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Expired/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(136,334&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,414,242&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.21&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.09&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,265,785&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;p style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at September 30, 2015&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13,848,923&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.49&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;59,095,453&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2015, our outstanding stock options had exercise prices ranging from $0.10 to $7.72 per share.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;Share-based compensation expense for options recognized in our results of operations (based on vested awards) for the three and nine months ended September 30, 2015 were $1,626,862 and $4,328,964, respectively, and $1,047,493 and $3,341,604, respectively, for the same periods in 2014. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At September 30, 2015, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $5,593,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.3 years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares Underlying Stock Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life in Years&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.92&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,996,311&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,231,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.38&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(472,867&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;Expired/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(136,334&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,414,242&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.21&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.09&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,265,785&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;p style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at September 30, 2015&lt;/p&gt;&#13;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13,848,923&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.49&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;59,095,453&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 15 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. On February 18, 2015, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The straight line rental expense related to our current lease totaled approximately $119,000 and $90,000 for the three months ended September 30, 2015 and 2014, respectively, and approximately $328,000 and $271,000 for the nine months ended September 30, 2015 and 2014, respectively. The 2014 amounts were partially offset by the rent income of approximately $6,000 and $42,000, respectively, for sublet space. We did not sublet any space during the nine months ended September 30, 2015.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of September 30, 2015, future minimum rental payments are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 43%; vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015 (3 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;121,698&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;493,790&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;388,976&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,511,551&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2015-01-01to2015-09-30">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of September 30, 2015, future minimum rental payments are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 43%; vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015 (3 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;121,698&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;493,790&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;388,976&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,511,551&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>txmd-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaKLybP9w5dzyelBtm9yHdnKHyAkmDaNTyzS1DXGQVMN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:txmd="http://therapeuticsmd.com/20150930" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20150930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000006 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpense" id="PrepaidExpense">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000013 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShare" id="NetLossPerShare">
	  <link:definition>00000015 - Disclosure - NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000023 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000025 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" id="PrepaidExpenseTables">
	  <link:definition>00000026 - Disclosure - PREPAID EXPENSE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000027 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
	  <link:definition>00000029 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000033 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
	  <link:definition>00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" id="FixedAssetsNetDetails">
	  <link:definition>00000036 - Disclosure - FIXED ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" id="PrepaidExpenseDetails">
	  <link:definition>00000037 - Disclosure - PREPAID EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000039 - Disclosure - INTANGIBLE ASSETS (Details )</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000040 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
	  <link:definition>00000042 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000049 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" id="SubsequentEventsDetailsNarative">
	  <link:definition>00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" name="ClassOfWarrantOrRightFairValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" name="ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpenseRecognized" name="ClassOfWarrantOrRightExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnamortizedCostsOfWarrants" name="UnamortizedCostsOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchDevelopmentCostsNoncurrent" name="PrepaidResearchDevelopmentCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" name="AdvancePaymentsForFutureResearchAndDevelopmentActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfPatents" name="NumberOfPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidVendorDeposits" name="PrepaidVendorDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsNoncurrent" name="PrepaidManufacturingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSites" name="NumberOfSites" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants1Member" name="SancilioAndCompanyWarrants1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants2Member" name="SancilioAndCompanyWarrants2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants3Member" name="SancilioAndCompanyWarrants3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredRevenueConcentrationRiskMember" name="DeferredRevenueConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" name="StockPurchaseAgreementWithPernixTherapeuticsLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk1Member" name="CustomerConcentrationRisk1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk2Member" name="CustomerConcentrationRisk2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk3Member" name="CustomerConcentrationRisk3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk4Member" name="CustomerConcentrationRisk4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleAdvanceRevolvingCreditNoteMember" name="MultipleAdvanceRevolvingCreditNoteMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonAmortizingIntangibleAssetsMember" name="NonAmortizingIntangibleAssetsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Option1Member" name="Option1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UPOMember" name="UPOMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelUnderwritersMember" name="StifelUnderwritersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultantMember" name="OutsideConsultantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantExercised1Member" name="WarrantExercised1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantExercised2Member" name="WarrantExercised2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetLossPerShareAbstract" name="NetLossPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetLossPerShareTablesAbstract" name="NetLossPerShareTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" name="SummaryOfActivityUnder2009And2012PlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOptionsAbstract" name="NumberOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>txmd-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20150930.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20150930.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20150930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20150930.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20150930.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20150930.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20150930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20150930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20150930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20150930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20150930.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20150930.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20150930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20150930.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20150930.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20150930.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20150930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20150930.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20150930.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20150930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20150930.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20150930.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20150930.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000048 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000049 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>txmd-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20150930.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20150930.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20150930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20150930.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20150930.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20150930.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20150930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20150930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20150930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20150930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20150930.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20150930.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20150930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20150930.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20150930.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20150930.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20150930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20150930.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20150930.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20150930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20150930.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20150930.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20150930.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonAmortizingIntangibleAssetsMember" xlink:label="loc_txmdNonAmortizingIntangibleAssetsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdNonAmortizingIntangibleAssetsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelUnderwritersMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_Option1Member" xlink:label="loc_txmdOption1Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_txmdOption1Member_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdUnamortizedCostsOfWarrants_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapOtherAssetsCurrent_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_240" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_240" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised1Member" xlink:label="loc_txmdWarrantExercised1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantExercised1Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised2Member" xlink:label="loc_txmdWarrantExercised2Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantExercised2Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_150" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000048 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000049 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_130" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfPatents" xlink:label="loc_txmdNumberOfPatents_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfPatents_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfSites" xlink:label="loc_txmdNumberOfSites_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfSites_20" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>txmd-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">Sancilio and Company Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="txmd_SancilioAndCompanyWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants1Member_lbl" xml:lang="en-US">Sancilio &amp;amp;amp; Company Warrants 1st Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="txmd_SancilioAndCompanyWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants2Member_lbl" xml:lang="en-US">Sancilio and Company Warrants 2nd Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="txmd_SancilioAndCompanyWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants3Member_lbl" xml:lang="en-US">Sancilio and Company Warrants 3rd Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="txmd_DeferredRevenueConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_lbl" xml:lang="en-US">Deferred revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xml:lang="en-US">Pernix Therapeutics LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">OPERA software patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development costs for corporate website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone therapy drug candidate patents - Pending [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple trademarks for vitamins/supplements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="txmd_CustomerConcentrationRisk1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk1Member_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="txmd_CustomerConcentrationRisk2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk2Member_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="txmd_CustomerConcentrationRisk3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk3Member_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="txmd_CustomerConcentrationRisk4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk4Member_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="txmd_CowenAndCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CowenAndCompanyLLCMember_lbl" xml:lang="en-US">Cowen and Company, LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonAmortizingIntangibleAssetsMember" xlink:label="txmd_NonAmortizingIntangibleAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAmortizingIntangibleAssetsMember" xlink:to="txmd_NonAmortizingIntangibleAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonAmortizingIntangibleAssetsMember_lbl" xml:lang="en-US">Non-Amortizing Intangible Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options exercised 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeByNatureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeByNatureAxis_lbl" xml:lang="en-US">Derivative, by Nature [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_Option1Member" xlink:label="txmd_Option1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Option1Member" xlink:to="txmd_Option1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Option1Member_lbl" xml:lang="en-US">Options exercised 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_UPOMember" xlink:label="txmd_UPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UPOMember" xlink:to="txmd_UPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UPOMember_lbl" xml:lang="en-US">Underwriiten Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StifelUnderwritersMember" xlink:label="txmd_StifelUnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelUnderwritersMember_lbl" xml:lang="en-US">Stifel Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Goldman Sachs Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_OutsideConsultantMember" xlink:label="txmd_OutsideConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultantMember_lbl" xml:lang="en-US">Outside Consultant Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised1Member" xlink:label="txmd_WarrantExercised1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantExercised1Member" xlink:to="txmd_WarrantExercised1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantExercised1Member_lbl" xml:lang="en-US">Warrant Exercised 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised2Member" xlink:label="txmd_WarrantExercised2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantExercised2Member" xlink:to="txmd_WarrantExercised2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantExercised2Member_lbl" xml:lang="en-US">Warrant Exercised 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $96,916 and $59,753, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,787,927 and 156,097,019 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Long term accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NetLossPerShareAbstract" xlink:label="txmd_NetLossPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetLossPerShareAbstract" xlink:to="txmd_NetLossPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetLossPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NetLossPerShareTablesAbstract" xlink:label="txmd_NetLossPerShareTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetLossPerShareTablesAbstract" xlink:to="txmd_NetLossPerShareTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetLossPerShareTablesAbstract_lbl" xml:lang="en-US">Net Loss Per Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsAndContingenciesTablesAbstract" xlink:to="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xml:lang="en-US">Advance payments for future research and development activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Long term prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Other receivables-related party (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidVendorDeposits" xlink:label="txmd_PrepaidVendorDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidVendorDeposits_lbl" xml:lang="en-US">Prepaid vendor deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">TOTAL PREPAID EXPENSE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfPatents" xlink:label="txmd_NumberOfPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfPatents" xlink:to="txmd_NumberOfPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfPatents_lbl" xml:lang="en-US">Number of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted Average Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Estimated amortization expense for the year:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2015 (3 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares issued during the period,value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Value of common stock issued during period for stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share based compensation options grants in period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="txmd_UnamortizedCostsOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnamortizedCostsOfWarrants_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased forfeit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xml:lang="en-US">Valuation method of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xml:lang="en-US">Non-cash compensation recognised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Stock issued for excercised warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Stock issued for excercised warrants, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:to="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOptionsAbstract" xlink:label="txmd_NumberOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOptionsAbstract" xlink:to="txmd_NumberOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOptionsAbstract_lbl" xml:lang="en-US">Number Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Receivables- legal fee reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xml:lang="en-US">Rental income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2015 (3 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfSites" xlink:label="txmd_NumberOfSites" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSites" xlink:to="txmd_NumberOfSites_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSites_lbl" xml:lang="en-US">Number of sites</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xml:lang="en-US">Carrying amount of advance payments made for future research and development activiites to be expensed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xml:lang="en-US">Refers to non cash compensation expenses of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xml:lang="en-US">Refers to fair value of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xml:lang="en-US">Refers to valuation method of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CowenAndCompanyLLCMember_doc" xml:lang="en-US">Refers to cowen and company llc member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk1Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk2Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk3Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk4Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_doc" xml:lang="en-US">Deferred Revenue Concentration Risk Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xml:lang="en-US">Multiple Advance Revolving Credit Note Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants1Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants2Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants3Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_doc" xml:lang="en-US">Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xml:lang="en-US">Stock Purchase Agreement With Pernix Therapeutics LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnamortizedCostsOfWarrants_doc" xml:lang="en-US">Refers to unamortized costs associated with warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidVendorDeposits_doc" xml:lang="en-US">It represents as a prepaid vendor deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAmortizingIntangibleAssetsMember" xlink:to="txmd_NonAmortizingIntangibleAssetsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonAmortizingIntangibleAssetsMember_doc" xml:lang="en-US">Non Amortizing Intangible Assets [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfPatents" xlink:to="txmd_NumberOfPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfPatents_doc" xml:lang="en-US">Number of patents outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Option1Member" xlink:to="txmd_Option1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Option1Member_doc" xml:lang="en-US">Option 1 member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UPOMember" xlink:to="txmd_UPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UPOMember_doc" xml:lang="en-US">UPO member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelUnderwritersMember_doc" xml:lang="en-US">Stifel Underwriters</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultantMember_doc" xml:lang="en-US">Outside consultant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantExercised1Member" xlink:to="txmd_WarrantExercised1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantExercised1Member_doc" xml:lang="en-US">Warrant Exercised 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantExercised2Member" xlink:to="txmd_WarrantExercised2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantExercised2Member_doc" xml:lang="en-US">Warrant Exercised 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSites" xlink:to="txmd_NumberOfSites_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSites_doc" xml:lang="en-US">Number of sites</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_2_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xml:lang="en-US">PrepaidResearchDevelopmentCostsNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>txmd-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20150930\txmd_093015.xfr; Date: 2015%2D11%2D05T17:15:16Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20150930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20150930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20150930.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20150930.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20150930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20150930.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20150930.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20150930.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20150930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20150930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20150930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20150930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20150930.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20150930.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20150930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20150930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20150930.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20150930.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20150930.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20150930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20150930.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20150930.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20150930.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20150930.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20150930.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20150930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20150930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20150930.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20150930.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20150930.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20150930.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20150930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20150930.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="loc_txmdPrepaidExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NetLossPerShareAbstract" xlink:label="loc_txmdNetLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNetLossPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NetLossPerShareTablesAbstract" xlink:label="loc_txmdNetLossPerShareTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNetLossPerShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_txmdCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfPatents" xlink:label="loc_txmdNumberOfPatents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_txmdNumberOfPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonAmortizingIntangibleAssetsMember" xlink:label="loc_txmdNonAmortizingIntangibleAssetsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdNonAmortizingIntangibleAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_Option1Member" xlink:label="loc_txmdOption1Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_txmdOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdUnamortizedCostsOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised1Member" xlink:label="loc_txmdWarrantExercised1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantExercised1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WarrantExercised2Member" xlink:label="loc_txmdWarrantExercised2Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantExercised2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdNumberOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000048 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000049 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfPatents" xlink:label="loc_txmdNumberOfPatents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20150930.xsd#txmd_NumberOfSites" xlink:label="loc_txmdNumberOfSites" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfSites" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760119772720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (135,936)<span></span>
</td>
<td class="num">$ (113,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">1,460,220<span></span>
</td>
<td class="nump">1,342,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">1,324,284<span></span>
</td>
<td class="nump">1,228,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone therapy drug candidate patents - Pending [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">585,241<span></span>
</td>
<td class="nump">675,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">585,241<span></span>
</td>
<td class="nump">675,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple trademarks for vitamins/supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">145,783<span></span>
</td>
<td class="nump">103,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">145,783<span></span>
</td>
<td class="nump">103,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">31,951<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,994)<span></span>
</td>
<td class="num">(2,496)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 27,957<span></span>
</td>
<td class="nump">$ 29,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">14 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development costs for corporate website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 91,743<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (91,743)<span></span>
</td>
<td class="num">$ (91,743)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 605,502<span></span>
</td>
<td class="nump">$ 439,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(40,199)<span></span>
</td>
<td class="num">(19,401)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 565,303<span></span>
</td>
<td class="nump">$ 419,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_NonAmortizingIntangibleAssetsMember', window );">Non-Amortizing Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
<td class="text">17 years 2 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_NonAmortizingIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_NonAmortizingIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187339456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Pernix Therapeutics LLC [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Receivables- legal fee reimbursement</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`/B.94>\#5@"[P$``"T@```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,W:S4[C,!`'\%>I<ETUKC_*+HAR`:Z`M+R`-YDV5N/8LDTI;[]V"FBW
MZJ[XJO2_-$W'GIEDDM^IY_=/GN)D:_LA+JHN)7_&6&PZLCK6SM.0(TL7K$[Y
M-*R8U\U:KXB)V>R$-6Y(-*1I*CFJB_/;#85@6II<[@(E]Z+2WO>FT<FX@6V&
M=B_KU"V7IJ'6-0\V;ZE3+DW?<KR:W.F0;K3-*=BV9V-@]\GK$F=?4S#Z0+J-
M'5&R?1W34T_Q4/U=Y*7R%2WU0Y_>5?CYWM6!^G%-[(Q_+G6]S5EB_FU1Y6A\
M4X7]C?_KS-@R-#^L_MI1SC]X+7LW<6/[JZ`?S5Z!S='&5(ZUU68X-*I'%]:_
MG%M_Y6-"Y:I::J<^Y(4AF0-/25Y\EZ.1Y=2?JOWRI#0NT)L*EH5'?"DZ':C]
MF4*>[^%WX\\%Q^NCS'7\_J^AC\'(QL,1D7A7'P*D#PG2AP+I8P[2QPE(']]!
M^O@!TL<I2!]\AM((BJ@<A52.8BI'096CJ,I16.4HKG(46#F*K`)%5H$BJT"1
M5:#(*E!D%2BR"A19!8JL`D56@2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$
MD56BR*I09%4HLBH4616*K`I%5H4BJT*15:'(JE!D52BRSE%DG:/(.G^5E8W_
M$KCX#5!+`P04````"`#XCF5'2'4%[L4````K`@``"P```%]R96QS+RYR96QS
MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][
MCZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@
M2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2
MENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`
MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`^(YE1[>K)I[H`0``V1\``!H`
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\79S6Z;0!B%X5NQN(`,W\\X
MB15GE4VV36\`V6-CQ0;$3-7F[D.]J-PD'&5AZ6Q`@/3-NT"/T/#0Y7KU(QV;
M<NB[W!Z&O/AS.G9Y-=U?5VTIPRJ$O&G3J<DW_9"ZZ>FN'T]-F2['?1B:S6NS
M3T'K>AG&RSG5X\/'V8OG[;H:G[=2+7XVXSZ5=?6['U]SFU+)X7R2FVF!Z?';
MD+ZS?+_;'3;IJ=_\.J6N?%$1_BU0A?D@G0]22I#-!QDER.>#G!(4YX,B)6@Y
M'[2D!-W.!]U2@N[F@^XH0??S0?>4(*F!C#4G"6'-T5H`U\+Q6@#8PA%;`-G"
M,5L`VL)16P#;PG%;`-S"D5L`W<*Q6P#>PM%;@=[*T5N!WDKZUD8?VQR]%>BM
M'+T5Z*T<O17HK1R]%>BM'+T5Z*T<O17HK1R]%>BM'+T-Z&T<O0WH;1R]#>AM
MI+T2M%G"T=N`WL;1VX#>QM';@-[&T=N`WL;1VX#>QM';@-[&T=N!WL[1VX'>
MSM';@=[.T=N!WD[:ZT:;W1R]'>CM'+T=Z.T<O1WH[1R]'>CM'+T=Z.T<O2/0
M.W+TCD#OR-$[`KTC1^]XH7=NFS%M7\IXZ/;YVC7_#8=%%WCG\G9,UT\Y3X4-
M%UJ7::44SL>KOS7GJ7]#PJ>_^(_O4$L#!!0````(`/B.94<+W5XF'P,``.X,
M```0````9&]C4')O<',O87!P+GAM;+U776_:,!3]*Q8OZZ2MH;3=0T4CF>`6
M:\')8M.UCVXP)6I(4.RB=K]^-TEAI(24\#!>N+D^YWX>K-!/=/?*S]*ERDRD
M-'I=Q(F^`N=U9V[,\LJR=#A7"ZE/`9+`Z2S-%M+`8_9DI;-9%*IA&KXL5&*L
M7K?[PU*O1B53-?V^W`3MV/T\"UXNXRB4)DH3>QR%6:K3F4'D-51QW_H(*!@0
MF:OP)8O,F]TM,=NN`L-#&2L'<MDS&6M5HOXY"XR3+I8R>;/*)S=*GO5D*=*A
M-&J;53THH\]EIJ:0M!)]XRPPHS?H,\ZYSEPF3VJZC=T]7,_B3F4Z[_2L=]J%
MSV8$:W\96\EIE#SY,LJTW5^9JY4*39J]KVEECMW2-`WSI>L[`?7I#GJ46N7F
M=6<ELT@FIH-T]`<>>YTR;>DM['BI36;_3K-G/5?*Z+ZU<1;F-G;;CB[LRUZ!
M`*N*M#:=V>]CJ_2=>T1D8J6]F2\S\Y]&4?2T'L3E^R3*1M<AD$RFB"0&Y(AH
M4J:"Y6V/9&,Y'N.>2X=8D"$:8!<SAR`^(D1P=#(YAG/^.8<+^!H3!GCO!GD^
M"=IR',Q'M1PQ(LCQQCYF#[7G`\QI$<$/"(=H6%"/(<R&*"`.8;4</AF/<?"0
MLSB]9?2&.I@)A!W'FS!!:SF4W4%T+ZBOPH,R`^1,@H#D@3B'T=4";^@]]%X"
MOB%&1"T*>O$Q'2)R[Q/&R9Z"!&:W=."2IGS5PER*!]2E@I)Z--2#7(]S!!L$
M`>"@/C47GO-SY+E#$O`OB/R:4%$_%LI@=00)?+\G84#<0@P^#O86-9APR@@4
M!?*!C8J@6'$]%M*-J2A5E6L`*(*R6\*<?='Y9,"A@WPZ)-_P/E2#8GJ]9L6@
M$R$?X5KY>K!TFAD[&FJ&?Q!3,WA'56V*WY)723M09,TYZM36S&A4`3IIO^'S
M3S<\5$9&<:L5-U)J=OR.1TQF64O.@<)H1-<HX].*&CBMDYRU5F#./%B!C;W7
M2W#3?GO.Q<41G,OVG&/:.3ODIJXN7YHV-_>:V_ZW>]D]@E/?S\Z]7^FHHIN=
M]\8/;XE6]=^-_1=02P,$%`````@`^(YE1_5Z>Q\^`0``:0,``!$```!D;V-0
M<F]P<R]C;W)E+GAM;,V334_#,`R&_PKJO4NS49"BK@=`G)B$Q!"(6TB\+:SY
M4.*IZ[\GR[J6K\MNW.K:[^/7<5()QX3U\.BM`X\*PL5>-R8PX>;9!M$Q0H+8
M@.9A$BM,3*ZLUQQCZ-?$<;'E:R#3HK@B&I!+CIP<@+D;B%E=2<&$!X[6]W@I
M!KS;^2;!I"#0@`:#@=`))5G];+;&MJ8BH[ZNHN.&!UQ8J58*Y$TWEOU.Q<X(
M7H>C'.30/OW]TT/*D*ROW`<U5+5M.VEGJ2X.3,GKXN$IG4VN3$!N!$154`P[
M!_/LU/EE=GNWO,_J:4'+G-*\*)?TFI4ENRS?#I-]\S<:UOT0_];QR6#:+BIL
MX,S=)HU,RTV?"20A"*\<*FO.PB7,%W&"A=W[!P@\']0+TV7;0M=:+T.=[M<8
M'5Y.7-G:^NZ8^A%]>U7U)U!+`P04````"`#XCF5'F5R<(Q`&``"<)P``$P``
M`'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEV
MV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYB
MZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#W(*+
M"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+
M5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4PL3`
M:F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q
M>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*
MC5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6U
MY4#3(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0
M!0X`-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=
M?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="
M?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>4
M1B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(
M]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76
M>)7`\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,C
MIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:K<(1
M*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW
M0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\F
MIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HW
MPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'
M5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+
M5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JV
ME+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ
M.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'N
MH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q
M6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5
M'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V
M$I<8O./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN
M>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86
M%S+D4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4
MBK`,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4
MS;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODRWSEP
MVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:
MI60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL
M.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#
M!!0````(`/B.94=S-N`83`(``'H*```-````>&PO<W1Y;&5S+GAM;,U66VO;
M,!3^*T(9HX41VRE-:6L;1B$PV,J@>>A;D6W9%NCBR7+F]-=/%U^20)8V34OS
MHJ-/1]_Y='2<H[!6:XH?2HP5:!GE=01+I:H;SZO3$C-43T6%N5[)A61(Z:DL
MO+J2&&6UV<2H-_/]N<<0X3`.><,63-4@%0U7$;P8(.#VWXD,1_#I[.N?1JC;
M+\"-DV^3B?]T?KN+G]F%<P@<QX\L@L'\$GHO)YWZ_GYBL[A#/G\E^?^X=ZBO
M#+77)2@.<\''/,V@`^*P?@8K1+5_8-Q3084$2E^$UF`1CAAV'G>(DD02`^:(
M$;IV\,P`]NXZ/T:XD#:VB[`;9^J/D6211-#O?B\/EXSL=C#'(Y1N'T\#<5@A
MI;#D"ST!G;U<5_IP7'#L1%J_`]Z%1.M@=KFQP0XZ;B)DAN40.8`]%(<4YTIO
MD*0HS:A$9:0+I0331D90(3BBAK+?T1F:-L64/I@OY3'?XFYSX'S,'?L0&!6]
MJ1/1F6,9V*1ZFVR.>Y/V.%[0YD,`O1M5%5U_IZ3@##NQ#EJ(;G:(/MA#'X>H
M9P6ED.19^YM"2#6`)00K+!5)-Y&_$E5+W*JN@KTVWZ?PV"._IZ;39VU4HTOP
MH]-S='`+W3<LP7)A_QA?+^GBZO"5V:\3[LC\V*HY0L()DF,:VZ>5-O^\TMZG
MIDY1[==O5.9UC6&C^VSUG@$%24.H(KR7@,QKX=[(IEMM8>P[FC-KQY9C5Q5*
M]$-P*XHFRW".&JI^DY50=C&"H_W3R`_F@]=RH(C@:/_"&6G8M54POC;C?U!+
M`P04````"`#XCF5'O0]-:&,$``"B$```#P```'AL+W=O<FMB;V]K+GAM;)67
M;7/:.!"`_XK&7RXW<W/@-]IF2F>,48*F8'.6R:4?'1!%4V,SMFAZ_?4GV="N
MPX;`)_#+/EJMG[6EC_7M<UE]>RK+;^3'-B_JVVIH;93:W?9Z]7(CMEG]=[D3
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M#:*0$CZA-.7D9@%!#@`YUX)<`'(!R'T#Q%/],Z.1AL1W))[3!(`\`/*N`H4!
MGP"0#T#^*2B=4!+&LWD0?0%!`Q`T.`T:!9PU8\T3RO6X0<KBB`31F"0TI!$`
MO0.@=Z<@OIC-@N2+07%V'[$[%@912H(PC!=1R@#H/0"]/P6QZ$'G$2=P$A]`
MR(?3D%A//2'A(DFH&9)S_32A6WTH5_\T_HX]ZMJW<7^1B*8PN&,FHJ8NW#Q@
M8T(?YS3B%(9"%VU$1J;K'=VST90B24/_;$3`[J2G+!BQ*4L9[4"@>S8BGYXK
MF<:<$ZVL;H,@Z>0/A;,1XW@:AY\G\71,$_X'H?\L6`J?F@W=LQ'Y6*1]I20-
M'KM90]5LQ+6$3IMNF0?)RPE#N6S$KM&"LXCJ">NVTWZG22-\!P%ELQ';=,XS
MEK9-:AI%DU(6W=,H[.;B0.T<1#N^&'%=-//XJ'&^$PRU<Q#MSO:;XT!4YY6(
M:GCH.'*C/PZYJ/^$T=!#YTT/6X]1$'3105P\Z4*4`IUT$"=?M"/*@%XZJ)<O
M^A*E0$L=Q-)7&[2E012TUD&L/6U3-"-HKH.8B_4K!G*AN2YB[MD6(#<0!3UV
MK_78A1Z[T&/WO,=CH3*9=R?5^:!?+#)&@B:[EYE\P)`HJRJ(@CJ[B,ZOHSH9
M0:-=Q.B3KL`@4&@7$1IIB]>F!85VT8_\JZA.2M!H%S'Z#,>&(`\:[2%&GVE6
M`X0H:+2'&(TU*U)N#^KL(3KCW?JKXA`%U?80M<^B/`^B.JM5Q.WS*!^BH-O>
MA<L'O%10;P_1^WRI;(B"DGMOKRVZBF<*HJ#DWN5KC2,2HJ#GWK5K#K\/-PG0
M=/_:=[</:^5#TWWTW?UB`=.I%FP:'\KN.X<=Y.]-H]XWRT*LS):Z;H;1>]*E
MV6?KGW8I[?EF86:.9WKO/;3,!EGOA?=Y'NIS<3$MLV8;V9*/.^M/_P-02P,$
M%`````@`^(YE1\N,E,EF`@``OP@``!@```!X;"]W;W)K<VAE971S+W-H965T
M,2YX;6R-EMN.FS`0AE_%X@$6;$[)BB`EJ:KVHM)J+]IK)W$"6H.I[83MV]<G
M6-)Z"3?!-O\_WQ@\&8J>\3=1$2+!>T-;L0DJ*;OG,!3'BC18/+&.M.K.F?$&
M2S7EEU!TG."3,34T1%&4A0VNVZ`LS-H++PMVE;1NR0L'XMHTF/_9$<KZ30"#
M8>&UOE12+X1E$8Z^4]V05M2L!9R<-\$6/N]AIB5&\;,FO9B,@4[^P-B;GGP_
M;8)(YT`H.4H=`JO+C>P)I3J2(O]V03^8VC@=#]&_FNVJ]`]8D#VCO^J3K%2V
M40!.Y(RO5+ZR_AMQ>TAUP".CPOR"XU5(U@R6`#3XW5[KUEQ[>R>!SN8W(&=`
MHP'-&V)GB$<#3,Q.;69F7U^PQ&7!60]$A_7;AL]*SG40%1D($TUM29C%K5Z]
ME5$1WG08IT`3Q<XJX*@(56PO``4^.S)V]#E@;Q7Q8T`\`.+I#F)C3Q[;D\&>
M3.V)L:?W^4T5.ZO('@-2+R`U]OP>D!I%:P%6@=(\6?`0,B\D,R%6,[NPBO5C
M0.X%Y/841#,$)UEP4E9>Q,KZT0S"218\IK47L;;^9`;A).EC!(R\#+.L(F0S
MD$&3+Z!`/\65Y=PK'S1+*,A/L;4)UW,45^'1`DKLI]@21G".XC1H`<5?Z-#6
M,8H_K\2]T\`\7R6K*%EPE*&_Z*&KZ7].6G:WI:'N%U#\50]M4:-LYL]ET$3_
M'>EPTB\:PB^FCPIP9-=6VG8QKHZ]>HM,O_F0ET6'+^0'YI>Z%>#`I.I:IL6<
M&9-$)1`]J70J]34Q3B@Y2SW,U9C;_FHGDG7#Y\+XS5+^!5!+`P04````"`#X
MCF5'5,T%!^@#``!9$0``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V8
M39/B-A"&_XJ+>];JUO<40]7BK:WDD*JM/21GSR`&:FU,;,^P^?>1+8D%(H0N
M8)NG6Z^^7K59GKK^Q[`S9BQ^MLUA>%[LQO'X5);#Z\ZT]?"I.YJ#_67;]6T]
MVMO^K1R.O:DW<U#;E$B(*-MZ?UBLEO.S;_UJV;V/S?Y@OO7%\-ZV=?_OVC3=
MZ7D!B_#@^_YM-TX/RM6R/,=M]JTY#/ON4/1F^[SX#$\5Z@F9B;_VYC1<7!>3
M^)>N^S'=_+%Y7I!)@VG,ZSBEJ.W7AZE,TTR9;,O_^*2_VIP"+Z]#]J]S=ZW\
MEWHP5=?\O=^,.ZN6+(J-V=;OS?B]._UN?!_XE/"U:X;YLWA]'\:N#2&+HJU_
MNN_]8?X^N5\4\6'Q`/0!>`X`E@R@/H#>!)1.V=RO+_58KY9]=RJ&8SW--CQ9
MO)^2V,S%,&>S71KFAY^GIQ\KE,OR8\KC$;Q`UAZY3U2>4&>DM.U'16`002]%
MH(O7C^-IB&>7\72.I^1:HIR1@^N$0Q0`4JW4?;!R(`<J0!#Y6!&+*F).$5PW
MQ"\5>40(P96XSU6.0^`,(4,/C^KAKC%,Z'&(DH1PG9#C,`"%`/2Q'!&5(YP<
MFI`C?+>1*,(3>AP'G$J6,UTRJD<Z/2RA1_KAD0H850E!#N0"*:>,/5:DHHJ4
M4Y3H^5KYAB1+R7&4H*@S9DM'MZ?V*_5Q/)!H9^;'-H-,],8S`!()3^R;*H`,
M)8J,/@'$-3G32DWEVC-`D:%*+(XJ@(B*JPP;!(QK<D9($_MO[1E`3@A)28IR
M]Q7%G16<';)$2VO/H$"@J05;!5`JHBZF^+ZFN+>"<T26,E?/:,*XYIA<3H[D
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MU#E5>=16KEK9XSQGI.*FB+[$2Q5GGOD-"=HJ$%3"U*O``F62:953:&'<&C'4
MA"EECI&2<XFW)GJMRYNHHDI#3G&-<8M$9VH\99&>B1_8UVM+IP[L\N(E^%B_
MF3_K_FU_&(J7;K3OT_/+[[;K1F,SD4^VMSM3;\XWC=F.TZ6TU[U[\W<W8W<,
M?V2<_TU9_0=02P,$%`````@`^(YE1R&X2[0_`@``)P@``!@```!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R-EMUNFS`8AF\%<0&Q#0%#1)!:IFD[F%3U8#MV
M$B>@`F:V$[J[GW\@I:DAR4&PS?-^?AR0G:QG_$V4E$KOO:E;L?5+*;L-`&)?
MTH:(%>MHJ^X<&6^(5%U^`J+CE!Q,J*E!`&$,&E*U?IZ9L1>>9^PLZZJE+]P3
MYZ8A_-\SK5F_]9$_#KQ6IU+J`9!GX)H[5`UM1<5:C]/CUG]"FP(9Q!"_*]J+
M2=O3\CO&WG3GYV'K0^U`:[J7N@11EPLM:%WK2FKFOT/1CSEU<-H>JW\WRU7Z
M.R)HP>H_U4&6RA;ZWH$>R;F6KZS_08<U1+K@GM7"?'O[LY"L&2.^UY!W>ZU:
M<^WMG3@>8NY`,`2":P"M%P/A$`AO`L":F75](Y+D&6>])SJBGS;:*)SK(JJR
M)TPUM21A!I_TZ"6/D@Q<=)T!"2;(LT6">:(8B(\B0,WOE`A&B7`J$5B)]'X^
M'//K:3XT^1A^5L0&:>TB+)+&*8KGJ2(<1'`4WG=9.UW6U@5]GB69NE@$KB!<
MH`H7->L2.5TBZW+SZ**IBT40M)]YL)@!9XUBIU%LC<(%(XLLJ=P2LP[8Z8"M
MPWK!`=]UN"5F'1*G0V(=HH6W)'GH+7%1LRZITR6U+O'"[V&1,+K_FE@R^$+.
M.B'HE#+#R@HO6`T,PA@G.`T6T&)$HQBF&*('=AJ$W%YVKXN3)2_TN!=:]`*3
M+;TC)_J+\%/5"F_'I#H=S%9^9$Q250JN5.%2G=K73DV/4C>Q:G-[CMF.9-UX
M+%__&^3_`5!+`P04````"`#XCF5'26@9KVP$```H$P``&````'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;(V837/B.!"&_PK%/4'=^DX1JH)A:O>P55-SV#T[
MP0G4V)BQG3#[[U>V9`>R<N-+P,K3W7K;MEZAY;FL?M;[+&MFOXO\6#_.]TUS
M>E@LZI=]5J3U?7G*CNX_KV55I(V[K-X6]:G*TET75.0+9$PMBO1PG*^6W=CW
M:K4LWYO\<,R^5[/ZO2C2ZM]UEI?GQSG,^X$?A[=]TPXL5LO%$+<[%-FQ/I3'
M696]/LZ?X&&+V"(=\?<A.]<7WV?MY)_+\F=[\>?N<<[:.61Y]M*T*5+W\9$E
M69ZWF5SE7R'I9\TV\/)[G_U;)]=-_SFMLZ3,_SGLFKV;+9O/=MEK^IXW/\KS
M'UG0(-N$+V5>=W]G+^]U4Q9]R'Q6I+_]Y^'8?9[]?S2&L'@`A@`<`H8Z\0`>
M`OAG@"`#1`@04RO($""_5%AX[5WG-FF3KI95>9[5I[1]GN#!X56;Q&6>U5TV
MU[2Z&WQJ1S]6RBX7'VV>@.`%LO:(9N/(QB,P$`M7/SH)G,<J8!>.XP423V@@
MYG`SR?9_24:GR?MI\LM><1^/M^-%'R\NXX6/Y]=3U!UR])WPB`3+0,MQ+O&<
M`*-0P3BW\1P("1RD&0>W`61:&3E%H8PJE%ZAN"XD+Q5Z!,!RJ^0XEP2.*:,8
MP6T\QU$S90ENZSG4%E&9V_I45)_R^H@Z:X]P:Q4"(_0%#D`KJ0A]*O0+!0K%
M"8%A;E8KSL1M@3KZB&N?1-V.-]$&&1^OB08%A"EF!?&@))Y33'`N"6[C.>>"
MQEIKB`9Y$)0"QD#>5FBC"JV?/E%H;4,A@>XE)FY9$D!A72LX\;!L/"B--I8S
M)#1Z$"V3Z-+>U@@L*K(;;A\F0F5@0$E!-"/I,=2">"HV`1-",*(1VX"YUXM-
M40=Q==ZN#%%H'1CDPEH4U$+5D\RM9Y(#I3$XJ;'(-2W3DT)JANS",,:58ERI
MMSQ#S&H=F#NPDG'&2:D]JHW0AEH&-SVJG*&`DTN)#2C7&J564^YKW)_!&[29
M8%\0=VCP-FB(EW8=&&S76:I7'G/^3+W8@=*@D5JZ`B:X@`F[%XB;,W@+-)0[
M0V^3U*R30%FNJ(4Y4"!!44O64%++";8#<6,&[WZ&V@$$YL[=$89Z0BD=+^4]
MTA"FO0Z,>YTLV4<=.J20;&1?T5#9M@&[`V/,Q>T;UQ>W</`^:2@/#XQ;,X1&
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MR+/7IOVJVSOB#W+\15.>^G.IX7!L]1]02P,$%`````@`^(YE1TF-S2H]!```
MU1(``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R-6$UOXS80_2N"[UES
MAE]BX!B(513MH<!B#^U9B9G86,ER)27>_OM2XM!1`H;AQ9;H-S-OAN0;FIM+
MU_\<#M:.Q:^V.0UWJ\,XGF_7Z^'Q8-MZ^-:=[<G]\M3U;3VZU_YY/9Q[6^]G
MH[99(V-JW=;'TVJ[F<>^]]M-]S(VQY/]WA?#2]O6_7\[VW27NQ6LPL"/X_-A
MG`;6V\WZ:K<_MO8T'+M3T=NGN]4]W%8<)\B,^/MH+\/BN9C(/W3=S^GES_W=
MBDT<;&,?Q\E%[;Y>;66;9O+D(O]+3M]B3H;+Y^#]]SE=1_^A'FS5-?\<]^/!
ML66K8F^?ZI=F_-%=_K"4@YP</G;-,'\6CR_#V+7!9%6T]2__?3S-WQ?_2\G(
M+&Z`9(!7@VN<N`$G`_YF(.9,/;,YK]_JL=YN^NY2#.=ZFFVX=?!^<N(\%\/L
MS:4TS(/WT^CKUN!F_3KY(0@N(#L/@2MB[9Q'(^`J9HZS>2)`Y1$Z(P(/$?@R
M!^YSX%_;BV`OEO9BMB_+]Q3U##GY)#SD1FEI!!?Z<V1%2*X-"(7F:TXRFI/T
M.8FO[54T)^7MY7NF<IF3AR`"$Y^CJH#2D%%?'>6B/1>5X*(I"J90E4>!A@7J
M4RYEE$OIN>@$%P_A&A1/</$HE#E39*)4C*=2)JAXB-""&98JC,=QPT7),TH#
M+$IH'G:,3"(285`QACHC$D17-Y"F,);A`N-DD5Q`HGX$N@$IC.28RHN00C&I
M9`8K'F?EM2@5:A<P@$RF=MX5IW3&UH.XMH'7(YY8RCL(ZH9@,+7F"0A&2Y6A
M;"#CE"3-7+)(,LP<J.2\!9QF693B:@E>Y42R2HHB,90R*9F$Y)(+L2#_.:FX
M;(*7.Y'2<,+<2$0%R:DCH)9"\(Q."W'Y!"][(I'^#H(T"D<IH6X5`0TSI<D1
M@KB,@J'EE)P\`J%CI#,4&^,*B8QBI?(GD-M.[JC@BI"H0(!RAEQJGD,L+J@8
M!#5#NC`NJ!@$-=6G,0@J://QT/@^LP`TG(N,C8EQ/45.I%(-FT!.*Z1,]:Z`
MX\SD;$N,*RJ2"+)4XR;0#7`N9:)#50&(;K%`SAD[?ES$H*DYI8YK('K5`F"I
MO.A<"5P+)9+%)DE%[4Z.,J.!85P%D0Y]D.KS!)*E*3%)2E-+E<M]^3FEN`AB
M2912#8Q`7+F34J*B57!6`LLY#6%<!)'T+=4#=@1R/9XSH5/*3$C!4>G29*PI
M'M=+3GH)*;TD$!JMD)>IS1+<8<ET*3/4DD.<%JDEI%HK@21P!2JE/U5`"C#@
M#L89M.(*S$F!X8,"O_LG2J#2K3YN4O]9*T(J98Q9SH"GM5[<%K2V?YYO48;B
ML7LYC?ZO_'7T>E-S/U_4?!C?P6WE[UO>W&PWY_K9_E7WS\?34#QTX]BU\\7#
M4]>-UI%CWUP%#[;>7U\:^S1.C]H]]_[6Q;^,W3E<(EUOLK;_`U!+`P04````
M"`#XCF5'6;A6U9\!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;(5374_L(!#]*X0?(&UWO>JFVV17<W/O@XGQ09_9=MH2@:E`M_KO!?IA8S;Q
MI<Q,SSES8"`?T+S9%L"1#R6UW=/6N6['F"U;4-Q>80?:_ZG1*.Y\:AIF.P.\
MBB0E698D?YCB0M,BC[4G4^38.RDT/!EB>Z6X^3R"Q&%/4SH7GD73NE!@1<X6
M7B44:"M0$P/UGA[2W7$;$!'P(F"PJY@$[R?$MY#\K_8T"19`0NF"`O?+&>Y!
MRB#D&[]/FM\M`W$=S^I_XVZ]^Q.W<(_R552N]6832BJH>2_=,P[_8-K"=1`L
M4=KX)65O':J90HGB'^,J=%R'\<]M,M$N$[*)D/T@L+%1M/G`'2]R@P.Q'0^S
M2W<>;H*(5R8VJGF'-A8/H7HNTO0F9^<@-&&R%>8X818$\^H76V3T$CV+].QW
M^F:F;]8.-Y/#V]\%MK/`=BVPO;S%->8X8^Y^-&&K,U5@FGAU+"FQUVX\TJ6Z
MW,Y#%F?R#2_RCC?PR$TCM"4G='ZR<0PUH@/?/KFZIJ3U[V=))-0NA#<^-N.5
M&A.'W?Q`EE=:?`%02P,$%`````@`^(YE1Y>\:WJ?`0``L0,``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6R%4]MNW"`0_17$!P2;W;31RFMI-U64/E2*
M\M`^L_;81@'&!;Q._[Z`+[&BE?(",\,Y9V88*$:T;ZX#\.1=*^..M/.^/S#F
MJ@ZT<'?8@PDG#5HM?'!MRUQO0=2)I!7C6?:-:2$-+8L4>[%E@8-7TL"+)6[0
M6MA_9U`X'FE.E\"K;#L?`ZPLV,JKI0;C)!IBH3G24WXX[R,B`7Y+&-W&)K'V
M"^);='[61YK%$D!!Y:.""-L5'D&I*!02_YTU/U)&XM9>U)]2MZ'ZBW#PB.J/
MK'T7BLTHJ:$1@_*O.#[#W,)]%*Q0N;22:G`>]4*A1(OW:9<F[>-T\I#-M-L$
M/A/X)P*;$J4R?P@ORL+B2%POXNSR0X#;*!*4B4MJH4*7@J<8O98YSPIVC4(S
MAF\PYQFS(EA0OYF"TUMTGNC\:_INH>^V%>ZF[/G#UP+[16"_%=C?;G&+.2^8
MSTVRS9UJL&UZ.HY4.!@_7>D:75_GB:>9?,#+HA<M_!*VE<:1"_HPV32&!M%#
M2)_=W5/2A?^S.@H:'\WOP;;3DYH<C_WR0=9?6OX'4$L#!!0````(`/B.94?9
MAPW^H0$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULA5/;;MP@
M$/T5Q`<$+W;::N6UM)NJ:A\J17EHGUE[;*,`XP)>IW]?P)=8U4IY,3/C<\X<
M&"@GM*^N!_#D32OC3K3W?C@RYNH>M'`/.(`)?UJT6OB0VHZYP8)H$DDKQK/L
M$]-"&EJ5J?9LJQ)'KZ2!9TO<J+6P?R^@<#K1`UT++[+K?2RPJF0;KY$:C)-H
MB(7V1,^'XZ6(B`3X)6%RNYA$[U?$UYC\:$XTBQ9`0>VC@@C+#9Y`J2@4&O]9
M--];1N(^7M6_I=T&]U?AX`G5;]GX/IC-*&F@%:/R+SA]AV4+CU&P1N72E]2C
M\ZA7"B5:O,VK-&F=YC]%OM#N$_A"X!OA2Y:,SXV2S:_"BZJT.!$WB#B[PS'`
M;10)RL0EM>#0I>(Y5F_5@?.2W:+0@N$[S&7!;`@6U.^VX/0>G2<Z_YB>K_1\
M[S!?'.8?"Q2K0+$7*.YO<8^YK)CBOR9L=Z8:;)>NCB,UCL;/1[I5M]MYYFDF
M[_"J'$0'/X7MI''DBCY,-HVA1?00VF</CY3TX?ULB8+6Q_!SB.U\I>;$X[`^
MD.V55O\`4$L#!!0````(`/B.94>V$K/UH0$``+$#```8````>&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULA5/;;N,@$/T5Q`<4AR1M%3F6DJY6NP\K57UHGXD]
MME&!\0*.NW]?P)=:JTA],3/C<\X<&,@'M.^N!?#D0ROCCK3UOCLPYLH6M'!W
MV($)?VJT6OB0VH:YSH*H$DDKQK/LGFDA#2WR5'NV18Z]5]+`LR6NUUK8?V=0
M.!SIALZ%%]FT/A98D;.%5TD-QDDTQ$)]I*?-X;R+B`1XE3"X54RB]POB>TQ^
M5T>:10N@H/11083E"D^@5!0*C?].FE\M(W$=S^H_TVZ#^XMP\(3J35:^#68S
M2BJH1:_\"PZ_8-K"/@J6J%SZDK)W'O5,H42+CW&5)JW#^&?+)]IM`I\(?"$\
M9LGXV"C9_"&\*'*+`W&=B+/;'`+<1I&@3%Q2"PY=*IYB]5IL^#YGUR@T8?@*
M<YXP"X(%]9LM.+U%YXG.OZ=O9_IV[7`[.;S_7F`W"^S6`KO;6UQCSC/FX;\F
M;'6F&FR3KHXC)?;&CT>Z5)?;>4I#9%_P(N]$`W^$;:1QY((^3#:-H4;T$-IG
M=WM*VO!^ED1![6/X$&([7JDQ\=C-#V1YI<4G4$L#!!0````(`/B.94=5+HH.
MHP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(53VV[C(!#]
M%<0'%(>DFV[D6$I:K78?5JKZL/M,[+&-"HP+..[^_0*^U*HB]<7,C,\Y<V`@
M']"^NA;`DW>MC#O2UOONP)@K6]#"W6$')ORIT6KA0VH;YCH+HDHDK1C/LF],
M"VEHD:?:LRUR[+V2!IXM<;W6POX[@\+A2#=T+KS(IO6QP(J<+;Q*:C!.HB$6
MZB,];0[G740DP!\)@UO%)'J_(+[&Y%=UI%FT``I*'Q5$6*[P"$I%H=#X;=+\
M:!F)ZWA6_Y%V&]Q?A(-'5']EY=M@-J.D@EKTRK_@\!.F+=Q'P1*52U]2]LZC
MGBF4:/$^KM*D=1C_[/<3[3:!3P2^$!ZR9'QLE&P^"2^*W.)`7"?B[#:'`+=1
M)"@3E]2"0Y>*IUB]%AO^D+-K%)HP?(4Y3Y@%P8+ZS1:<WJ+S1.=?T[<S?;MV
MN)T<?O]:8#<+[-8"N]M;7&/.$V:;?6K"5F>JP3;IZCA28F_\>*1+=;F=)YYF
M\@$O\DXT\%O81AI'+NC#9-,8:D0/H7UV=T])&][/DBBH?0SW(;;CE1H3C]W\
M0)976OP'4$L#!!0````(`/B.94>FV1V'HP$``+$#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;(U3VV[<(!#]%<0'!-_25BNOI=U44?M0*<I#^\S:
M8QL%&`?P.OW[`K[$J59J7\S,^)PS!P;*"<V+[0$<>5-2VR/MG1L.C-FZ!\7M
M'0Z@_9\6C>+.IZ9C=C#`FTA2DF5)\HDI+C2MREA[,E6)HY-"PY,A=E2*F]]G
MD#@=:4K7PK/H>A<*K"K9QFN$`FT%:F*@/=)3>C@7`1$!/P5,=A>3X/V"^!*2
M[\V1)L$"2*A=4.!^N<(#2!F$?./71?.]92#NXU7],>[6N[]P"P\H?XG&]=YL
M0DD#+1^E>\;I&RQ;N`^"-4H;OZ0>K4.U4BA1_&U>A8[K-/\ITH5VFY`MA&PC
M?$FB\;E1M/F5.UZ5!B=B!QYFEQX\W`01KTQL5/,.;2R>0O5:I7E:LFL06C#9
M#G->,!N">?6;+3)ZBYY%>O9O>K[2\[W#?''X'P+%*E#L!8I%(/^XQ3WFO&**
MOYJPW9DJ,%V\.I;4.&HW'^E6W6[G*8LS>8=7Y<`[^,%-)[0E%W1^LG$,+:(#
MWSZYNZ>D]^]G2R2T+H2??6SF*S4G#H?U@6ROM/H#4$L#!!0````(`/B.94>]
M%E4!H@$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;(53VV[C
M(!#]%<0'%,=QTE7D6$JRJMJ'E:H^[#X3>VRC`N,"CKM_OX`OM5:1^F)FQN><
M.3"0#VC>;0O@R*>2VAYIZUQW8,R6+2AN'[`#[?_4:!1W/C4-LYT!7D62DBQ-
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M-S^0Y946_P!02P,$%`````@`^(YE1^ZM7^ZC`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3,N>&ULA5/;;MP@$/T5Q`<$K^UMTY77TFZJJGV(%.4A
M?6;ML8T"C`MXG?Q]`%]B52OEQ<R,SSES8*`8T;S:#L"1-R6U/=+.N?[`F*TZ
M4-S>80_:_VG0*.Y\:EIF>P.\CB0E69HDWYCB0M.RB+4G4Q8X."DT/!EB!Z6X
M>3^#Q/%(=W0I/(NV<Z'`RH*MO%HHT%:@)@::(SWM#N<\("+@1<!H-S$)WB^(
MKR'Y4Q]I$BR`A,H%!>Z7*SR`E$'(-_XW:WZV#,1MO*C_BKOU[B_<P@/*OZ)V
MG3>;4%)#PP?IGG'\#?,6]D&P0FGCEU2#=:@6"B6*OTVKT'$=IS_[;*;=)J0S
M(5T)]TDT/C6*-G]RQ\O"X$ALS\/L=@</-T'$*Q,;U;Q#&XNG4+V6N^R^8-<@
M-&/2#>8\8U8$\^HW6Z3T%CV-]/1K>K;0LZW#;';XXVN!?!'(MP+Y[2UN,><9
MDR?_-6&;,U5@VGAU+*EPT&XZTK6ZWLY3&F?R"2^+GK?PR$TKM"47='ZR<0P-
MH@/?/KG;4]+Y][,F$AH7PN\^-M.5FA*'_?)`UE=:?@!02P,$%`````@`^(YE
M1S4F?+BA`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULC5/+
M;N0@$/P5Q`<$V^/LKD8>2S.)HMW#2E$.R9FQVS8*T`[@<?;O%_`C5C12<C'=
M[:KJ@H9B1/-J.P!'WI74]D`[Y_H]8[;J0'%[@SUH_Z=!H[CSJ6F9[0WP.I*4
M9%F2_&"*"TW+(M8>35G@X*30\&B('93BYM\))(X'FM*E\"3:SH4"*PNV\FJA
M0%N!FAAH#O28[D]Y0$3`LX#1;F(2O)\17T/RIS[0)%@`"94+"MPO%[@#*8.0
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M8;\\D/65EO\!4$L#!!0````(`/B.94?_MF<^H0$``+$#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;(53VV[C(!#]%<0'%,=QNFWD6$JZJMJ'E:H^
MM,_$'MNHP+B`X^[?+^!+K56DOIB9\3EG#@SD`YH/VP(X\J6DM@?:.M?M&;-E
M"XK;&^Q`^S\U&L6=3TW#;&>`5Y&D)$N3Y)8I+C0M\EA[,46.O9-"PXLAME>*
MF[\GD#@<Z(;.A5?1M"X46)&SA5<)!=H*U,1`?:#'S?Z4!40$O`D8["HFP?L9
M\2,DS]6!)L$"2"A=4.!^N<`#2!F$?.//2?.[92"NXUG],>[6NS]S"P\HWT7E
M6F\VH:2"FO?2O>+P!-,6=D&P1&GCEY2]=:AF"B6*?XVKT'$=IC_W$^TZ(9T(
MZ4*X2Z+QL5&T^9L[7N0&!V(['F:WV7NX"2)>F=BHYAW:6#R&ZJ789%G.+D%H
MPJ0KS&G"+`CFU:^V2.DU>AKIZ<_T[4S?KAUN)X>[GP6R62!;"V37M[C&G&;,
M[7]-V.I,%9@F7AU+2NRU&X]TJ2ZW\YC&F7S#B[SC#?SAIA':DC,Z/]DXAAK1
M@6^?W.PH:?W[61()M0OA+Q^;\4J-B<-N?B#+*RW^`5!+`P04````"`#XCF5'
MG+<8-*$!``"P`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R-4]N.
MVR`0_17$!RP.<;JKR+&4;%6U#Y56^]`^$WMLHP7&!1QO_[Z`+VM5D=H7,S,^
MY\R!@6)$^^8Z`$_>M3+N1#OO^R-CKNI`"_>`/9CPIT&KA0^I;9GK+8@ZD;1B
M/,L^,2VDH661:B^V+'#P2AIXL<0-6@O[^P(*QQ/=T:7P*MO.QP(K"[;R:JG!
M.(F&6&A.]+P[7O*(2(`?$D:WB4GT?D5\B\FW^D2S:`$45#XJB+#<X!F4BD*A
M\:]9\Z-E)&[C1?U+VFUP?Q4.GE']E+7O@MF,DAH:,2C_BN-7F+=PB((5*I>^
MI!J<1[U0*-'B?5JE2>LX_>%\IMTG\)G`5\)3EHQ/C9+-S\*+LK`X$M>+.+O=
M,<!M%`G*Q"6UX-"EXCE6;^4N?RS8+0K-&+[!7&;,BF!!_6X+3N_1>:+S?]/W
M"WV_=;A/],-_M,\7?K[EY_=WN,5<%LS37TW8YD@UV#;='$<J'(R?3G2MKI?S
MG&;(/N!ET8L6O@O;2N/(%7T8;)I"@^@AM,\>#I1TX?FLB8+&Q_`QQ':Z45/B
ML5_>Q_I(RS]02P,$%`````@`^(YE1Z$@%F2B`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3<N>&ULA5/;;J,P$/T5RQ]0$R![B0A2TM6J?5BIZL/N
MLP,#6+4]K&U"^_>US:6HBM07/#.<<^:,+\6(YL5V`(Z\*JGMD7;.]0?&;-6!
MXO8.>]#^3X-&<>=3TS+;&^!U)"G)TB3YQA07FI9%K#V9LL#!2:'AR1`[*,7-
MVQDDCD>ZHTOA6;2="P56%FSEU4*!M@(U,=`<Z6EW..<!$0%_!8QV$Y/@_8+X
M$I+'^DB38`$D5"XH<+]<X1ZD#$*^\?]9\Z-E(&[C1?UWG-:[OW`+]RC_B=IU
MWFQ"20T-'Z1[QO$!YA'V0;!":>.75(-UJ!8*)8J_3JO0<1VG/UDVTVX3TIF0
MKH0?230^-8HV?W''R\+@2&S/P]GM#AYN@HA7)C:J>8<V%D^A>BUW^<^"78/0
MC$DWF/.,61',J]]LD=);]#32TZ_IV4+/M@ZSJ?L^^5H@7P3RK4!^>\0MYCQC
M]I^'9)L]56#:>'4LJ7#0;MK2M;K>SE,:S^0#7A8];^$/-ZW0EES0^9.-Q]`@
M.O#MD[L])9U_/VLBH7$A_.YC,UVI*7'8+P]D?:7E.U!+`P04````"`#XCF5'
MK]*Z1J$!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R%4]MN
MXR`0_17$!Q3'=G:KR+&4M%KM/JQ4]:%])O;81@7&!1QW_WX!7VI5D?IB9L;G
MG#DP4(QHWFP'X,B'DMH>:>=<?V#,5ATH;N^P!^W_-&@4=SXU+;.]`5Y'DI(L
M39(?3'&A:5G$VI,I"QR<%!J>#+&#4MS\.X/$\4AW="D\B[9SH<#*@JV\6BC0
M5J`F!IHC/>T.YSP@(N!%P&@W,0G>+XAO(?E3'VD2+("$R@4%[I<K/("40<@W
M?I\U/UL&XC9>U'_%W7KW%V[A`>6KJ%WGS2:4U-#P0;IG''_#O(5]$*Q0VO@E
MU6`=JH5"B>(?TRIT7,?I3W8_TVX3TIF0KH3[)!J?&D6;C]SQLC`X$MOS,+O=
MP<--$/'*Q$8U[]#&XBE4K^5NGQ;L&H1F3+K!G&?,BF!>_6:+E-ZBIY&>?D_/
M%GJV=9C-#K/O!?)%(-\*Y+>WN,6<%TS^I0G;G*D"T\:K8TF%@W;3D:[5]7:>
MTCB33WA9]+R%O]RT0EMR0><G&\?0(#KP[9.[/26=?S]K(J%Q(?SI8S-=J2EQ
MV"\/9'VEY7]02P,$%`````@`^(YE1U,[PI^?`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3DN>&ULA5/+3L,P$/P5RQ^`T[0%5*616A""`Q+B`&<W
MV206MC?83@-_C^T\B%`E+O'N9F9V[+6S'LV';0`<^5)2VSUMG&MWC-FB`<7M
M%;:@_9\*C>+.IZ9FMC7`RTA2DJ5)<LT4%YKF6:R]F#S#SDFAX<40VRG%S?<1
M)/9[NJ)3X574C0L%EF=LYI5"@;8"-3%0[>EAM3MN`B("W@3T=A&3X/V$^!&2
MIW)/DV`!)!0N*'"_G.$.I`Q"OO'GJ/G;,A"7\:3^$'?KW9^XA3N4[Z)TC3>;
M4%)"Q3OI7K%_A'$+VR!8H+3Q2XK..E03A1+%OX95Z+CVPY_U1+M,2$=".A-N
MDVA\:!1MWG/'\\Q@3VS+P^Q6.P\W0<0K$QO5O$,;BX=0/>>K[39CYR`T8M(%
MYCAB9@3SZA=;I/02/8WT]'_Z>J*OEP[7H\/K_P4VD\!F*;"YO,4EYCAA;OXT
M88LS56#J>'4L*;#3;CC2N3K?SD,:9_(+S[.6U_#,32VT)2=T?K)Q#!6B`]\^
MN=I2TOCW,R<2*A?"&Q^;X4H-B<-V>B#S*\U_`%!+`P04````"`#XCF5'4CP7
M,Z(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R%4]MNXR`0
M_17$!Q3'2=INY%A*6E7MPTI5'[K/Q![;J,"X@./NWQ?PI585*2]F9GS.F0,#
M68_FPS8`CGPIJ>V>-LZU.\9LT8#B]@9;T/Y/A49QYU-3,]L:X&4D*<G2)+EE
MB@M-\RS67DV>8>>DT/!JB.V4XN;_$23V>[JB4^%-U(T+!99G;.:50H&V`C4Q
M4.WI8;4[;@(B`MX%]'81D^#]A/@1DI=R3Y-@`204+BAPOYSA`:0,0K[QYZCY
MTS(0E_&D_A1WZ]V?N(4'E/]$Z1IO-J&DA(IWTKUA_PSC%K9!L$!IXY<4G76H
M)@HEBG\-J]!Q[8<_VW2D72:D(R&="?=)-#XTBC8?N>-Y9K`GMN5A=JN=AYL@
MXI6)C6K>H8W%0ZB>\]7V/F/G(#1BT@7F.&)F!//J%UND]!(]C?3T.GT]T==+
MA^O1X9_K`IM)8+,4V%S>XA)S'#&WR:\F;'&F"DP=KXXE!7;:#4<Z5^?;>8A#
M9#_P/&MY#7^YJ86VY(3.3S:.H4)TX-LG-UM*&O]^YD1"Y4)XYV,S7*DA<=A.
M#V1^I?DW4$L#!!0````(`/B.94>:DSMMH@$``+$#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;(U3VV[<(!#]%<0'!)O=I.W*:VDW5=0^5(KRT#ZS
M]MA&`<8!O$[_OH`OL:J5VA<S,S[GS(&!8D3[ZCH`3]ZU,NY(.^_[`V.NZD`+
M=X<]F/"G0:N%#ZEMF>LMB#J1M&(\RQZ8%M+0LDBU9UL6.'@E#3Q;X@:MA?U]
M!H7CD>9T*;S(MO.QP,J"K;Q::C!.HB$6FB,]Y8?S/B(2X*>$T6UB$KU?$%]C
M\KT^TBQ:``65CPHB+%=X!*6B4&C\-FM^M(S$;;RH/Z7=!O<7X>`1U2]9^RZ8
MS2BIH1&#\B\X?H-Y"_=1L$+ETI=4@_.H%PHE6KQ/JS1I':<__,M,NTW@,X&O
MA,]9,CXU2C:_"B_*PN)(7"_B[/)#@-LH$I2)2VK!H4O%4ZQ>R_PA+]@U"LT8
MOL&<9\R*8$']9@M.;]%YHO-_TW<+?;=UN)L=_H?`?A'8;P7VM[>XQ9P7S.ZO
M)FQSIAILFZZ.(Q4.QD]'NE;7VWGB:28?\++H10L_A&VE<>2"/DPVC:%!]!#:
M9W?WE'3A_:R)@L;'\%.([72EIL1COSR0]966?P!02P,$%`````@`^(YE1Q2Y
M/%+<`0``104``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULC91=CYP@
M%(;_"O$'K-\?G3@F,]LT[463S5ZTUXP>/[(@%G#<_OL"HFL;,_9&X/B^[W.(
M0CXQ_B9:`(G>*>G%V6FE'$ZN*\H6*!9/;(!>O:D9IUBJ)6]<,7#`E3%1X@:>
ME[@4=[U3Y*;VPHN<C9)T/;QP)$9*,?]]!<*FL^,[2^&U:UJI"VZ1NZNOZBCT
MHF,]XE"?G8M_NF9:800_.IC$9HYT[S?&WO3B6W5V/-T"$"BE3L!JN,,S$**#
M%/B7S?Q`:N-VOJ1_,;M5W=^P@&=&?G:5;%6SGH,JJ/%(Y"N;OH+=0JP#2T:$
M>:)R%)+1Q>(@BM_GL>O-.,UOXLC:]@V!-02K(?-,XS/(M/D92USDG$U(#%A_
M._^DY%R'J&0D3)KJ4)CB15?OA9]$N7O70583;#17JUD5KDK?103.GCTP]N#8
M'B[V<-MA.-.#\#@@6@*B;4!DMQC_O<6MYKIHDF-(O`N);4#Z`+)HLF-(L@M)
M;,"G!Q"K2;UC2+H+26V`_P"R:/[CHV:[D,P&A`\@BR;Z!^)N_G,*O#''6:"2
MC;V<?_.UNMX8E\"<DP]YD0^X@>^8-UTOT(U)==K,T:@9DZ#PWE/LH%;=:>N"
M0"WU-%5S/A_S>2'9L%Q:Z\U9_`%02P,$%`````@`^(YE1\J(RM"E`0``L0,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA5/;;J,P$/T5RQ]0$W);
M100I:56U#RM5?=A]=F``J[:'VB9T_WYM<RFM(O4%SPSGG#GC2]:C>;,-@",?
M2FI[I(US[8$Q6S2@N+W#%K3_4Z%1W/G4U,RV!G@924JR-$EV3'&A:9[%VHO)
M,^R<%!I>#+&=4MS\.X/$_DA7="J\BKIQH<#RC,V\4BC05J`F!JHC/:T.YTU`
M1,`?`;U=Q"1XOR"^A>2Y/-(D6``)A0L*W"]7N`<I@Y!O_#YJ?K8,Q&4\J3_&
M:;W["[=PC_*O*%WCS2:4E%#Q3KI7[)]@'&$;!`N4-GY)T5F':J)0HOC'L`H=
MUW[XLTY'VFU".A+2F?`KB<:'1M'F`W<\SPSVQ+8\G-WJX.$FB'AE8J.:=VAC
M\12JUWRUWV;L&H1&3+K`G$?,C&!>_6:+E-ZBIY&>_DQ?3_3UTN%ZZ)[N?A;8
M3`*;I<!F'''W=<0EYCQA]M^:L,6>*C!UO#J6%-AI-VSI7)UOYRD>(ON$YUG+
M:_C-32VT)1=T_F3C,52(#GS[Y&Y+2>/?SYQ(J%P(]SXVPY4:$H?M]$#F5YK_
M!U!+`P04````"`#XCF5'9]-8_*<!``"Q`P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6R%4]M.XS`0_17+'X!3M]!2I9%:$&(?5D(\[#Z[R>0B;$^P
MG8;]^[6="P%5XB6>F9QSYHPO:8_FS=8`CGPHJ>V!ULZU>\9L7H,2]@9;T/Y/
MB48)YU-3,=L:$$4D*<EXDMPQ)1I-LS367DR68N=DH^'%$-LI)<R_$TCL#W1%
MI\)K4]4N%%B6LIE7-`JT;5`3`^6!'E?[TR8@(N!/`[U=Q"1X/R.^A>17<:!)
ML``2<A<4A%\N\`!2!B'?^'W4_&P9B,MX4G^*TWKW9V'A`>7?IG"U-YM04D`I
M.NE>L7^&<83;()BCM/%+\LXZ5!.%$B4^AK71<>V'/]OM2+M.X".!SX1=$HT/
MC:+-1^%$EAKLB6U%.+O5WL--$/'*Q$8U[]#&XC%4+]EJNTO9)0B-&+[`G$;,
MC&!>_6H+3J_1>:3SG^GKB;Y>.EP/W?G]SP*;26"S%-B,(]Y_'7&).8V87?*M
M"5OLJ0)3Q:MC28Z==L.6SM7Y=AYY/)-/>):VHH+?PE2-MN2,SI]L/(82T8%O
MG]S<4E+[]S,G$DH7PJV/S7"EAL1A.SV0^95F_P%02P,$%`````@`^(YE1V=I
MGH6D`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULC5/;;MP@
M$/T5Q`<$W])&*Z^EW415^U`IRD/[S-IC&P48!_`Z_?L"OL2M5FI?S,SXG#-G
MN)03FE?;`SCRKJ2V1]H[-QP8LW4/BML['$#[/RT:Q9U/3<?L8(`WD:0DRY+D
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M>X?YW#W_#X%B%2CV`L4R8O;GB'O,><7D?S5ANSU58+IX=2RI<=1NWM*MNMW.
M4Q;/Y`->E0/OX#LWG="67-#YDXW'T"(Z\.V3NWM*>O]^MD1"ZT+XV<=FOE)S
MXG!8'\CV2JO?4$L#!!0````(`/B.94=Z$T)@I`$``+$#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;(53VVZC,!#]%<L?4!-"NE5$D)*NJMV'E:H^
MM,\.#&#5]E#;A/;O:YM+Z2I27_#,<,Z9,[[D`YI7VP(X\JZDM@?:.M?M&;-E
M"XK;&^Q`^S\U&L6=3TW#;&>`5Y&D)$N3Y)8I+C0M\EA[-$6.O9-"PZ,AME>*
MFX\32!P.=$/GPI-H6A<*K,C9PJN$`FT%:F*@/M#C9G_*`B("G@4,=A63X/V,
M^!J2O]6!)L$"2"A=4.!^N<`]2!F$?..W2?.K92"NXUG](4[KW9^YA7N4+Z)R
MK3>;4%)!S7OIGG#X`],(NR!8HK3Q2\K>.E0SA1+%W\=5Z+@.XY\LFVC7">E$
M2!?"71*-CXVBS=_<\2(W.!#;\7!VF[V'FR#BE8F-:MZAC<5CJ%Z*S5V6LTL0
MFC#I"G.:,`N">?6K+5)ZC9Y&>OHS?3O3MVN'V['[]O9G@6P6R-8"V33B[ON(
M:\QIQOS?A*WV5(%IXM6QI,1>NW%+E^IR.X]I/),O>)%WO(%_W#1"6W)&YT\V
M'D.-Z,"W3VYVE+3^_2R)A-J%\)>/S7BEQL1A-S^0Y946GU!+`P04````"`#X
MCF5'`:V(D+(!```6!```&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R-
M5-UNFS`4?A7+#U`3"&T:$:2DT]1=3*IZL5T[<`"K-H?9)G1O/]O\E%91NQML
M'[X_<VRR`?6+:0`L>56R-0?:6-OM&3-%`XJ;&^R@=6\JU(I;M]0U,YT&7@:2
MDBR.HENFN&AIGH7:D\XS[*T4+3QI8GJEN/Y[`HG#@6[H7'@6=6-]@>496WBE
M4-`:@2W14!WH<;,_I1X1`+\$#&8U)S[[&?'%+WZ4!QKY"""AL%Z!N^$"#R"E
M%W+&?R;--TM/7,]G]>]AMR[]F1MX0/E;E+9Q82-*2JAX+^TS#H\P;2$D+%":
M\"1%;RRJF4*)XJ_C*-HP#N.;-)EHUPGQ1(@7PBX*P4>C$/,;MSS/-`[$=-SW
M;K-W<.U%G#(Q0<TE-*%X]-5+OMG=9>SBA29,O,*<)LR"8$[]JD5,K]'C0(^_
MIB<S/5DG3$;WY/YK@>TLL%T+;*<M[MYO<8TYS9C_,$FOFJ2CP'WTB<F,^?@E
MV:IQ"G0=SJ<A!?:M'?NV5)<K<(Q#X]_@>=;Q&GYR78O6D#-:=WQ"KRM$"\X^
MNDDI:=PE7182*NNG=VZNQW,[+BQV\RU<?@7Y/U!+`P04````"`#XCF5'R\Y,
ML*0!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-4]MNW"`0
M_17$!P0OZ_2R\EK:352U#Y6B/+3/K#VV48!Q`*_3OR_@2]QJI?8%9H9SSLPP
M4(QH7UP'X,F;5L8=:>=]?V#,51UHX>ZP!Q-.&K1:^.#:EKG>@J@322O&L^P#
MTT(:6A8I]F3+`@>OI($G2]R@M;"_SJ!P/-(=70+/LNU\#+"R8"NOEAJ,DVB(
MA>9(3[O#.8^(!/@A870;F\3:+X@OT?E6'VD62P`%E8\*(FQ7>`"EHE!(_#IK
MOJ>,Q*V]J'])W8;J+\+!`ZJ?LO9=*#:CI(9&#,H_X_@5YA;NHV"%RJ655(/S
MJ!<*)5J\3;LT:1^GDSR;:;<)?";PE?`I$=B4*)7Y*+PH"XLC<;V(L]L=`MQ&
MD:!,7%(+%;H4/,7HM=Q]Y@6[1J$9PS>8\XQ9$2RHWTS!Z2TZ3W3^;_I^H>^W
M%>ZG[/E_".2+0+X5R.<6]W^VN,6<%TS^5Q*VN5,-MDU/QY$*!^.G*UVCZ^L\
M\323=WA9]**%[\*VTCAR01\FF\;0('H(Z;.[>TJZ\']61T'CH_DQV'9Z4I/C
ML5\^R/I+R]]02P,$%`````@`^(YE1Y_4&(^E`0``L0,``!D```!X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULA5/;;N,@$/T5Q`<4QW':;N182KI:M0\K57WH
M/A-[;*,"XP4<=_^^@"]U5Y'Z8F;&YYPY,)`/:-YL"^#(NY+:'FCK7+=GS)8M
M*&YOL`/M_]1H%'<^-0VSG0%>19*2+$V26Z:XT+3(8^W9%#GV3@H-SX;87BEN
M_IU`XG"@&SH77D33NE!@1<X67B44:"M0$P/U@1XW^U,6$!'P*F"PJY@$[V?$
MMY`\50>:!`L@H71!@?OE`@\@91#RC?].FI\M`W$=S^J_XFZ]^S.W\(#RCZA<
MZ\TFE%10\UZZ%QP>8=K"+@B6*&W\DK*W#M5,H43Q]W$5.J[#^"?+)MIU0CH1
MTH5PGT3C8Z-H\R=WO,@-#L1V/,QNL_=P$T2\,K%1S3NTL7@,U4NQ^;'+V24(
M39ATA3E-F`7!O/K5%BF]1D\C/?V>OIWIV[7#[>3P]GN!;!;(U@+9)'#W=8MK
MS&G&W/_7A*W.5(%IXM6QI,1>N_%(E^IR.X]IG,DGO,@[WL!O;AJA+3FC\Y.-
M8Z@1'?CVR<V.DM:_GR614+L0WOG8C%=J3!QV\P-97FGQ`5!+`P04````"`#X
MCF5'((Q^#[,!```6!```&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R-
M5-MNW"`0_17$!P1?=IMFY;6TFZIJ'RI%>6B?67MLHP#C`EZG?U_`E[C5JNF+
MF1G..7/0@(L1S8OM`!QY55+;(^V<ZP^,V:H#Q>T=]J#]3H-&<>=3TS+;&^!U
M)"G)LB3YP!07FI9%K#V9LL#!2:'AR1`[*,7-KS-('(\TI4OA6;2="P56%FSE
MU4*!M@(U,=`<Z2D]G/<!$0'?!8QV$Y/@_8+X$I*O]9$FP0)(J%Q0X'ZYPB-(
M&81\XY^SYEO+0-S&B_KG>%KO_L(M/*+\(6K7>;,))34T?)#N&<<O,!\A.JQ0
MVO@EU6`=JH5"B>*OTRIT7,=IYSZ?:;<)V4S(5L+')!J?&D6;G[CC96%P)+;G
M87;IP<--$/'*Q$8U[]#&XBE4KV7Z\%"P:Q":,=D&<YXQ*X)Y]9LM,GJ+GD5Z
M]CX]7^CYUF$^T9/D?8'=(K#;"NQF@?3/(VXQYP7S'R[W-YOL9X'\'TT6S.ZO
M)FPS.`6FC??3D@H'[::YK=7U"9RR./@W>%GTO(5OW+1"6W)!YZ]/G'6#Z,"W
M3^[VE'3^D:Z)A,:%\-['9KJW4^*P7U[A^BLH?P-02P,$%`````@`^(YE1X`9
M,H*E`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULA5/;;N,@
M$/T5Q`<4QW':*G(L):U6NP\K57UHGXD]ME&!<0''[=\7\*7>5:2^F)GQ.6<.
M#.0#FC?;`CCRH:2V!]HZU^T9LV4+BML;[$#[/S4:Q9U/3<-L9X!7D:0D2Y/D
MEBDN-"WR6'LR18Z]DT+#DR&V5XJ;SQ-('`YT0^?"LVA:%PJLR-G"JX0";05J
M8J`^T.-F?\H"(@)>!`QV%9/@_8SX%I(_U8$FP0)(*%U0X'ZYP`-(&81\X_=)
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M$X?=_$"65UI\`5!+`P04````"`#XCF5'O=-$Q>L!```X!0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6R-5-UNFS`8?17$`]38YB=$!*EEJK:+254O
MMFLGF(!J,+6=T+W]_$=&(YKL!ML?YYSO'(Q=3%R\R992%7ST;)"[L%5JW`(@
M#RWMB7S@(QWTFX:+GBB]%$<@1T%);4D]`RB*4M"3;@C+PM9>1%GPDV+=0%]$
M($]]3\2?)\KXM`MA.!=>NV.K3`&4!;CPZJZG@^SX$`C:[,)'N*U2@["`7QV=
MY&(>&.][SM_,XD>]"R-C@3)Z4$:!Z.%,*\J8$=*-W[WFOY:&N)S/ZL\VK7:_
M)Y)6G/WN:M5JLU$8U+0A)Z9>^?2=^@B)$3QP)NTS.)RDXOU,"8.>?+BQ&^PX
MN3<9]K1U`O($="'`^"8!>P*^(@#GS.;Z1A0I"\&G0([$;#;<:K@P(EHYD%9-
M1Y*V^&BJYQ)%>0'.1LACT`+SY#%?(RJ/V%P@0!M8=8%F%WCI`ED^1/B^`)X%
MXJ4`=@9@]-ED9C&#B^$P>;R)\_QK6.5@$&9)M$'W_<2K?F(K$E_U299V8I\9
MXDT6?\8MI2HOE=ZWDJQ:2?RG@3>\.$R6)##YC\CI:I_4]T$WML!A8(YQG-W8
M@M1'QAF*KNR`Q4\^DB/]2<2Q&V2PYTJ?%_MS-YPKJF6B!YVQU=?89<%HH\PT
MTW/A3K9;*#[.]]3ELBS_`E!+`P04````"`#XCF5'362+Q/`!``!=!0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R-E-MNFS`<QE\%\0`U&'-H1)`:
MIFJ[F%3U8KMV@@FH!E/;"=W;SR<8J2C9#3[P?9]_?XR=CXR_B880Z7UTM!=[
MOY%RV`$@3@WIL'A@`^G5FYKQ#DLUY&<@!DYP94P=!3`($M#AMO>+W,R]\")G
M%TG;GKQP3URZ#O,_!T+9N/=#?YIX;<^-U!.@R,'LJ]J.]*)EO<=)O?>?PEV9
M:(41_&K)*!9]3[,?&7O3@Q_5W@\T`J'D)'4"5LV5E(12':06?G>9_Y;4QF5_
M2G\VU2KZ(Q:D9/1W6\E&P0:^5Y$:7ZA\9>-WXDJ(=>")46&>WNDB).LFB^]U
M^,.V;6_:T;Z)`F=;-T!G@+,A1)N&R!FB3P9@R4Q=W[#$1<[9Z(D!Z\T.=TK.
M=8A*]H1)4R4),_FD9Z\%#*,<7'60T\"%YN`T7RM*I\AF"5``JQ1PHHB6%-#X
M(WC?'TU^M/1'K@ITRY@:36^KL)HT2V$$OY:55I:E"#ZB^SAH%0<YG'@#QVHR
MF,'T5A4O::PJC.,(A?=IXE6:V-$DM^LL-0>K0<D&2NQ0($K_8Y^3593$H:0;
M'R9Q&Q`$\>/&/EE9&&8P7/R\E@<L3L*`S^0GYN>V%]Z1276HS`FH&9-$Y00/
MJLA&W77S@)):ZFZJ^MP>?SN0;)@NL_E&+?X"4$L#!!0````(`/B.94>D*6I;
M+`(``.D&```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(V5W6Z;,!B&
M;P5Q`<5__+@B2`W3M!U,JGJP'3N)$U`!,]L)W=W/QB:E%2$]";9YW_=[/@AV
M/@CYJBK.=?#6-IW:A)76_6,4J7W%6Z8>1,\[<^<H9,NTF<I3I'K)V6$TM4V$
M`$BBEM5=6.3CVK,L<G'63=WQ9QFH<]LR^6_+&S%L0AA."R_UJ=)V(2KRZ.H[
MU"WO5"VZ0/+C)GR"CR6UBE'PN^:#FHT#R[X3XM5.?AXV(;`(O.%[;1.8N5QX
MR9O&!IG"?WWF>TEKG(^G].]CMX9^QQ0O1?.G/NC*P((P./`C.S?Z10P_N&\A
MMH%[T:CQ-]B?E1;M9`F#EKVY:]V-U\'=(<C;E@W(&]#5`,FJ`7L#_F2('-G8
MUS>F69%+,02J9_9EPT<CES;$)`=J3#,MJ7'QR:Y>"@2S/+K8(*]!,\W6:VXK
M2J]X#XD,P"(%FBCPG`)Y"GH_`$\!9!Z`70`"'R'34=.Y-IPF2P$E]+:L=#),
M299^H1^RB$,\#OQ8)Y[C.`W.8`;Q;5GIHZB!_@).O(@3>QRT@N,T.,48TQ4<
M)R,09@FYCY,LXB0>9Z7MK=<02K.5AU@NRF[BI(LXJ<<A*SCI]`<%6;*"XV3F
MC<*9["9.MHB3>9QX!<=KX@2G]\O0Q3+4ETE6OABO@0AD(%[Y9)P.QC@EX#-0
M--N5>G;BOY@\U9T*=D*;#6[<C8Y":&YRP(-ILC+GSG72\*.VP]2,I=N*W42+
M?CI8KJ=;\1]02P,$%`````@`^(YE1\P@WA'Z`0``<04``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&ULC53;CILP$/T5BP]8@R%+%!&DA*1J'RJM]J%]
M=L@DH+4QM9VP_?OZ`H2F8;<OV!Z?<^;,R$S6"?FF*@"-WCEKU#JHM&Y7&*NR
M`D[5DVBA,3<G(3G5YBC/6+42Z-&1.,,D#)\QIW43Y)F+O<@\$Q?-Z@9>)%(7
MSJG\O04FNG40!4/@M3Y7V@9PGN&1=ZPY-*H6#9)P6@>;:+5/+,(!?M30J<D>
M6>\'(=[LX=MQ'836`C`HM56@9KE"`8Q9(9/X5Z]Y2VF)T_V@_L55:]P?J()"
ML)_U45?&;!B@(YSHA>E7T7V%OH2%%2P%4^Z+RHO2@@^4`''Z[M>Z<6OG;Y)E
M3WM,(#V!C(0QSV-"W!/B&R'YD)#TA.1_,RQZPN(N`_:UN\[MJ*9Y)D6'5$OM
M<XI6!BZMB%%&RJF9IBD7W-CH-2<DS?#5"O48,L%L/28-YR$[#XE&!#8&'KH@
MP:,,Q+N83U!X1!I]X.%3D?T_(K,VX\%F/&U6[*N,R><"R2"03`62OMO+OTVF
M#M/X7GA,NEP\SX.*'A01,@_:#=FB,)E'[0=4&L5W9>')@^(@S^Y75J@4ET;[
M%HW1<5ILB'V0=_%MM"JB!_&=F2Y^&-SD\ZRE9_A.Y;EN%#H(;7X#]V9/0F@P
MAL,GT^'*S+_QP."D[3:UK?<CP1^T:(<!-T[9_`]02P,$%`````@`^(YE1P<=
M=<`%`@``,`8``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULC95-;YLP
M'(>_"N*^&@P&$A&DEJK:#I.J'K:S$TQ`-9C93NB^_?Q&1BI">HE?>/X_/PY@
M\I'Q=]$0(KV/CO9BYS=2#EL`Q*$A'18/;""]NE(SWF&IAOP(Q,`)KDQ11P$,
M@@1TN.W](C=SK[S(V4G2MB>OW!.GKL/\[Q.A;-SYH3]-O+7'1NH)4.3@4E>U
M'>E%RWJ/DWKG/X;;,M.$`7ZU9!2SOJ?=]XR]Z\&/:N<'6H%0<I`Z`:OF3$I"
MJ0Y2"_]QF?^7U(7S_I3^8G:K[/=8D)+1WVTE&R4;^%Y%:GRB\HV-WXG;`M*!
M!T:%^?4.)R%9-Y7X7H<_;-OVIAWME2AS9<L%T!7`2T$8KQ9$KB#Z5`"LF=G7
M,Y:XR#D;/3%@?;/#K<*Y#E')GC!I:DO"3#[JV7,!X28'9QWD&#ACGAQSFR@=
MD5T0H`06+>!D$<\MH*V/@NLU4L/TUL(Q09@$\6VLM%B8*0K=UXD6=2*G$UZO
M@^8ZEOD6QG&&DMM<.7$0I@C>%XH7A6(G!%>$+(.2-,Y6="R51'`3W9=!BS+(
MR7PA(%D,2);O]M5N+!-&,$0K6+F(W=1)%W52IQ/?#\@6`[(O/+V6238Q6GMX
M+86B;//YV06SEWO`1_(3\V/;"V_/I#HGS$M=,R:)2@D>U%_4J./[,J"DEKJ;
MJCZW)YH=2#9,Y_/E(U'\`U!+`P04````"`#XCF5''?Z(T]@!``#5!```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R%E-MNI"`<QE^%^`!%P4,[<4Q:
MFV;W8I.F%[O7S(BC*8@%9NR^_7+2M<T<;N3@[_OX_HB4DY#OJJ-4@T_.!K6-
M.JW'#81JWU%.U)T8Z6#>M$)RHLU0'J`:)26-$W$&41SGD)-^B*K2S;W*JA1'
MS?J!ODJ@CIP3^?>),C%MHR2:)][Z0Z?M!*Q*N.B:GM-!]6(`DK;;Z#'9U)DE
M'/"[IY-:]8'-OA/BW0Y^-MLHMA$HHWMM'8AI3K2FC%DCL_!'\/R_I!6N^[/[
MBZO6I-\116O!_O2-[DS8.`(-;<F1Z3<Q_:"A!)=P+YAR3[`_*BWX+(D`)Y^^
M[0?73OY-F@;9>0$*`K0(DNL"'`3XFP#Z9*ZN9Z))54HQ`342^[&3C<&E-3'.
M0#DW4Y)RDX]V]E0AG)7P9(T"@U;,4V`N$W4@[A<$F@!G4Z`Y!5ZG0$Z?X/RV
M`9X-TK4!#F7D7T,6CAE\&9YY*.Z+.+V,U0'+<9;BVW'2LW%2'P<E7]?)UG$\
MDSQ@G!:7L=IC:8X+%-^.DYV-DX7=*:[LCF>2Q"R3)5>V)W`I*E#^?7_@Z@2.
MY$!_$7GH!P5V0IO#[$Y>*X2FQB>^,U5VYHY9!HRVVG8+TY?^M_,#+<;Y$EEN
MLNH?4$L#!!0````(`/B.94?BY-1<#@(``/X%```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;(U4VXZ;,!#]%8L/6(.!9!,1I`12M0^55OO0/CN)$]#:
MF-I.V/Y]?8.E65CE!=O#.6?.#'BRCHLW61&BP#NCC=P$E5+M&D)YK`C#\HFW
MI-%OSEPPK/117*!L!<$G2V(4HC!<0(;K)L@S&WL1><:OBM8->1%`7AG#XN^.
M4-YM@BCH`Z_UI5(F`/,,#KQ3S4@C:]X`0<Z;8!NM]ZE!6,"OFG1RM`?&^X'S
M-W/X<=H$H;%`*#DJHX#U<B,%H=0(Z<1_O.9'2D,<[WOU;[9:[?Z`)2DX_5V?
M5*7-A@$XD3.^4O7*N^_$EV`='CF5]@F.5ZDXZRD!8/C=K75CU\Z]26-/FR8@
M3T`#`45?$F)/B!\E))Z0/$I(/2&](T!7N^U<B17.,\$[(%ML?J=HK>'"B&AE
M(*V:;IJTP:V)WG(4/V?P9H0\!HTP.X=9AO.0TD&B`0&U@4D7*)C*@+R+U7R*
MPF.2KVP\H+/_K#-K-N[-QN.6Q:[649)9@:072,8"B7<0_>]R:3&-ZXC#/"]6
M:!Y4.%"Z0.D\J/39$%HMYE%[AXJ6T0@U6U8Z65;JR[ISG([+2GWOYB'E)XBS
M`4=_-R/B8N>*!$=^;93[4D-T&%U;9&['77P7K8MH(E[J4>=NTX=\GK7X0GYB
M<:D;"0Y<Z3MI+]"9<T6TV_!)>Z_T,!X.E)R5V2Y-J]Q\<@?%VW[:#B,__P=0
M2P,$%`````@`^(YE1W-Q??R@`P``G1$``!D```!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&ULE9A=;YLP%(;_"N*^!7\!KM)(+=.T74RJ=K%=T\1)4`%G0)KN
MW\]@FT)V(,Y-`.?Q\6O.X<5F=9;U6W,0HO4^RJ)J'OU#VQX?@J#9'$29-??R
M*"KUST[69=:JRWH?-,=:9-N^4UD$.`RCH,SRRE^O^K:7>KV2I[;(*_%2>\VI
M++/Z[[,HY/G11[YM^)GO#VW7$*Q7P=!OFY>B:G)9>;78/?I/Z"$EK$-ZXE<N
MSLWHW.O$OTKYUEU\WS[Z8:=!%&+3=B$R=7@7J2B*+I(:^8\)^CEFUW%\;J-_
M[:>KY+]FC4AE\3O?M@>E-O2]K=AEIZ+]*<_?A)E#KW`CBZ;_]3:GII6E[>)[
M9?:ACWG5'\_Z'Y:8;G`';#K@H0..%CL0TX$,'5`_0J"5]?/ZDK79>E7+L]<<
MLR[;Z$'A=1=$1?::/IJ:4M,W/G6M[VM,R2IX[P(9!H^89\V@>2*U4>C`!$H!
M*`/[T!!8!U@8PA#)]1&('8&,)TJ,1'8]`+4!Z#@`-0&BJ<BX9RH]#<W<(<(X
M6>!2RR$2T?"Z(`;.B!E!\?4`$3BCR`1(IDK9>$::030*,0[GN=1PA&+LDJ,8
M%!0;07Q!4&P&PA0G=$&0X90:EC@(2D!!B1;$''+$P1QQ]QRA$)30-U_+DH%8
MPC!%"S?%<%',>((=)"%8$G+(DX&N2T*W2<*P)&,/##F$@`T"D1MR!5L$HBZY
MHN:18G%"EFZ,X4)"(H<"1@R6Q%QRQ1PEL=LDP;:#C.\PEW3'<*ZL4SBX.8(?
M;92XY$I#!'&V6,,0-B^(PX*L5T1+@C1T1SA?,C^+J;1'UP5AV'EP")?.Y(UG
MH9BS>!Y++<8I<T@9AGT'&]]A%S4ZAIX'B,Y#Z0"YB($=!UO'<;G!L./@&]8D
M&'8</.,XTQQIB*/X<IDWS1&$S0N"_08SN(JG@C1T=U41R,U+@OT&1W`=3\M&
M0Y>RIU7S'S,O!5[@8.-;S.$=@Q.X:)(;B@9V&LQ=BD9#4<A8B)=RI#E*.$H<
MEO\$]AH2PF4S,3\#W=$0\87766HYQ!7I(`EV&S*SRIG<)0.QB)%PJ9(-1Q$?
MOV'G)<&>0ZSG+!A@.D`N6R4"CV.,B7&'$!0L4T+=RY3`5D*8@]U;*+I<H@>C
MW7`IZGW_E:#Q-O)4M7HS/+0.7R*><+^;_L37JV.V%S^R>I]7C?<J6[4G[S?0
M.RE;H<8/[U7E'42V'2X*L6N[TUB=U_KK@;YHY=%^#!F^R*S_`5!+`P04````
M"`#XCF5'T"G)"<4!``#:!```&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6R5E,V.FS`4A5_%X@'&_)-$!"F9JFH7E4:S:-=.N`0T-J:V$Z9O7_]@RDA,
MIK/!]N7<\QW+X'+DXD6V``J],MK+?=`J->PPEN<6&)$/?(!>OVFX8$3II;A@
M.0@@M6UB%,=AF&-&NCZH2EM[$E7)KXIV/3P))*^,$?'G")2/^R`*?.&YN[3*
M%'!5XKFO[ACTLN,]$M#L@T.T.Q9&804_.QCE8HY,]A/G+V;QO=X'H8D`%,[*
M.!`]W.`1*#5&&OQ[\OR'-(W+N7?_:G>KTY^(A$=.?W6U:G78,$`U-.1*U3,?
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MYNNL^@M02P,$%`````@`^(YE1X;Q9N72`@``)@H``!D```!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&ULC9;=;ILP%(!?!?$`Q7\8B`A2&S1M%Y.J7FS7;N(D
MJ(`S[#3=V\]_8:0E3FX2.'SG^+,-MLN3&-[DGG,5?71M+Y?Q7JG#(DGD>L\[
M)A_$@??ZR58,'5/Z=M@E\C!PMK%)79L@`&C2L::/J]+&GH>J%$?5-CU_'B)Y
M[#HV_'WBK3@M8QB?`R_-;J],(*G*9,S;-!WO92/Z:.#;9?P(%S4D!K'$KX:?
MY.0Z,O*O0KR9FQ^;90R,`V_Y6ID23/^]\Q5O6U-)M_S'%_W?IDF<7I^K?[/=
MU?JO3/*5:'\W&[77MB".-GS+CJUZ$:?OW/<A-077HI7V-UH?I1+=.26..O;A
M_IO>_I_<$T)]VGP"\@EH3,A!,`'[!#PFN*&[FD!\`OF4D+BNV(&HF6)5.8A3
M)`_,O!YPH?'!%-&5(VFKZ3&0-OAHHN\5HJ1,WDTASZ`)L_+,=:+V1#XBB1:8
MM4!G"SRU0#8?$G2[`#X7(-,"V'<CO93,+-.[;C@&IR@'%%[G:L?!#-#T'B$R
M*T2\$+UL*)T*.:;`H(#X.E8[+->C`]+;.NFL3NIULH".8RA,"Q*PKGVIC)(,
MW-:ALSK4Z^0!'<>0`L!).U]U/$80P7?H9+,ZF=<I+MN9,D^>";FL'(/S/-BS
MVF$P3PMZQX3FL\JYUX$!'<^`'']^WR]T'%8`,IGVJS;%K$WA;5#`QC$%)20T
MG8Z"%*0`W[:!8%;'AHU/X+-:>2BG11&:+(_I3Y3>L;Q!."_D%\B,A(0<1"!%
MH1'R6*;G_HX7'J)Y(>2%0@NFARC.:99E@173@S@G@.+B#BFWB(\%'FT@G#*_
MS$(R_UE>?+HC]/G]3B8[9L>'G3UZR&@MCKUR.\T8'8\W3_8P\B6.%RO=B:]/
M=./ZB=NE_S=1E0>VXS_9L&MZ&;T*I?=ZNS%OA5!<.X,'/>=[?6@;;UJ^5>8R
MT]>#.\:X&R4.YU/9>#2L_@%02P,$%`````@`^(YE1PUACM<D`@``>@8``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULC57;CILP$/T5Q`<LV%P,$4%*
M4E7M0Z75/K3/3N($M#:FMA.V?U_?(.R*W>0%V\,Y9\X,,%0#%Z^R(40%;XQV
M<ATV2O6K*)*'AC`LGWA/.GWGQ`7#2A_%.9*](/AH28Q&,([SB.&V"^O*QIY%
M7?&+HFU'GD4@+XQA\6]+*!_6(0C'P$M[;I0)1'453;QCRT@G6]X%@IS6X0:L
M=B`V$(OXW9)!SO:!,;_G_-4<?A[786P\$$H.RDA@O5S)CE!JE'3FOU[TEM,0
MY_M1_;LM5]O?8TEVG/YICZK1;N,P.)(3OE#UPH<?Q->0&<$#I])>@\-%*LY&
M2A@P_.;6MK/KX.X4L:<M$Z`GP(DPY5DF))Z0W`BIK=0YLW5]PPK7E>!#('ML
MGC98:;@P(EHYD%9-ER1M<&.BUQHB5$57(^0Q<(;9.@R8$)%67TP!PR4Z="D^
M3[!S"/1`AF3,D,R+2'P1Q7V!=!1(YP*I%RC?F\PLIG-E.$P2@R3/4?(Y<#<"
M$2J+K+QO*5NTE#E+17Q?(%]L2OYX4]"B`_1`4QP&H!2D,(5?-,4#\R(#99K<
MMU0L6BI\4QYX4\K%II2/-P7$BQ9L^%Y;/`A`!&&:@"_Z,B*34BN"_(.M:/9)
M,R+.=M3)X,`OG7*?VQ2=QND&FI'P(;XU8]:.BIM,7?7X3'YA<6X[&>RYT@/'
M3H<3YXIH<_&3MMKH'\%TH.2DS!;IO7"CT1T4[\=)/_UNZO]02P,$%`````@`
M^(YE1_N??&+7`P``I!,``!D```!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
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MMO^:E&9EL[_20W6JW:)9=##'Y".KOMOK5^-_`V\*OMFL;/]';Q]E9?-.,HOR
MY*?[3,_MY]5](XF7A07$"\A-@-FH@'H!A0J8%S"H@'L!APJ$%PBH0'J!A`J4
M%RBH0'N!A@J:-7<KA\"2VV+C.TGLNJ3ML>>D2I:+PEZC\I(T9QY^:/BBJ5,7
MC\JV8-U?97OP2W/T<TD46<2?327/D![SU#%TF%EU#!MFGCN&#S/KCA'#S$O'
MR&%FTS%JF/GJF6%B.TGL'"'Q,++OK-R0N%Z>\!J1;HU8?XU(6T#<V>`M<G8_
MQ2$8N;]A<`L%]P/@L'<:]$Z=][OY47WO#D%SA$:H+8C:AZAARRQHF3G+8F2Z
M'4+Y]'R#R;TCR6_DL'T>M,^=?3EBWR%82JFD)B/D%DSN/<D%TA)A#;`O@O:%
MLZ]&[`NP?3"Y%__;O@S:E_YDUR/^':/Y>.<XBLDZ"T>,[QPF-56@GE%!U\JY
MUG=^9-^U8[1B4@U36T=QI?NNA^WHH!WM[>"1Z7$,)A2/3N/.<1QX2F$4--0>
M;AP12`T<KH&G6V/G(2$9;#EQ^(J!R?2"[CQ$,>=,0,8*)SRF?BP*J1&.7,PF
M0VOG&8RIHI#6PN%XQ!RR##[-L!8(-%8XR[#P4\,@-<*!@GVB:#[L]\E#C!&*
MY,@DKCQ(%1.8@UR%`P-WB7%WE=3_&<Q!<@ZY]<'A*,!=%LCA3EYYB!+HE9.$
M3W."IGMCY2$NA2:0EB?A."`^#C3HOG#@QI!,]\:SA^I+&Y:_W>?WR75'4JX0
M`44""4<"H=/=L?80FR,.&2D<'(1-M\?:0UQC<'^$LX,`LF/=08A*1$&3&`X/
MTH4'Y&:$A,.#`,+CQ4-:<831R%WOQH.*"UY?=2&NPN%!`.&Q\1";@^XC2#@]
M""`]-AYB1($?=<+Q00'QL?$0KA^5I;YOC[CW#'])WLT?2?&>GLOHU5:5S=M'
M]Z.UE:D+H7E=]F22PVTG,\>JV93U=N%>(KF=REZZ=V*W%W/+?P%02P,$%```
M``@`^(YE1UTWWB'"!```41L``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&ULE9G;<J-(#(9?Q>4',+3Z`*0<5TT29^R+K9J:BYUK$I/8-6"\0.+9MU\.
M:@=GU8UR$QORZ4"C7XCV\EQ6O^M]EC6S/T5^K&_G^Z8YW01!_;S/BK1>E*?L
MV/[GI:R*M&D/J]>@/E59NNN-BCR`,#1!D1Z.\]6R/_>C6BW+MR8_'+,?U:Q^
M*XJT^O<NR\OS[5S,[8F?A]=]TYT(5LO@8K<[%-FQ/I3'696]W,Z_B9NM-AW2
M$W\?LG,]^C[KDG\JR]_=P79W.P^['+(\>VXZ%VG[\9[=9WG>>6HC_X-./V)V
MAN/OUOMC?[EM^D]IG=V7^:_#KMFWV8;SV2Y[2=_RYF=YWF1X#;IS^%SF=?]W
M]OQ6-V5A3>:S(OTS?!Z._>=Y^(]1:$8;`!K`Q0!"KX%$`WDQ$,9KH-!`?1CX
M4])HH+D1#!H8;H0(#2*N08P&\<<J2:]!@@;)IPC!</_ZN_^0-NEJ697G67U*
M.TV(FQ:O.B>MYUG=>VMO?-V?_-:=?5_),%P&[YTC9&#$W%E&N)E[RX";>;",
M=#-KRR@W\S@PGDC?!R+R)+R9=++]GY.@755R:<$NK1PO+>"EZ&D'TCI08P<2
M'9CK)*.>.0YK,3`"H@B4%&YPXP"=*2DR)84I1=>1DG%*`R,6B71#&P)RIJ+)
M5/20BO0LSH!$6@L-GJ4A,6<VALS&X,+$UW'T.([!6R!%^%EO8VX[<#H<4\YT
M(C*="--)IAW$9/'&_.)-R`R2P8'X=*%C9F,91CF*D(S2GYXHR`>$8!%R`@DZ
M$#8FX2LDA+2)6+=.`!T*&X>0[AIY0"AF5HF@.XS`%B.4+]0`Q5+R0M&=0V#K
M$(R*$IJL2:'Y12EHF0HSO;;W"$%[Q9+1G@0M08$:%,:M@/L+%#'BQ'0<E*J(
MW95YAY`*=6@,(Q2M:6$%F[@OZ<Y"P*@5H%4-J&H0GC@7B-&S@18UH*A!^N)8
M2#'BT(H&5#1H7QP+,>X/T'(&E#-$OC@6BAEQ:"T#:AD23\DAQ"TYH)_R8!_S
MG&HR9-L`PV\;0&L9HNFV<8<0MVT`+6?@R!DA94`DG+6EY0P<.<,7Y"QI.4N.
MG"W$F4TE+6?)D;.%)*-M2%K.DB-G^04Y2\?\+VF9C:ONT4*Q%I&[8KZ[L:L1
M%3$A=#L-N]UM:<Y]@70?D6IZAD>FBZ0\W(;FW!G1[4;:=L-Q0;<;^85V(^EV
M(QGMYE&.VHUG?-O0G#LENBU);$LL%PF],`E_813=253(>*NPD.3$H3N)LML0
MWO?<`3(+J=W4AJ+<Z=`-1V$OD9Y1<G.!&*.DHAN.<C2<*T$BI`",9V-B@UAL
MPI`Q:"C'=H/=;_"]5B/$?!-2M/"5%3XG65KXZ@O"5[3P531==VL++1A/,$6K
M6<73#6:-D`#NRM)3ADJFBW=]@1@;%IKN#=KV!E\<"RG&]6BZ-VB[$^`9T-8(
MB4B(1#,F`$T+7]NM`,^$MK:08CR(-2U\;87OF=#6%E*,NM.TGK5]<?!,:&L+
M<1[CVK$WJ*<GM/4%XMP?>CM!H^25\G1"A$(WLD4$VF8)G]MW,-K6/Z6OV5]I
M]7HXUK.GLFG*HM_.?RG+)FO]A(M6P/LLW5T.\NREZ;Y&[?=J^,5G.&C*D_T!
MZ_(KVNH_4$L#!!0````(`/B.94?0F7G]A0,``"T0```9````>&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;(V8S7*;,!#'7X7A`8RT(`$>QS.QL:<]=";30WLF
MMFPS`>0"CM.W+R!!B+N`+@'DW^[^5Q\K*:N[+-[*BQ"5]9&E>?ED7ZKJNG2<
M\G`165PNY%7D]2\G661Q57\69Z>\%B(^MD99Z@`AW,GB)+?7J[;MI5BOY*U*
MDUR\%%9YR[*X^+L1J;P_V=3N&GXFYTO5-#CKE=/;'9-,Y&4B<ZL0IR?[F2[W
M$#1(2_Q*Q+T<O%N-^%<IWYJ/[\<GFS0:1"H.5>,BKA_O8BO2M/%41_ZCG7[&
M;`R'[YWW?9MN+?\U+L56IK^38W6IU1+;.HI3?$NKG_+^3>@<6./P(-.R_6L=
M;F4EL\[$MK+X0SV3O'W>U2_,U6:X`6@#Z`WZ.+B!JPW<3P-OTL#3!EYO$)!)
M`Z8-F&D$K@WX@X&C.JOMZBBNXO6JD'>KO,;-!*3+&B\:)[5GJVR]U;U<MHW/
M3>O[VO78RGEO'&D&!LQ&,3X91R*%T)YP:@&H"K"Q"-":PWB`K2)\.J%AULEN
MWLE>.PGF,W&[3+QA?[JZ/_G7&&'+Y"I;Q<`"Z#@4F4![!=%%8*#70_5Z6J__
M-8H_U*L8RH$'',:YK>:(YWNA.\Y%BO-<"$+NC7,[K<WU*"?>?((,39#I!(.)
M!!7#6.@20B:$X]RH((X*XEI0^#70D(DTPPR"^&@07SMXF#QLF(UB*+CTOZR'
MW$YQC!CE'*!R`BT')L)HAC,6N/-Q0C1.J.-,S+Z=8FA`C?*A!`W4-C>1#.8E
MI;@+.M\ID89"CWD!,P@%>"B8[Y>H@S@WZQB\_E%=`)F)6KPD4;WN&1_OF(V&
MP`4:^E,=B'+CDO`B0MG\6&TZB)+)]13AW+@DO(S0KD:89(47">H;;%8:(HNI
MS0J!QL7@)8)V-<)@*Z/XZJ>A23X*\A<^3"6$4.-G&KQ&0%<C0@,7>(T`72,X
MF=@L>LCD^(47".C6_L3\WFL(VIW`9.8"7B+`G5_?D88H\SSF<X,Y`7@Q@:Z8
M3.V$&GK<"L=CX54"],+F!OL7X*L:N,F`=Y#!Y@/XT@??9,#U"8$8#SB^M"$P
M&7`%T9`']?GQ(98SN-IDHCBWM]#2.LA;7JF3>-_:WW2?H;D:/;1OZ')+D?:(
M+G?J'OOI?KVZQF?Q(R[.25Y:K[*J+V3M[>DD925JS6119W"I[^[]1RI.5?/J
MU^^%NLVJCTI>N\MY_Q^"]3]02P,$%`````@`^(YE1Q7W9BQ0`@``C`@``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#8N>&ULC5;;CILP%/P5BP]8L+DE$4%*
M6%7M0Z75/K3/3N($M(!9VPG;OZ]OL'3K$%YB^S`SGG-B?,AZRMYX28@`'TW=
M\JU7"M%M?)\?2])@_D0[TLHG9\H:+.2277S>,8)/FM34/@J"Q&]PU7IYIF,O
M+,_H5=152UX8X->FP>S/GM2TWWK0&P*OU:44*N#GF3_R3E5#6E[1%C!RWGH[
MN"E@I"`:\:LB/9_,@3)_H/1-+7Z<MEZ@/)":'(62P'*XD8+4M5*2.[];T<\]
M%7$Z']2_Z72E_0/FI*#U[^HD2NDV\,")G/&U%J^T_TYL#K$2/-*:ZU]PO')!
MFX'B@09_F+%J]=B;)^G:TMP$9`EH)*!XEA!:0OB%X!MG.J]G+'">,=H#WF'U
M;\.-A#,E(I4!UVHR):Z#.Q6]Y6$29_Y-"5D,FF#V!@-'A"_5G5L@ST5'FH[N
M;U`81+I@AW#8(9PF$=HDDL<"T2`0304B*Y#^:W**V5L,2NYCBO\Q=XW$3B.Q
M$8C3QP*)LQ3)\E*D3@>I%5C-E&+`K&=*83%I\-C(RFED907@C)$!@V:,#)CP
ML9&UT\C:","9;/<6DT8S1BP&+:@(#)Q.=%@=C]4"">@\'Q`N/R`0N5V@!4=D
M`*7Q3$5&T!(SH=M,N."8C*"9][L804N*Z[Y&8+3@J`R@=.[M<8",&7]RR3>$
M773SX^!(KZTP%_`8'1OL#JDF\26^5XU7-X]/F3SK\(7\Q.Q2M1P<J)`M2/>+
M,Z6"2%_!4^R!4GX:C(N:G(6:IG+.3+,T"T&[H?>/'R#Y7U!+`P04````"`#X
MCF5'_&\XY4(#``#1#0``&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R-
METUOHS`0AO\*XK[!7WRX2B(UB5:[AY6J'G;/-'$25,!93)KNOU\;&TJJP>62
M@//,O*\'/+&7-]F\JK,0;?!>E;5:A>>VO3Q$D=J?196KA;R(6O]RE$V5M_JV
M.47JTHC\T`5594002J(J+^IPO>S&GIKU4E[;LJC%4Q.H:U7ES;^-*.5M%>*P
M'W@N3N?6#$3K933$'8I*U*J0=="(XRI\Q`\[P@S2$;\+<5.CZ\"8?Y'RU=S\
M/*Q"9#R(4NQ;DR+77V]B*\K29-+*?UW2#TT3.+[NLW_OIJOMO^1*;&7YISBT
M9^T6A<%!'/-KV3[+VP_AYA";A'M9JNXSV%]5*ZL^)`RJ_-U^%W7W?;._,.;"
MX`#B`L@0,.C``=0%T"&`^`.8"V`?"IVER$ZE*\0N;_/ULI&W0%UR\WK@!XTW
M)HG.'*@NFZZ!Z@8?S>C;FF9H&;V91(XA(V9CF=2#;"V"!R+2!D`7)(042!=.
M/`)?$CM+I#,\T-X#'5>"NDK,2,#Z!&R<@+D$GTS&'5/;:5@&)RDGC-&OE6)0
M*;9**/,H6083BA%"T]S.<C$:4Y-V$M!.XB9.IV4VEOG&8Z^;K<-82K(D];AV
M7,KUFSO#=PKZ3IUOYC%DF6^8)I2RKX4R4"AS0K&G0);!*<.,,-\K-`%.6N*@
M)>XL)1Y+EL&Z0!DGGH>[G0`G+6$$KL!NV)A*9Z3`X+0PAA<A']MU$%YDV0PA
M`@L1)_1I#9H_G)&2I9(%G:-$8:6^,7&O$G5S(O$,);B!8=?!./(J.6J!9G1*
M##<P',,K8OR8-@XB"X*]?@!LV@_<P7`"+X=[/XDK<<Q]+Q=`3=M)X87@.A.?
M,R.XY>`,7@AC:-M#?$8;P7`?P1Q^DO<Z#N(S>@-!H`Y!\!.ZT^DA/J-3$PR6
MGK@&PF<L(P*W!D+@TJ?CU\1!C'*>4#QGXP1W!T+A^H_%-@Y*&$GBU/<OM)TB
MIVW!K80P^''=V[)0S!&/64Q]U9H@K:UHM/&M1'/J3A`JV,MKW=H=YS`ZG%(>
MB=DX?QK?ZM.+/6M\I%DO+_E)_,J;4U&KX$6V>EO>[:&/4K9"FT,+7<&S/E\-
M-Z4XMN8RU=>-/7'8FU9>^@/4<(I;_P=02P,$%`````@`^(YE1S(9;%JC`0``
M`00``!D```!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL?9/;CILP%$5_Q?('
MC`GDUH@@S5!5[4.ET3RTSTXX!&M\H;83IG]?WZ"T(N$!'Q_VWEZ6<3DH_6XZ
M`(L^!)?FB#MK^P,AYMR!H.9)]2#=EU9I0:V;Z@LQO0;:!)/@),^R+1&425R5
MH?>JJU)=+6<27C4R5R&H_OT"7`U'O,)CXXU=.NL;I"K)Y&N8`&F8DDA#>\3/
MJT-=>$40_&`PF%F-//M)J7<_^=8<<>81@,/9^@3JAAO4P+D/<@O_2IE_E_3&
M>3VF?PF[=?0G:J!6_"=K;.=@,XP::.F5VS<U?(6TA8T//"MNPAN=K\8J,5HP
M$O0CCDR&<8A?]EFR+1OR9,@GPVK]T%`D0_&?@42RL*_/U-*JU&I`IJ?^L%<'
M)]<^Q"4C$]+<EDQH/OONK2H^;4MR\T%)D\\T+U&3WU?42;&?),0!+%+D(\5Z
M3I$GBMV_:^R"1D:*J,DWF7ONR^I%V5V<8A&G2#C[!SA1L]X^IEE211@R.ZV>
M7N`[U1<F#3HIZPX^G%*KE`67DCUM,.K<?9PF'%KKRYVK=?Q%X\2J?KQPTZVO
M_@!02P,$%`````@`^(YE1\)\`OKU`@``Q0P``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&ULE5?;<MHP$/T5CS^@ULJ6+QE@)@$Z[4-G,GEHGQT0X(EM
M44N$].^KFQT",H@7;*W/'IT]XQ7KR9%U;WQ'J0@^FKKETW`GQ/XABOAJ1YN2
M?V-[VLHG&]8UI9#+;AOQ?4?+M4YJZ@@CE$9-6;7A;*)CS]ULP@ZBKEKZW`7\
MT#1E]^^)UNPX#2'L`R_5=B=4()I-HB%O736TY15K@XYNIN$C/"PQ41"-^%W1
M(S^Y#Y3X5\;>U.+G>AHBI8'6="4412DO[W1.ZUHQR9W_6M+//57BZ7W/_EV7
M*^6_EIS.6?VG6HN=5(O"8$TWY:$6+^SX@]H:M,(5J[G^#58'+EC3IX1!4WZ8
M:]7JZ]$\R9%-<R=@FX"'A&$?=T)L$^+/A.1J0F(3$M\=B$T@9SM$IG;MW*(4
MY6S2L6/`]Z5ZG^!!PCM%(ID#KMFD:5P''U7T?187Q21Z5T06@T\P3P:3H7'(
MPD!@0$12@%,%#ET[8)V.QS>8&T0&5S3<)%E>D(S*C'N9\:E9L<Y/$+I-D/0$
MR2E!8@G.RL@TIC5>&`R!`D%&QG%SRP5YBM,K?`N#@X1`#"0?!RXM$&5I3C)\
MNT3B+)'8$CT(4J?)J;_)F5-!9@GBK[6>8A8])AG'+'L,N2TD=PK)+4%ZFZ!P
M6E'X6P'(*4&';YDQ@+(K;@R@W$,,N,6`I2@\*+#3$<!W6!*[5<0^EE@0H&N6
M7(+&Q;@/!.B[V.-,`N*VA-QA2>I6T??<M7/$@M(B1@BA*^>(!<9GP'%1[C8&
MVW_@<9)`[K8FO\.:PJVB\+'&@&2]Y,(:\L4:`X0\2;VLP>ZNQK87(?:@`*<U
M&/RMP=BM`KNM^5*Q!0$I_%X&[&Y:W+=:XD&1N"M.[JC8_=^&R>V786E!0`BY
MK#@ZF=$:VFWU=,R#%3NTPDP=0W28P!^QFO'.XD_P,`='?"$G=C-??]+/)OMR
M2W^5W;9J>?#*A)PL]1BX84Q0J1E]DV7OY#?%L*CI1JC;3/EAIFRS$&S??S0,
M7RZS_U!+`P04````"`#XCF5'SRGYZQ\"``!G!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6R-5=N.FS`0_17$!ZPQUTU$D'*KVH=*JWUHGQWB!+0V
MIK83MG]?WR#L+B%]P?9PSIDS(SSD'>-OHL)8>N^4-&+E5U*V2P!$66&*Q!-K
M<:/>G!BG2*HC/P/1<HR.AD0)"(,@!135C5_D)O;"BYQ=)*D;_,(]<:$4\;\;
M3%BW\J'?!U[K<R5U`!0Y&'C'FN)&U*SQ.#ZM_#5<[E.-,(!?->[$:.]I[P?&
MWO3AQW'E!]H")KB46@&IY8JWF!`MI!+_<9JWE)HXWO?JWTRUROT!";QEY'=]
ME)4R&_C>$9_0A<A7UGW'KH1$"Y:,"//TRHN0C/84WZ/HW:YU8];.ODD#1YLF
MA(X0#H0ASS0A<H3H1HAG";$CQ/^;(7&$Y%,&8&LWG=LAB8J<L\X3+=*?$UPJ
M.-<B2MD31DTU39C@6D>O10R3'%RUD,.$(\S&8K+@/F1G(7!``&5@TD7H3V4(
M#3V\GV!K$1F<\?!09/]%Y*[-J+<9C9L5V2J3Q6.!N!>(QP*QZW;ZT>08L^LQ
MV>,DR622Q`D\?TR2&4QC&VXQ$"Z"(+@/VUJ8!LV@=A85A<^SL+V%A1D<P^[6
MED[6EKK:%C.F+2:=-^.$PJ]>P.@:4<S/9H`)KV271MH/8X@.,W(=ZFOX*;Z!
MRRV<B._43+4C\"9?Y"TZXY^(G^M&>`<FU>4W-_7$F,3*</"DVE*IJ3\<"#Y)
MO<UTO^P@M`?)VGZL#_^6XA]02P,$%`````@`^(YE1\<N^8':`0``X`0``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-3$N>&ULA93+CILP&(5?!?$`XPL70T20
MDJE&[:+2:!;MV@DFH#&8L9TP??OZ`BE3H;#!]L_YSW>0C8M1R'?5,*:#SX[W
M:A\V6@\[`-2Y81U53V)@O7E3"]E1;9;R`M0@&:U<4\<!AC`%'6W[L"Q<[566
MA;AJWO;L50;JVG54_CDR+L9]B,*Y\-9>&FT+H"S`O:]J.]:K5O2!9/4^/*#=
MD5B%$_QJV:@6\\!F/PGQ;A<_JGT(;03&V5E;!VJ&&WMFG%LC`_Z8//\A;>-R
M/KN_N*\UZ4]4L6?!?[>5;DQ8&`85J^F5ZS<Q?F?3)R36\"RX<L_@?%5:='-+
M&'3TTX]M[\;1OTG(U+;>@*<&?&_`/K@'N9C?J*9E(<48J(':O4,[(Y?6Q#@'
MRKF9A,H5#[9Z*V,,"W"S1I,&+S1'K\%1?M<`X[\*P3,D6D+P!$';!M%L$"\-
M(I\@C;ZF)$[3^Y1>@S!*\VR;$\^<9.%QB#T'HO0K:"DZ>E&<1R2'VZ!D%93,
M(/(`Y$4))#`CVZ!T%93.H.P!R(NB+,M)N@TBJUM$ICW&#[;(:U""4)+\?Q;`
MXO0.],)^4GEI>Q6<A#8_@CNUM1":&1_X9-(WYKJY+SBKM9T2,Y?^#_0++8;Y
M/KE?:N5?4$L#!!0````(`/B.94>S@2?&K`$``%8$```9````>&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;(54RVZC,!3]%8L/J,%`(T4$J4E5S2Q&JKIHUTZX
M!*M^,+83.G\_?@##5+398/OZO*YL4PU*OYL.P*(/P:79)9VU_19C<^I`4'.G
M>I!NIU5:4.N6^HQ-KX$V@20X)FEZCP5E,JFK4'O6=:4NEC,)SQJ9BQ!4_]D#
M5\,NR9*I\,+.G?4%7%=XYC5,@#1,2:2AW24/V?90>D0`O#(8S&*.?/:C4N]^
M\;/9):F/`!Q.UBM0-USA`)Q[(6?\>]3\9^F)R_FD_A2Z=>F/U,!!\3?6V,Z%
M31/40$LOW+ZHX0>,+82$)\5-^*+3Q5@E)DJ"!/V((Y-A'.).OAEIZP0R$LA,
MR(IO"?E(R#\1<$P6^GJDEM:55@,R/?6'G6T=7'L1IXQ,4',MF5!\\-5K79"\
MPE<O-&+(`K.?,,77F$/$D!F!78+5&&2*42QCD$@OR/\69<#(:!$Q67[;(U_U
MR,<VRML"Q:I`<3OD/F*R39G>=BE77<HQYOTW+A&3I9]-\.(*]/0,OZ@^,VG0
M45EWF\+1MTI9<!KIG5/LW".?%QQ:ZZ<;-]?QWL>%5?WTBN=?2?T74$L#!!0`
M```(`/B.94=3>ZJ'$4T``+D6`0`4````>&PO<VAA<F5D4W1R:6YG<RYX;6SM
M?=MRX]B1X//@*TYTE'=4$1";`._='D>P5%*W["JI+*JZ[7#L`T1"$EP@00-@
MJ>38KYAQ[/[%O.Y[?]GF[5QPHZBJ\NS,KA^ZBR*!<_+DR<R3F2<OORZ*4GU:
MIYOB7[ZY+\OM=]]^6RSOXW54]+)MO(%?;K-\'97P9W[W;;'-XVA5W,=QN4Z_
M#?O]\;?K*-E\HW:;Y"^[^"3;;<I_^6883K[YS:^+Y#>_+G_S.EONUO&F5-%F
MI4XW95(^JO,-CYED&W6LBOLHCXM??UO^YM??XCO\WDR]S3;E?0'OK.)5_==%
MO.VI0=]783\8U7^\R#[V5#]L_]'`,V^%I_ZX/'$5WR5%F4?PWD6TCNM/7=_'
M>;2-=V6R+-Z^]F'`9:]CI!.8.X]2>&05?U*_BQ\[`;Q^W#8F"OK'O^]\X5V<
M)QDN:J5>1V7C78TS[Y_^J0TQ<QAC1>.<I=%=_=?;*"T:(Y[L\IQ>2(HE+.F/
M<91WSGY\'(3'@Z`#*Y'Z.4[3XP^;[&&C%G%49)MXI<Z+8A?GS>WM'.2G+`4"
MC/)'`"EMOLG/_7,!V[G-\C+9W*E%&96[0LE*ZB_\L4F7,A>-KTY@H7=9WMC#
M^7(9P^_PZVH?).HD6Z^!!Q9EMOS@JP4Q@KK<E44)W`+@=6ZU8%QV_`R^;@#Z
M^\%3;]-^M;Y[<GFQN'QS_GI^??I:O9J_F5^<G*K%CZ>GUPMU]'X3[58)+.TE
M,._[Q6MU].)E8ZIX";06$`L.N\AF7A1Q67S7^#DJ[EL0BJ*E4'F\C)./T4T:
M^VH3ERJ[55&:9@_19ADKX&*URG8WY>TN59%^!1YY,1O[LV!,,NC%:.9/1@,?
MABJV\;),/L9I8P//-Q\!PI:=O2R!U=525A#1"AK2("L!N_N?.4L^`6WP;[22
M]HDZ4/0NC[=1LE+Q)Q#13;X\!Q[8W"6`I'TS+&(`$:EP!=Q0)(W?>1D9P;%O
MH>V_Z4U^DT0W29J42=Q<AMG5;?2(6[H?V:D=J4ENMS$\M((]A7W;U0?"\^V[
M8ALMXW_Y!@ZP(LX_QM_\1NW?MSW3O<DV=\?7<;Y^:G7Y#F`Z;=\DGFW/+"05
M[K-T%>?%/ZO3O^Q@K]HH099>X./`D5M@ZH]1NHO5BWZOWP^^5T'?[_?I/SEK
M5;0K[[,\^6N\^EYM,OUM@N)V14R2=<L@D5G=TPU&=CX<*QSMG3^83/S)=.+/
MP@D]'HS&?G\V\?O!K`.B_:P[7X%P@I,<D$L\DFS4,MHF@.R6#=JM=RE)Z55\
MFRR[>*"H[$1,._'D=A+4A[QYJ+`]>A<A8=['H&5$Z1[ABV=:3((>1-]9L@'9
MF.!A@4R.*M>?YC>HRRS+_][`R'Y1^@3Q^0XQ'`':5UF:1CEP-S`Q;7P#TL8`
M#?HX]`VFE$.?/I"\G[^@ZMM/KJ;U\?:EM#ZZ;QTN52VNX9^WIQ=`49=GZO+=
MZ=7\^AP>..PP'QRLBC>.>E"$LW6L+$5VT]X5B^[VL^HD*XB:[[)L5:@"&*K^
MQ`]Y5L#.Y-EMDXLOMZB+H;HG!V936"^B%*>^BS?P:.H3\T:K=;(AM1\E31/>
M`O2GY3T]N@+@TVR[;M$A7\=PY``#$NO1L&O4/?_::F[(F5N'MWM!*:RZ_=A,
M&/5',L3+QI+?@A8(2G>TB3/0@/GQ%DTB!D(K.WX6X0)P+&&#.O2#K!6<YID*
MVW<3@]R)];-E]*EY*EZ`TM>V:'K?,*:O;J(B6?+>).D."+RQ?CW2WK?J+_T<
M)W?W>&!$'V$+[F*UV:UOX'V@S:5P:(,U#QAV#[>>S!<_JK,WES\?R*W.\V=7
MEV\UMU_\H.8GU^<_G5^?GRZ:9^:?=T6)U%NH,D,E.X-M!?5QHW$$W^+G)>CF
MZA8.B4+MBI@.5TNL$9[([;J0RP1-P]/R`^(QJ6NO3:F>?4P*?/J@4XKT*-P"
M@!?V",GO(#A6^NRXW4_E)_<`+LKM"BX(<MKR]!`-V-HU[=S<C@E41%6)BF@D
MRJ86<&W$?N#F/450YQ<_G2Z>(*AW(.]!VK?BZ]T.I";L!N(8Y#5`@+8[(`K5
MHU81V@%\`D9:\4S@S\XO0+]Z`O@\6\8QG#.W>;96!9P,+GOS`2RV9_L"*^_'
MG^)\F?!RLRT2US->>(AR=#H]M9U;Y`@XF]7-HT.MW5B!8SF/<0M(.6Z:VVB"
M@]2*[Y+-!D?"G2)70_N#,>KG78]<_WBJ3B[?OIM?_+%!VOE=M!&.\]4)8"9+
MDY4]*=^AK0;20'.DU66-0E'LT2@N+J]/O4#]\C^5`X.J^>H\]-7!>:\NXH_1
M*H(=S;=9+B"!>*D^CM\`/Z+C9AMM'GT%A`Q?Y'&L'D#-3Q]5]H">JV)W4R2K
M),H3U"I@$Z*W\0H]@V_>G.!DK^,T@KV-O319HSPW0N*11!0-#5/]Q"_ZZE6V
MC'Z`63;:N[@'8O,L:S$XQ@E,1=A<Y@F1H%J`#9PL`3BS_K,4=-26X?3[/?5^
M`SI20>N'\Z&,/Y5\MC\@L>;(O3FNMNX,;2ZB"IBW!,1I:TXAI`6<_F6RCE$L
MB@R&\P<P_4VVRPV"OE'?/,3X?_@2_@%0O]D5O6_4153N8%2@EU>[(MD@R#_'
M'HX;J0<8>?/+OQ;J/H[2\AZ('[X&[EGMEJ4>&$Z5)8D80!.R"4N8#1T>:V3-
M*$W^BM_)>X"1*+^+2Y*^RQ3FI(7@V433];PY.:$0;T#<L7P&G.WT<8[X%-JW
MYPT9GIK,??40$VY<X+(-SH^@T)ZDH*VB7Z_,X=T"1!3L;Q'ECQZ"DL=W:.IF
M.:!XB_("/3>U11E&0S1'JX]H":X4V"X@^&*<`_;U46U!P5E'2]I@-+(%"SW<
M>+7*=W!,HMZ#:V%9[>%!@QM7`Q"7LXJ+Y&XC&PQD\#%!#.%RBL?UMLS6A#H$
M%*A@M^2?9//RI/B`)%+L4D("24_`5K:-8-KC/";3WM/PLXD?`V:12D''3'>H
MG<'Z2A"C(,CP:Y#G<0;T#[9RP63Z,0(I"$"O0%W.UH#*L@?T),"3UB\;`!M:
M1Q5BP[/8@$V\3\!B0.Z)`"DQ"JY5DO%.`")!C8#3'$>(4OQ_EI.$SM8W``)S
MY$,"*T<D1,F:M128D6T4M!>`"6%GZ>P5;'OQ+:P[6L*^HR[W$*/*5"`P"&4,
M)T:\`;V#B1P^W_.N@_B*%;P*C,E651HS@R`W$A"D2Y4N(_34)6QSC02(\XB/
MD+1QBR*UA9W!*Q=<@,%9O+S?9&EV]PB``:@$5<SBQK7$F$+EK8)!N0>E7-TD
M6?0Q2E(M2`F%7@.%/9"?,"`[B8BMUM%F=PL'R`Y%!.GH,%-R`WJZNH'3=R4>
M*+(-08W?NG(4_H!A@3Q0Q@.02#0`%-A5^&\&1L(Q+."8M+PX]Q&<R^L3WSS>
MN"9Z-5^<D][_[NIT`38`&>IJ?O%:79V>P-]O_JC.%XOW8";,3TXNWU^0(O;N
MZO("/I^PU=!Z#H9X#GZ%P169A,G::SV,001XJ(>3($72L"(NX?>>%G6XO6T7
M:II[F'-C$BG=AZY7W&>[%#0B/)HB=@-FFS_O-DO:-\M&ATI@HH%-5C))YC$(
M+(&$-6F`9K[9[.`=OEWR8)8SI/&@?_P[.@UPND>\<XF)IEZ#?";;4=^3$.D@
MHZTL>.*DU_[$TT]+LC;HYB@I"GU(TZ.G0%?$8(0G[P$%5`Z'T8H7ZFY+9;4W
M44H^/[K6);*];0+'XOT9>^NU(O$>[&;8DY@XAX4)(`^'S5<$!*U<3#F8Q-OF
M@.5DBY)`G#.H)"R7\98GIK6]WQ`81(@$_GR-K!H1;GZ8S]\IGW9`PVE!2^S5
MKX<(-HA/4*CNB%C(^M5;^7O:ASE8BDN0B$$?9[OBLY7TJN,_]-2<E@/0IZ#&
M@0K"QQ;K-AH$]VBO;X_W.5RSRI`Z#7<`GK32X:S1(6)1V,AF(!0A@A"&%%29
MULU[-@FT`PHZ':I[!&%D'0\^O9J008?*VP9A3M$PWN4YG4[NLW1$D,M&2`"/
M84=[`9D>W=&$OE6$2,E0MU&26W@TDEB-*!`+'B.-U\-&34%2'QZ/5STM`<TK
MN*V(>CU/`A2:P/&W)+\A3N`,C@#L8.4H"(@\4>/4+C*6K#QE#\AJ"3.FC]XY
M7X/,#5>`+I]MX/-24'J^\7Z[@UGQ7I_)R4IGYZT%.J2B'%;S*H-_:/JS^>*5
MKR]:;DG3N=LES(N$9*W8@]0J61`!%M=@/:*2G>A[4E0N<%Y6,,0RQO'14`8!
MC-HE>G38F0[G."X8QM]TOKB.\@_P[M&;2[#<7C+M:<@\4&%3!"7;I+2K&@[\
MCA1OT;/0<PFL$:./)-DPL8-M<8\[FED80/LKCX&0;I,</F0[G/;\[/*E%JT@
M[4&Q<%;+8ZBCJW,$[=1@!A$&NJ?"M_%E^!U$"FPWJGS)!I8.P.(#\2>F=)4`
M+R4Y4>(Z6\6I<-DF?K#[L,I`C4(*$^%/VGZ4+K7006YI0[/H40(<DJEA>@!#
MCX"F*\AC1.DC^YP%-,*\IZ'HJ8NV.1+6T-`1LR:>+T#W8:40[$O#G2@.D0.!
M%G-V;=R(<>8KLBIS"OJ`@1^1U8!Y2IS$(P>+N%]0,M&!!PK:-BO$@,&HG`(/
M7-'NWL/ARKOFXA`L=2`P4,=\BQ#:F$T&I`=(14JMX<5C"A%:)RA^^3<FR]XO
M?ZL0)**!E67D>*3`[0YTZJ59I9T5?[SE``R4`87C9HEN@4X]<_0B+P-'C]D.
MJ0LD/*D(NZ#,5P8$>HQR/"17[&Y"V+9(_R5)+[%=Y)H;GHMQ(\E\8,$'!+D4
ML0AOFA5F8L0=I">AL91FA+8>2R?0\!WI!$)'RYQ6^?1^BQ.0@)HOWOOJ(NO1
MZ\=!WU?7:"F0(7F2P2+DC,9IS]=HV9IC-4-G!C[@K1+8'%@O"&C`=_F`"@A(
MB[NJO"-R`O!:03K)8!"2Z:)SS1>@;RU3D/>WC_2:I369EMT7-"LI%^OH`U@;
MR08U$0=2V'>B'*0`X"H08F"](/[A3%L"_DQDE@@8@\%5#`/`L'AG@LHOP$KT
MA_M;H4;/I8]GDI-?)U!5)]`1BRR)%+'`5L#PDC7`BM9]^DA$*/H*.JR7I5AY
M0K"HP"W>ZPW'?22U,5(H8=!WH`W3Y]"D5Z?)^>X.]`G1O!M4"?,+T0V/<9V'
M^"*/?\@02R<9['B^44>+W0WM(8PR.A[V7WZG7AL84,5YC\^A)X#E\PT>/'`:
M<7`8>JGF8LH"!D[T`0+Z>:0J$_4TMA!2>UY;%0C?%RXG88\;Y9$1PZ(@V[`U
MS$R$][":U/((?7N&MM`-@M<M`BL,X<4&V,@"NZP`>Y>)R4%8$4)#DY^,(:8I
MQ'_[SJ'.S'MRA-H26_AP,L`T-^8G<X(!@\*/+W$AH-7<JB+SM3"2\Q`M_2K&
M&K([8CM.LT9,MW@UXO>T=-['3;6!GF*D\5[1[8(&+)T8+53',NIIK`+4B57B
M)V0_.&L_)MFN@$G)*F-\/LV@GHO`K\.@C4/C;?18YTXMH4D%9W_.7A57'9W#
M:R];N;H_\Y4$';#9C"R&%PF\?=X)2(<,[,A"'5T3%X_[8]%#"YD%R7Z9D0M9
MK%36A]`V,>YD4C/P2O5ND_PUUB%J3+))R?K++4X#)P+8]&`Y<Y0#[&(A7GKB
M*0,.$1:&$>R0M5E')Y/*^.;1>2>^,GC3TH(&B?>4A@4>(A9.V9J.Q<'@L<,"
MN:8!#7G05L34R%X\J%6H1(U"+9=.IC_O5G<F`IR/0/Q::XP%J^`[4MLT.3I:
MYS5Y5M?1HS%M87$`\>VCT#P9MZ2A@,9U%[$@$[US*5OJZ^FTLURP!T(8#US2
M9RMX\ZQ[1X]%&Q4MQ>V7B+Z`T:=+.V[S(92]$>"_0'<'"N`.D`FKUHKS+,V3
MNUZ\.'AA2JHO#$L7U*Q]&_&E+Q@,>_9GAEK1^-%B=[^DV:N(E@X#=.J]%757
MA%934NT3B![,.&D5KG1R)9N]JJRJJK(N.@Z525Y#)OT<>R(4;V(P/S^RHQ]8
MF3R-UK75*@?W^^`ZI/3*<0_DVAW`P@ST,CB"$9A'L,O,)OB.\\QL4R%PX69;
MKYF.=!5_0R-NXOW;M_.K/Z*[>''^P\7YV?G)_.*ZXAF^?'-^TA9.XC@J8(5X
MX?+4->T`W=.'SXB:OIC-J$A10.X;<G5RQ#1N%8H2L`#96,YSPCG9K$5WY`$'
M;.!H*8W6B$5A-Z*UV5&*HUFIM2;TH7$\"-YZ+9-\N5OC+BPI0(1\0K'1XI.\
M`1G*.28P.C(PR`@F)RF(A`;Z%!BLSOQT.?;H@LQP>JM=;F02W4^3YP]L49"^
M%,S'3N@%^E'9T2O9-!RS2Q[?,YC%^XG,_(K&>TZ^4:;1RUWNN>Y4^XNX\U`,
MKMDIAL"V!?)'M3AP%JRUB!8^>0V^C`#W/G](%JV?S#&$&T+>079MW,1+O$C4
M'L+B'J37,47;K/&*.2$KS2MV="=AUDUB8LF)(7C>TUUJ:S20<6+R?"M%VJF9
M'KVUCOL38\B0ALB'25MZG.+]H_O*?0+TDB_O'[VHH/M.<7F!J:JF(6PP[JCB
M'7W+;@V&V7M#0P7HT"4W*[SWEUV&_]`IQDH'2WGV@`@GT%&\-%D`2/_."K^7
M<</:8/AJD:Q!D\_;7VR9CMSWVUWIH"V[096$ME??K]!H[F"/OA<G)#]7"=KD
M2(8YL:+\!:C,=G?WVM^(IGMV8P(@"%)K_J1LZ9,'ERA!:*.-`[XGJY,1,`#$
M.M#*0KJ!!@.E]#IXL^7>Z"&FLV*3=6"3,/80/X?2B-T\]R&,S".:2LJX(FMH
MMKH`0LU`/&<KGF"3;8[KY(S>,3BF$E"-T;<"#.WBR1,\'0D27\HMWB9V+O%0
M_!FWIB,9@:7+GE;PO2O6O^DU.AOJZCB"B+%6=W+VMMQ*(1>-^R-K-3B#DC+2
M-BI0#&GZK+R12[0`@8G9/QB\*)YI%EIP(!6[".-'X#A!UEK&+.!=T-@_*[=&
MHI*+]H9J)2H&'-=!037:*$]<#RM(!]H7NJ_W+J]/)/Y@S[VV#79!QK,W<:0]
ML\JMQ62TMB$UA+<BQ9A9=&\;!QKA%\$5%[:XQY`#@2!8U/.Y\:BL[\ZZ[G9T
MC?X<L,5/7<"KC%4X&!"=/:7C$?/"D\LC'+I[)'C1<*Y>IY$F8&L!?V_-D/H^
MZC`HO;:Q/R8H[Y-\=0P&!&PE/!.CE_<5J(7/Q0(%)]MM,A@'&;>E2^LRCM9J
M5R82XJ2%M'V0PC0PUQ>C/71XPPF'-WCO]#S`8DPCH.T@B+EK9^N%861EX:@'
M%'F,%RVD.NS6M,I6MFH99K>EV&M6XWS/\%R.M,?;\```X1,<3I04'_!;BFXF
MU7V+@HM,5VU%(P@$@0TY*&]@J2L/A]GJN##0]U9TY7$;\\F5NZD,S(XW:!K#
MN.LJH)71S:!&/R%Q5\]\Z'ESV(\_9Z*`L#%CG`.:@ICH9#LX7@>O53!L%.P!
M!@J.C1T('.1CUIWTU5*!YFI9IBQPT%QXR!@QH'9X-]'F`X*YBAYA@T[LL+(5
M&*NSQNUJT<QTL`%^E_+]*(Q+[Q$N)))5D4?`.":!E`?]8Y@/E=?X\?@F6GX`
M&0Y*&-`V6AB/XC]@5\=#+!$"AD;X60FP1=0(H9'R?\(A<+'%8HWL^`6']("D
MO8(S1B00V-Y_R52^((/"QG9T'U&=#(FE5PG*K+`/7J/1Q!MD5(I#VA>%I&63
M9291:R@:"\-D8H0G+R26CE8OD7Q)W,%GGO!9<R9577UCJ2#]\KL8MTG6K5$+
M0]^@MDU:LFR2WAP8:+>!H8A.]$0$@B5O[5A5>O<Y`QIA2#YITP:P@#(THYEW
M6_P4A/K'VPR3W#BTA*<`=DMRN3V\;,IJ0:WU,HBOL[B/4Y`?R2T=)^'03(`0
MN\&>3GP9Z'6TSM_"5QB9R1K<B#0XT#%S"B*UGBJ-&4Y>`&CNX>C/<E*X!0$Y
MV2Z\J:BNH`(&4]G`3#-(=!>A<LK7>I(%BW:"L/X*B5'P)N`I%SR3#L$7XE:=
MHO@&HT3)C495F4)G0&K%,;^"4'GV^I74&G8]>UA3@D9!]0*SDYAJ*$0RC];:
M!1K?8C@FQ2/H%R(=EDBB9:M3'L7CP<?8-HWT95]&3E<P382$75+UTNPQ2E$7
MOW;.@QHH'%Y@8U@Y:I&=<DA\14P(!1-BG;!3F.0_^4=[ZOQ6SAKZ\B^P:Z`A
M49PH"@#D>#W=\CY>?M!GDQZ9N%9+'K8D*@F<-9@=.D+!@J=,GL3ZXA.4>U@X
M1G)P9E.!ARC%VR'ZT96B54MC(2:W-K;&9R4?U@!$C)Y%L2)TFIS'IHM)D]-I
MT47U"2>1CBY9K_Y;M-Y^_]IWST3ME:4K@%0_XJ0[^-9QCJ+YDSRHG<%$_)2Z
MESD)"`4%9YY<75(DDD0=B)-&!RZ;%X&L<!K+V93FA9>F\?%N*W'#)I>!AF/<
MR26I`;6GKS)2K[:.Q^:203*B88H!**BOI;S4*)4T@QLX&FX3/1.:6WR2H\YW
MW,Q_<CPK<X[U]D0G-A<#_``Y#&]W%!^;=V0].DMB0_/%;#CUA[,9FII-0]:G
MY!8BKQ>3T<@/1B$ZMSPWHK*MU`)7<`AF`W\PG)`[S'TC->E0M0()3_M?12WQ
M*`;28D1]38P$?C`9^?UIB#AIL>*S6T^C)`C\P3AL++`;)</QP)^$_2]#B=<=
M%HJ*WM7E'MK$_#[-)@Z=LI"Q=WS5'``X\W8KX@):F=<]O).^0%(M-5D9:7P'
M`Y'JS79O82,5S0:0=EA&'\`HP$N07=XR(.99>=93LDP!ORB.T:/1O<L-2/$M
MBI_R74A1;]'2$Y,7,:EJAWZHX_L,?8QP^-_"]J.>+L4-D.+T\7?V>LY'"$7\
MXMF#4A=YOH9/YQ<J/X#Y#B5:W>H!HXAA5C@J@!PJ"1`<B2L:49DMLY1169T5
MD/J&4.V@]?.Q)<D9?(U%_A^8WB46^,%8D$"/$5\N45IAH<_NVUTN,7RQZTRH
MS"@8L391LHW3Q,TW8/K;E7CYYS$UH1H+"C@<IT5FD^LP#2(F7+A'@=[3)1%I
M1'&_G0CP*TMP:%"VI>?Q=6<KC1OD$<;9Y2!'%2`_P_1:'3INMM27LYL^DCHL
MG$!$F>4?#&),OHC.SB&=@#(L[]A00U."+056[_<=P<W#SF%JV#I)/*68$^(=
ME&E:^?M0E;MX)EO5);H#&W1US&H4"#:35>->$9O7424448Z>-!(XCZQJLPE;
MQJQ%B52$4S./;P%)Y'^,ZJ<`(HLM<6(O<SU/?(`F_DULTE/E?&C!C7%.&-1@
M&B%'Q6LO'H9XF.=X2GO!J%7V2B"M=3,RM.2!C5:QV'9T&69O04B<VXN0=M'\
MZ)DG#/[-HBVH3,OH6=\XU_JD/F5$S$2B)CK'NEAT2"=NR%UEAR*;U.J!Q$82
MT+93FS;Q4)%`<-*&P<"?3H;:*:EO?LP:>76:>9QCLE:UIR*I&.BBK&TX':L2
ME^>L"5TSF]AX:*K);SUUJCT&G@8.=T0@XH"^/\LQ@)M7:%ZA^R8Y-]D*B3D_
MWT[M\JA]5Y.XV$)B.2<;SXD5BI9Z<7?(\3E&?\G"]4!X+8;5&:A66P]V@X([
M/%M239(M.?Q,BO=LI1@:)I<`3FSLKS$QOGK2)5KR)OK6%3<.;#=8-`X/XS2N
MA,NA$U0":W!5A<8!>FOHRDOOJN0!N_%2LE;/Q'O@:5.X$<^J?LS3'?]MU64G
M_CD95))ER,4"EG/<GL%2&1@C6&S,B<G0FZ=IS7/*F8R<*&0RWDT$326UII;:
M`O"15,E<5/,6>XPY8G=;9*!@8FF$&F!)@8OKRZM&AKBIP^9$3G:'$K37^:+X
M@B'&%YAIE!G7DUMJ<WUAW$/?M=V_-;1V3(-+0$->&:2^4%C-*AR$\`DDD!_.
MAMY5]&!#0J:A/PTG*@"S9S`,/%.[C%G_E_\%OX3^<#+UKB^OYV\<H'&\OM\?
MS>`3V!(P3A`,&E7,+J]_/+U2)^^OKDXQ=F*Q.&UF!)HY3]@R/>$"65BBR->&
M`JL+;AFZ+]V#$>Y!&WBB_=?L&AT_\)D;H^V=!#2IG$YQQM]LB/@;S(9P/DS-
M4YT:*^_*8!KX4T!V.)N!46M?<_2TP02,TL%,#<%VFXZ'WJ4)VF'/=Z$3DA5?
MXQQ=H-LI&+Q4X7#FSZ:!_E?>W)HI$(`PF('E.%;!%'=^;```,E[1/2*YNN"Y
MD3\>3("*A'I:T?U"`>F$?7_:'Q$IC083?]B?-$CI[/P/F`I*+_GJXO2ZI7`%
M!=$`T:21KO%J8FFZ0W[<@5O#@<9(*HWI%55-])R:AE]*)!98P,,`L#+JVT_>
MV2X'Z:?3@F^33R7E@8R!!D9#-0(-8S;",#5_W!_"SHS]_G#D5:O*.;6?CH(A
MT-QHK%["QS#T)Z-0O91M:B[UA1J-_<EP"A_`M`]G`^76T-%ZF;DLY!B?0T-[
MR$WP8D+0D/M@XB-$E;IZS/\OX.L`5J<_3X`)=(K<LZ*)JH,W3H!W5Z?OYN>O
MU>D?WIU>+$Z["EZ*5M8439\CCR9(9+6)M?0S"#ZBR`94#5^J+STK]"HJ;D-A
M\!=J-IGZ$T`U?((='PT'APHG[0X3'Y"05'UA=&9,0C@_`OH\#.&4&C?/C_.+
MZ_G%#^>OWIQV,.@/8(R0ZDL9-S9`[JL<$FK*!W4-!N:):Q?GBI4+'90G:;MW
M5`:N%B5&X6"&*=WZ:^PII6(Z];@R\<_4X_^B#AND/32GC3`\+E5WHF><TXP5
MN>&6HO(P[8Z?4;KZV+&:2_FQ2M$J*0=\])@7O9>>_$1)AO5E?.=163#UR[_C
M61CX,R**HX$_FPU!/L$!,8'O0$D9>J\;]);=>KI(3`PZX`TZP]4L`&DU4$?R
M[TM49#;?1MY<1R]+Q0;*.VG6QC!^$0RP&?5#=33L^\%L!@.-QJ`H]0<JF/3"
MD7>1;8ZCMI5Y>F4_[BW"H2?RCK:<UP$33$=^.`P08OT1(7^+!SN&]&.1CABO
MCC@[6)=N^)9\\'+#%0Q'_F0Z(/5-/MIH*8\+X1'7C?M^&.(A<Q0,1OYL,"9T
M!_X@!%5Q.O2:4N,_+[F`FCIC^$,\$D>P]-YD]!]-,</!#%2B(2`4@.@',-`0
M/N$.!-._![F,)[!OTQ#!U1^?3RY]$-GC*9&+?&PEE\$P!'*9$KD$`W\\[`NY
MP)?^:#HE0]\H[^Y55U'-J*]&X6HO)SWD.#@*JC8AONF*L]6LJ:<NZ<90?D;3
M_0Y+E*'E\!!KX:H#28Q9H1\7>O@8Z\1JO+FE0I9RC\X.+'J6@P,YW2"/D)2/
MR7/+R=?F]M0"@I:R"PSZO./C[)9CI#NAB22+!DM.]=2UW3XJ#A7GVYCNT\EW
M)JG^>IFK?4ZIE@4ZN":.`H824%`C<\*189]`3>,$89UTT3T6N;AJ;%,A:-5D
MFY8))SJ!^/47!X_[.C6B$;%NHDQ6E4H\5&$2+ZOQOD-X3>-&7(=\2]MY`ILP
M6%!1)=]+UNI<=GSG_?*_R04E&?PR@SA[4@X$SS@*4#;(=;`X18IT#2/'A\5E
M:&X>@7+9?8[9C^][BY[Z,R"TP*1VNKZ1'>?H52?\A"-&D@TL)YQ]CY"6#W'Z
M,>:`/`K]*YW<3`)70^M4.*I5DMJLG$)3SC6)\;Y1*'4-=/RN"W)Q8-7@+ACP
M04C.,(ZHZ][&A@],QXV8XFAZ+OANGM_A-=8F\M4<8Q2`B2-T6FRB5<1L=KI#
M2Q20^7Y#8=OG11[%J:_>QI^29>:K5WGTUP3^_FVTC>#GJUU1X!"+;(=QO;<8
M44/+YB]^E^5QU*L>EMH>(,MIZH]G(=M$8&^'H\\TPZHVD;&QPIE890&89?!9
M#_XE]I9U-U?UW[H=N<&J?K?H^V79DY#&RTHW'):ZQ0?N:D53L<-7E!$"Z6@@
M4./11:CS*'$65(FA/QE/.=/+_6M:^6MF_GK"V?7F?/[J_$UK34\V%IUR_5_J
MS)HUG5G.]#6/EAN+_X4>BWG])H-O:[01"88C:`;],=MXD_X8#,G0O+2-'G.8
MSU<WV69G[GU,*2D990;3ST"(3H&*PO[(O,U:@UPAZ00O34!C$,"SX1@,A[$_
MG/0MG#KB!"GOIN`2#,,9*/>3OAJ">C,<],7CU4C/&4RG8*).08^#L<<`2"VZ
M">\`34`CQ;B%_2DH4X&"\8?#<>T%$P5I*[QA+0Z,')@!T*!;!:"=C_H#`SQM
MWG0,5M$4U550T^Q/%!R&&SH,0`3TU02=(_U6MYM+&"_4V!_`D),)D;P_!3MG
M/)@U*!OMW3>7BX6"4T@M?IQ?-7PBJ.A3U6O0X[EWS.'4&_21?)MS<.Z2K@O3
M*%MMZT&;FMF2`"O7>FZ17&E[X*AQ#]H>:1;/UE6ST5!H+\#/[27<8MU97FF@
MXY;<5D[Z&U]T29D95`1EKLH%FX[8QQ@PH)7;..%P3<F[BTGOLU#JRY_VR5M'
M5I61:R>&UJ^\PY/S%EA7S).JH!3Y:#='PAY%(\)TDD\2$E0!DP'?:KV**X99
MG<!9A@7<K6_HZ?+$-F?!J>W<0)$)OJ[5+NHF+DY"8D?/#=B4#[H,%R=S;#-4
M$3@MBP;!<ZNP%?/XEK:6G%LOVO<$,-XS*#TAD?ZHR07]X65B`#,X:E04\UIL
M"#XZ2>0OW'T"+=T?HF`>AB"N_.D(K/'AP/M9[T0`8BA$J1J`'HQ-5;#QD0<#
M!H.Q/YX,<.S)9`8O-F7.XOKRY'<_7KYY?7JU^&=U^OOWY]?U&[D]GKN`2BV[
M8_SRKS*(LHTX>#'S]J!`K<`W&L8`=FI#-$6#[S3:X.1$,`*X'H\AZPH/UX&B
M;1/+@8)B#*OTJH2\'_I!L]\-3%89P`+JP.8VPNEXSX60[M5=$"^E?,#,@2>F
M_@TK21N5*@LZ%(PB:=;&%%F48%6";G`!&G,:@1U`@2NVU#7V\A`?#L_^P^X.
M]/+[.%D[92IUB>M"3-:MJ9OS,;8Y8I@R#;J$`8<BTG0=2X*#ZWB9WSA;!"5Z
M=1TEQLQPR8$,T\2D6CF>JV,_&`T[=P"#L>LO<GX>]@N;]*9]5PS9HF(4<J37
MT8Y.PKSX(;I6!+-+1HO47\!0="T\.64!T_[N[C"FC-,(1J!9S<*!L9@QBJ5U
M<=JNDY'18M$UY24P*4UUE3D)D,/B\Q23;K,7#%:(Z*J>@A=@Y85JG:0IG3)<
MO&$5ZVK4%;28K)":LNF&B-GL&3.K40)U`C?9IE)I2C]$97TH9H0H7]>CTL$3
MPBE#?Q@._/YDLN?\)O8YBV]RSGOH/YN'#/F>9`]`DW.'&)"Y^%N$R_!3-Y\<
MQ"8\XA=Q"1P0HVD?CI)Q)R4]P2?#7G]T`)\T<5)ED.9:/H,_0K\_F,!_X[\;
MAQS&&Z-9+_A/Q1N6K">M_`%T/H:?PFGX%(-P>9J9DW;^G`/F!U"3UO#,(EK>
MV].%:_2Z/SW!%2XW4';<2E>$,;Q1G>F+>&3JT_U3T'66FUSEI8F4DU%TZ4M#
M*^@Y&O;&DZ]WL'2O\T#^L8P2X.V3/YEUB0*[_[K7E_\4"):E.(VF!1)R7#\'
MB(L6?D3/ZSZ&'(:]Z5=DR`8;=C*>5!@<,KYJ7(<J.&CE_?%>ICL5'!;:)\]N
MH;I__@FST3?N52Q\\3%9[3#"V^Y/Q1*L;-!LM$^/12W[Q6R*T6JZE4SE\N`0
MC^7GPS:<A/YTW*DL$W"C*>`YG%GHVA`Z?";,P\^'>3(#U;03H3VUZ'QSGTE@
M9W:<M>HHP<O*H1_,!F9$0LH`L#Z"0U^00H1YE,#303#SQ_V)]0G`[&A#E5JT
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MI/AP?(L2/M&=&"F&0E\)NS6(9+U<1U`2N)%"*UK#@T.LAKK@V-W/0"UE=W!&
M[6#A]5[%L*"/N#`I"4$!KL@4F.-$(,]UFI)V$PBV^8F?]0*NZU]1?@Q=E3;H
M9M`+^W6ZJ;Z+7,[G\>6RS)S+E('BJC./G-FI1:BI'H`"P+GDS"Q:98!9RW2^
MYKPJ0;X(?$SJG(W&/BF"4H=)!)'3%HIW2ISFD=E@K&Y`?/D]UHBN$,YPV`MG
MO_J>*YH0K>0R7+\WG?[J>[ZQ471.8>;X8Q*G5#&A_ZL>MK7XG+O%%WVYK1P#
MW823>N3H`Y<5D'($1;V#XB'TU""+SZNA2-P@A60'+19+)=.NY@_#P4!G;/&#
M]8AR%R?G/@LBBG?B0`NWC5'FIH.A2-*A&6#88`T"FJO6+DD7/#5I5J8Z#%?H
MT=*-:Q\47%Q@B2F.:+0"0=R07D)W]V=9QIZZUSC'O-)$R?#>V>NY;UN"Z6S`
M&E2NV(I,2ZQEM`7<.7<9F+BCRQ)^W*4?L;S;QK;0BLH\V]Y+:[N?YK0W;73@
M&#R`8\GX<ZXAB#.EL`^W*Z7:-:VR;3H8[%4-S`'/NZ7E9%WQ,=99)/*AE6Z8
M#I'<Q-0.*3ZH6I%W9TR^JF%GE\DB`#[0ZO6ZJLO:+[!A42_"GGM=QBM%.:KE
M8<X);/@G6=PV0<^OW/D'/15.,;=AH&=CG3/*-RS!:+U:I))RQ85=(EN_[-PF
MDI*A=Q$_,%$Z,2'HQ1""E*JQ-FY%RA?40IE(N2BRV_(.#N&#B!*H[GO;":)S
MD\O[N'6#I>@:8P&`H$L>7)E4.*$V!R(N!WPXU(Z!81\,JK&-Z9"Q[!E5&8($
M:;5[B;U-;=-$:N>)5G#KIXD-\&@Y3D:]:?MQ$O2"\(GC1*H(D=PO[[FT-)8^
MT,NF:#"I2U&I1<%!797%?^^%#<KKP%,[JL>A&SYC3:@O1*IK.3P7L<,.Q`Z#
M)Q"[UX0P*'\1D&4WH/.F;*D5D7Q6'>)ZK!:GH!(RGXP5=*OH/Z555)8RF/HC
M*0#-RQH%C025+FKZZLOD6IX#38_F6LE(4&M4TFFT+266+N/84VZLA)+-G+1T
MEM0$&LEH%/KW<;J-L<B/5$>`HY(B7/%">9EL.>Z3JPAC!>Z/K+10.QN0<\LE
M)F1R+W776!WOHZ/=Q@2U=A05H*LL`,XQK,CXIK@_T:;QS`/<E1'6DZ\[QL<3
M.K/(#R:YTS8:E(."(Z>B5]";C*H1J0>G'3UM\QSB,<BX*(13(,2+R@X[A$Q@
M;9;50SKA@3D\FJHQ@A?V65X1FCHH6(=558)\$Q-Q(<[DT`_'$BN(V6?]:9U#
MVJ-,GL*>\6F8A19?R>7(5>RX.ORC8W.U;M$@V+M']=-;C^&ZI9R-$O]481U4
M(:;YS0YS4!WF??L/!>DK^RS;MV`,@G<ZV.MBQ914W";C8KVTWLMV?]@Y"@QL
MO_$0FYKTN`S\DFJYJVL\3\'0BKFAT8G+&IAJ:JP7>H6_*4VIEDIVO(Q!X&@7
M8.%+^92,'%U8D2?6+B^G&I"VM4PGC_N,`J-L#-!&-XHMLP>JLT^:(]4OD`H0
M%';(X4>Z":X3,Z0KC3\*Z+*AZYH'V5X^\/<$)\H,NSR#D3D!PA*&/]NF.8[M
M81#G!J36(L)DLJV3Q,I6E]_PES:_80^J7VEWH8/ZG*_DJ?H*T<(BU[2L@`["
M)2`[-NT+S`ITE!YN33BJQ]YT!`7QG2'AXS.N+)S3)?##`3,`2G)=PZ]^!]""
M^"=21VS88?>H%2?>R!]BYMEXVL6MKG.Y%1[BRR!LX4LXU#7K:IZLL2$\P=]$
M-8BW2&-L9J.1N6:D)N9VS.KO9A#1T&U510HS4^P#-"2ON*UY*2YL.Z-<W6UC
MRCKX$#^Z?)]A-VQB=E<"X!LB'5W^-_6ZLKPN#%RB:XU7ZPCXZB;"KTL-_FR,
M]W*=`5!=Q"!;\*4.^"ID;1[XK^A4=YQ3-EKB\[WKOJO'Q231W.RTRM*DTIP#
MB_;W=5F3S[OE<G+V*20W+B7963<ELK&Q/>\"QWO+XYTVQW-"2J\Z[A7`$IT<
M![W14/T*/H^G\'DR4;_R?K+('$WAJ^-QV)OA0^-9+Q@=3_IX>_,KCX[M(P"-
MM/:7:M0+X=%>.%(C^L=[735N,6X3!I%_KO==>!@,(S&Q-XA,+NX6$*^JSV,-
M&O77.,]T;57RAU[GU)#@$=,?L$D;5:<RO3QT021)B]MB87OK1C*D@#3OIM,X
M=$;Y7M+T0%.+Y)/?/#IMN(S5T`B13@IGHDS=ICN\J2MC;B%%_?+<QB[B=<#;
M03PGN7QQ*PN0[6CNWP0VIYKP7FZQ5>QC#$@R_5,)?Y7G2$9Q_`LF-&F]@P&K
M15IWP=E6[+@*3,50C%$<NAX\@WE1A'X6'_S>%3=7M]J9@![D8A)J.SP\L*2B
M.Q!5)Y2:N@Z<(AG,C:<K2=Q5BJ_17,I6G)"NK''S81,XT/@(T,FP6*IQ3?T2
MD"!T7;G:,6\L=!3Q.G.&#4PWR]&X?B^,M%WP*4+Q/=PFF`E6='U/IYJ;3',=
M9X%%I9=Q\_<K<_=\XBS^#6%GHS#/K/#FYLK['!7M#6:C4/,:[Y74)FTKI(IA
M\9-9"-K0`).@>M.I&N.U]@LUQ/H&8W\0!-X/#>WM!3PUF'JGQB`ZTO$EE'&-
MTNL4S?IX]>T97T/@,QA5C_X@?&;0ZP<N9"W"W`G>?Z'"7AC`I'W,;QO#EV.L
M&S#R?F(?)]7286"X@5'[@!CI/*6X8`1R-`.92P6.1C._/P.5<#3H"E='>NU,
M!Z&PA*=N_[DWZXM);Q*Z5["+)PH.\R63S.,X@.223#=+1ZZT9=N.#,.(#YC9
M^^5GNCA,2=YQ.(9-EF3.H3\(`9GC86LI'*"3(>S?C#U=+[#H"I7^Z7*Z<"<4
M<7^RDVS8HRXRDV"*C6V-BF/3:TRA89NNR84%,3D=4<)W0\RY'W6\*G8H@K%L
M,S?*11&><@?G7BHVD-54:^QU40D[J78;9Y\L;$^YK'8;[;"7W3;7:_J.G0P#
M\I$U\]%?C/S1C&_O;(7/F]C6'Z=6VEQE4YJN25L9O5Z4P4EA^L"[1VNK[[$1
M+6.=D6%OH'V1%P!V]$F7VY;+;BDL(*=&9%K@4HHY5F5PZ!D#;K*"(@>;U7=.
M+M^>JNOY'YHYK)B``41P#7,?DKPJF7XA%]2QPRI=_0VK;>.`N)B.#F5<&]!>
ME5B]JZVC-ID!QO5BVSV2.HT8HYY/K+O'TF"Q,ILDGIN^4?;$BS<1[QP,8UL>
MI-%#K19GLM$M%TTY5!=2:DDM5.!Q94VP!>.V?K<9M5*A?$&G/=5MO**0?&P+
M5O(=I,$ADB.K[`45[D<QAJO%.#Q2(VC/S16']TQ+P.<8/2=<5@8T9*T%#\=U
MK?CDYE<!6]_"KS`"#$%=.S0I>JFIF(0#L+]%&G\@DPK1S]NZ2HH`,_>E]I*;
MC#5K/E;[$MA6$M$G3]],W6(S7""/;Z@[;)I\B*F+"6BML"O?\"X7B&H4.MF&
M+G1SG;2(`.CR]_BW.X.F;7,_<H/5*9E?G[A8<]I*4,NWK@4A%"U3]M0K1\LC
MT4CXXO[TV/O"^(!Q+5J@D(?`D%5<V.K`FG3J>:GFUJPBIQTA5>AC!&TOQI=7
M;\?:J,EV=?IF?GWZ6KV;7[6EU%^)G']'Y0RO;>/;)YM]!M3MLS:\NMQX)E-!
M<@Q"'[1#I%1U@BEX:9JPLSPCH5LBAV]-2586"#E6OF!-1%RLF.D'\C?Y1$B+
MMO&N3)9.`!K_2$%+7IR:`X)]3J+7WU`S:20L[33JJ3,Z1/%8QG,,_G72;2LQ
M1CIZ0&X8!1@QX#>H=5/%\;R@IO"ZD"J7:J4[2&>$*->UG/GF&MD<RVQ0](F&
MK>ZW1@KE8'8XB6*W*E!VZX[@=8WP[/NWZJ6NCI2(-W?1'8=M`%2E2S$.9CI4
M$;J!;>F:X#C'V-9FTTVPC'*HE@V`%V5][/"@Y2CH;%['*$Y.G`R(S&E:#L!6
M).L;W#DI;>.DEB@\U.[$>T8J``C.&/9`*]#XQ%)7,_2H.M2C$TND[[`%FN9"
M=,PF</8-MH([M"9=@\]?O5^<7YPN%NKD\N+D].+Z:GY]?GG1Y/>D^,#'[ON-
M.$O+`SK[@D%VK#JFP'(#-F7<+7_,A8@E_TV:G4C[IQH>1L-?$5"3R:^,(2]#
M%OI-*6R,H7=2,%6.2N^+:JJX;;H.;,!'[=A;RE#@;<L6;UE2]$29OESNM]6G
MR65]#WO@40P!>B-TQKOMSDC0N7,W&G_YZCXKJ"Y6Y1(&&T6!"BUZAM,73;>^
MU+T95MPC[!910$WIG%Y=4B5$%)/JKLWZO&NSD=DUY^0RS=:>CD[UGMRE$PV0
MYV`'H2)%@S2,H&^@<&MBH^*GRY;;9?WR;_-?_N;#/Z_XGY-?_D9S__)OKW_Y
MVV=$*F!O/3OZ'O!T6T&NR'&0\NC9V]_;:I_``^;YG%0>W>9M[E!(36Z-?2PP
M(S?&E369MU\YX-4SC^'-4?WM_9`V"^L,?0<3<U^]`CV#A>6^B05L'ST!4SY&
MZ/-HUC=Q+?CGR,#'7?*\O95OP3![>W[]%H3B0LTO7J.$Q%;GIQ=MG=5/Z!"W
M[71.R,H$F)=?7M)(!52@>R\\:">E,66D.-'$E)N)UVJ*!L:5O\J6D;J*2@PT
M/DNS/%E%E>B(2(VE*I0$P,"1DM:JQ?-$Q+34!0`><7*]G1!^"K=AGW]CJZ>U
MS.[IGLQN>_C"WWJ9QMIZ_HJK$::<;PD4N5N;Z#*:1+P4YD=*1R8C-J&B)7?)
MAARE'$(4N#F\:-+PZFV(%DS-D;""/W*)MV/F^M[65J0^!53QR+::<7TY+#ZD
MGA6/W![FA4EDAAV$-;Y&?31IGU0O1#"UDX63H#+;%QWN<B,]-!H8WVU@XQ@Z
M6V'_\39.@I9S5MG(:&NJ:F,+XS!DN=%T&18[(/^2"8H=$J(VRP_DBB!J>Z;C
M8)^1*^XS:MD*I"?;;_K=4+1+K?Y;T58`KJ726Q`&_G@VY5IOP]G`G\SZ7.IM
MU)_X_>F$*[UAD:_99.R]%1"8M@P$5)\^0*D:-.O5O'^U./W]>RRQ=8I-$AKB
M<F']HJ<?:;BGE%4J/-\85YUO/)T\9*2']%M!A^@&JZJY6OO5Z;LWIQ?GBQ^Y
M/!M&16PYH$KZV\!V7/_AN-\/?KS"=[99@5(]VT8[.#.XA8DI$(D^B&7I[8"3
M=98_%WVKATDP'/6JGOYDU$<G9,([6M9_QZ@%;&?8.)D6[]^^G5_]45V>J<7Y
M#Q?G9^<G<VPB<')R^9[.!/7N\LTY'0M'[[`++YQ!+QM.2UOY$]:,P5W';ZC5
M")<+[W[<:WN<>[=3TQ'R.>FBR!1W0$2^E98$?#"8\O[D'+`]ZIMUO<GI8F%%
M[R%:'QQ;2RWNQ<7L88Q(DB]WZZ+D3L883[<TX;LEMXRL08:N:_8]D9Z+=@W=
MBUYW5$F5N&$'9/&9KKZX-&MCG\\P<N,G';EQ9ARXYV`$Y#MBPX.4"!S'VS\.
M-9QWH_/L+SH,K5*HN*6#M&^_U.4O(M/5RA8/E*ZMC;+NWN</Z3).(?OL1+W<
MQ,M(XE0XLR/+2VH<8$,,8'HZ]IUU][CD7AG?47P0';,=SG@B+Y3(DCP(?[E!
M-]P5&8]H7##[VB7)C2CE.,4\-?>5>["IL:_`HT>"Y%:G0^`5U30$NG$HXRW[
MY!EF[PT-%6#0N+Z,^<LNDYL=Y@F^A-8]=X7!T,M$E^:R1'2FV!5^+^.&M<'H
M=)1.]*TOMDQ'/M3MKG30QJ$BM+U:0Z#1W,$>?2].R`1F7UCZR".9OW1?;9X'
MJ#;/,^IV23EU<HZC9!`U@>Y$T'?LAB:T<0"G&#`"!H!8!UI92#?0Z#)K*Q_:
MZO\Q6><@<=JQ:9/B#J8TKM17C0&S%<TK(HQFJ\LU:E:GKWUH`C0+ZN3,]T'N
M?8R+)T_P="1(?-F69XI25=SP*U?@`DN7S>LX[>ZXLOVN.Q[QG$?XE*HU4Z=5
MN4VQB6;1;T_7"`0<,AXV0%`M\[:W:(=1TT>G]1]%%B4%R-A/,>7XZ=L[EG-P
M-((]@LW2X&!#;C09>@YHW(J[D&0WSD/%_3$-_W2@=(K><B%!;A,=%1G.A`*%
MMI("?[S+:[:N#_21(:]:'Q;V0)48`"U9Z5Y=VFT1WHJ4+)AUMB*ZT$&!;K5K
MCW.]D6FI6MXU8XLB9NP-H;G*I`+@SP-;@AP+>)6Q*CILST3!YX4G7B8<NGLD
MO'@TU2)EG48`/=PGJ2VT:5WUAT'IM8W],<$C(LE7Q]R:"IXA9]\K="L_$PLZ
MV52VR6!<YR][U%R/"IK_E9F9Y;I]D#*HD[^06^<2%*5C&.SXA#R)N?=.SP,L
M9OK#(HC&9<@WEVZ#.ZM16`^H;HU>=+!5RS!T[5W<LT+IV^:<DHB,V_```.$3
M')^!>7[P+=VO<CUTE'5.)TD&@2#06=[9KKR!I:X\'&:K+\]!\URE='$0\V&G
M'5_4!(O9\09]`90[4`&T,KH9U.E:S-$1&%E"34:++,6"I.S,=8+CK+],4U#%
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M)4_HR2;IS8&!=AL8BNA$3T0@6/)&2DY8P^'=-R%`6(-#C"P3OX0S<SFU(-0_
MFI+NGI["Y@-R)&P[:L6[ECZRM(BP\WIZ:V+/PZ&90(=OZ>1"VU`LULX>*57B
M!8Z_D]H>VP`NY#"-F;:@6T&`#;>Q)3TXLJQ.^]%=A/HL)Z6*6>A%FCE1&WBG
M\:8KJ;C@V0B*>T,J.IC$4:)THD9%F>+\>R..^16$"J,L4-M$4Q[5&M-D6B([
M=(MUIAINJ!NM63O;2)4-!-@)!>'<DH1$BRZUK1T_?(Q1=0\.>Z(8CS56PI&;
M)8=4O92*R(NS49\'-5!0KZ@Z>3C]3((YP.+,V9U\LTY*@HY3D3,J"7FNBQG0
MESIS!(,H4`!0PKE,M[R/.?'5'9E[8XOD8>.C5H._`K-#1U2CA/JYDUZ%RP9[
M`+MW/.J@Z,+W3.L4'=,@3EYM5":W(`"PN`G0BL]V`:P!B#@'+F'#HZF/.\WR
MW%94NJ-SUPM>UPNJ\D2EFSN@0/I[^^Z9RJ?MGO;HOJWO@J+=MFWB4&C;\2_+
M[Z*-=-,`?&')^ZM+ZNQD^Q`F3G=I\R*Y]/QJJT&8%9Z)CW=;*<M"Z?"F\8-[
M`6Q!Q;0P!L^KK>.QN620K&@+8\->N7KG8PJ8##_I:"2>R60^%T\$#&,L#'=B
M]]R^\#>F;;O;;[VS6:+;@)V"?V?#J3^<S=HCJYW"W"\FHY$?C$**$'++QW/;
MBEJ)!;X%E):,#Y'!#;UA^XSKWH[ZIN7)ZD:BUH!B&%-HV;S>F_XK8`0[1([\
M_C1L#:Q'E'@:)0&VPP@;"^Q&B72G_#*4>&TH41HEV$"]FS8QBU6SB4.G+*3L
ME6JML8IT6N])1Y?NX?/X#DU-'-(M';-9V7`A756T*'7>F-T`TB[+Z$-,=7!8
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M+9Q`1)GE'PQB-"5Y1$G28LT6E@)M#$T1MC38/-AW!#</.X>I\;[;YIZPQ$*9
MII7'#U6YBV>R57VXD-<QJV&8S>4[^0M&&NG74:4444Y!TWP_2*HZF\`EWP9K
MJ0BG9A[?`I+(Y1G53P%$%EORQ%Y:RZ@$R>^JYT,+;HQSPZ#&Q"`;+R#H)M8)
MPE/:+BM:Y4?K@1D`T[J-FY*A):=OM(K%-J1K/7OQ0N+<WKVTB^9'SSQA\&\6
M;4&53+='_-GDO+#ZE!$Q$XF:`FC614-7O,BQL"%WE1V*"L-W'DAL)($GHLD=
M"00G;8BI6Y.AR5:L]_7BU6GF<8Y)W8'JM$52,=!%6=MP.E8E`MQ9$[IV-B81
MM8K=PLEQ]31PN","4;4_$.4B:5[ANDE\;K(5@^*->^;(U"Z/VG<UB8LMI1-R
M-YY-G45=5H<Y(L?G26%V2P^$-W$8A_%ADSULFK?:\1W1WI4.?^]XP#,/D",!
M@R2B#="`=%[9ZBBQ@G"HH[:=;I"WV7(G%,D50414+MD_DT3B`;7QF8@.LL^Q
M6U/!30&I<1F&`_0\]!SH>2KBR8$-*!$(%(9-]7=RNQ&ME72-W.JZD8BS=R9\
MWJ8C<\2WS8B1M8*]"!(;3SL\G8C0#31UM8"BSF^K+D+Q!\J@+/\I!A:P4U;O
MQ&PJJCNP1U'Y`H,>EL/DJYY:CM[,2?YP(#%]+63U?D.IFXM2\M[H#@8Q]DA<
M2E(H<U'-6RSY$K48M8*)I4%EYQ<8.')Y]4=U=(VO-`,C%F!PK[!0(>`)RR-N
M\)0]Z)[=/.U]:4/Z,PQHNV?%@?#W0F$'HG"`Z:D@G/QP-O2NH@<\_&.2N=/0
MGX83%8!%-!@&GDXE$ZF`[8Q'(9:#ESYX%@TX7M_OCV;<B![&"8)F\_EJWSSN
M_7X0!MNJW1V$S&JC1C%8OK!'HS9D$E"1<CJ>>?4SRLP=S(8@^*?FJ4Y5E'$Z
MF`;^%%`5SF9@K=K7'`5L,,&B=#,U!*-L.AY*.T7K$B^.]1'!]SM'5)DY&+Q4
MX7#FSZ:!_E?>W)HI$(`0X_FF8X5UGH+IV``@D?2KF'Q@!9;>&0\F0`.M/1!E
M+U\HV/BP[T_[(P[M&DS\87_2((2S\S^<OI:7?&I4>`@5\*WG,W;_#%^0%#3V
M-7_AUI^:B"-8'1;S&O7M)^]LEV^X_1_N-4#+6;EC[)X^5"-0"&8CC(K#K&+`
M]]CO#T>53N^KV*G%=!0,@9)&V(']*`A#?S(*U4M!?A-_+]1H[$^&V%H5+/%P
MUF2^=U>G[^;GK]7I']Z=7BQ.#\+XMFJS'X1T(2"MN:DCB@9`W>:E^E*)IHFS
MXO<RW5%GDZD_`=3")\#!:#@XE`FU/T><&(+D.L)(LDU"D'+<?G48@BP=-Q%]
M?G$]O_CA_-6;T^>(N$;,VD'(OG:1*.5B=,";!`S?Y28#U(9*44R4H;M*SV#R
MW<5E2W"5>`SJL75=';O;XU/:=MK[@6`\T3/.:<8*:U3Z#F.;&'Y&Z<H3QZ;T
M1*6O\SM6,H\>P;1]Z<E/W+F@MHSO/.H(KG[Y=Q3B6,L==_D(:TIP_0?LM3B"
MLW'HO6X0$#4VE>YYH&7<H'L66\I.A@-U)/^^Q/-S\VWDS6NMW"D[3;=R]YJM
MW#%D9-0/U=&P[P>S&0Q$/8OZ`Q5,L&[%1;8YCMI6YNF5_=C2,[XYD7<D';UA
M@NG(#X<!0JP_(N1O\43:H@&5@UV'ER%$:)Z$"13?DE=8[FP"+%<V'9#6(!]M
MR)!W384'B(W&?3\,48X>!8.1/QN,N22'/PB'V#"HF17XGYA<0#N:,?PA2OT1
M++TW&?U'4\QP,(.S?`@(!2#Z`0PTA$^X`\'T[T$NXPGLVS1$</7'YY-+?X`=
MF(E<Y&,KN0RP+&HX)7(!&WL\[`NYP)?^:-IL(NX*V7AOF_2#).Z7=%KW_NMU
M6O\,]=R)-?P,'?T?S=3_T4S]BYNI=U)MLZNZXB?W:L'[&U$?JJC]H]/U_\U.
MU]V"S%DY/`P6'MC09$)W9Q.YU/&<ZI#UTIGU<:___M4FO?\OJDWN/:TX,$O?
M?1S$OO^HO_>/^GL=]?>>E?'=*87<U.]Y(_7[Z3-J?Z;G833^_VH:Z>%YCJ\I
MKK50%W@*X6'W4AVK]XO7ZNA%8\<:$3I.O;H#8G(:&CCK=>*A9F6X_LP;<TNX
MWS'GWD_(DO8LI'Y-T(B@<VX(ZK]5;P@:QUGUEN"PZX"G`694G8C!T)YIVG#2
M=SVPWS78]99US[<#=X!WOOW%BG.^:_::;[X=[6W8/<`/_QP6>.WZJT_;2;%[
MBKTD:3W]/GLP&^S7X3=O1X8+1?T)Z]3_TUL250UUK^K8/].._:['&Y[VIQ>\
MQ['=OJ#:'`?XH)L;V[P:W_:,U.\`U'UFV"49G_:M_,;J/N).>L8*]N`1E"]7
M9VT3=64L.>?GUJ?7+D.Z'(K-RITF$_+`D5L=F&VV:OLO;0XZU70#'H.5RX=P
M%Z5V>.A4JX>N:Q!VA&*COH<HU[-W/MU055L<L(U=';(1T/6]FHE&T110=;\K
M>T/JCM<N8(WC56/\6C!.W0U/#,;?"<:[Q@$-IG4!Z(MUO,P-NND><"(K-VDI
M@S[E4SV#C8(&]QSHV\29OZN_6U/MGN%@?%HZ[G/D=3U[D/^NZ^5][KM.X%J\
M=QU*7LUY5W_J3T&3$)]RY^U_H=N=U[6:-O6SX<\[1/%PMKHI-[G/8TBMS2A%
M:)E&N5AG'-6F*^39QHG8CJW?&SIMH5M[+6"84II6_5J4-H3Q0&Y#RH`.,X3`
MI@0,`W\`QAY7VHTQ:!4`2]8<@:4SE)PJI%1XY2VID8-@W^UG(Y*HS7?I,`2W
M=VELA.N.6U@_X>DG<0E26!3&>NU*XQ`\C7)T"+BNSS^]02?/.=A[19/B8(YC
MZXQD!T5<F2#6(]J=<)R0K7XV\6ATGP[:_=?U0+MK[SE*ZV]W:0_;*=$NM?[8
MG[7_>!;?]'3KWXX?^^T_SG=W,.R0::!U3BF)V_C1ZDFNHU;W9A3_GX124GF*
MBH_5]'^K#VOJN'S549FJ6C)]*@7B*51OVWK07]9G4$&WVM%X-NRFFC*YC5/V
MKV$B`G)LU[,6XT+T5:Q8SW?[ZKE&`_HM5W#\X!%MN*-Y&W'H5#Y5W6CZC![B
MC10*E.[E;]Z<J"-WF2\[U_D#2"XP-]0B6MX7AZ'F0.8#S6(?^VV,`3%HZ*/1
M8\\TFV[]<=#QXV^QJ577CUJJ-)06(VZ<3AD-I:C1#=3T4CQLES6ABE.T@53=
MB-[92/6D'/RYWLO`;3*3&^\O9A<W=$?N--2E,[]O=(IUEOPD!>O*%8UE=C^I
M6SIT(H82&/1_310%14E%J"(NTM:-LY^DK;/.J^Y:E"91[Y_^J8V:SBIE<+H&
M.74[2M5_'+6;`\[-")HG]9^Y=W?#/5=I.-W8;.SJW3"+*C<G]5_Q!J7QRD^U
M7G'[EMYR4]5F^#3;XDI6>-O)LI=)PLWJ,`K@)MU-'`V#YHW1WAD'^8$S2EX7
M^O,EQ^]IWA8&#0)MVP5HVK406+T+<=>&S+=Y3XV9GL-^IQ-`>[2OXH]9^I$N
MC[@V![DLC]YAJIB&OOM<T9*8N6?60,BR='YN,->XG3.&PU[8)/U^;SIM?%GQ
M)YBB`Y)_T.54._1D"_>YI;=B+5?;*K4>$BW7T$]D23=LK>=V[FG(#?MB1V.<
MAHDO/H>!H<M9J\_ALMH.J-T0$%4'M4NP*NIMBOT.R^>P=UNU)=WT^O0`W;+Y
M;+=NV:'$-;A,;JXZ77'1I[V_']X]N7.(UTY9$G2\PK.U1SIB5_[+M%YV^H+\
M_5HO/TD`'>U@6SQF[7UWNR\6_JMTSWV6>$616@EWZ+8_'!E9(?NY4]X.MMQ]
M[ITDH]+N[?5X&(UMM5<]Z@AW:5$J)BV:QKAY8)EYK?K7T!<Q3J;Q(L7+-+X=
MU:7TM%5(8V!."WQMTV!X3N-;"M-I/GN@6WK_>;O/?A1NNVP/H-(4Y-ASOJVQ
MWO7T:9=#0S]P0@7LT^X'*O/%K7:D$W@2V\"3+KNN(]*G8<2W'[&="^I<R#,B
MB+KV_`E]U3PFC0'"5L+0U#O28X63UN<Z@Y<:[%KK0]7N*VQI(46^%"V)NNGQ
MRKGI[VH=U)#C4H;X6%5B`QIV5$=;G6>Y.V'W\$P02X&,Q7U"4$J3-AE6FO2H
MMO$ZQ'7ST<9N#]MLS<FD[5O=Z&4?!.I_J`4E`^L*JUV@S5J-W-GHJT\,/SRE
M^06ML)S87BO/7MV)[;3R^>^>?,&[KS_CW?UA<\\A^8LG6HZT.&1TNY*6\F$4
MZ]81W"*_<F>(SUM1,_9E;["=S[Z!N!E<UV5P5$/E&GS=:(;@HKH]3D2;\*U7
M'?6F#(?835C,S/[\;5&4O_D_4$L!`A0#%`````@`^(YE1[P-6`+O`0``+2``
M`!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4
M````"`#XCF5'2'4%[L4````K`@``"P``````````````@`$@`@``7W)E;',O
M+G)E;'-02P$"%`,4````"`#XCF5'MZLFGN@!``#9'P``&@``````````````
M@`$.`P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`#X
MCF5'"]U>)A\#``#N#```$```````````````@`$N!0``9&]C4')O<',O87!P
M+GAM;%!+`0(4`Q0````(`/B.94?U>GL?/@$``&D#```1``````````````"`
M`7L(``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(4`Q0````(`/B.94>97)PC$`8`
M`)PG```3``````````````"``>@)``!X;"]T:&5M92]T:&5M93$N>&UL4$L!
M`A0#%`````@`^(YE1W,VX!A,`@``>@H```T``````````````(`!*1```'AL
M+W-T>6QE<RYX;6Q02P$"%`,4````"`#XCF5'O0]-:&,$``"B$```#P``````
M````````@`&@$@``>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`^(YE1\N,
ME,EF`@``OP@``!@``````````````(`!,!<``'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+`0(4`Q0````(`/B.94=4S04'Z`,``%D1```8````````````
M``"``<P9``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"%`,4````"`#X
MCF5'(;A+M#\"```G"```&```````````````@`'J'0``>&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L!`A0#%`````@`^(YE1TEH&:]L!```*!,``!@`````
M`````````(`!7R```'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(4`Q0`
M```(`/B.94=)C<TJ/00``-42```8``````````````"``0$E``!X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"%`,4````"`#XCF5'6;A6U9\!``"Q`P``
M&```````````````@`%T*0``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M`A0#%`````@`^(YE1Y>\:WJ?`0``L0,``!@``````````````(`!22L``'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(4`Q0````(`/B.94?9APW^H0$`
M`+$#```8``````````````"``1XM``!X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"%`,4````"`#XCF5'MA*S]:$!``"Q`P``&```````````````@`'U
M+@``>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`A0#%`````@`^(YE1U4N
MB@ZC`0``L0,``!D``````````````(`!S#```'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"%`,4````"`#XCF5'IMD=AZ,!``"Q`P``&0``````````
M````@`&F,@``>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(4`Q0````(
M`/B.94>]%E4!H@$``+$#```9``````````````"``8`T``!X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L!`A0#%`````@`^(YE1^ZM7^ZC`0``L0,``!D`
M`````````````(`!638``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M%`,4````"`#XCF5'-29\N*$!``"Q`P``&0``````````````@`$S.```>&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(4`Q0````(`/B.94?_MF<^H0$`
M`+$#```9``````````````"``0LZ``!X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L!`A0#%`````@`^(YE1YRW&#2A`0``L`,``!D``````````````(`!
MXSL``'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"%`,4````"`#XCF5'
MH2`69*(!``"Q`P``&0``````````````@`&[/0``>&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+`0(4`Q0````(`/B.94>OTKI&H0$``+$#```9````````
M``````"``90_``!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`A0#%```
M``@`^(YE1U,[PI^?`0``L0,``!D``````````````(`!;$$``'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"%`,4````"`#XCF5'4CP7,Z(!``"Q`P``
M&0``````````````@`%"0P``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M`0(4`Q0````(`/B.94>:DSMMH@$``+$#```9``````````````"``1M%``!X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`A0#%`````@`^(YE1Q2Y/%+<
M`0``104``!D``````````````(`!]$8``'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"%`,4````"`#XCF5'RHC*T*4!``"Q`P``&0``````````````
M@`$'20``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(4`Q0````(`/B.
M94=GTUC\IP$``+$#```9``````````````"``>-*``!X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L!`A0#%`````@`^(YE1V=IGH6D`0``L0,``!D`````
M`````````(`!P4P``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"%`,4
M````"`#XCF5'>A-"8*0!``"Q`P``&0``````````````@`&<3@``>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+`0(4`Q0````(`/B.94<!K8B0L@$``!8$
M```9``````````````"``7=0``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L!`A0#%`````@`^(YE1\O.3+"D`0``L0,``!D``````````````(`!8%(`
M`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"%`,4````"`#XCF5'G]08
MCZ4!``"Q`P``&0``````````````@`$[5```>&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+`0(4`Q0````(`/B.94<@C'X/LP$``!8$```9````````````
M``"``1=6``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`A0#%`````@`
M^(YE1X`9,H*E`0``L0,``!D``````````````(`!`5@``'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"%`,4````"`#XCF5'O=-$Q>L!```X!0``&0``
M````````````@`'=60``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(4
M`Q0````(`/B.94=-9(O$\`$``%T%```9``````````````"``?];``!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L!`A0#%`````@`^(YE1Z0I:ELL`@``
MZ08``!D``````````````(`!)EX``'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"%`,4````"`#XCF5'S"#>$?H!``!Q!0``&0``````````````@`&)
M8```>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+`0(4`Q0````(`/B.94<'
M'77`!0(``#`&```9``````````````"``;IB``!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L!`A0#%`````@`^(YE1QW^B-/8`0``U00``!D`````````
M`````(`!]F0``'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"%`,4````
M"`#XCF5'XN347`X"``#^!0``&0``````````````@`$%9P``>&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;%!+`0(4`Q0````(`/B.94=S<7W\H`,``)T1```9
M``````````````"``4II``!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L!
M`A0#%`````@`^(YE1]`IR0G%`0``V@0``!D``````````````(`!(6T``'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"%`,4````"`#XCF5'AO%FY=("
M```F"@``&0``````````````@`$=;P``>&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;%!+`0(4`Q0````(`/B.94<-88[7)`(``'H&```9``````````````"`
M`29R``!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!`A0#%`````@`^(YE
M1_N??&+7`P``I!,``!D``````````````(`!@70``'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"%`,4````"`#XCF5'73?>(<($``!1&P``&0``````
M````````@`&/>```>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+`0(4`Q0`
M```(`/B.94?0F7G]A0,``"T0```9``````````````"``8A]``!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L!`A0#%`````@`^(YE1Q7W9BQ0`@``C`@`
M`!D``````````````(`!1($``'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"%`,4````"`#XCF5'_&\XY4(#``#1#0``&0``````````````@`'+@P``
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+`0(4`Q0````(`/B.94<R&6Q:
MHP$```$$```9``````````````"``42'``!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L!`A0#%`````@`^(YE1\)\`OKU`@``Q0P``!D`````````````
M`(`!'HD``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"%`,4````"`#X
MCF5'SRGYZQ\"``!G!@``&0``````````````@`%*C```>&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+`0(4`Q0````(`/B.94?'+OF!V@$``.`$```9````
M``````````"``:".``!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!`A0#
M%`````@`^(YE1[.!)\:L`0``5@0``!D``````````````(`!L9```'AL+W=O
M<FMS:&5E=',O<VAE970U,BYX;6Q02P$"%`,4````"`#XCF5'4WNJAQ%-``"Y
M%@$`%```````````````@`&4D@``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&
2`````#T`/0"=$```U]\`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760185557904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">58.77%<span></span>
</td>
<td class="nump">69.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 8 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">1.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">62.94%<span></span>
</td>
<td class="nump">70.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117988432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 787,232<span></span>
</td>
<td class="nump">$ 874,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">$ 82,827<span></span>
</td>
<td class="nump">155,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">152,478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 870,059<span></span>
</td>
<td class="nump">$ 1,182,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760119732656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,895</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">201,604</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(144,856</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">56,748</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,293</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187346720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental Expense</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001387131-15-003188-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-15-003188-xbrl.zip
M4$L#!!0````(``."94>J%W%W')H``+\V"``1`!P`='AM9"TR,#$U,#DS,"YX
M;6Q55`D``Q;'.U86QSM6=7@+``$$)0X```0Y`0``[%UK<]LXEOV^5?L?-*[:
M;RV;[X<GR91BQ1E7QX[:SF.RE:HNFH1D;BA"#9*VU;]^`3XDBB)%\"61$E,U
M,QX1!.X].+BX`"XNW_SK=6X-G@%R3&B_/6//F;,!L'5HF/;L[=G7A^'HX>KF
MYFSPKW?__5\#_._-/X;#P;4)+.-R,(;Z\,:>PG\.[K0YN!Q\!#9`F@O1/P??
M-,LCO\!KTP)H<`7G"PNX`#\(6KH<".?JXV`XI*CV&[`-B+[>WZRJ?7+=Q>7%
MQ<O+R[D-G[47B'XYYSJDJ^X!>D@'J[HFES\_C#^.[LV_`?IY99G`=IV?7YZP
M(@O@N:;NW(Y__N?]_:>?',.*C,HS/]W7N?$G^8L5SU^G6-FQYN**R//_X<8L
MB_^+$;^P\B4K7K+2_U)*Y6JNYZRD8EZ9\%_P^IO71V29E^2_![C#;.?RU3'?
MGL6`>.'/(9I=<`S#7OSG]M.#_@3FVM"T'5>S=7`6O669]J^T]UA552_\IU'1
MK9*D\:@-_H(\?M2<=<U$P!WEMR3!3PUW]4*\L'@1/-PH:J86E8*B9E34`(ER
M#M#/9_#Y`C_`Y5EAR+!#GHV*(S#-%%FZP$^C@J8#!8Z5=^D7E(A>\)SA3-,6
MJQ>FFO/H%PX?$&'$36'P$P0MX*2^XS])><F&MNW-T^4R7'3A+A?@`A<:XE(`
MF?KJO?R7-E_`,I"?TZ7SGZ1(1X;*Z@4W-JCF!AZO\XMH3)U%(X2PZM+QN7L/
MI@.?D)=/?C>1NH;1"^>OCG$6/B:-OSUS3&)BS@87457!B-&A[8)7=V!B.4;.
MYVD@HSI<M[DJBD>^Z2Y7OZY^-PWR9&IB.^9+!C:`BPAV=?/[V3M_Q'*B+/!O
M+I(OKYN[2&TO;&V!08=&BA3^^''?K158-1$^2=:_45/T8XA'-DC7",ZCCF18
M%W86,`P*<HEI?K=6)ZII_6SK-3S9Q%Z*XQP]J0?GD(S"D.7P@/GSPU^>N9AC
M#6_!_!&@@V&]A@_,B#BQ!^$C`POSNK!,W0QE'1@F+AGX#Z%UNYP@B&%QEQ,+
M,W-D&ROUWB^_X.$Z>C6=LW=1X83N;RY2FXF+>)$N8^61%?9&,R-KT_ST/=Z*
M'F_4EB;&^+6';-/U$,#P7)NOY"_G!#L_&X83&?D]#]K+@WWX5D+,MQ*BV0![
MKW`)P(,+]5^?%RZ&-5#ZSUO3-N?>_#@(,GK1D)$R'V1IG\^$(JW?:_8LT?(&
MNOOFW8:+*I1Q484F7=3LI<"?(7P[:!N5Z.E[&O1MWPJKG+757GNZ-D?7.+J]
MM:6UMCU=3YVN[;.NFVO;CNT-'FCA=Y0^4=N\DCUO[FSU[3%9Y+;9Q#WW+3]D
M1+)QIWN."^=_/FBV;EHF'-D&.=#6[.5W#2'<ZI'LWEQ9FH,5#Y7ZC.[-V9,;
M]#XY?+O,T_^`;`A[JM%M&[^-T#/KF=%J9FSX3F&_%?.=$H1JQ'?RVV`I2,2>
M.HO8=A@8=A\&1ED;F)X;[>5&BHE12I@8MG$3(Q'OM*=12VFT:6*DIH^>_#8X
M-3(Q/3?:S(VDB2$]5]C$2$WO`%'3B#MU&G&]B>FYT2YN=,/$1'ML/8U:2J/#
M!R?WW&@K-[IQCD5-(_[4:<2?NHGY!.W9%X#F-[9.5'@&!"",KT9.IDGD(\<P
MZG&PA&A#[J?%B%%`^][2[(H&[]G4;C;M*T8@W^#<0?L/3[-(GQCX*><'PJP0
M(R@=+3]H5>]-#86IZ7G4.AZUP,A$@2L/W@*K#-`5]&%!O@F^-YU?QT&*+;72
MKJ3D8-!;&=H`ZYY4W2!5^\*@TZ<NWUY//*0_:0X8S1``!(GOIOLT`<@V7^,)
M.SY]NCH.=MT#"^-J3'"?++_@M;>CZ80ZSOME_$E\T5X&I6.=\C+B,\D"PW,!
M>H!3]T5#X,;&;<[,1PN,'`<<R67L:],V7?`)NS9&0C],GEOM_R#R]W\V[105
M,L>Z[5.%+:O2^"D>9\`=P[EF^B[HD<3_E>)3)AI'SJ%HZNHM3M<MSC[FIU)L
MZ2U.9RS./GV<T%G^-T1S:(/`VUN.D3>[TFS#-+#+.,'_.9JH]!O;`-,B//&=
M9%ITCGR6*LF9J/RM9[GFP@)X76*`N89^.=<0?3-=;8ZE]5>\_MKCI)E6#*,C
MYUMB0=_;J([;J'WZ1KV-ZFW4H8]'^E5<IU9QW3@ZV7D>ETQWT75RC7"]AFEY
MY,3U`>@>,ET3.!]>=<LS@$$0"9CDGX]\GG[0D&W:,V>"F?6$:?5^F5Y!XK"E
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MOBZ>C.\<&<_DR_*X3Z'U;-JS*P0,T[V#+C@.;I,D.2Y`\S%X=!,\HH7@@!OR
M8:<UNB'/Q\QB3Y*ND"29?+2XT4EP:V^;#3VW.L6M3BWE>VYUBEOM<Y;RN=4G
MR6UUDMSV46I]9Y0;LBL:7<$78*\A['S>'0.8EY_`3+,^^/+&EVL9FA[0K0[[
MHNDX%P[3*G)]^KX_9-\G/1K2,X4]FCAE]NTM]Q_):_%'\MKG(J?G*>AC-8\H
M5O/`B=SOH#V:0^2:?^-%11+=4Z4/!2B]H<I?;_4IP([E\GC)U=A&%/K>"-?/
MDD<R2[:<@JL#.;^-CEU2VCB<VGMVMCZ5\3&F,MY/RC86FP&NNZ,M5*!1?[]X
MA$Q_-ZL3<3/]W:R:W(*]Q.?+B35WQXQ6<LDIMW7)*0^/ZKYX<9P/Q.?^*+43
M1ZE=&KH]I3I!J=9:J5V>;Y]XI@V)9]KGL*T2HG31>=C(^K&7C.EXX*OK?1QS
M"JROM@'0"S)=@#J^EYH=`9&EZ6&W6^18_$-3)X>X#27R^OJ^/V3?IWAU2F&O
M+DZ9!A<*,<JP8D^9CE.&%9NF3"+&3NYC[+H>8R<WOW;DE,C1QW^O)J:/T#+F
MFOV@Z4]':U^V=3RT4T]ZH[!33[JM::>^I\8!?=1$'S=UVA4W!<J0$?K^[IPI
M(-UVL*VA8]H-&F.0GC62P/K]\DYS/938%NIW@LHP)30H`7A'DB<NBRF^6=G0
MM.?)CAW#GAL']"X.&3O_V7,=W`-7T'8\RSV:CRCD'4UEJ'WH=6K+(N+3`Q][
MRAR2,ON_=I,5,M'SH$VFHYWA$3MFGA#@#Z\`Z:8#C"-Q.O+HDZ'VH>G3LIFG
M.'U.)*8F0^V>/@4GKYX^;:)/=R:O6JX@=)YEIW?9X!3-9V-7<'K^]_SOP-ZH
M.&29^.W_!^_1`7]Y6-4/N$./9+F;4&J;.JE:'W37P^^5^G8]/-L,NOWKPWBK
M-^=`<SP$WID.%#A6OL1EHLJB1YM-D-HRZO>_S^ID-A'BY1<JW0:6;Y+1CF$^
M8QIM8TO>O?.P<=!<F&*$"F"0E#&MUEBC8V##N6GG-9N/2[+=M(JCYQLH4``Z
MP<WD=-D"_TG?8>04/#@`OP<STW&)/WZGS<$@).<]F.[R0,_>Q:],WXY_&]S8
M^OF;BZQJMYN]\B<`Z\8VP.OO8$G=;MPJ9=86;VX,=6\>VA3J5O#@_B.H/_YZ
M6K43?X1_""P_=?UQWRFSMGAS(_S4("6N+6U&W<Q4LQP0M+!10;SF*P\A\K/I
MZ)KU`VBHJ"[#*.O!KMJV"?`=6-;O-GRQ'S!9H0V,&\?Q\.Q`V^P=C!,@H[;M
M9K]!R[/QY+Z\-BV`G)+-)6I)H7>`PSU8D.Q']NS!U5R/OK4?Q,CDU;;=JB_-
M%89[!A']D!KI.K"(B03&P*\AWO1&E6D#(.CJ@+C7^#=Z)?_@-\F_55-V<X19
MQ1HC?Z<UMZHI:BSR."8(3`&&W?!O_02SV<ASGR`R_\9`Q=O=/*$Z&Q!#ZS\(
MY\"!`71SCL?BV[.;NVMB78)_;R[H&JLN6IB^9=^B333T&1&R`N.;9GD@^CP\
M'7HQ+R(I)G/.$%^]6*OUR;H-9].R7L'Y'-KU4Y$7MSI\1U,5I:)F(5>O5/Y<
M4''(RK*LR"HG[Y`H:*:"-/2C5)085698M5EI=@3EY(O(\@I?`UKDH-,E2;3L
M6>,=&&NKJERU=N4.N?Q2`91C#^$"P?09O'<'7OQ'6;-DX73,^=KPHL)P@K16
MAD[`6M4J?,\NWTHJ@L2*0HNTHK@*EJN5('`\(\L'U:KP;26:`<7*G,(=3JUB
M-VIR%5)$2>19IC7ZY%P+R-5'542&9:J;"/)X@DP]RYLL:-%V>'#".2/&Q%TU
M7%BD@M9HATCRN<)4%ZD(.W?B(\E4PNSJZ%AR!6=U,DR[O,NW==@D2+2F+E64
M9I1).=W*5T96>86A-0A[5*81EX)C>)GA:<W%?K7=RDN6;_Q$IJ4]5[_7),J2
MRO'M4[;F^9GE%$%66TA0ZGM:N2I*LM!*@T-]OXABN:I*S#[F!W^7I\&%&3D^
MC"G'X&&HLHF]%"K1ZM2G@FW9UH?G#JI.6>NQK8C`*4UK4I-3E4(J1:7QI[*%
M:$J+'5/RMA8JMMQ*VY0H8;93!@DKBA3;,/2J14GSL/7QPSF+;\QM"\ERLLP)
M?&QS?%<KD43Q$-)UP>^`_`\P1L\`:3-R,<)%FNYZFG4/YIIIXPH^86-#R7WZ
MKTQ-V!_J[9N+2D(=0K/,>S-8(9:]9<<UZ;0S)CABF[]:7#UTPJ<.6_F<B#U7
M8PYH*1D:4X0?,F+L*QNY5*-2F#N/GS6U3N%2W]*F4IP_YYBV*DXY]*CTE,YY
M<1]ZWGE$IL_3!Z#C^<(U@7.E618PWB^3]=7+[<Q-T,1Q8#69]P4!2P$!]1J%
M4WC\KV,82(5R$1\A!M0>!5\(`Z%+&%2W_)E[+\W8A2"/7+IQ79A!X+I#XMJV
MS6N:'\;'_+"R6)`()C5X-W3-RLG7D(IE7$V.X9@A@]<X4L,:?0,."9LKU&%B
MM&=1V)"_6UN^77KM%*H9G6HA(1^%OC>FVK5F(G]EFJ-8T5EF>Z9-V91A1$;:
MR<<=TAU.M>T)-$4UB6/5-JE6?360W%"06585JZJX<9#YJ#G`!QO8CF^$1N2E
MF?\!L??+=9&)MB0_^1GD5VV,',>;1QLK"Z#C9?,7@.8L[;9/9N+YY&>C)N*/
MQ`%L(W(?%J%=-V&SD8I*;"/&WRKCXT>M(*^TUPV4I!_<+<^<`$QIY.IA2G,B
MI"&G1DY$L7GW-,Q4*8BX4X.HNBN*!]W!D'J?W]+[(BU]@Q:NQB+WYC*N7E5Q
M#]8NDW^/</N"@J2RR0"W9C5L":AU>A2Y((N*G(R2.PF0JS@@N:#*3/R`YW1`
MK>*NY)L#3A5.$=1*SDTNJH*HJ#VJI?<SLE$]5:Y6=J'RP16X(Z(LR31SC0"X
MP6`BX+@'<;485E(:@C1-OU8`NE<W"_=94VY6:P%NU,5BV,;\UM8"VJA[Q6Q>
M)3P)0)MUK1B6Y7I$ZW2KL!UA3Q#1YETJAE&.9OZ/?+BQG\W*-@XT^),7(9M4
MK[MXT@_]D\.SE'_:`WDP"WIJL.ZZ$=)5?H[F))79WWXSGZ?7IDT,%Z8#=/R[
M!F/3T:%G%XXUJR6,)(8+K9AUJK?C5F,MZG$2P\3SX!35,3NX9CO0\AJB*3#=
MG##1C:@[=AUU5VL$.<_[D:*U2$\1GH?'A!:,1O<)&M0A>A5.U]];FOYK^*`_
M00LX@UMH`&MGD%Z>A%21HMA48!KJ<&9O9?VJU_LK$ZJW)5]-*I6Z,483HL>R
MHBCFQ?<VHM(.H]-5E79\>*.:2KPBDH]R'Z23Y$8ZZ6`:E0@;WZ6'@J<VI65<
M*Z.'P'$E+5LTJ4\06&BF$9:[@[8>Y)`M?5>7E3E&W,QCF=I`%4%2\VHF!1$X
MF9-X>D%\$+_:6N#E$`<7^S7KV:[N&\$[;\U+\MH'R1:IMD7'&#@Z,GVGO*":
MGZ`](^%/-_Z7&LQG$&]Y8FDVQS!JY'A\@8,%@L37'TP#[U&S!F;TIC-PX0"$
MRQ3GMX%A(KPZ@`C_J1G/I@/\OVQ_6(4CQ!G`Z0!Z)!FT#_'@Y0D.L((#[=$"
MI#JB##(?/9?\/Z(I;N0)KYT0\`7T7T?^6T_:<_@['K@.00F[1P9`@V>R:!D\
M+D/1R35V7,5\X)"%U``&*QE?+HA_1^'OOIR:\Q13[S?2%&G=A]PY']2PJHIU
M7`O(@,?4'YYFD2\_&/@I%R03B``@;%C%Y.&_!R^:@VGOF#,;0XX["_<P[@.-
M@+F&;3#%J"'@!C?&!W]%]8=,P)JYQ$C\`LLX=^!T:NH^8>(L(F\`1*K:X!#Y
MW6<8+I4@U'E+^VBU!/'7,%39=,N,6.H$O#7`E*52&S"C)G:)O-GM!2RH.$@&
M<F,'B4`:G!XH,G8*@BC7$A:1IEJ;<*N1<*JD"'(=Y\AMQRSTBK8^DIAOQ'B.
M5>L(76@+0D4_(WDD"(6IB6*I@!(Y:#827E3.&<.=<W4<?1>3ND5@%?JX`7M>
MRW%V9\%*'A=F!:OM_#X$6X?;<#P09D13[<R&+-<1_U,-PI%E09TL,]/;#_<G
MZDB^)_"<HDJQN9^NZ?H$WIVU.&5[D1=8B3F@P$43`[(2)RD2=U"$DSN]NP5F
ML#,8OPI33N`:ATZPC*GXS0Z!%3BAF:$=R'<0`.@_#B+)*B<(==QPVA<`'_T=
MS,@'_(B@0_V-+HIL/SQ;SQH[6]CVX-',6OMX(2R52E^L:=.F=6A4.E@[&K#"
M``Z/+$Z+[3[DHS%D>6DC#UL#PM:-1^C`DF.4.N9G7A&4S13_=<M7&`"'KH4U
MQ-3+%5IG/7NIS!6Y9%^K(G7SB"3XPBW9QBI5`B0_[6N+ACT7Z[B76(LR#7J0
M-^20TW9,W0^P+'MR+PF<),I*'0D>\D0\*!8TP0,"KZH2SS:SO[<;BQN;?+@>
MDD\&VZ;S!(R/$!J[,H;N5$169(Z/+8S2:R\O`PV8BBQL)`HH*,.]]G*+%ZC(
MQ/65A4'AE'@D:VK=I06@BD8113Y^4XI*@G'X!5@_[..J<%S.JV->VJ;U]LQ%
M'C@;7)2MGDX_;N,3"6EU9P)\!TJ'&RDRP\1M?+S.HNU1Z<DJ',ORNQOTPW;"
M<*/0>R9QTM4"JWB9YWDUC`G*JKRT!%1&$2M/=A.I)$A$7=W@8HB$HE?H:%6(
M=72RWC+MTBC-JX(2)W9>NV,/$`?P'EAD4VVB(3^-<+6NYP1556+&8U<;5>6A
MP:2*/)])D-1F*%Y5=%B546*?,,ENH9HL5.9!(6.DC"R;A;"3Z;\Z<AQ0QO0G
M`.(8)?YE2HJV:A*/;NK@92'^3:U2XL$%0.Z2;'.YQ$/_RS,7Q`7;WO<H`ARS
M>1JQNY7J,D511ZN2-&'S/,>*S/YD7&4Y:+&,$8[7'K+]?1+\UK7YZN^8T$3?
M\HHJ[A_1DM)*JB#NGZ,Y5A`/F]((CG3=FWO^5#(&"X0K]I=:^&\+^&LNVXC?
M1,NLO'0$NR`H8LR&UR7//O6DZB6.DT6N>3TS"U9P^T7RI4D*@J6L`HJ*0P.E
MQ',J7TR<N!-]#QR@(?UI#)Z!!?V2_KJIAML8*L\+\J;+GM]:?3)2+2LD7N:8
MLC)&F).]!!=\,I])8)FKV3/ST0*!SY!K>:.($K*SX^&U^`.<NB\:`HF*J#ZG
MI\;OON0)=3`E5J7]'"`V<,>0?)/M3IM3S3DJ*\</F_>A9C2G=[JO2BG1W;X*
MSQ%'"W)U!AC_AF@.;?`%._/:8CE&WNR*;(@:>,:9:.06!]7'4'F5C6=RW.<0
M:T(?B1%%AFM$G]WS:XTCB9-54:92(64^WI,"Q4=1WO9I<<'KMV$<=O[%_2&_
M)_O5'/*-6"16E14Z"ULK_9O0191$GBFMRTC'CBX"QHZW$B>D7QTP]:PBGZ4M
M-G;>35CA1WR)4U[`0RB[O@T4KKR"T\.-1M::RLF/B[19W<THK#)VT>];\DWE
MKJI;=@!CQ96&2.WOM'XRM4>2:;GZP87$*Y(<SPJ;47\%,:C.<!2!D7BUL!@C
M7<<3$%Z,XM5G-2`42565C:V61,7EFJ917F5YB:II?_W]H%G`665RN@>NAVR2
MW(F$B;^0\R['/ZRG_^+VUI:ZPDM1EA?:QFJ3D`HO1A"DD@(F089+S:IA&`FL
M%/]H=4;M%82@P47F9)9>"!^^%4S7$'WWLTUA/#&<04H&B*Y!96A421"BO:,"
MS=4I)M5>*U[F$;^JK)PQU'TJ3K0EB7TD5`SZH9+--@T\3T'H#AEFR&S93H5+
MV`]:"6H6/@/GN/#LUD&$J$IB7<*3@A,$I\!Q3&AK5@WTE5A1%:2M49712G69
MJ$[W94F0MT=Z,9F^:;I_2E#5\JD,FR)+HO;R,E#M3PN<P)>5`<\@&JH^`Z@\
MH\:CCM)K+R\#51@?*W",2"M#8.F"(E<6=DUUS?I"HMQ*!K-M&B614YB5&Y'7
M2F61J"R\S$@BN8)62*0(RYC]P4;)S_80I!]RR-F1NRS-&T8053%^3SVOI3HD
MH\%+_'_VKKVW<5O9?Q6A!RA:($GU?C2X!;Q)MB?W;AYWDVWO_JE8=*)36?+1
M(]F<3W]G2,JF9-D6)3J/15&@Z]@2Y\?A<&8X'`X#W0ML\5"X+#)U7/(\Q_%,
M<<=:%?5>^L6W_,`0$V!V4_],"R*1Z"S,L2Q2T=B[G<73>/#4.C1UT[)M0XQH
M[::F!E\?;AT:%IY@A57$&'R3*(I+:LJN:3+?2;B(2YRB<UB"4_8/7N!X@6=:
MKBT:C)W$U,#KEYIA!K[I-WP.:7C"3Z-.'!B>YXD:H-WN$+K],LY<72QGLHNN
MH)D&=]4,=!,\JTYU)TFO5Q=U-]`MOUOQ;Z$WTC`;ANO[MKB?M=NS5A?GV=KI
M3?FQ/%'],WDDJ90H]TVOW])R+T-IFJ[H^K6:W;'(&CF>CJ4;KKEY!=5OI3=R
M6%W+]`SQ@KF>(&CH4YWGQ-KK3V68%[2-ROA\(-,U#<MRVN0VI]7T(=QO4>GK
MOK/&S<V$3\DB*^*R4-5S@Y8J%*=1=_MC</3+NAN&HV/[[>S;-*GP0!D&(9_B
M)!G,&\NT3;]Q0FLW,54`>Z8J^HXX2X8`5))+[X/'8MC6VH3=JH-&ZC_'-2T'
M?/*^-*=UN'I*XD=Z1)J,W;^P7-=U?'==!7<1&0NHESXQ8+%M>,,`G6!AWJ$"
M8!BF%32\5FBM+X5>PVU8KN&*ZT$9"E8?"K81&*:K#^U#C[BF&P2!8=C;*8B!
M\-.LNBMG5;(^CJ-W"`)#%%P9FLH!]_,)/,=2!%A8V5R'^55^4^*BF"YRKDE.
M#RR//F2/%P09G8NI3205H90J0#@>Y77./6_ZEEC)<E1QC,:YF$T4QF'I74=*
M&1;AM/L^F2.048!*%9NVH*(;RGSEUD[O&ECDS[#!8!B.6%VS260`!MFZ?8;N
MN;[3J*TX&L.VY*_6ZSS/D.?3G-!_2'Z2T4)8.=VEP3LO^]P5Y`96JWC1/ICY
M`AVQU'=$_8CTNG)&UYTW/R*]+CCR;??-=\3JTQ$G>/MSQ.[5$4>U:,D6$'4,
MW.%V%/-2JB2H;?BNZ1J](31-GNP&P*ZH:<_6-SC2FUIG%R2QC8U/)"S(U5T2
MWU-A*;!F8E]#_-NU:UW4]RUM;FXMGW%!4#+3>_IP@<EW_'3[307.>X@7-*70
M5BMK;:`UMLV&4/<GKARVE!RZBE!W5J/H<2B`+0:J?/H`C4_N<T++.OT9EP^P
M(DCC;RPQEU1E/"T^?3KI<SJC50BQ$]E@^.T+I]X&_%9L7K;NR/YZTS*^?7"J
MZMO>1TI!W]8,*&#!+\)[TCF[MSJ#U6*1Q!U&N>^-PV)!@VW`QG9BJ]LQMA.>
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MUG8:!1;>`G=:X0HUI6`\)_#-[Z*?^Y`"W6H<9![*':I09%_N5XI#J2X8BO,-
M]7./NN`M<6>?NN`[Z.<>=<%8[FQ*)Z65MM2EU]JN;HH'^/N14P>RE\-EV:9I
M;DFQ[0>RSPEK%<G<AN6+EUK+D54/6G([<DE8J*=Z-6MS7$5V$(QI(*[GMA(<
M#T\Z<<@S7A*>[.Z\[P;FBS)/:L/4:9[,D4(G5OA5(V>&6"E=;%Z6M*P,F:;7
M/!\UG+2L?'B-0M$C.RTU]IYAFOTH7^?9E)"H0$*8P(D+Z:O9IJ.D`X<_,"S/
M=IOW<^P@JP2G?&J$!\+B6`-P=I4G;L8=E%0V\`W?L+J+(6^FI@YCK[,706`'
M_BB,[-*^JQEW%/MQJW._9LFL5I/RY`Q=K$%W4]T5Y-\5IIW@!3_]-H\P:+4=
MSC+'"D6+Y5.?5CDX5.QN/A:C/,G21Y(75)%_`8+JKC&U7,<10RER,-1W8DO1
M0QZ[KN_0B]:37C?T$>]#\-NU'-Y'']?32#>-H]'*P'S]/K8-Y_OH(TTP5##?
MNM)]C3[PNP$H1S]JHG6>!U37N;/Y(LF>";DA^6,\)=TW+5YB*_3^3;Q4L;C-
M6(F*Y>]H:BZS\BL!R-/L/HW_0R(&XF.6\Z_PN;X)%3_\=FU^M2Z,0*BG^K)`
MUV1@[$VPS7N47^P^6_=(/"[[@KV09F#_>Y?9);`QRPMY>99:1[K"JTE']:N3
MR7>[P=SMOMFY>4_JX)*C3J`'CNVT;Y_>"\9FI5)U5\:V1N`SP0KJ>.EBALE)
MT[(*$\P[[T[$WI#(_M4P+HS3NM+I*V!];6:94LRZ,%^15^8>IUE/#!*BY7QU
M+DSO="\3KB_:M2I#>&0`U!L[-<"/$J@(?5BFWW"%.@D-1B,=#/.,/:*1C8\9
M1K!?WDC%S%JGUK:"B4C\ZUE:QN6S$`KJ>;;9@!$S^Z0D>K[MZ[C7VX]:FU%T
M1P;+LL9J#A(;IFW:KF`G!0*2M&7%U@L\UQ(#R,-)R\HHWO1NBIG;HWHM)9"6
M87BN&$'>0AJ7#5<S6F[\)DLB-9K+T]UFMG.#Q@`(\NHJ,!OEI<=#&*"CK$:1
M:"5<D)(#0W=]5^\/87DVCBLM)3N%GA^8EM=Y!*\F,PB'=(C>\713%Q/7U>"0
ME0O3LH.@4116&3^DA,/403H=,3]Y)PYQ.ZAU:Z<*2;%MNU7!;!.UD<!D10=4
MN1Z\!#!I'>,ZXG6E>^68G.8Q/=L;!*Q[PT>A7^WXH)$LL93H5I*C\4F;KD!W
M3$/<\MPO/GF9PP)ICO6"_),3/1LF:Z.POA2^&Y(DF(=$4E"&"0IK-(>%8$'/
M:CT2A8)HZKH?-*[OZ4=;'6+IK0?7A56@X;P>8NE$"MT%8;!?E<62Q0ILRW)&
M`UZ:\O-TFLW)I_8%I`-%]M#U7-\`=Z[#:5A1&@A&5AH/+<\S'<\-]@%&5M`.
MC<#1+=WJ<NM4<$9*B`X-S[<]WY,#<YFE6?,IA<K.=WWQB.]&6J-`24N0X?N^
MNW=8TI$#W7H17LF95<<U[0&@FNF#'^,T3*<TK%JHV0XW75TWQ7JM6^BM9S[C
MCBHZ`ZP+]")9^$9)U,LQW,:9FVY28R#)!T4\,2BT#TC2BV'/U??.)+E@KN7:
M\HCHQ8_K<T))_,3PQ/3Y#91&`)(.I%BV8>P3T``A$MW]O7!(SHEKU$#NB6=E
MF-E)X!0>K>!I;KFSM/A`9AE>6HO/W8;?\.@P>(%9'H&2RY_/2S*GIPEPPRJC
M3J-*?7:()X=@Z#UQ<NP-\2LS9X`K&ABV*]XE\?TR9X!K;'NF*T8\OU_F#''5
M+=-TC%=ASB4IE2\0VUJB04,:@(*9.`Z``FD?S8&Q$K450+O,Q(>PB*<8*L-*
M%638AN"F_+)#_4B\+GL':05(=XK/%J2F^Y)(=\K9%J2B._8B/-TND-N0FH.1
MMA)TZG,0]%4AF6&T^&[,JC`</W#$;>UAB/;7KT$G-PP;-;8O)BJ\M7YMGQJ;
MLV!,W37$'("WUJ_M$VE3OQS3U'7;42Z'S<!)?1O<"31RKV8#?GNDID6P7XZU
MDEUGS]8#7=#UW:2&`Y+?;;;LQC6D_0!=Y]ECC*<A.NYS49+5XQEN\WSC1G)C
MH4E+%FBP8<C`+<HQ7>^4L'_/TVVW*PYUBMM7+>ZDJ@2FM.OL.7:C7IT"F*T*
M"$JX:>BFX^CV-IPMLDIP2D]CO%JM&0(>#9.&DI9;.>JJ.:P%J_L05@=7OKJ#
M[@9[@LM/%:OCK6L:@;EU\J_35855?D,L\)P>K)4$BU'TM,SR=MV^H1K`,DS=
MV:H`!(JCX<F'((Q&?=R1Z-;O9%,SX^W`L7IIIQ5A56"E=QQ<W7&=<5CQUL:P
M>*#.042B#\]?"JSIM%(2W:4E!\?!3-NR'?$Z]/X`U$*7%U_=M!S/LE5`WZX_
M-MU'/C2A"OAM6'Y?[;7EXO)1L&49'NA!(S="(>KU<E-*=$>[2E8?PFMK`EYS
M]3:;3/]=Q3D!Z0)Y*I^ODQ`L2QJ=P;<T44^-NG/$2KS]B:N%+>U#ZH'HERF$
MO8^:8(;A!<$VN+N*1PU"*>T\!I9E;Y.%72@W:$.6*J#>DN"]ZJU@?D_R:H%+
MVQ%:_5P)<+&64JNJA)K01JOJQ#9Z8[&-+?<Q%)M0S+]8EN10DT\?^.:&`EV=
M1)6@E-:D8`%$;TP:Y0;I72:8J9WUL&*T=-OS=\Z>#OIJD<MG!YFNYP>!"N3T
M-5HIHNUA*'$7`\\U+5^\O'DCO7'(I.>\Z>N>[]A#D/&Z:3P;L\X]&EL7%6VF
M)\Z>+41&(^I3*\YV+<_4!R*B/S/C/K*LG@>FV1%<GO661]&N2RG=X$Q)X@Q<
M/-P""--GKOJ+7A?$HNZS^H`4*^_]0=(HRT_)(BO:M9\D&&0Z+IX6V-QP%^F+
M,*UF6',AKS-WQXMPX/D>!HW[TE&!JX\@!ZY%!T<65SV8'S=7J!8WV/C$8&4M
M(MP>_!@7TS#Y2L)\*$N;56P5`!G7-VSA]BD;7"'3]L3-XD&T%73@(2<RU]XJ
M[@)2']^)CUDU6*A&]P&)*^@"//MZ78!G7ZR8G>C]#BZ%Y=!;X5^@HIV(=N-I
M*G:U+[O*AU^U6*_R3Z4NE6YODAF-E7A/>@-A@H<,DHSB,'A8+-\''U<:L$!Y
M,':J24:!=W1/][L.&O8G/1S]4S8*NQU87M!5\:(OX2'(E=IVPS1<\6CR8``-
M/VJ9F@0*<8_5DO5VL61*;XVG^7V8<N5[`NHD2_".$5:A`!RQ`LLW-4Z1A<D-
M?,.*29Y"!Y.L`/*WT(4/B42]\]]^3,KCA5:4SPGYKQ]F\-*OFJ$O2NTVG@-7
M+LF3]CF;A^D!^^)``R4:SXZU>9C?Q^FOFGZL(9G#,(GOX<]_P1(AGCW_\.-]
M>8PM8X.RC2]?OJL_5/CA\NKV[,=_&-:QH?T8SA?'_S`<('[[SS/MY.KB>G+Y
M%9_\I:K?^67Y]B](>/G'@G["=MC_WGKW65==_3OHE'CE]\7I`85ZGDZ/#K00
MWGL,HQ"D-E]D[&#!@9;E6O,5_`:6BQI?=AYH#V$!7Z"3^O20)<FSECVE)-(*
MF*AQ%(>XIWV@/<9E>$$BH*A]^G2"Q$Y)$H*5)Q1!$L]CS(E,^/;0,X#@S0.Y
M/]C+!]J';!K^#I12;&<'ZN6S\$P:T39.@)R&$WF:Q]1AT+@W4C3Y\#')\KBC
MR;J-(^U+FI"BH'S@<US+<`W]%!=$RPG=-8!>MYC=T9$F.(IB"DPD&`$CP$M$
M7&1S4M*!S7FVE59F&G"=R:5E'S/OFC%L^>7JYR?2]2V\)'P-W5O^415'R\_O
M5<Y;<_8]]F"I=$,TK11J-M,^5$6<@O"U-.U[[."['Z(_V:C@)`VU)YBF*>^3
M[1X7V@,)D_)!F^+/BSR+JFE9SU)MEDTKW,C`!.&<4#^*:@+X?8[[#8#T/_@=
M?P]4#29!HXHD>#%6P;3##&8M)7M$<4P*#00$E1)>C<8_@T*JTK"*8IYSSKT:
M^&-6.S'0]]J+.=">"%4Z(L`L10P(ARJ\!)P\\.6T,H=W"RTEH$"+,'^F&!!2
M3NZK)"RS'/37`GKP"`^W.\>2HP$BZJZ0W;H::0_LIC>D@U>]:0M8)L[#*=6@
MT$C-C2/4K%J45_?`77X37*$A7HHA3FFK;:#8K8@4(`)<@X*>?8R14]BMXGF^
M*+,Y92&"!35;3=E/?"#SN/@+=7"!U\L!,V;@T6G`M6P1`NG#'`Q:R1'4_<#[
MXJ8Q`2ZCX,0IO],,^EEJLR0L'O!K6-22#`Q-5L0%LP>/(8@M`(_`I\SFP-+R
M2/N3\`[0>D5\,&!PVRQ#KC`[LN0,#.I#/'V@I@K\<8U@K9@HSMBH`%/O<=&=
M8RMA@O^',8QQW.=W`(.9OZ<8.(#,".,YLB@B0)75G`$H:/%@E&G4DW.=8B`S
MZ'\X!3DHM21[(KD6904"0K3D[EDC:7B7,.&'SP],"L!O(!J\"E80T<UBFC0&
M$P=-'P6"?Y%2G"!'VA4,>4LDEK.3SC$4>1RR4%O`2`%7:4>6_"/3AS1+LOMG
M``=P*3+";'PH5-AA4LO?*AB<A_C^0;N+L_`QC)/:@Z&L9%J[S<XC<%Z@T2CF
MO"6@J>H`+Z&#$B&U^*X"X;S+X0O`CE_?8]&?>`J]%IP8^`.:!7%YY%<<'J!S
M\$22!/_-'DE^")TXI/EP)#^H(5W=GAPL7SG:H(*%]9[BQ5%[\86'46#)Q_/V
MVB5O][EZVNM"R1072A\F-^<WVM5'[?KSV<W9Y>WD]OSJ4IM<GFJ?ST[@[T]?
MM?.;FR]GI]KDY.3JR^7M^>7O\.S5)7P^.;N`)VY>98'UMZT7AI8>G8[G%.M2
MU+65K/_MF+UJ#XY!;\#Z[5?M'Z:#_]6K7F8+IMP!0_VR<HMB-J2[W2-4_>U%
M'5LU,@O++#RA[L?FU3"%4CQD51)I=[A>#"-F(-)_5>F4ZO25N>WKN5'[D&8E
M,UDY`0>'HZ&-(Z))FE;PSF<"SD;)S$"J?40[:.B'_T.]223YC%%"0FW.*?AV
M&##3+.-`P_U+:EK0($<KB#=D6N4L700QG'V;/F"U?8P0S..BJ%?/]-$SL#G4
M"%-^40Q/Z-3DN!G".BP.4:/7=V&"_H$&7A,IJ6F;K0-DKJ'$.#.OM8NA#^$C
M6%]8I*.%9<X',!*;SB,*9&UV#)YQE)?ATO113(L<Q@^O,2Z8V0]1FN`9LF!=
MH=S":X[@+ZI]*$,F<W000LKQWR>3ZS:LCLEQ0$>^YLV*%7&*/A(UZFSRI,*@
MQ^C\55.V202R5HO1_U(9F.0P.\!K,W3$])FM!VC`Y?#_CK0)92'T,WD^`&<O
M96XV"W;4,,0E25LL*)HALS?*<(8L9REPM%XP"7T5)A*/Y(#H/5-F4D8AC@26
M8AL%1UH$N\'F9(9Q((HRC%`U<G;@JW&QE!/H08K8$W@#4P*H-RT^3]U9X.U!
M+32X?!!67R"2(;L<XV"UF*,+)&T6QOD*4\TLM@0JD!L4`6,@Z]>"YB05U$.%
M5TB$OB[[J7X-AQF'H:85@US'X+)/0PQZ(1&!`(*H@`.HE*A0X^J9QMIJDFRR
M4+(=7NP;=XOV"O&PS!9K-G:*HY(O'[G+2ECUBIUY@UQZS_Y(TWG$XTAIF;!8
M";O&3A.6/->P"(?/T[\]R;?2@W-F^_Z[`B6%BTYFC59^OS!X-UA6`?,6M`\9
M_$.UU<?)S0?0NVR@9S2H<U_%S'V@>KG>+`"'JV0^%"C>.0F+.N0;\Z.!-(:"
MM%D<!;3D-"M*I)$2;(8&U?!XW2/>#Z;E(=610"/=^"+P[B]X]Z=/5R=7%S\S
MLU6C8Q9_L4@04I8FU"#$PKE(&GOD825H+@;K"D8QG\<ILY=S4CZ@(<A6.)*P
M*`_!!LWB'#YD%9(^_WCU<^T=@M,:QDFKUZP=[:?/YPCQ;,DE9%Y5$`U;P`;@
M=_!.P%)@V"#&$_``&!\@WYBQU&(PQW%.#=D\BTC"#74*H[\<DRCC42,T4-R/
MI4'/,)G6/@P:W"Z6\[`1!XA6;ND_`)2Z!=PF`Y<264M=@R4\.@J4=HWF""2S
M@T[,@E)X1F).W8>"580&FXO7_]5&GA?_`GY4>4'-ZAW?.CC0Z.X59@MG&.5Z
M1FL-]K=$(GP/JF"+'>[L4!\^BHM%5O!8;IF':8'K"![0^H+;_)2PR,\#[0&$
M[I&`Z5XRA@Y2FH$X`G-1>EO\84X-E1H^#RB2.K+N'3.Q/:J_\(\;@HOL8;%#
M="902A?571)/E[U?(<$?9S0O@;H7!3C[H$M2ZD#-0)8IDN4*`^<^:`"7A6C;
M_@XZQI3S&?!:;!1D-LS1<X\R%JX#?`N<)R5UCGA8E^=RPG,$!SE<>G?4MP+!
MG7+O"]Y>]C3C<>Y>2\-H&8+;&.Q[\\KX.S(G*1'-"5B)VDAT&I0O"QQ=:E$F
M-U\.M,OL2./),4`$(]=TH^,D`RGB:S(<\_,Y[KXLEU&8"4L?H!BB&&8)"!TX
MX2#XY1,N=$&UWS>-%)WK`+$3UDD&C5"_G:_Q)S>POI\FX-//GNEK*T7`2;,]
M;$IUN:B<AW\1#0P'KD(%Q#`)Z33&Z0BJ#ZQ.^4PG`:Q?IC"O8*F;1NQ)JGJ7
MG(P(-`#-9KAY7MUAN2.J#'"B-50#7\*M)JODW#YH:PRMK2T<9F.8.@M7@!M0
MF,6;`V;<C4J>J5;@:U7R;8%<8[L07(/@,O_F2RT`.*XT5!%J:`YPKZO>/)%1
M$%PF_E82;R]ZR97&I+H'"CP,MZ8V0""X5K`/4?C$/1F4F*Y0]>'O&8KN20;3
M,4^UGVZJ.SJYH!7GT-9__E5;;=S4L88O^"QN(S(OYP[=./#MV*6"XO;WA.^#
M@7B>U"Y9"&]H#:)'M2@CZI4WO(I)X/O<)E+7"6=2;1ES;CRSE&VE,:V'I8AJ
MG9"'F)&S5`*XIXH%H#AN=0&\D@>8R1H;PA4;I@TVW&<\PDEYSW4,[D32^"M3
M)SC*W1,60V5LY'_"H`C;>.3>&Y"Z6_Z\]#9!3\,#/R.+8$4RTXKLH'8*N.^*
M&Y#-\5CSI4(60JXU(V&74S9U'TL0Y-[2-H7::FR7+G6WNE(B/*[9XV7@"1U5
MZB%S4JO%RT8.4Y6*&AA\X\<XJPH@3(/!_]_>ES:WC22)?G\1^Q\JO)X(=P1$
M$R1XM:<G@FW+/9IG2WZ2>GKVTP8$%D6,08"-0S+GU[_,K"H`),%+O`"J>J=[
M*1*HRJH\*BM/L:_K9;3@V=QF[D=.:T6N%"N0,OFK/9T7R$IC(K.G\/>OM!.P
M=U?PVD^%@KS>,Y@JZ$9N$Y2DV'Q8\!"!\)$R`CE<7][=D_!NU]OR,A_)F?+R
MR`DH'$GZ%L1E$NW#:6@2W<]"E5\!G\3T)$?<6%S\AC@=:&IC5\7</`9TV0_A
M,BI"*DG@I:`1MX,"A'N@#!]DWDZ#*#'H0\97P)L9<RJP!)/1L"#<2,YZP@_"
MI<,IC3\2BMH"1!1U,2"IB[)/#)S=2.4]%$T&I#G^.QD\T@&4J:CXM;IV1\*F
MD="]5\F(N>O[/47HC.UIZG*`1?I(@%(8D=.!KG)P17VTQ1DF+_".1+6AIE0!
M6'(7X2Q&I5B55,KV3YT!Z9QB/$*<[<B0$5?J]K;G!4XV]N)#>/S:@(L(76!X
M!B\!FW8W,Y.EEU?!$Q0&)CU\\%'8$6#H`=X&A#DC/6=4\%HJ.^N]E)+1LJ3.
MR-7'P=H;?)QCD*5&@QE;@3Q=%H^352>7B`*IFYW"DY"4&-=?:0=@LS:`_+9L
M>G"D5RU]>)1A!3)N5*H/#]QS0<@*6F#/%!:0^9X+M875CO(E^LP@YSL+\WX(
M<?+`91948@1HRN.,&XR<7SKEETC"AIR7.:-5XO-29]Q<2-E"R-="25W8=C(P
M^''VT#=8)\93OH8TFV8^>NSN]Z]?^[?_@_%C=U>_75]]OOK8O[Z?"16[^7+U
M\>KR-$%BA[@,>QQD>7@1@>P#S/_,L&!\:Q*?B1C(0LI2SX2Z97\)_,<+RA!F
M(C%8^P)/OP(IME'7@Z>$6R@,2?Z29X;\%!-9@4V8(M+:;_@7>CPN/$*JF^9]
M,UL4,AL*ZZ?R4*&ZC8X39<W`P!/2<B,5XNZXH9.,42*CMBT#*'AJ"G7#!>A0
M$14'#NGW6!P>`"`U%0\>.T*W3`X&BH2?YL$6L(K#BVI1"*61LK\H;,;U44WV
MXU$D(\CN,%Q)1&C5A464'J10K0K2P0?V8#O?'T,XBP87TE3WQ\B-^9F0>"J2
M/@,1$*#_))_CC`'QBF*_=(A"259PDRA'1A:YER)(18OA;6XL8JV0K56M_3`M
MCVMD7TYDS7.Z'XJZG73]]B,N?>:I9$GOHFEX[<N&%3?$'^G-&L47!9\)E_<#
M=S#'1@6@12.X@%U@M`$JQQA\.E4@1`F%X:;KKZ*0.1.ZE,<EGDJ/08BV),KU
M$L<=G8>Y*K0J2%$@?,#(')WB'Z,R<^&-#WAQP#,48Q3I]+GP,"\J_\K(A>,M
M=$;BBF-'E(LE8U/Z=Q]9MP'G$:[/5>*."5'W500=R%!.VF]ZA`B_:`+V"&>C
ML&-A(A`7S!:$TNK_9Q+@'8FL*0BTY!2R-(A0!GGXDVD(?8M+MNC=%UJC^9-4
M)I[G9TK\X`&-7<1EKC])XO2EYD\UJ4BFOK[\T*@.A(/<36Y%W/4,8LAFD2(8
MGY5)@W9N?X!K!30B>CSP`/;HYZJ2=8XQMV/16)CJN.=-,/?+?\2Z&O2WO-_0
MWQ*D!\1'B"J&9T\B_C-3GSZPS;?BV1W$(WRT_I<W&3P(2JCF`260B$YM4QQ,
M9O?-X\-X\SFS:?`B3U,-U%02FGJMY?K;CCB[T_%@_33F]I.H>[CDL[F[\\I)
MMYHH\45\-G#*O'!@FP@&^"['O#/0T<?P]+@^&'9WP6CC8!B=12,B+7+'KF>'
MQ2@K0#1E8)#$3D_"G#!7J3DT6GZPJ;`O<Y>L>@,70VQ0Q0OI0BC_@A,R2!Y'
M*MX3(W&"A[2P!4&;.<@]$;A#0?>D84F=JTB[_$"'B2:_S<BO>4"!LGCP+R>9
MVAJ,O1=QH,<ZBV=WOQHZ0%\8ZI88-PJRYIXY&>#]8(E`(*9_YMOHOU6\V9R[
M^43EF>91A\HOW3U@F3-F-**!>=L:>B)EV+/4H_W`OYB_^F`H\R.+,O?(C.XO
M+82S^K_,,/5Y+L$4K7MIC'K.\`=W\%B35ZF6-I]&1$$9!*LLA4F>_Q-;X^27
M2.\XH-3T%W'RG.%$FTC(HS`?;8.<C_6\'Z7W=C;QF)@7C1CM>BL+$,H1`L43
M%(T*VAT%\H@X#$H7B:3Q\`<*G##-XA'&NPD/H\3&<D.,8[%^"OH84BQ/!I[(
M89&)NC+:1@9C8*0(NI9%^1\J;*8"(MU\!HHTTI#8.Y'DT<3[0KOSS?U'64AH
M15&:K)(57FVRA'8*81)Q3\JX:X^S>EE$Z9&'[8PQ:2O--B".0.*225FY7`*\
MX\#I*`S5PNH]95FR0Y;KD%`-G&U`EYE7$;PJ^&`B"IW6V#?X9F0#[4?*@ZN&
M7SX:O)QJZ6J]Z9T-J`QT^4DZK$K6W@Q2`J)H_"<7#:9N.+B8V.BDA&<XYBC]
M&L`^;[D;$=9PSE"6[CS<)B=IA8F8VV.6Q*ZL9Z:NQ=G#5'?)_3,Y64"2YOL7
M:"'NC#IRHVI,?10UI@CZ;XH69Y42]YCJB4;JEIJ($,PQ)UD0YB./E02);*Q(
MDGD3XT#F[9+3(!F3."G4/@J&228@8:*1B)$0IJQ4/0E1Z`NY]PQ`X5.B,)\;
M?<=OO2"24?H3O#I1\*[R72`8",4"-N;WYR("",4FT3;D*OC$#T@HPJD(<T]4
MB<81_(?2;8=<6/+D^B*LGA$+5><!(XH!F/'L"FECU`SIH*D/E&YH$<5=B.#E
M*/`&LK0C$,"_`^GH%#&?:6RUDO/B>)#"693)P[3>&+VU`YG:]LSA[IC0R2M\
MM"J].<((WSCVA$*';J#G0.QHR`5I/-C^=P1W8$\!PQ^SH24NL43>&/%=X`56
M/B3\#@_L)XHKIO=H3R:B%12C@.HTG0<.G6;]`N;#D!(^O4#VE?IRG(1P$F$D
MX%2&8(N(\6<N2^2DA":>C03UX19):J7PG(^B(B7/=G..=L4+.?H%OA`D@;`3
MQA$A62ZVG,Z0FT(5'!-*OYR=$(EG@P-O[C^[R(Z750/90U1C::IG'_M0J.A1
ML'B^YVMFZ[.]<@B59SN6B2"!YJ.Z3F5%5Q455;>4[*27;B0JLHK5[3C*N#"2
MY7))JLJ"O2Y?H@0(6X-0!!9G8[-2=4&$PETH?.2(:2E/E=B&X1\P<DA?(2I%
MD?*H5D<TH#SQ`>FD,2B2(&+)E!V5.LJ4#D"Y!D0M[@\5>DI!,53!#&@DF>`G
MLZ%^%/$G694],0TH8:[PB(I*PL7,D*7GR$S.:,0]4$7=(9D#&E8Z"4*=K\2=
M*_"+D3CXU3_@*U4V6SB*6N0HBF*XFF-L7);VI78H#:\9N1'6X7$H'8DV(J3(
M.<&*,I@'I\NJ9J>#V(\VNG!%,1',$@]E"0);J6R8WOI-[:$$D^5!'*2-"$8I
MDZM$\YP)4V:*SYHR,8O#RS1\\0I"1C!DA6'(J'@R:V#UN?2``DBR+S;W(?RB
M$2]((BF%J:)X:(]5UB<?8@5SJFNE7K!5!6^Z"E#?1TK@$S<_81R:>+:J/Q)0
MKFD0<WDDY$6_B&4+IK873V5PJKP`SH$C2E1EY=]%@6^1>XAB(N)$[E'R,'9%
M/BS=W2@EM,:NAO)R25_^"7SE#JFH^[,Z7/$T55,Z(^Y\5Q=2-3J=B.JF('SS
M*(G(HB\*2\[`G>-V/+3QEABZ7-5D@;,&-@"K@F$8_Z.J*BO+T"(J,$E!F=[3
M>"-WF)5X-(1_$=8"X@83*;5;N7Q+F_?[11QC*E-S]R?1#H`N[;)?H([)+[/H
M7,#@(,,@E5"ZE:UWNA\^&7G3D,KEIJ("7OXQ$4I&<21&EGZ/5HD?\F&52DZG
M/<X.$V75_*.T)<#'VQO4LE7Q-YE%I-IHI"]'+C65&.>;TL+,\`R_2":R@X5J
M#R"&$V)(ED%*P:VI(@FBZ%_!FJ:+6P#J(<:N86U`=#1X8MFV)SM-/<!M9NBJ
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M`VIL?^<^E5=(PH(!;55%((M4<SS8:]2",'9I.=87H,6WJ.2ED8<6+W9*67ER
M*;X)(7']BU&`J3]P*QI*<D#3-DPGBNX$J?;Y^5-?:&]4<Q[5/E1T4";,[6WN
M%YPOP@X],;J6V3/6L8>904,#\HCR+7M$#?C<M3$.X&00VSH[,VSP%]KVW!:_
M?-=D6R%1+(,BOB0(>0*"'U//#="H+4I8P%^*NN"!81+*4JP\[SF?F57N3.9.
M<"?<<_/=<01-)C&6&Q&J-RT5+301AR5[4:"L^=1::,AI3_+'A\*Q0X1K4R7X
MI1MAS"PC1Y<21<(](@JM%-)^NI&T^\*_+H\X0$3@N+2[1%,IB@VI/M-'LB%(
M#B%"#<+OZ0;-=#M2?:9(/<=&QE0;Y4ETJA(&,6'!6G>,+QZ6.:8'5`836>H%
MUX`TBK*/2E+)>]GW63F-YWHN-><QY'QP(6XW(`0CU;TB7Z@F?1UO:U+T8^`/
M"::IL%$(;U#,Q<5&2E`X<4,^A`U+(Q'M^9,#-T\XN(C]TH)!Q"/H.7O@U,PK
M=Z8LV:?469AN$W:C%#T;5/"1J@:6/BNFSBIL*)O'3,WD+$I*0$UQF?:`2[,F
M98!GB8QT!&2YC,7B?)JR+3V5XB/=@`QD0>L8R._G"@Z12A80H1/YID7=,M>G
MJM:+"'J<P9@=I7PIW'G3[9VC2$?*>E6DRCS/B#<XWAMFT^AV+!7:H[(^T\W)
MMD5Q9.YL[LNG+PM$H5AM%,]1#9WELA1H;C/09>KSU',ZVQ>NQBZ5]TX9)6E:
M1*F$2M01_;<\;Q#[D6(^RC>5A[6P-%!CT"`W?9[QLW<5OTB;A[1CRO3`7&TZ
MVU&+Q#1#]'ZGZ%:#87IL,.;LNQ\\^W/W]\-%U^^IN\!1C?+5OYKNT9APQQ_3
MDB.WJJ;5&1@/4O?E+*J.ZIP\8*=141I5G!%"$1"J)$JXK,)[:@@\2*=1])"D
M]=3SVD@./KA*V-C=Y]%3W\G<`GNL*@`BS45*FJ&3F5(=E9R6':;SE3;E>J7%
M51:D0P4URM>W9_,W!*I[-9P-D)'1,')@V>&)G(TAK+ZX#=+,P$+E"W*%\=)6
ME'W/FPMT$JT[19<K\@V)KXNZ.,WU1P(82=D(\ELNT"UC8:@*/VH!$A$89BE8
M>WT)KLTJ;,W7Y;I2W1E>5]-[*U^-Z^KZGY?7]S>WY]7ROO*G6TJ:J=G&S:R9
MF>_W'*H/;+*"?=4<R%42>$F&+H&R-!%8:(G[R?PM5`1WV>$L3W;[Y-P/3.YZ
MJ@B;Q<7KBE.!T;X$)^`O;YIOMI^Y2"N7"%;`_.K9(*\!)$:VS90X]T?V8N+=
MJ7[FLKF$\%DY0<<C;QFK:OHJ"9+ROH?*D9>U&7EM7IA!R>-%)VCX^/"N4;>,
M1K-K-%JMG_9:&*;5_LN2B[RB<BP0`<_5K,FV=2(^8__VD3!)HUJ^E/4D+-VM
MC[D75*B96^X+RE^\7;<.LS$W"<5<;3E+I]L!C#?6SK7[>C8X>S6"%F?I=H`E
M>]8I$;0/Z4(A.P=4`W<7([?V<UJ.>^?3>VNR/#QS[4R(#:/;Z&PT_&$6\(KW
MWFRUC*9E'GWSRZM7K!0".8UY'Y+ADXJ()I?14B04SGXPHEVMCV]327">>#8E
MZL-`0.R1!Z%E+B_+N#$:#L_B&OO[Q;[9:AA6IUL.-)=8`Q++G-^-1JVU']E7
MR'HK/]W?W/>_S)G0-T&@!/FX+$.34M]`;ZOJJX5<L_Q"<+"Y,W[I=NI&O=7;
M=KN/+Q@UGG>3BX8)FKAI-LN"Z>4E)C-7Y"JGXKP#DH)B/XJ(WSX%_![?_WA0
M5V,K[VJ\N?_[Y2W[^/OM[27V^[F[N[P_EQ8_92T5L(?J6&G<]EQDNFK(\#*7
MI';H:8?>&3A<M$-/TY=VZ&F'WHOOG"IQR_5!4:1D->TPVL9A5#=ZUO*+H/;H
MG1A!S9YE=%=8MK1';\]R9&DBWFI[_BOV-S6[IM%=86+0SKX#;GZCUS.LWG+Y
M4&:A<`)GW^[R(<LMU>18(`LZ3:/97*Y/:%EPP,VW3!#$[>71/V66!>57$$1U
MB:R4;72ATE!%!?5WUUB7RFS^I$FSX)BR>D:O>_R8%+WY)]S\5Z<C"!$Q234%
M?6$HID>S9]2[;2T,3K'Y9A>=PL??_"HI"7L."517AR?N#ZBQ$M6YU+&!QXH.
M:[2,=G-Y,+*.`3P++%<A`K0:&E%)HP271K_H0+*#!Y(U#+-1-[KUUK8;KD,&
M*X9ITV@U.X95W_R\/%+(H%<<+;@B`G`^6/!;B(51XNDW#ZN<^(/+/Q/1CNF4
MU4L.&CW8SD</?K[ZU^4G*3<-=GUY3UNJ0P?+NZC/V(M5U'LBRA8-473<H(X;
M?/5Q7:\L;O!(E\4"^MJ>:K8%+(^DN8J2\]4CM\[%G`O^F\PL>H__''`1:1R@
M#OV;FSG5WY:RC8XH*S``-^$RUZJOG4N'_+U>!+UB8_WG)/1=*C6.`8!#]P=^
MUK;Z8UEQVSW#:BT/8=&V^K/`<JMI='N;VQ*U37Z?:I/VCZ]1MXUV_?A!='KS
M4?7IMHVZM5PPE%D&5%3?Z3M.0BV`.*8[8(\JUZ;VWOHL/,Y9^,ZT+*/;6AZ1
M<XC3<'F0JD;OOM';:!B=UO*BF<=`;S5TG)+&'13[S;0K^N"NZ%;;Z%B;%_72
M$0?51'.[:31Z%:A05&9W\;DWOOZ4UTP13M4U#?L1H1<\'H6<LS&,.8JPT3IV
MT5EH3$<F/?2G4"/8MQU4NT2#V(Z!Q[3JZ$.MCD3#Q[?PM5FWTL\=LXESBIX_
M,*^/33$WG79V@O5->;8)6%'!+O&/\>!G&7&L&N:]KNX\G7S0R[?;RV_]JT_L
M\E_?+J_O+FF7SR7DI?)<+<ETAJ'?8=_'"^S[^!/;L6N/#G71H2XZU.64H.M0
M%QWJHD-=]IA"!K\FV`DXP>[D:S),=6S%XBR]3M?HK/#NZ."74R.HW31:UG)K
MP.L.?BFVD.XY3?6%%;"TXV#//0UZ3:-IZ;35,T>S!0*OTU@>[:=C8:KB)RHR
M-6GWP3%Z''0:1KVUO+Z-=A2="Z:M1L=HM$OG*YIQ$_WU_88F^,)>%E]<^\'U
MW-@]K=7^H`;ZWO*>%E^N^K]>?;FZO[H\K\86E3?5+W:Q\#)*U2FIVDZO[?3:
M3J_M]-I.7^([Y!'L]'W'"1-L_NJY/BZ5Q=@A6AOJMR\D;;0:7:/>7GZKTZ;Z
M4^>I&IUZVVA9RT.;7[>Q_@!B96)/0U!W#5B,G\"MDDST3C`>NU'D!KXN.;O4
MK00J64_WJ#C-YG=-.,E7E(XKLVRH5&:G$A,>?P2E`V6#[3BP&NQ6P62`G2;0
MQ2G:9LOH6;H@]4DVO]%I&U9GN0.LS-*A.IH#*`G(_I3F:3]$W'=6%+5XQ=1H
M]>J&>0)JU)N/FV\U#*M935%0*45!-*JPI6R0FH&6!T5VB"Z@LWW\_FIZ\]'"
MT`6]K%W-BT,%5`-TTF''7$JB@WO")/"%12'D<1+Z6AX4FKZ[1G.%55++@T-:
M<>J&=8)KVJM3#V8EP_,H\'AD>YP-W"@.W8<DAF^'7"L,Q0'L0*/Z_G`:?:%=
M-UKUXUMY7XF^(*\+X:J*NZ^8^KIMHW>"3LQZ[U'JFJ"5Z2[8)RLA)P1#,+4]
MC`=<B@>=/++GY!'3:)<E=T1C^5!8[F#9F9)@N<2J3DG3@E8'N.NTD</7%S.:
MH)IU.J7I:*8Q?2!,-XVN53?:S5Y9,+U)[[K5&3_S24*7=NC#`J)O/+P;V:^C
MH)=9SR<,75^"%+VYNV/?0*S>_;U_>UY%O;PS[&/W!Q>90[;G4*5IT`DBUQ'U
M!5POP9@$;&P'I!^Q"0>-`BF;V1[0-:4&Q0$%.08^S`ZD/@H\D"012R*,:\*$
MHV>.,H`/+FS00NQ'SOR$@NR#H1@+*X@)$'+#&*`4A.S)]A+.WM9K];J936ZP
M(&0?Q<-W^#`+DCB*`6*<<B#*K^#,\(8;#`R0&A'Z3J9JOBAY^#=W8@0]Y),D
M=$9V)'8!;:=!..349*3&[D$$X`+@/WZ000OSK0"@<'0V,S*;K8R(>XVU"@F$
M3>L5+JM06'J"JWZ^W9WK.P)9SX`\0*?K,SO')=A!W@W@3?AY!%3/^`_'2Q"?
M,W0B*&>"C\+PP%%(6L\C%ZM[P*`Y.LHH!YZ+8%AXUHX$!'88VGX<I22545P!
MG0[A[*%O%;MC8#(\N)S37TQF[X%$K5UQ]8'):\E_-UKX?YKZX@\@E$2%4Q*_
M#]P+GMD$Z\(@%1`%!#%\=H&@I@*Q+I!@Q!T0C)00&H_LF#T'B3<0U/G`N0\D
M+$D4:'D#`B$(MC@.7$H^G2I9&H,8B]T4N)1V26!':CE\\%J$G,ZR/426[;&S
M(#O'RX+LDQZRF-6ZBS%(X_7TV:UILN_K6_=\X;_R^F^.D*MZEU<.EQ)$M3(?
M-T_EW$\*9,>P,+GIM#F0&ED;1H<8W99I]'1UR1/YB?^0]\A3'SZOQG%H-HQ.
M`U,J-J^-IEW$U<1TT^@U.D;//&X;N0H&QAS#/_QZW'TO)?T]^_WJAMEL&^U.
M:2H#:IP?`>>=3@\TNJHX>Y=Z;N==O%>^$XSYO?WC;`M`FHV\0_?J^N/-UTMV
MW__7B8H^:HL_UB4;\C#DHA>32Q3(8OL'LZ.(QR(K+%_P$0WR`XY=FER?#]"?
M"__%!#(V<(<P$N67LP<>/Z/AGVI"NK[M.U@,*^23(*22%#@J3H+N8#(VBMD(
MAH49L9H%S#KF-G+$(.?]Y;[MH.,`APKM6#[LV<_*#^%Z'L"";@<.P#GPS4A"
ME8<61\=46!Q+>#_0NPKZ2L1K[`]X-B"O@G@$G1`3>RI<OH`*=PA*#>S]D(/@
M@T4&J/"@JSNWE^B"$/Y5F`S+["<>E<Q\Y_Y$P*#3`^`(N8/B4\"0<S5OTFK.
M@,%@-!1\:-8!0.2@:F&I'R3D8]N%4<A)+EZ%77L/O\((,`1Z8;#[G(V8(E#(
M:>?`'6Z*@SS;X2`2SKY)Z,)K4VZ'48WULXHCY(:DQT+^9^*&G":F6J$#&ECX
M?6SRP8L_[9G,HX$D2MP]012"&MTA<V,&)"/XKFE]&`<PNN=^Y]X4<>XCIM(?
M!15$B`8L@Q#X6+X4AI?N4`3J@?M\Z(I.8_E9%?T3"2'V'X1C+.3`@/_A`UCO
MHI5<;N<S8`NV.+;)=3M,8(1E"T5("J:ML5^)L0(BUHBK?<1N#)%!@/A`AF'P
MY%+Y)QA)+H1&S4@/"&!D1\(+I\AK/O1`?<\2'S\"2?]'`I-N#NRBX+>!W#>Y
M%XJ?A6]M?5_#52?<_&EXRZDW^3<[C*?WH>U'P.MHL#S?P[&9/QQO+[_T[R\_
ML6_]6UT4N6PKN!&]2#_SAS"Q02PV>L3[#8-]#%!VLH\U^.1Y+@9?/(\":CL:
MX]F#WF<0@GXLCZKPD4>Q<'0+=S8R&&B*OON#V-2>\`2NS3#,ER\?*3A)_&C@
MD`0$]X1\AW,IXN$31Z&!3O:'`"2P<*\#6\<!RFCD#1:[8W*EX__/A9&@XX5<
M]/"3_1AR(6Q``,8C!9`KSDX_",=4VS()56C3D#W@L<PC/`A`ID4)!IIDH^`1
M"T>JRY]1:9@R/(`F>);!1J3PJ:@2E-5XO*)\%$7NXIAS56L:Y0T\F!M!G)=+
M1GDM7OX2KN`3J3!"H]J^8^XS*FD#H7GYCQC;A\<ID$6<.PSRY`F4%R\9DF#(
M5^"5<\3906B/47N)V"#ABMQ119G`(?O#'<-)!`K&6ZMMU.MU35(G6T$_U6^]
MJ:$HJPB%(,02J:5*;*)B).KC#3D*(W?\@/*+&ER%J&N0N@VRC^'%XU%H:X#X
M&`.1@*;&^#L-B$\XU+-6D5:43"9`'ZG`4Y)20;1(28U6'4D)-:N'`$AX"2LL
MT.QZ'6L+O6E>Y?H8^.B`%QKZK1M]/U]=RV(7[-??[ZZN+^_NV,>;ZX^7U_>W
M_?NKF^O*FB*\\PT@S^).X6`'/AHD3BRY.\*+NHT:!["@B^&`="3,LEO+^@NQ
M4Z?S%Z4>J"$C]>9`!K#"(?4$QY.(J4[O.@=H]U[ZS:_^<2'))\*89D$Z/')"
MER)?\`_?CH%TGMS8!NF>$1:<`H6U3V!L1*MK>_&434!G']N.RV>^G7V:JC2/
M;%=<%P9A0I'9H8J3?83[=4BAM`1A?OZ0Q[;KS4PR"J()0.K)<0,JY08WC-B-
M$VGS<6#CX(*-JOXM\(4/!Z&80UFVB,2'N!5C^]]8_$F]H`K&2D/1+/OTZH)]
M>JV4?7*6@E#.I`Q,*UB%8-#L4M85?%34(#6KE$21+,C21B8VLYZ2`7*(,@JC
M-524&8UR="5WQ>I\Z*N/W0]&[NM?B[_^F'U-A)+]\BG[I;*T\H*K$=Q6GH/<
MQJ[`C.1(80[?S)"<YTQ@2!(16\U58Y^VM5BK\5E_3DK-Z<IM`ZNXH[;L^K-K
M2T?X-0?BW-M->+,U__9J:`F(!8@M([<C?8/]:K"/0DE?-;D$W6!O3:,K[H_T
MN=63%P`8`/]LI3`23QG2PKI>+F::_R;J^[S*?Y<\1/S/!%Z[?$)+S:M(*VWG
M#:UWO_]Z=_G_?L<<_<M_PG_/R]1ZCI>"*Z%.W3AQ@.R9.EW0XN=QY$+N8[>,
M_$W\]O+;E\OKJ[N_B\8\H$*A;@4WBB:`D`RF*,KN_W51KYM_O\5W)D$4P_O!
MQ$Z`']DS<+TO;Q:8SQ3#I9J`2&(>)A&Y5&3+'S3UBL-0&&4%+'."P30ZK3J;
M`*<*\V@\_SN(@LB-05"MY?JE'+P07C">V&Z(FW(3@F2`%=K>S?!+X#]^`0$S
MZ)/GZ5O@N<[TK*0`L7*V>&6PQH5?T,J96/H<WU>0,:JO@?ZA/(OH*A!>8_0[
MXTE-^=ID2@-&F?`PGM+9B8Y1T:6>'"J(5(^0BDSJ/[J8^R9]N>0:3>F`8@'0
M>,`X\0VZ&^"NYC_R2,9",,<-G62,WFP,$W#]@>N@9Y\48X#-#1>@&]M3Z2VF
M&Q*:)@"`U.,*HL$/\C"@8="?YL'.14+D-+?97.Z-#1$;>&1?(!3F!<MG&.&?
MN/Z;X6<5['$%]](P(>>/>/ML)`FNEM!#2T8,IHMFN55K:7+Z%=PD`E-9")*;
M(2CM73L)X=0-78]T`&D&H6`<[CXA]QK9EQ-[2LFTLL/.3!%]H0.D`D&8_E7Y
MB9</FU<,(BEUAD""LG[%`W=`0^$JG"4:!6%\@>%9Z+K`I.RI`H%<LKGU5_;N
M7'VZ3,NBQ/PQ"-W_"+OVDH@[.FW0PD(('Z"NF,,_1A0A424AG14BH$[X\,6A
M<>'!\>;E7QFY<"J%SF@J(ZLP`$D$\TU9_^XCZS;@&,'UN4K<,2'JOHH(/$$]
M],1[>H0(OV@"]@AGB*@;,'(?1UPP6T!4"1#^F02HK,-7XGB5G$)9^X""[^F9
MC4Y^:JJY9(O>?:$UFC])'>!Y?J;$#QXP.(*XS/4G29R^U/RI)O6_U)N7'SH-
MCI+W"!0:F+E!E_T'VZ-(KFC$>3R'&,18AF`5*4GHRO:'XA@0&BJ](;IG1YOU
MSBXA61<6Q=MD+?NJ4+#Y5N1J&6Q:H2`.)KN'D*_,K*S76JY_A`3.[2=15@3)
M9W,FA)63;C51XML#)$?@E'GAP#81#.CBSYAW69S^27%],.SN@M'&P3`ZBT9$
M6N2.7<\.BU%6@&B*9R6)G9Z$.6&NG$XT6GXP&1["77*3B>@P;RI&2_^"$S)(
M'D=R+I`D81B`?+%%A26"-GG`^Y^L>$/Q[!C/2QJ6U+F*M$OR66CRVY#\F@<4
M*(L'_W*2J:W!6);=<Y2S>';WJZ$#].-BY\F2<"89?XIA?DL$@DCDX-OHOU6\
MV2S-]C^3*X\J+)9'G0CB!?$)RYRQ?A$-S)O$,.TCS0$BM/N!?S%_]1')0?G$
MG+P(D(:]6?T?SQQ0ZWU.<7+*R#]5.1>#O+T.[N#Q*R2OS%ZXD:UO,96#O*ZW
M(F8$=_E<W0QRI40%N>6>VA@HOW0I7#Z]:"R2Q'-&$MI"0WX(&>64!CFAX,%B
M)H\RL8'T5301D"&`9`?:4-KUEI&&8.4(@?()BT8%Y3+-321E&<2=M%W^0'D7
MIEF7PG8XX6&4@,3#S(TGO`<Y7#@3\N`Q_L.-T+A`ID&0@6)<?!F4H#$?R`@U
MN$"#\)-*$#X0@IP-<"9E(R*I>R+!IXGWA6;OFWL1G[)AU"/>K+*(Q"<[=&V1
M8Z%LR_:8JZ<%I4<>9N6S<3"@PU8\#4,B<<GZGH)^``AQQ8+#6=C)A=%]FLO#
M39.&T1:Z)>BN,#)&\*K@@XD]10:HL6\RS%?&M,FP-1Q^^6B8WIM6#97K3:^,
M0&5>5@@W2S?:#%(1S5PP_I.+]EHW'%Q,,'`?8:`PSE\Q.6#+W1!E4U.4I3M/
MD<Y!*#3TF-MCEL3`\O\1&I.XE6</Q]P9^>Z?R?(8!,WWY>+[U&:?JB,W3SR\
M`$*X^$BQO4(L?%.T.*N4N,=43S12M]1$5(0AR8(TXEHDX0L)(D)Q,V=F%D2.
M/HM$1(47:A\%PU!%AV@D(BN$)2U53Z@4BY![SP`4/B6:![O1=_R6R@503ND$
M;VX4!*5<)P@&0K&`C?G]N8@`0K%)M`VJAC16.7]`0A$^39A[H@I*C.`_'B5I
M<6%(5,&>!M8T$*K.`Z;S`S#CV172QJ@9TD%3%RQ=$".*UG@,L(9T%'B@#2$$
M?1%(+_RL;#9J5LGYF:05.C@=T*;<&)W%`QG-_\SAZIK0R2M<Q+)F@AW!,<OC
MV,ORRIX#L:,A%Z3Q8/O?J3F!/04,?\R&EKB$LP&$.^"[P`FM7%B13(%[HLPY
M>H_VA$H,#-`S#?=H0&!:7:)9OX#Y,!"%3R^0?:6^C/VCV41$?"1494(4G7^F
MZ?DD3@E-]IK.RL9+:J6@'BPLS_$LSV4TS-"N>"%'O\`7@B0H>E94L1@RN*Z3
MYSQM;6W(31FXD=@,8VY"))X-#KRY_^PB.R[B8+(@/U0A7/F(JF14[3RQEZVT
M(H)Z\?3]EE/7],E;U9,W31[S49E^""E(!_ZE$]EUYI5R=8?(SF'I8Z+LKS2M
M+!11#`MI7L5'=):[530;FY5Y"P(.;BKA(T=,JY0TE381PK<K@HRU@E]*BI0'
MJ3I``>6)#TBG\UR1!!%+IHJ@UN$*5XDXH:E@#U&+^T.%DXIR3A@ZY&--+_QD
M-M2/(CA%)2VI:4!%<H6[M,9N%F_!DAG01`\H!F8@M=#&@!D/%$5W2)?UAI5.
M0O5)L#P7JKKP$^Q#,K0=T3%)5%SZ!WQEA\(P9>9*+D4Q7)PQ<$X<^:@1J1U*
M8V]&+J9?4L2`W(BL;%@:Z8/3V=Z"GF(_VNC?Q5LZ:DM4:T5%4$F5;5!CW]0>
M2C!9'L2LTM,H97)5#"MG8'1X*&I'Y0V-6%K+R_1O\0I"1C#X`3E,,)@937ZO
MI[G)`832P0209-^T-AB:V((DDE(8">XQM,?"IDP5ZX*0RLWEBHEAB@N/75+4
M52LH%9HF3#<3SW9$)&E,%<+&0<Q5FF9.](M`-^K;/)61J_)Z-@<.VM9FTUE$
M*QY9#BP!/J`K0_(PAFL'0D@W*ZJ_46-70WGUHR__!+YRAY3,_*P.5SQ-U93.
MB#O?U751C4XGHM+CA>-^IH3:'-PY;L=#&^]PH4OV15P^G#6P`<"6LE]<I.ZV
M>$<AOA8UBL0YF08CN4,X7.&6%`%'&\+Y"&L!<1."3%OI<\[7Y5CC!%OTFD4<
MPP3[_N`3NBH#NJI>BDOIF075J[6FYN+<BIE<L@ZI+[-P6\#@(,,@U2V[E649
MNQ\^&7G3BC"ZN'@)1,-"[C$1"49A((9R7Y$*``L3#R/YAS8=TF)VF.C1!LU9
M^"($<V-#Q]L;U(.#*%;>#,S=\5Q?J@+R9<JX,W)*!R@1,#,\PR\28>1ZLBGX
M%\4N#9>OQ9"!"X)/KD=X@A?7-%W<`E#@,/0L`.DD2Y((:P6<$OA)%6,4,V+L
M@S`.H;'_0L@\.AU`%23PLKR$_N#)5DT%I6.$:DP\</40A3</$VH?F>[&'!)S
MRQ/Q.&][5M>P>CV,R"E*[TX;#K[MM%J&V6JD)>OR_>"H%:[2$/,!WF_-7M-H
M6AW*FLJ_@8J.","#"_;$=M-<"5DND^Q<5/L-=<"B@&UI.^14:5/N#MOGSIB&
MV6D9]6X#]Z8@Z$FF9*CM,4VCV6XL+'3YUECMIM%IU'?;&I&#L#2>'6V)MS<K
MZ!5T_92%<K0K3EQ9]@\U#O6,2(_%;%OB$%I=%O)?.$7(']&/B,/2,>^EU8/3
M2EYR$N1%H<?DD$$&R-C^SGW,;1`FP_D!J2\).<320#/'@[U&/85*62S%^@*T
M^!;5)S3RT.+52ZD36*X5RQ<F&(5Z,0HP<P?N+4-)#F@:EBG_2(5*/_S\J2_T
MJRB2URI415`FS.UM[A><+W(PNQA=L^P9VS/"S**>&?PN8*;:K4@I8>YB%P?8
MI(M&F)T9-O@+;7MNBU^^:Z&H4X8+%?JE`B%/0/!CZOD`&K5)XYO8<4I=V,`T
M"8E1*!8W\SS/S"IW)C/'NQ/N828E>3GA('P4-)G$6)U3*,>T5+2A1!R6[$6!
MLH:C(S88<MJ3_/&A<.P0X=KA0-Q!BS?"F%E&CBXEBH1[X9ZJ_Q;2?KJ1M/O"
M/RV/.$!$X+BTNT13*8H-J>#21[KE2PXA0@W"[^D&*<H2K('4%4D%^@EU\4?A
M*T";EC!9"1O3NF-\\;#,,3V@4M:=QC`"(=E0]@W(821N3M]GY32>Z[G,&BR_
M-[@0]P\0@GC-(`F+6;FIU%*OXWU*BGZJ12W*`)`507A38E']6TE0.'%#/H0-
M2P,)[?F3`S=/.(B(_93&,E.+/)D]4Y;L4^IL2[<I+>.<!N^`KC/KF!-39VU7
ME54"C1R"0>!:F449":@IK-(><&EXI+SK+`^1CH`L%;%8G$]3MJ6G4GRD&Y"!
M+&@=X_#]]$XG5;*`")W(%Y6?M..KN#]290>7.K]B*=`<QNPHY4OA#IMN[UQ$
M.EI3T3LGWN!X;YA-H]NQ5&B,2MI,-R?;%L61N;.Y+Y^^+!"%8K51/$<U=);+
M*MRYS4"7HY]V8YY%#2SH4GF_E-F0ID642JAF.T$C]B/%?)0N*@]K80M`^2DZ
M\,KI\XR?O:OX15HEI*519O<)?B1);3MJD9@EB-[C%-UJ,,QNQ4+FW_W@V=_D
MAKWVPKQ0_H8_XC.WJI*Y>.I<HU/E:F5TJESR&=RJ4\_;[/7ZJ'ZU0]GZL?.%
M[8/,$\)3G)!"QT+65V6WU5'GXBGD)%(".R&W4[7!$2YNUY8A7UFY0>1@,IUC
M*_F(JDW16495;X0B@L9]-=?,,9V##W1L$,HPM*>^DS'S]E@PNF@8$"DV_Y;6
M0L_:R5/)[ES3#;E>:2P$+08U0=3<2%:G$,VKSE0^?#@;>2'#+.3`0B>B\HZP
M2_%L&A>>5G:6#2`'%KH0EEF7<*BA1<WSV0@:41,OI/-7%"JEKZ54_!US'@;L
M+B;W&_7.('71F])A0Z=PD-]R@6X99(&[2,=CVJ<#8"+6WJ!<T"82;T%,.B,^
M2#Q^,[SRL5@*Z*D?Q;7T'N$X&TF9KBZ]&[N9R2AS@9U#AO8F*]"=XP_187QS
M<BCHW+AY7F9!I^W-9]Z^)W=*G/LC>S'Q[E2_V,E^D?!9.4%/6[87L*JFKY(@
M*6_@K1QY69N15WG[NLK#I=7^RQ*7U^X=7C_#O3H:";L?JGA+6:]:;=C?KEO'
M7KJO=[H=P'AC[5S';"NO$92;I=L!ENQ9IT30/J0+I3,?4`W<78S<VL]HW>=H
MG=OY]-Z:+`_/7#L38L/H-CH;#7^8!;SBO3=;+:-IF4??_/+J%2N%0$YCWH=D
M4$UXA5U^*1(*9S\8T:[6QT_637QG"+)6XJH*O+F\=-W&:#A^0WF-_=VP;[8:
MAM7IE@/-)=:`Q#+G=Z-1:^U']A6RWLI/]S?W_2_LZAJ[-=S<_L_&")0@'Y=E
M:%(V")(';ZL*E85<L_Q"<+"Y,W[I=NI&O=7;=KN/+Q@UGG>3BX8)FKAI-LN"
M:24;O7P%OIQ':T/GU'*G%H4BRG?Z%&9Y7FZM+-1R+IA4E4!_F8-+NX>T>^@,
MS/?:/:3I2[N'M'OHQ3<8E6OA^E$24GZ)=C]LXWZH&SUK^;5"^X=.C*!FSS*Z
M*^PDVC^T9SFR-'=FM77X%7LOFEW3Z*ZXL&K7T0$WO]'K&59ON7PHLU`X@>MH
M=_F0I8-I<BR0!9VFT6PNUR>T+#C@YELF".+V\EB2,LN"\BL((B$\J]X87:C,
M,5$T^-TU%GLQFS]ITBPXIJR>T>L>/\)!;_X)-__5Z0A"1$Q234%?&(KIT>P9
M]6Y;"X-3;+[911?C\3>_2DK"G@/,U-7AB?L#ZB5"Q>-TI-FQ8HT:+:/=7![:
MJB/*S@++58@GK(9&5-*8LYO[OU_>LH^_W]Y>7M^S_MW=Y?W=QFC584F[B5##
M;-2-;KVU[8;K`+2*8=HT6LV.8=4W/R^/%("F9.8A^L#NY*U?T][1V[[C0U%X
MW;HPN?D`NV\AUJ>(I]\\&U[P!Y=_)J+=RMD$UGW&YGRR"#CNAZC!KZ/J=%3=
MJX]Z>F51=4>Z2A70U_94LRU@>23--?*9;]JS==[;7&C<9&;1>_SG@(M(H^1T
M8-S<S.F!OY1M=+Q5@7FT"5>=5GWM7#H@[O4BZ!6;LC\GH>]2[5P,CQNZ/_"S
MMF0?R\;9[AE6:WF`A[9DGP666TVCV]O<TJ8MUOM4F[3W>(VZ;;3KQP\QTYN/
MJD^W;=2MY8*AS#*@HOI.WW$2ZFG!,1D`FZZX-G64U6?A<<["=Z9E&=W6\GB5
M0YR&RT,X-7KWC=Y&P^BTEA<H/`9ZJZ'CE-0K__GJ7Y>?I#?>8->7]]I1>QQ'
M;:MM=*S-"RAI?WPUT=QN&HU>5:K!K'<ZKZD#(SS;UX$O:Z6<C;-:QH#FFS6Q
M=]B5Z`*[$OW$=FQWH/W6VF^M_=:G!%W[K;7?6ONM]Y@M,<XW@EZ33*4=I8NS
M]#I=H[/"5*L]V:=&$*CV+6NY:O^Z/=G%YHX]9V2]L-B+M@+NN1BT:#9?#H^G
M1O.AT&R!P.LTEH?N:,=V58R^WVXOO_6O/K'+?WV[O+Z[U+;`8^7FF)V&46\M
M+^6@K;[G@FFKT3$:[:H8?C<UXRXS_P9#;/,6\R_8LO?*CVW_T85)Q#B?$XPR
M[(^Q9^Y_R/TNVXJ?5Z'PM&$\LW-+35NZ8T]HM`S[,#<;8M?V*>BN$3:=MB/B
M$F$SCJK8('=-#MTL56IC^"DM>_\#5,<N?=Q7MF"*>V56SHQE\]*I,IKF*4Q`
M5G,/II.=+?7L79.-X:51]-.B2"F+M<S<7NZ4TURV%YQWC7;OI(U,2V\L*UN\
M*C":+O*U#;OL7'W5,CIM70NX8CRBFZYJ'M&'1P%C'!]+FC$JR1BO^/#0I=9?
M$8^L,;[NPX@Z;Z#-EYWZXMH/KN?&+C_[%HU>ME1=44I'YNK(7!V9>RXVZQDD
MZ<C<(G+1D;F%,_<=)TPX4*T':@8LE<6A"__5H;E;JY%&J]$UZNWE<1PZ./?$
M*#*-3KUMM"SM<3AXQ14E5B;V-`1UUX#%^$D$+V%0KA.,QVX482"$[J>R+)`<
M5+*>;L!XFLWOFG"2KZB+7F;94*G"3$I,>/P1E`Z4#;;CP&JP%:,*DM($NCA%
MVVP9/4L[8D]CH>VT#:NS/.2]S-*A.IH#*`G(_B)V\B'BOK.B)N4KID:K5S?,
M$U"CWGS<?*MA6,UJBH)**0JB"Z,M98/4#+0\*+)#=`&=)_!GZ<U'"T,7]+)V
M-2\.%5`-T$EG@R)`>1-P3Y@$OK`HA#Q.0E_+@T+3=]=HKK!*:GEP2"M.W;!.
M<$U[=>K!K&1X'@4>CVR/LX$;Q:'[D,3P[9!KA:&01N$V:^G[PVGTA7;=:-6/
M;^5])?J"O"Z$JQKFO&+JZ[:-7D_?%$XC=4W0RG1D[H8R8/\5X(5@"*:VA_&`
M2_&@R\7LN5R,:;3+4BU&8_E06.XTC(Y9$BR76-4I:2&@V9[L7Z[ZOUY]N;J_
MNM2-V0\Z=ZX\N-$$U:S3*4V[;HWI`V&Z:72MNM%N+L_X*5=)H(TR1Y:7@^_[
ML3MPO21VG_@==Y*0WK[\X7C)@`\PR>1C,)XDL8VI+#?#2SOT8>W1-Q[>C>SP
M?')3[D><Z%WDD3QP+WAF$ZQ;Z<<1Y:-,@A@^N[;G39G:,!:E.P;/V#%[#A)O
MP$;V$P[!?>;Z8A_A`PN2D,'1YF";(XRS"X9B'/@5&ZI[023*"TTX'(>XMPSF
M"AR")PXH0@_>BF+8[%'@`1M$S*54F2E[YO"T'\3,SF&3J4I&,*`;#"*U'#ZH
M$2VMRZ@I(9)T@:(2Y`0=.V>C<[R<C3[UA5C,P=E%==5X/7TN3IJ:]/K6/5^8
MO+S6IB-DUMSAX<F""9Z_YY)*LT6=J[TD;'0,"T.Q3YNQH9&UH2_+Z+9,HZ>K
MWY_(JOV''8:@DVMC]K',G&;#Z#0P`'3SVLW:H%U-3#>-7J-C]%;4OJN<4?LP
MBM4QK-FOQSCY4M+?LY6R;IC-MM'NE*9RN<;Y$7#>Z?1`HRN=:5K)O,P^77U3
M8E'1_7T9RY>;X^FY7^V(#[[94VR1U'^VPP'=6V_$M?6?MI?0^/TH2L;BN_,J
M$W4_XLS.%L>22!C0T99-?'4!^X7AI.QK,.`>&XC6=52TW_6Y+#C-N(^&]QEC
M'J.:U+8O^L.B=82AG3WB,1K+XY&:)><$T+;R,[655U2_/X59_!JYZJO@JLM%
MKBJ%B;SJZ-36<&T-WRPHZ>7WM5LW^GXQ##F'<PZVET<Q"^U85W,HFF*7H]>L
M69T+L]:R%D_>`P06_T7C;^_X:W<!?S+8Z]CX*YFY?'>Q\\\`(UX\-YYJ2MTS
MI;:Z0*47[4:M=QQ94P3L1>3^AXL1<O2\%A*-\I>AO-VKP0V^4Z_UFI453]51
MF>YY.&;O7%\T`?Q)4_.^!5BM`?*KUBBH'*SSWRJ%R!)@L62:T[*`IGW)ID_N
MDSO@_H!-7>X-ENZVCI!9,5V]5E^>%+6_52V_HVGLE`\[&S=AWH>W9MX7M**W
M2-]QDC&F#_!!OL'(C+^G']T,<SX>EL!H],/O=Y_>L`%WW+'M16C,_YO9;/6:
M[6Q=V\]\&-BM"[-QT317PVXVVU:]?+#+??]?.>K_"G\@#^^"80RTP>>&_DI&
M])4K;?9ZUIFL,WWZ"LV//H\_`4.Z_K4-_+C!3O3,CM4LWU9(<MTCRAM6K[QL
MJ5&>;8631*!&_F]_,@D#&/'O03@.?'X_XJ$]F7X*D\>/MC]P!S#D-QNSQS99
MLMFSZF;YEJP8_A!+A@7W>OM<\OQKG]S(\8(HV3E?<;73_ICW+7SY07U(R$M[
M<W_)NDRJ:"T`\>KZOG_]V]6O7RY9_^[N\O[.8->7]Z36)*F"DPZR-$2@I!NP
M67Q#.8&_SS<XD^$F2*@R#`5C4.!:&D7,L<-PBL_88ZS!;F"]5<4!^%W&LUAS
M$?-(Y][`A#;,/'53EL#8&IS*7DQV2^-C6+[%$'YKK>["5LY=WIQ$MHI^>5&(
M2^K+7@R:.7STRT%,7,>+&YB/&3!;\Y%(>XXRS[5$6^2/(NB.$?-R9DAL'@^'
M&\LH%7921A%5/MA_HQ/JHSIO^G3>K%N&)K[R(+!Z)%=E=LG=75C^\J(YID(<
MD^[7-5\KZLH'OA;1A03W!T??!!]<L#ZH:_8CG^%/]HUC_1SV;AI&M9^*P%ZN
M_2WZ%Y^%?_%0:F&A5W%']XC<##SC%VZ1/Z\FF(-HJ0?Q8:V>YD7N]'(MI\JP
M:U24!G:-BM+`?A:HV.;L_&_'X7PX//+I*<U]5GT/X1-[NOL4?+KY=GG;Q_&C
M9))[NF-]H&"0]_+K2#KKV(2\,XNJX%(JD-O0W%^@RJ'".=YN-M$\/E_4V<LT
M>BWS6`O;<BLUJO)3O6L:O9YUK(45WA,TAE;GYW6`F3J:F8ZTHKW@S#P:1^U/
MC3C%%7R/)_TG_L2]8(+AALP)HAC=N%K)K<ARJ@R[1D5I8->H*`WL9X&*\M_"
M][?\K3\Y03@)L%`">^8/D3M;,$$3<WZ>GFET9HO-:IER`C2\.P(>UMQP7_/V
MJQ!<LUBPE&&)KQH]NUAA_??V%D;3TAS:%70[KSZ450("&XD,!$WN%5E.E6'7
MJ"@-[!H5I8']+%"A;\`K/L4BO8\-PN11TW%%EE-EV#4J2@.[1D5I8#\+5+SJ
M6^L:0[-*G9?169$FY67SM.LMHU5OE&(MKQD/[ZRZ8?9Z!UV+MC0OG:?5;AG-
MNG:XG!H/9D<5/RS_H7J:V^M6@UX'_H5=E'6D*;`BRZDR[!H5I8%=HZ(TL)\%
M*LI^^=SYJFGKK-Q*+:?*L&M4E`9VC8K2P'X6J"C_??*@9EI9U91IOV<%EU-E
MV#4J2@.[1D5I8#\+5)3]ZJG]GIJ4M52I[G*J#+M&16E@/PM4O/+KZ^I/[R;<
M1X!T6,7RL(INRVA8:^HZ:6%R+&&B$RG+B1[-)N7``XZ&+[QH+W1":SD.[:^)
M%[L3C[,XM`=\;(??J1N0IOJ*+*?*L&M4E`9VC8K2P'X6J"CE57BF?\2AZR6N
M_O3DQO;8]2,LD`RG[WB]^?D(33`4A@[2^`+WN01@$$>)X'FK972Z:Y(8"G?]
M2()`8WS/&-_E7J\)X8P(0;-^U90:UQ_P(35H+AO22F@]4(MOU%JGUW3N@]CV
MMD.:A/MX$HXF9(,@>?#XSD)N3>GZ@P&0$V^&U:X;C4;]1=M^(A&GD;X;TM^9
MS9;1:[9/@?,U/CV-ZGWS=[-A&8WNFB8(KX>_*Z+$[+AU1U5CWE-O^IFOBAJ+
M'L5A]($M4:66*R<+KJ797J.T..9PSY-[_<N;^AOZ.YK8COI;@IDV+JEOT8P%
M8!:"`.#U[$G$?V;JTYSZ]FI[MN_B/ER%ZD68T^ZN9NL`[5V7X2W/KYOV&3[%
M#G[B#A\_\)`U38,UZK*WS@KNV?P*]-I(>MU,NJ_UQEQ<]J;6OX5!%+&/=AA.
ML5B([G&MB>]XL/<=)QDGGAWSP4S3<$U_%:*_RE%=AN%KOE;4E0]\+:(+6>0/
MCE=9/KA@?5#7[$<^(U'8-W@Y&+!WTS"J%=IY2F@`WV?X7+^H(!BS=<&32BVG
MRK!K5)0&=HV*TL!^%J@H99C<S.DIC9_6?-?FEVS%GFYK!9]NOEW>]G'\*)GD
MGNY8'QAML_PZ"H;QLQVJA.]-3(>S-N`*M.,^8N?TIFGT6FOR<'3G]%*@ZEW#
ML'IK?,/[6]@:?[#&4,%4C9YAM=84<];,M+\9]X$STZIU2H*RLM_"]WC8?^)/
MW`LF&#//G""*(Q8,M9Y;D>54&7:-BM+`KE%1&MC/`A7EOXB?LE!:$$Z"$`NE
M/?.':&T,?O6POS]B[IE&Q]*-<4Z-AG='P(,N9+1N'EU`IZ3HV<40JPNWE./(
M[D\F8?#$!VPDJH9K<J_(<JH,NT9%:6#7J"@-[&>!"GT#7O%)=^2HX'*J#+M&
M16E@UZ@H#>QG@8I7?6M=8VC6'3DVG<=J]@QS704`+5(.;VDV>X95/VPQ:FUI
M7LX&L/UK*WEI-C@X'LQN14[4TUQ=MQKT.O`O[**L(TU^%5E.E6'7J"@-[!H5
MI8']+%!1]IOGSO=,6V?E5FHY589=HZ(TL&M4E`;VLT!%^>^3![71_ET$%#'M
M]*S@<JH,NT9%:6#7J"@-[&>!BK)?/;734Y.REBK574Z58=>H*`WL9X&*5WY]
M7?WIW83[")".J5@Z3[O3,GK=1BG6\IKQ(.?1693E1(]FDW+@`4?#%UZT%SJ;
MM1R']M?$B]V)QUD<V@,^ML/O$0P?:JJOR'*J#+M&16E@UZ@H#>QG@8I27H5G
M^D><MCGODQO;8]>/L$`RG+[C]>9GW8M\W[W(ZTVCV5X3/O\Z>I&_$HSO<J_7
MA'!&A*!9OW)*S2ZV!M<?\*'KJ_J)FYD<CH_^$MHAYAHAGU9GN@]BV]L.:;KA
M^8Z"TFA:#:/1V%)4GF_#\]>`]'>FV33:5OT4.%_C'=2HWC=_`V\;K:[F[XJI
M0[MMW5'5F/>QC2G4^:_6M2C]=Q+%[G!Z3!UQ;DTS.N+Z_JH[P;E4N]MJU#\X
M<^R)"RJ2^Q_.8#-YZ-N>Z--AP/_S(Q<VU7]DD]`%R%UORH(A8/\Q>RCDHK%Q
M'+"(.TF(3P=)J,(CF>T/<FZB&KOQ'<YL^3-S(_88VCX,8+!G^%XDTE,V0PZR
M@7I<-A`!#9:>"&%04-%A1L\=<@0-OY7/)A'^@%]$,#_RRX7G^IR->3P*!C5V
M-?,T`.('\0PPSR%LZ$4P',(:ILNAL6,8!_\#FUL[/!W,DEPEJ*RBS'&?.3>I
M"QT/)SQ.@/*1I/$;)!A%L4!0?6QM`^]/8CY^``IMU@W6J)LMHXA6<VPCVN$)
MO&(//$E=SS;,BV6#?P#KQ1Q8S[38E-NAY*F58^*O]ES-X9D4(;80R%PT84=,
M6&.?!&/CL/$HY)Q`\(F=8$M'$>-P71X4+)X>A`\6[0)L&L[B!\P=3VPWI*Y`
M(7>"1Y_VL**4LMLYL/]#;#^KNO(9:@+45QI(RD_&',:,F(S)4W0*)..YCHV/
MP>OV4B8`B3JR!VQAAUY\^II-D-I1DLKCR-AP'^AMYOJ.E^!"?EY$V@H,DF+"
M'.YY4D_ZY4W]#?T=36Q'_3V#Y523`F3+;^)@0G^F_<WJ6_=L6[3XS!MV8)+=
MK3H2PGJMT7+]EPC^I7KFKB//$\[%T!Z#AO(SNYN.'P(OSYG=9@%>-U*T7\:0
M0:IG*"XA%4$(Z`BY"56D><'O^D.0U+9@..Z,?*#9QRF;P$OX@X'4ZXQ050F>
M?2#[ARDH.21@X2N;_5Z[JP&\H1L-7(<&42>)&X_@,=#O)FXHAB?![_K`FHW>
MEG;%@U#9(9%?*);W%`50;C*,G[GWQ%D2NYX;3].#/D>+BA2=8/S@^H(V0`-X
MY!%<!9"*D;HX*M`#-_`PR&N<>$K6"W)$36B>'O&[9>08"7J<(\9(4&.S46-_
MX$'QQ%>=,V*(D$<3[L2X!@>($E0A>06(,J4&ONN'C_`15F>P?H)+\5SX^-'V
M[8$M=+/+)`PF'#CD=Q]&-]A5%-K<,]A7_L-U`H/]&MK_<>'O?]@3W.?;)(IP
MB+L@`2CZPQ#`HF6++_YO$'*[MK=;KOB_&LG(LJH*Y5![*JVS;?5R7]PZ!/L`
M)W$_$IKUVZ[1[C6(&-^VC':CA2R;4]LWU]8E<[E/>!&@\1H-H]%KB\]FQS#A
MLQI\RYM`?NP:NX3M&]/%Q2Y:5CH';#D;PCOR$H1G'H:=>E[P'!7H<-55O#<G
MS:V4T1?IFA^8M"C#>CQ[$O&?F?JTJ1JZLW\1)H3E^+^\::9K.8RSWX%S@H<T
M__\`C;%+<0!]XHXD9=,XN0O^%)N1<6A>\.SJCCYX"-_)VE5;S3VTJ][I@""!
M^ZXI9?)/6VB=I^WQ?=`)CM5A?B_HIX.\'*@J48Q)15QMP'[M4O@,R^CO7,-$
MN^Y]TS(ZZ\+T2L,N!S\#J\,P'<TPFF'T^;(INYP289I=JL(N^GQ)&::G&48S
MS.9F]SW$Y?SU?1)=/-KVY.>KM"M(GXJ>?W(CQPNB).3WL/!?O<#Y_K?_^C\,
M_OFK>N7.&?%!XO&;X?S+?7_P6Q`,GEW/N\>%I$-@P!9NY"T?_O+F<QB,T0IP
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MZU@+6U.H16.HR'/=`69:$QNEF6F_4<B[XLP\&D=5)K#JT%7@/O$G[@63<:Y*
MR%`KN1593I5AUZ@H#>P:%:6!_2Q04?Y;^/Z6O_4G)P@G08@E!)[Y0Z3*Y&IB
M+IBG9QH=JUF*I;QF-+P[`AYTH\)U\^@&>25%SRY66-V8K1Q'=G^NY)\F]XHL
MI\JP:U24!G:-BM+`?A:HT#?@%9_RY70U'5=D.56&7:.B-+!K5)0&]K-`Q:N^
MM:XQ-,\7JM>DO&R>=KUEM.IKJH9ID7)X2[-5-\S>80M.:$OSTGE:[9;1K&N'
MRZGQ8'9JC<+$\!(>JJ>YO6XUZ'7@7]A%64>:`BNRG"K#KE%1&M@U*DH#^UF@
MHNR7SYVOFK;.RJW4<JH,NT9%:6#7J"@-[&>!BO+?)P]JIOU[01M13;$564Z5
M8=>H*`WL&A6E@?TL4%'VJZ?V>VI2UE*ENLNI,NP:%:6!_2Q0\<JOKZL_O9/=
MIG58Q?*PBF[+:%AKZCII87(L8:(3*<N)'LTFY<`#CH8OO&@O=$)K.0[MKXD7
MNQ./LSBT!WQLA]^I&Y"F^HHLI\JP:U24!G:-BM+`?A:H*.55>*9_Q*'K):[^
M].3&]MCU(RR0#*?O>+WY^0A-,!2&#M+X`O>Y!&`01XG@>:ME=+IKDA@*=_U(
M@D!C?,\8W^5>KPGAC`A!LW[5E!K7'_"AZZ^M@GA\I)70>J`6WZBU3J_IW`>Q
M[6V'-`GW\20<3<@&0?+@\9V%W)K2]0<#("?>#*M=-QJ-^HNV_40B3B-]-Z2_
M,YLMH]=LGP+G:WQZ&M7[YN]FPS(:W35-$%X/?U=$B=EQZXZJQKRGWO0S7Q4U
M%CV*P^@#6Z)*%:UKQJ$TVV&4EL0<[GERAW]Y4W]#?T<3VU%_2^#2=B7U+5JP
M`*2"_0%*SYY$_&>F/LTI;:^V4_LN3L-5J%Z$.>WI:K8.T-1U&=[R7+II=^%3
M[.`G[O#Q`P]9TS18HRX[ZJS@GLTO/J^-I-?-I+M9;\S%96]E_5L81!'[:(?A
M%$N$Z,[6FOB.!WO?<9)QXMDQ'\RT"M?T5R'ZJQS591B^YFM%7?G`UR*ZD$7^
MX'B!Y8,+U@=US7[D,Q*%?8.7@P%[-PVC6J%UIX1F[WT&S?6+RH`Q6Y<YJ=1R
MJ@R[1D5I8->H*`WL9X&*4@;'S9R>TOAIS?=J?LE6[.FV5O#IYMOE;1_'CY))
M[NF.]8'1-LNOHV`8/]NA2O/>Q'0X:P.N0!/N(_9+;YI&K[4F^T;W2R\%JMXU
M#*NWQB.\OX6M\0)K#!5,U>@95FM-"6?-3/N;<1\X,ZU:IR0H*_LM?(^'_2?^
MQ+U@@I'RS`FB.&+!4.NY%5E.E6'7J"@-[!H5I8']+%!1_HOX*<NC!>$D"+$\
MVC-_B-9&WE</^_LCYB/TO=<R98/K[A'PH,L7K9M'E\TI*7IV,<3J<BWE.++[
MDTD8//$!&XE:X9K<*[*<*L.N45$:V#4J2@/[6:!"WX!7?-)]."JXG"K#KE%1
M&M@U*DH#^UF@XE7?6M<8FG4?CDWGL9H]PUR7]Z]%RN$MS6;/L.J'+4&M+<W+
MV0"V?VW]+LT&!\>#V:W(B7J:J^M6@UX'_H5=E'6DR:\BRZDR[!H5I8%=HZ(T
ML)\%*LI^\]SYGFGKK-Q*+:?*L&M4E`9VC8K2P'X6J"C_??*@-MJ_BX`BIIV>
M%5Q.E6'7J"@-[!H5I8']+%!1]JNG=GIJ4M92I;K+J3+L&A6E@?TL4/'*KZ^K
M/[V;<!\!TC$52^=I=UI&K]LHQ5I>,Q[D/#J+LISHT6Q2#CS@:/C"B_9"9[.6
MX]#^FGBQ._$XBT-[P,=V^#V"X4--]1593I5AUZ@H#>P:%:6!_2Q04<JK\$S_
MB-.VY'UR8WOL^A$62(;3=[S>_*P[D.^[`WF]:33;:\+G7T<'\E>"\5WN]9H0
MSH@0-.M73JG9Q=;@^@,^='U5/W$SD\/QT5]".\1<^^/3ZDSW06Q[VR%-MSG?
M45`:3:MA-!I;BLKS;7/^&I#^SC2;1MNJGP+G:[R#&M7[YF_@;:/5U?Q=,75H
MMZT[JAKS/K8QA3K_U;H6I?].HM@=3H^I(\ZM:49'I!96?WV?1!>/MCWY^<X9
M\4'B\9OA59HAWJ<$N+X_^"T(!L^NY]WCHN]A3;]Z@?/];__U?QC\\]=TB!B^
M'`4>\'=T^6?BQM/K(.:?W,CQ@B@)LQ>9`X#`'[=\^,N;SV$P;M3-UD7=A/_%
M@?C<NVC6W_QMV;8><0?AY0?U(<$/US?WE\PTF;IW`SAW]S<?_^_?;[Y\NKR]
MDU];[0_L\O_]?G7_/[392;KMZ6#;=KLM$=64!4Z%DF\A'_(PY`-&)#BWX^6%
M?Z=]/K%HZ<?PQR3FXP<>LF;=8,BW!GOF;&0/8!"C7J=_632R0XY-==@<F@RX
M>87LR?82SM[6:_6Z:3`[B4=!Z/X'GAD&(7.C*+%]AQOX.MP.G1'S@^4CPNPA
MIY?@&W@]2.(HMBE`JU:M+?[`EMR.JT\X*==^#,;CP-\'RYYZ155&QVH^;K:*
M&#F/N1S+YKC4['2,3K=C]!J=9>_E>15XM,+,6GTBN/'9/Q)OFJVAEZ,#ZNT.
M2'+].`!,,1!)/'P.W1C+"=F/(2=''WMVXQ&@UAURSV#7+@@M.XGF+5[-[@>D
M@HGM3PUVY:>M8`0)_)8\/G)_Q-TQP.8D.`7"^>7+1S@9(LP@92&?`#'!?';L
M/@FJPJ\CCLWFO0PV4$$-/`+P1P$4^WWFMY![-JU@;E$Q]]D$[J&N`V/#X8*/
MP"1-HVNU#;-E+66#F-D++TY"U^'XZ-M.K5MG$V`Q>KTF@"'H`)QQNH[BO24T
M/(:VCQNU9$4P>[-^,;"G+)C$+H`%ZYHDH3.R(QAV(I=I/\*8CY@=!!.V.FU@
MT";#ZQ2^`OM7O#A#<K4<^1EPP7_PT'$C(@LV3#ROQNX!,)_'L.C`X7P0X91)
MQ(:@WQ/0Z:X0Y]O8<."'.P98O"E[VVS4&FP,5PR8`)`]A"6Q`5Q('-J)F6T9
MP(4"SL4X(IIQ`$Z0(O":^#O`/&/&@87&1%?IK/S'A/L1+&YB3_$:PQZF`)X`
M.WT(;RKXTCP_("L@0]`4SZG<L@RKT33JG;R0"Y)P9O.T,#N^,/O,'\+$#J>H
MAVXKR%*Q\3%X!EG0SS$A2CCQ+9)!*L>6RZ>-Q),8<2?I9#:-5K=N-*SV4@Y>
M(Y^L6KVU@7Q:W)-9P;2XEA?(I891;W;@W_;!)--F,JG5JYFEDDD967<*Q1'0
M>1M^:G0;Y9='2[U_KTI0X2G#&D+;LK;6MGX+O`$,S>YL9Q2QO(9%PF7FYS42
M*B^9F&^/!3^'W/53.34[VT[RJFNTVBVC:2Z[5`@.$-()1L39Y2C`T[-\"ZL"
MX=7N[$^Y6K[.#659)K1,X$7+Z/26B>4:4S0@;UY``VM`R,0;/.B&19#@"%L!
M<5T@&]UHM7"T&K7N'H7C@DA<*@3[R2.P*JA>M%]S$K!G=.'&:M;;Y1>`9VN2
M=6>L/)>27B/V*2%,XKDU9^Y)WZC"PF8Q\6+03TQ0$ADD(T<@"1FP1PRRA@/C
M#@HM0@X/8QO$K^L/W"=WD-A>7AA%=`D6PBB:D4:]UBKK$5IYW_:ZAM7IHFQW
M[&A48SG@?-<_(&Q6IV%TVTM-5`1<JPM"I=%+H:L@LL]+>EC[DAZ5QDIYY,<&
M+&J]G$4[O:;172H_:I)3B]Y<97?.9K8Q,]#S@N?H9_;._8FU.Y9A]IKIB"0#
MFB!D6G"YEC*`E(YW+CP]OX<>!Y4WO(@FM@/;\S.[J-?,UD2&I9@]HUWOJ)$-
MA!3=6[%2<6<V(>='QBD]'D6HHSVY$2E<ST(Y9QC5U&UN8F2OL;X7!6RP+>(R
MY:JUT@\@E%\^GGC!E*,Z'`A5_0GOO4+MA]=BT.GC%.&)[\9X*[%C`:E2PV%A
MG[@C(`$HF@5"M[Q"K$+"EH3H'W:(VT[,\TTQSPQJM4/]&(XX8JD5OKAGA:><
MIVQ&X,W;T<R&T0$%QVJ:2\4#6A%LF`"CM?C@PD8SY2.G^)S0=F*0TL"T8Y#;
M.)?G#L6XM5Z#3;F-%W^4A$J8B@M[Q$(,'X+GZ2;YMEYK6`CFVW:MF3,QHLT@
MPC1MZDF1`X(I(&:')2LES-S,7?0KB.6E.3K56@;>S3%RPR;CPYC'HV`0>,$C
MFB_1-`'G#$?;BRL*O[*A[:I0#WDC3ZG9%68I"@2]N'-&`1QU%U]!6X"!<U,$
M`_0K2E/4S,/L*_XF[`4%/P"=_9FX2/UD`XH(`IOY"7$9?H;3;:S.9-=WO(0X
MZRE`DY;GQM/4BD\\0]0HS#2A&WV_&.+MR26K710S=&824RCKDWI9KK<D-*NM
MKQ^N?/8/VR=S.JH8,V;`Y]R1F(I7TVBLUH!0.PQ\GSO"%X&R%3&O@I@$W=UR
M(*PG)+"/(1^X,<,823IZ@=P"(IU^%`6."X2D?-^2ZL43\K@6]#[S%9P2$>E@
MBX*S66O,N)\7WT4U31C8;IPXH`/(I`.H23"-[2E[R.O-,#:"%3#4X/B/B1L*
M1@VR;94#]`JF,]31,RL8WII&QS2-7JMMD&67?B"@</T#>:[A9\(4<#.9<E-&
MB]P?XF#Z`%_.,K!EU1J]OWP@GF7$LZ$<KE[K=N$'7*7-Z'("RC";NMP;T,]_
MJ;'/$@.;6"-H(*$ZOZW3'V\;;:";1H>.O`F2QQ/WIF*%(7<P(%[<0UP?Z(2L
MG4&$DG$]/2V0A=HKVW&$>U(,YU..(3F?Y"SH4HOA"TK2+HE4>E7"YZN=$SRS
M7A]"F-2-Y@-L$'>>&[#B>)H:"8N[CU>&.(.!T(()E5R'%3LC7YS1\-,#%R<U
MT!B>QB-9I#WD$SA!Q7ST5EI.5ACD\5K-PR=2\\11"5\DDTD0QNI@YT.X,@O1
M&24./!BA$Q9X\('N_[_7[I"?`A'Q\PGGZ`]`3W#A:D@2)!5WGS_U#>%U`#%`
M]W`<?@ZJ_(D-+&\#?N%AQY[`_G%ZB0[BD-LQ+0J`?$J\)SNDZ=7S=AP&D]&4
MIO[G/_LUV,I"ULLYC6"/Q9^D[<!$0P["'(4AI3[0^H&Y.?K8"H^3;K.Y\CJ=
M7HH%MM31-&\T2#U<MA3)A;0C6!])3KJ.&S4X9NA9$'=2=">IVVS6.98M4TA=
M^$"K5^N:7=;J,Q(6];91JYO98216BD>7.H)`.70]C_XDKR70@.<ZZ!\W\N::
MO;$]?8GIM,C`]5K+]<LIQRCEA#G<\V0&S"]OZF_H;VEOHK\E#,_N(!XA$/6_
MO#AS-DW5G<_(C8/)[NFX$D*K._E1EOU>FG(D86U8".N)SPZSX+3>*"?K!+`V
MNDVCV6PJ:2!LKW;H"Z6.Y)'2,LE@"&H+*%2IMNR#(";[X:,MG=DX&1T:4BB0
MX'J8J@.#)#ZJP'B:#-S`NWBP\9B;/36$P2$*AO$CW`\W.C3@5/@`I^0S!G(M
M6FYGP@R*!+"X+\I=`""8'PB5&X0NZ*CL'PD<OE*#;-981J/W"Y?GMU:]9=3;
M[11..6JFP,\,1EIF>AD?B`@C90$NNB[/*=O*?#NO:@_Q8%NF:[=JW6)=VZR9
MC36Z=K;V/WBF'B-(L(]PC\\V`!;F!_X%6>11V^5^).C!)ES,;,-Z9C_3##]]
M>NC38T8B5_?T6"+A:H5E-0KD9KMAF+U4;F8>PATE9-[)M:V4M)9(2<M<+26+
MEKS2@9`*TK<F^3*;=/.CT"LG"4,\Y6S*]E41=ML9$,0529HWY-5O)/>W$-B%
M^!-<;&9>P>N!&PPVLK+,K*[9-5IF1YA=:*4M<][LLO38V/O*"86'.GC*(?/T
M&5/&,^9XL!:YYLM]G*097*F1(8M5((,-C$5'@+B!3(GK/;I<I,8H,K?,W2G(
MC(%VD1'W)B`L$CQ4(EAK7J6]BM'?!3<'UW$GMH@XAM<HW!:N%F3E`ZCP=A`X
M()C9`X?CBL]$0[37;_FYZ[(E!'[YZ9OX]C@`Z81)[<*P;RL'SR`S+2+EY'RB
M%'`#!U+J@$&;'4BUV/;063"7J-+ND,V-8J&1?A[$D?CHTZ0!"$<T#]*1*O2+
M3DMH)=KP?Y*X.8)P\_#6=9[)30*S,&@$]$AEG8`Q"`A,"ROT&%*TAG)DY_Q[
M2NOMPZ,>:R.(C;KP\!%U+M&M9%B_2!01QF04>@2#,B.+7(Z&T<"[/2IPW3:L
MJSNOOZ7VF0*]<?DNKJ;T$E-,E>+)9H-WE4M245<T%T=VI+#_V?VKB(38-3*?
M[HX^F<S@MIFY[0OE1]-<)4#F5[,JQG7!,JKF*PIGS4D=&=<:98&MC2;>UC<*
M;)TAH?TD#VRU?1@8TC*L;FNITVLNQKAGK7P\7QE#A!^WVX2?A?#C5=C<"FV;
MQ4J?`KEL44"<_,1?LI6O*7IJS_'_Q83<;AFM;G-E=H[9-?.L\2)]]A1GY)ZR
MR(X+.AW=-UFJQ2&BQ2NM;9T^JJA1K_=$T,8@F*B,9OR2?0F`7^_1+GWE.WBP
M/1'>,A7]FV=GP3?TBO@&61)E.%P>,@.HJ\8@0E!9'P#-P(6;9QQ0;/@`!#]7
M4>+9Q2/-RI5V5C@6X(J"*<9H/83A*/S<?4@H,!)$PT#$[CKHD*48PR$%B<!;
M(_M)?J]R2D3]26GV?YA*T*6L&L\E&F7YQ^)[@A-/V&QYZ8[T"1!QTQ&?F?UD
MNQX!G87.I!LG@FLB\A[/S&JHR>`2S]$,@$L204/&0HK,XC<B:<;`ZSQ(P#'Y
MRN6C^:_D4_,KQ``A4B'D"LA(Y<!F"W/#S`IHK8@6^+?1FJ\#MJ14GR@;0/OQ
M@D3.W$T7M*JFD.UXH_P3#@QWZ"ZDBA5L/$4V+;'%$'!"OU@UZHQV![H:Z&N=
M=G?9093/QRB"IQR29$W(MX^$X[T>,6DV"L2DV9`HS43DG%2$)\0W]AP!39#E
M1=`>AJR-!8V[:;T"$=AQGQ]$.A[11BPL(AA:R9D(XDXE$'%7R&.9A)/-*(LI
M3'B,=N/O?)H7P\%PZ#HD>_,"&=^0>EA>'--M!X4U/#4GF_,RH+"HYY):@,ME
MPGZ9T^BU,7E\:5FV9;PI45`2WGP]*LINB4.SA%"4.;3'9*!<9'%6NNGE64%&
MWIK*Z3Q7"74+R;\"_CPL*EA[64S"=FF]F?N<&#OB,?)K/%(S"#_N`_>"Y_/F
MD,,[K#\PV?$`#EW/GD3\9Z8^;>K+WE?_FUWV\)1-G6"_`!O^+V\Z*2H.TTO+
MH30,`NH:F>BK8*++12;:Q.FJ$;H6H<WC(30M._0*%VYM1ZXG;&:ZSQ;AM\7G
M\&HB.`A+5:7_RBYGKEFS.A=FK66],![H!?OR%XW*`Z&RW054=CHG1F4)6P>^
MO$?@/].+@Z;:@U!MJPL4>]%NU'I'%$%%$%]$[G^X&"%'VYN!H['_0NRW>S6S
M==&IUWK-"DFM2NI5Y$-ZY_HB@G!-;T--T"\59[4&2+-:HW5$8;;AOFB<OA2G
MI4)HV=4K:6YKM?^RL\CZ-)-#M7K/Y;3=K9-2-J1`947<?57;SMB8F_(E](]]
MVHZUOC7W.XVH4B/JC-+:2NCBN%]5?B[U&Z&+3!1`H!2GX($\S(/9YR-,:/T/
M#S'NAAZC$CWW(;>C))R"C/<'$0;;1)R-[1B[<DU5+HD;B52428C9+&ED?NK@
M0D]>C5T6><_P53:F.5(?F#W&-@$8M2.ZNL2C7$;"?!E_'"&;*&!#+\&"E3$6
MF(!W43G->\541BX6R<38EQJ[2<)BQQYE:*5E*"5L(S>*@Q`/O]4^P-2!/N'8
M\P4#B%VN]F_F.7)TB[86WC2+)1*`P3Q.@M.(<*=E<`KDPC,Y\&:!F<G]X>A3
MSQ>M2'=>!C?](<M"K5SQXNH&2=JG@^S7Z*I-,`+!Q="$W$`#.[817!PB!Z?T
M=Z:%/_/^T?PJ97F-M#;I3-V-O`<UE\$=N>.)C",0[N;J>S0W".M9*^%*&VC:
M!](9C[%^('(K9OT@V<W%5:49<1C$(0)85&:1ZU,,'%'!WDM%E?%TTCYL[?(L
M]F&G42UW(CB*&@EY5-=`'*$REOM5[L[&S"_>*2?OEP_V/U09[[X\S54+#_8-
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M`1C$+N(L-IMMK+?_@FT_[`%]/$R7^]1NUNIK#%V'0$Z)@K+.\U#12--(J^K5
M62V_46OM1T7(.8T7JV!MAQ()T_%4`IJ0#8+DP>.GU0KV`4FF&)@=PS(MHV&M
M\8HM0<")1-DAT5]N/:%1:VRI)VA,G?C8:=?J/8VR*C!7&P1ANV5TNB\[C4JC
M(AS9@E"H(.#P15M"WZ@&[^*AE\$S%SB80E/_P.0W<3#9/E_JGZ*Q*68Q21L_
MI?0LUUE>&D!;8C8[FA^]:72MKM%KK(EVT_*Q'/+1K+7T258M%H-[FD99)9BK
MU3/JO99AM4HH#$O3PW1-XX2C9R?H51UZ5?TBQ<N@H@7Y?@*SU>A']F"NCV;$
M0MM_Q">'83!F;^LULXYE$MYV:IT&EF0030M*4H]`$\3R42E_^D*4H2AL:XJ5
M3Q0AY#KONJ+21<BQU8:H#`)HM\5S[]*R%D]2_Z<B'#^QES4X%?5$WII&N]$V
MNNV&:*%J&<T&:+MPRYSKHDJ_FD;=ZAA63[08?MLTFA:\7U]X6$$4V6,N:XE$
MLCNQ56/]NX^L8W8O@+K3]@I#X71-J-5"@`V)LQ(FU/`:E@>[C%M"#7]D"8<G
M5_8YB)*'",;"\B'I?%0.`LM^Y`<?N,,A[`)Q&-6>D=-$`%<Q&XLVM8F?PU,&
MV[JFM8DOD:6PK=H5`<?C)@6B!PQUR:5&,'.=FHU6KTD=5$2%F[$]Q;VQ!TCM
MLFO*,,&5,6<$PH/3-N?6BY52W(CZ2,\7P"EL^OPL<W@O5'&5K`MTH]:43:#9
M-8!M_X`1?#YT10>;D`,?XD"RMHM-A5=<'YM23FSL?^CGZ!EDG!=$$2]+0^DC
M";._OD^BBT?;GOQ\E_4>BRZ!!^+I=1#S3V[DP+X`XNYAB;]Z\,S?_NO_,/CG
MK^F+SH@/$H_?#$G(_(HR(=^6C0:6=1KZLAK*/6I"Z8B$&/CCE@]_>?,9^`#)
M_*)NPO_B0'SN733K;_ZV;/MWVNGM#E9=VV6[0U+7=JF`1UK7=BG;[FS,_#I+
M?9N7=6V7LR%#7=M%UW;1M5U>%<M7^>2I,NRZMLOZ"71M%UW;I:QXT[5=*H(H
M7=NE:AC3M5W*%%NG:[OL81I=VZ6"<3"ZMDL)N*!DRZDR[&>!BO)?=_=X1NK:
M+FOGT;5=3A2`K6N[G)SV2[:<*L-^%J@HX>U1UW8YG(-)UW;9]("N3`$*7=NE
M"E@JVZ&BD::15M6KLZ[MHFN[Z`S0DND)NK9+Y8X=7=NE*LRE:[OL3T'`X75M
MEVJRF:[M4E'$Z=HN5<&4KNU2.93IVBZYO\^[MDLN3WSG=._Y!')X>^S&8]!_
MHKX_P-0BP";W'9='!>GG.R>+GSIU&EY^4!\2_'!]<W_)S!:32&@!C!]OOGZ]
MNO]Z>7U_Q_K7G^#OZ_NKZ]\NKS]>7=X15I(4/^E@5<LA3S=BEOBJNIX_.(@9
MX`9F#\:N[T8QEI5XP@(A0]?A#-/=*>WLU\"QV:T=!S#(9^!8=V"S21)&"181
MH3H5[:8HE<+\P+]PT$+HD<J=*U5!$U&A#@>X!YA%U&'Y1^)-F<@Z$151.+D9
M(_QM05OOUMB-SS[SAS#!@@9F5]47>>:,<HRH7@%"Y#/[,>0<610A5,L<N,CE
MMO>"%1NS2_9Q-.X/DC'^&27.2$PBBX6D/V)=#SX<BKHN[($#ZC&!DO4GH>O)
MA;=HX<^NY\G5PV?82ZS.`%/#&P"PW#\>CI?LS(GH;Y83RE%W9,JQ3,4+AJT8
M_]YC>2`@8=14F(?UBD*@=]LK*J*#-9&<),0'%"UA31Z\)L^6RS'-'A7+H>I$
MO3I]GJV.M*XHDBPF4EC^:&XR+)243M;HF#.S;52!J7@RY$).WS-[#*011Z)4
MT\0.8]?V/"R&,HQXS!ZF-!5MB^N#9*+R2'-0MC,8K09^+JK5%*$Q/Q8BI,9`
MM`[<`8C#6/U@^U,I7P9)B!)@TR6^B+/UH?C2]?2I9EA1$2M9)`H/CC%(=LEK
M$WM*BB`#U9+96(7K%=3(.2O)+@K^$.2_O)%YY5O6_^E4K?S/*?+TJ7H!NQ2%
M'/,IQ]M=EH]3M>!<(P-.EAII86[DLE7M"LHN4H_4B'?R`A/]M"@M3IZW6)R=
M>=`)CI5G2E2QLTV[81KM7DFRN$ODY#L241Z(J8$OVZ6PWY?1D'TLWX/5:QJ=
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M7\73":P*GJ;LES?RVS#`M8[B>/+S^_?/S\^U'P^A5PO"Q_>->KWY'G]^CP^^
MD<.K"6#&F7'A;SL.0C7L*$1ORW]_!C`NZO6+NOK>LQ^X]\L;^?W_PEMOV/N=
MAC:W&5IM2S^<G<(.'34,?%RS)_*)]T/;B2_4B.IU[-0^!X2<*!!?X\,7=8":
M./Z7-^9R*&=`#'D4)*'#MT'</'"Y+4K!^#'VX'MT(G#_XO>[-W^[PDQ1G[I5
M=RG=<\`=SPYEE9>)[<('ABE9KNVQ@?OD8OHENJC>UFM6'3NPLPB3OZE_>A(R
M=`%B'B6U[<5\3L\#%LOZB>-SV-D]'*"W"OZ@V4WR<B$$\(WH)O_6,HUFJP</
M8VM,@"?Q`3#@M`'FECEP`L/78FXUM!VSKX"ND>JV)I+8%GJPU?[Z?F;C%2N]
M7^`E^.6O[W&GW9_QO_#G_P=02P,$%`````@``X)E1_DM-VF-$0``S^0``!4`
M'`!T>&UD+3(P,34P.3,P7V-A;"YX;6Q55`D``Q;'.U86QSM6=7@+``$$)0X`
M``0Y`0``[5UM;]M&$OY^P/T'GHO#I<`IMNRXK=WD"EFB$N)D22?*:7((4-#D
MRB9"D0I?;+F__G:IEXC<MZ$L<M?`]4-JRSNK9^;9G9E]?_O;<AX8#RA._"A\
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MT!/DXM^")RM),N1U7#?*<!</[\9Q%.(?W95Q9+`/4?<A=;6S^=R)GT8SV[\+
M_1GN0MA[??]^S+[K(ZE6U6HY)'XK?,"FB6)I>Z$*'A+%B/RAF\7$$762!."`
M^1*'Q-7WE[@YY=4/42K#Q"Y]2#RXV2\<WS.7"Q3F2800#[OT85L/SD[N_-L`
MP5CCE:^K+0U\Y]8/_!30!25BAT2(&\<@2I(QBNU[''MER#C%#^K%TLC]>A\%
M'AYJF-\RG'A)/197XK#M"_^(ILY2SA^CZ"&13%!`HCC.E2"-B5WZH#$V2_P0
M)0E.,4CH`^918JD#9R%S/\W#+H[/^/M((,.#9H#Q`**'C>"W"?J6X:\S'R`9
M"*]\\UG%8;.+1K*,J8-]/Z`O,XO7FW'`H,GDZLL^8/A$,O5E(C!L(IDZLQ)H
MHQ-)-9"A5&^`7.$:LQ482J%0O9D+#*!,KJ%8"`,+KJ#Y&-1#J>,'R=")23+Q
M($UFGU=K+3%I_67@H%0J7V]4`H*3"M87EZJV`)AT[7CW@EE_)`6B$PK5&4NK
ML@V5;P#SGE`;1-C>$V*[P2QE#X?$EZXQ3P'B%$O5FZE4CIW@&IK%+6VV%:IH
M%OGI\Y&?-HI\;[R-HMR_0=32#HJS<55['4RZ_KF]JKBKU=+0>*>J$GM4U:PF
MSU>@B3G-[[8"#M)`XB+$KA.X69"WN0'^O2"!EBD*/>1MZB&0#[*M!'],:EIO
M`VH;+6,CM?NC$WK&J@JC4$?-"LBWC!30GV+(VST#^.?N:&B/!E:O,S5[QE5G
MT!EV3</^8)I3VWAU$SJ9Y^.*?]SLW=FH$41N`7I`-@]%<;$%K)'G.X1F3G*;
M;Q/*DM:=XRR.2<LX1D&:;#[)VTKKI+W>+?3#^N,_5BGI.N?;?$'@W*(@_]H_
MUN5*Q8[5`2;;,/@X5W\MP]MI%IW8-:(8A[!W1]NPY<1NH3'0&Z_6)8X3,A%"
MJFEAWN8;^5D<S4766ELF8B#=-1K^DB/C$?EW]VD.3J&1UY,["=FBX3^0V2J<
M<LL;B5`*1LJI4E(@>FM'UG:.:V?_`DU.L12,C#.E9+#TTL[XQ3D='.?R,330
MJX*$852]44I5!2MHQ^!ZNA`GW+`@N%M2FX8'@<^7T"->TCH(6QFCN&Y-JSSS
MAQV9N72#C)Q!>!]%WJ,?!"*/#9'6(ZQ*N:MB"NUX[*%%E/AX,`AV%7P)/2*O
ME"^9RMIQ5-R;R'/>BEUVM$!Q^C0.G-60^%OF+\A(49BXB:7T<-U<ARU7&-:0
MU'@UWBAA_[Q&36\7ZO$"^O;.6I0TIV:5U6`D/7:>R'`2/(8NEU?=S_D4<(;0
M;(6U:UH]-$,8H3=!>+"9(5%$+Q54[:+`C'!4U(Z*?,Q8I:MS!51[73`U$I6U
MHXAQQD+H@;7R6QP.7I#Y2[X59U3XDSA#WHX.H(F,BO5HY.I@40=H&>T(YA_0
MH4EDE54['[4*,SFN_'B_<"J*+JS:50A.1U'S4#Q5M6M19"D["B&<T"55=WLP
M(3PEM6.CXWD^T=L)QH[O66'76?BI$^S@%SAM@*SJQ`?,&-P0VG$X(?LJ0N29
M3ASZX5V"`TTVS_+M1CC3]EU?$'@ALJK7>\`<P@VA'8<[60%.%:I$7;FDZC`&
MU8V?!NL]-;>G?K*SSSPUWQZ7M1S@WQ7M.F+?^E+8@G2VWQ8DXU6A[A\;W5DE
MN1VFH-\;D7[V%/_OVAQBW49]8S0V)YVIA0MHLMGJ?4QVK<?13!0C"H54CD6<
M`"7K.2/A`@554+4'9)BY[`S8NFD7I[I1DHYF9'TTL;'K$B7OI8*JO;2<`XYN
M#`Y:BN<E5QXIO%MO/!!,?3&*JNS!*`C(\GI^76%`YD2\N1_Z2;K:$5RZ8H;1
ML8'RJOL[EZ!RKZ]D#^V<P00E",.YQ\![V'4%4;Z4*F51(J;:44#)`VFO'6<]
MM(B1ZV^N/.O,HSCU_RSL?V=N'N$+J1[B0_D":*X=6UO=5O<2D3.&`%^_6U@;
M5TAK4.*'%:"U'._!5>(W3>URBF$41D6]I'Y<(*)ZT9:&)EFT90FH[CI22EAK
MMWS-M7-N9#M]DA]J6P&UPA3%^!,^57P)U3ZA*E<RW;4C:S=<CF9]/W1"%^M*
MQDRB/8Y"*=690U72(#;0S[-_CU)];(#5V=$,P_X^KW6%9E&,=JX^-)=X!(+-
MCS6,GRQLPGRI&DMBZP:YL>0]M<8O5>V8&[`H+Y%@I!Q:YDC-FTC>F75SJ4.4
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M13LR<6X5(X?<C+OZOQ72]_$(!W@`:1BU/^M+;14C:3D[6D*_N>5'."R2B,%(
M_>4ED<HPRTM@D__"%X14EC2,VXN7Q*WL&;070/%W]?<CF9('S@V<O#B>.99Z
M"4R7#E7N$WJWHD!^-9[\`=OG!>15X%L/`*)`9C6>.P+;YP4P*WD1L6H4WN<L
MO\;S3)7M]0(8IP^Z5W34E#209XWGH*I823N*.=JO]C`];QV)68?*"53G*5\7
MG$8=]UOFDR5JZ)PX0%33]28!D>6I5*AY],LF*>C<N^`J4"RH0],%K&=P+368
M?J1SC+#=NO<,S\6L0^W2CXN0E^^X(0_8DS.ZHQGH(@>`J*:>2T`DO0@$,X]V
MT7<7>8YTM,BW4)E+%+M^@@2',`&BFKJI_8@5FD=K8G\G[\^0TV,KT.+%6H&4
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M9>C6\".V]VA2?\,3K`3N0FR?E"&.</>8&-V;R<0D1K5MLX'V47Q=F8VT74;:
MMSZ11ITC_*<Q-*>UPRP^$\*&>5J&B;OEN&/U#//3V!S:9@-MDC.34X!Y1C?-
M:6?XWKH:F$V1+IL@+^!](VZG`ZMS90VL:1.=OO1&,!OO>1DO;I_&8&3;QAC#
MMC]T)O6W!,'%9`6L5(2TIZ/NOS^,!CUS8O_#,/]S8TWK]U@[9XC8,*G(9PUQ
M&#>-:>=3`ZP7WWUE(Z1"U<0<Y.=+QIU)(TV3_<@K&RP5G*YN;&MHXA;:'0U)
MXK"^X:R!^]JX;Z(RD9]2,0LW@VMKNCJ_0Q(?K`#)`\QA(TE`^7E4-F@J?-DW
M5S;N6L1[F1\URL*$V=@I%=[@V9CQ:E-U_7<`;A.S*=D_P=&%$0/7Z9GQ:B57
M/U`Z3Q,AED3!5>!N#GPQ;1,!I\(AE;PUA[J8Q8E04X&QE,LUA[F<U(E0,^)D
M*;53T[QW<CP1?"J(<C.]YM0HI7PB^%18I1._YG#3&:``^AD55UEY8'/@!7F!
M2`LJT`JS@P:Y`$5?[C/V!1V?%8777V%LOZ/!<%Q^Y+Z@E2@>KP55GL(^Q&O(
M*N#VR4V4]\C++T0%`"^55[V&P7RLF?.>,U-5[5:9MG`GSN,U'E3&OA-`B"D6
M5[W$4H47EJ+:T;(]S$:N@9(^$<8NK7KY!T"*2$W]EG;H\9$PA``'2!I$D^:?
M=V]>.2O$+)`-.E)-=DJJCC=57IQGOB).:7U`3Y<NYUYN]).+LY/<Y.23C;W9
M-QE+_!FIH(*\ZK"S!ST5-6R8-'*?41:0,0"((T9QU4'G>91P]=<O0<@0V<U4
M7`F0)PI"*=67<NSO[2#6T(["7+NBSK#'8#DRJF_EV)\^N24:\X`?<5H8Q3VT
MB!*?>3!CQUN4RZJ^4.-YOH^MN7Y9>'&B'S9'!9GR5S`5Q52%K0$U_<_7H.E5
M"R%N:@&`6K;0;OP#>5N8+U%C*EW.$H5`&8FF2%ZOD0[C$6-^_BPW2V/1X]H)
MLYGCIEF\N<(;RI%84J^!#H@=B"GT"R[EM4U8>*&6"1FKG$I6.IC*L'5@[`_E
MZJ#25Y-I]10-L`&]LG["M1"9G,*!@`!:_G[-7DJM)57[=1A=I?$`U"#:#>D$
MP'?>#8:]C[5/7:KCQ*'9EAA-PQO!.3ZWS72Z;ZA=#@*GVU:V0T84-]Y06QP$
M6V0T2/5S%7=T@\VXL`14W@>ZNN;#=@(GANC`*Z\Z.$C(*%_W*=1:NUBPAOO1
M<7-+0$FBRJOVZ7N1Q-&Z_H%8)PBB1[+@U8_BW^^QFHD3H!YY_=2_S7`E?23J
M+Z2*2C6H7NX`DE-9+[W[%'G0$27D]FTG$!-:;)5<.=4K'WOU,8D5&NAK*QQ=
M7-+'%IN2+36`!5ZYF.J5C"J]"FB#^MG(7WLGF=CZFN0TBT.R677;[Y-\)UJ;
MPPI<7/4R1P5VJMI$1X>W>_DF@4Y=\0;Q?O!*5%\=7MD55K6/CAP3Q)/HR0F@
M?+(%5-\0OE<8X^FM+4]DG0%*T6Y9U7=\[\<.K:U^L_:E(S'"^0KJN`+K3$QC
M*ZGTH1C0BL,;ZG@"^WB,@D4'N4:<N3!JNRQ0I28FQN1*G;*5HC8>0)4Z5:@4
M6Q70R7P=N@ZG?5$[$<14--"JBMO58!U?=JQ?29]G'_6'*00]^J]$,<&Q/Y!V
MY]6N!]!41[9J5<\VZC#YO[DZ;D`N(4OZ&1X/HFL\<I]G\\W-M#W10P'@"E1N
M*P5@G*"YX^.6$I,7YQ/<I#XC)WZ>VIPJE2\Q5*.<]T3ZOK;4;A`#M(<53A\C
MHHA@\\$>52E?RZB]-3!M]X);`?Y6=+!VL%.9\H63AEH"9;^7VQ;Z418?JBGL
MU*5\[:69ED!93[]IE/+E4=]37$&&R[C^H7275"&KW4UJUSJ2?VZQ\?`G_P-0
M2P,$%`````@``X)E1SWL.%MS&0``,I0!`!4`'`!T>&UD+3(P,34P.3,P7V1E
M9BYX;6Q55`D``Q;'.U86QSM6=7@+``$$)0X```0Y`0``[5W[;]NXEOY]@?T?
MM+E8[`RP:>(\VFGN="\46^D8U[$]EM.9610(%(E.="N+'DK*8_[Z2\J/2);X
MD"R)5.H!IG5MDOK.^0[)0_+PZ.=_/,\][1&@P(7^IX/.N^,##?@V=%S__M/!
MC7FHF]U^_T`+0LMW+`_ZX-.!#P_^\7__^1\:_N_G_SH\U*Y<X#D76@_:AWU_
M!O^N#:TYN-`^`Q\@*X3H[]H7RXO(-_#*]0#2NG"^\$`(\`_+!U]H9^\^WFF'
MAP+-?@&^`]'-I+]I]B$,%Q='1T]/3^]\^&@]0?0M>&=#L>9,&"$;;-H:7WPU
M>I_UB?L70%^[G@O\,/@Z?<""+$`4NG9PW?OZ^^5D\/7DN'-^_/'T^&OX/'=N
MR:?.^;OG&1:V9X6X(?+[?Y_T.AW\Q_'YM//AHG-^T7G__X*H0BN,@@VJX^?C
MU7_+ZC][KO_M@OQQ9P5`PQ3ZP<5SX'XZ2.CBZ?0=1/=')\?'G:/?KP>F_0#F
MUJ'K$RIM<+"N15K)J]?Y^/'C4?SKNFBFY/,=\M;/.#U:P]FTC']UPDV%9.'S
MH^6/R:(NH^D$Z,"]"&))!M"VPMAHN8@T:@GRK\-UL4/RU6'GY/"T\^XY<`[6
M/,7*1M`#$S#3R-_8^#9/#1.V,7>PV<V/2)$CS&@TQ]:C^X[AAV[X0NA%\Q@R
M%B-N\P&!V:<#8D"':W,B#_Z;2-WP98&[8N"2GG2@'>V$M0O]`'JN@PW7N;0\
MHFGS`8`PX`'E5FP$Y=A"6%D/`%>PO-*0<UNI"S_IWX!0'(QFHP49)C&UA=3-
M;J$)W%TK>+CRX%-IV)D&JD4]7UC^"Q];JEB5""ZMP,52CA$(L+PQ/[A#3X"-
M_^6]](,@`HYNVS#"7=R_'R/HXX_V4CD\V%6T7:6L9C2?6^AE-#/=>]^=X2Z$
M1Z_7YV/V;1=PI2K62I7X^_XC5@U$7'O)%*P2Q8C\T(T0&8CT(!`8@.DUJL1U
MY3YC<XJ;'X*0ARF_=)5XL-DO+-<QGA?`C_T-)I[\TM5:#_9.[MT[#XBQ1BM?
MERT-7.O.]=Q0H`MRJE6)$!O'``;!&"#S`<^]/&24XI6.8B&TOSU`S\&K$N//
M"#M>W!&+6J-:^\(?P=1ZYO.74[1*)!/@D5D<^THBQI1?NM(Y-@I<'P0!=C'(
MU"?H1[%K5>R%S-TPGG;Q_(R?1R8RO+X64)Y`U6IG\+L`_!GAQQF/(AX(K7SS
M7D6UWD4C7L;4PF._0%_.+5ZOQR$&C5>O/N]##!^K3GV>B!@V5ITZO1)1HV/5
M:L!#*6Z`U,HU>BMB*)F5ZO5<Q`#RZC4T%XJ!%6Z@^3FH!T++]8*AA8@S\<AU
M9G=KM98Y:?4PX4EIJWR]LY(@.&[%^N:EHA8@5KMVO*5@UC^3"J)C5JIS+BW*
MMFC]!C"7A-H@PDY)B)T&O902`Q*]=HU^BB!.=JUZ/97"<Z=P"\WBYIIM@2::
M17ZR._*31I&7QMLHRO(&48L=I'?CBO8ZL=KU[^T5Q5VLE8;6.T6%*-%4LY+L
M+D`3>YJONA)<I`E59R&VD+T&G5<X^7Q*C,HZ5(8$IYS'L!YP$\B.[L"AXV*-
M!G%0R.I!2:UL6G']\`@7/5J5.<IMH'[<FX<=.G!NN05!9VLW@#A^TN$<S.\`
M*@@W7;5^K);G%4,85Z@?EP]#O2BT=9U&;1+,K,@+2QOENGH:,_[:]5TRY0SP
M/U.XP7,(?`<X:^2DP4JBRO#7I*55P&!'.]36M9(?+=_1EDUHJ3;JQ<\/&$N!
M/\&(-Q%#^'-W-#1'@WY/GQH][5(?Z,.NH9F_&,;4U'ZX\:W(<7'#/TJ3(C^&
M+"72:3F1M!]2;3<J(B?4+"7>&4L\<XK_NC:&6+31E38:&Q-]VL<%9'''#D9+
MR74N+E=7-W_1K@:CWQJ6*QW(ED+_GO1\-[`]&$0(X'],?S&P"-=C??A'W<`J
M"55+2?-A6YI+W>S'JA]/#!/3$%N5I@][VL3HXG\/_M#ZIGF#F=*[W='-<-H?
M?L9E1T/\N;LDKFXM%`QM2\G[T[:\YLWUM3[Y@TAL]C\/^U?]KCZ<IH3#MMGM
M&[6+E0V'2R'_N(V\/_R"M3V:U&YUC,"X),+.\3;"$>X:$ZU[,YD81*6F:=1O
M')2(N130SC;0J_[OQ*!C@/^K#8UIW2@I<70IE"?;*'&/'.O]GF;\/C:&IE&_
M/5(BZU(H3[-F.=6'G_N7`Z,AQGEA=BFX9VP;'?3UR_Z@/VV@N]-B\%)PS[?A
M8MO4!B/3U/"$CUT;?5*[&3#"\E)0,_.B.1UU__G+:-`S)N;_:,:O-_UI[4-5
M7LA>"F5FONL/\=QM:%/]]_HII\3PI0!F)JB),8@=H[$^:<(L.?%\*:R9*>GR
MQNP/#6R=V*4CSL+*)VW`7^.&]R6!GV1F*FP#U_WITNTDO@[&3^9^8]C$Q$\-
M_TMASDQ:YLVEB7L5&;:,+^KX74S_ZR0SJ8G[7WC9MFJZ]@4`+5HP)4K.S+=R
MR+0?EO5JQ\D-'4P!YLQ]R]FZ,>S,L,(4[LPDF''7&@/-C#=,@<Y,AUO>6V.0
M.4&(*=`YL^.6,R?%M.E!B2GTF:F3ZMLU)@4[:#&%/C.99EV]QF!S0QF3R$\S
MLVF>Y]<8=O'(QI00F>F5Z1(TQ\1NP8TI$7>:>U>/T#;/:&X2WC[53`G%FH57
M%25,PTS(@O-P4^@%HR=3(HA,R<U;##O`,B5`9GJF"_#C.GG!&K8'[116CV1/
M@"CWV"P^[II9P5U\YA4%A_>6M3@B1^-'P`N#]3?Q8?GA<6>5+N%OJZ]O-]OD
M6$&@CS]NQ/&L.^#%S[Y=%<XK>Z0`]'BD%("]*K<-^=5(=+0&OSHS%#R871Y4
M7MAX*L!F97CQTSX=!.">?%@CFR$XY^ISI3O(E""I8`SD0(,(3Z2?#CK'KUBP
MW0'GTT&(HAR1&V1IC.`"H/!E[%G+DU`\VR^(+)<O4_QL_=EE6)Q0Y4KYS`VW
MX/&7I@46%X%*J)K4$>"]56!'8>J2E2NE+AMT0N&M""6"9&8UDB7SY/A-LWG;
MR9&O*D+7`1LE1]I:&8\%IY%^*I?T#=SK56P3C>"M@K>5<YD.L2K*4T[_@CS\
M:@ZJ5Q'"2L0N(18/NY/D4\`CAUZGADY7,U$<6:BD*3H5?D8P*./`Q/5N/\AA
M3]CQ%(!/(TSNN*?;=C2/XL.P'E@@8+OQ,1/^[(%54(L^ARAT_XJ_I\I)9[:J
M)RAO`Y4*JN:83,6<"/`HT+=Q+>59Y8*G>K&)/9:CG$V6!D]'F/LOF9.&S/%(
M4]M?PM=)4_@S9PTY)R4RMDS9]TU3(N0$E%%%V.^![??`WNP>V!71+1C@#NIL
M=Z#+EVOK7Q!U/2L(V'MAA1I1>T^LA#Y4<QD8(KP*0-)#\W96"C<D9\^L#&7"
MI+,TIMP^FBSF5=Y?:]PZ5-YS(Y<[HA`@$\[")PN!+7EXFSU"U27MSY7MP["<
MA&H._1@N0#X(ES(2:;D;>-0JLO;OJB&2+5;E6WG92]_QZQSTQ0)!+,@O$,VA
M#Y;O?WCIH>B^:_E.?'ELC/_W0SI-I)VBS=SFS4/J4U=:5.IT7#&=0ZR[Y7Z2
MZ]]G)&0Q*%#SMI,W.;2#-6'QJ!WO5/;`N5+TKDNAP@VIO1PJJ1?FWIQZ]!9S
MCDLU)F=I5):^0D;0JB62;$M0>:DDS5KJ63)1)O$=?3%AQT32;+Y+9X4EQ:12
M5['_=8VMVUUX8(HL!\PM]"VX@NB+&UISUP_,:+%86CJ;P&*-W)ZUFL82PM+(
M/%-V5W,(0OTN")%E,XY$Q>K?=E0_'2TBAYH!$`P)."$KO)K2V"M!BC"K"<G4
MW'1B8$\$:"0#,4HQ3&GK37+.E%7-)19;'67'Y3?)[D8NJM\D.4#MS\A%P&%(
M\!MP[Q^(<3YB]_`>W`1@%GD#=\8XYM^EU?9:P>Y24]TQE9?1QK/M1>35SY\A
M=)Y<S^/[9V5;5-]CVTTR&O_O6\5_=;Q+X[L2&G>S#+9%?*AVL5T47/XL3YHJ
MT=*;8'DGV6DL_R3[@#F[."G4VT7JOPGV2TA,7=_)WC//N#X[4)Y7^RT33I=7
M)`JA^4!V[DMQDH'49YG\)XQ`ZHZLQ#FL4/"S3/(31N:<IN+R.:_12>'/9#;)
MRYVC0#H'W0]=Q_4B<AG`!':$8FJ670,OD'#/7`9?Q3L=HYEA(1_WF(T.,EYV
MSA*SLB?(#)NW'X`3>6`TVU$<7MA]Q<]1)FR_:CO;#O:OA9]V7!;84>++E_P&
MV!$UM3Y47O1-/68$FU.=FH<1^8A%@CGX->7$\#1!HHC9M""XIS[R50[;4<]`
M5+X"$:=W'"V(+GBA\9FBDJXV"/?'[6N).?#5'+5_([>$^9E@4L5DW4\HR486
MN\CR7YE!5'@XT><D/V=M[MRR>5DY#&I>6U2G&X'(G^9WE@J\<#>UPY%)<YJ?
M8S<GY8`"M]\%]BWV%_>_VXO[`;#?W</'(P>XA*`S\H'P<I;@!7]U.P#WEK=\
MS1YEM8Q+90HI>K<D#VJ=?HFHDI=XJ$L%7"1=HN'U($-MD(*PUG5:/6I5<J55
M6/6-WF@P0W<&O!L\'Z,G[#+@V949`$\KWKA#33-7*(BU<@>:HM\N?`)^G$\_
M?C7B8-!EZI=6O/&K!`+Z96*EZ;?T30"*?C]CEW!N^:9E/[`M-UNP\86`@$XI
M*&G:_"!WN=<#R'V,W>7+EZ$59[]D;L?3RBOJ:W!04R=(13@1V;O,+RUGLYJC
M9QHI+=A;WIT3)3V;JGA3><M7;+<WM5,J*Q<#LTM`#EZJ/U3U/<SEHSO,N3I5
MYK8CZ1JEB#XI:*G:E'P1<HS;`@B1MXY#^UN\\1?H4?@`D?O7ZX9<7DY85CWU
MP^A%\`ML>TIG;&RA$8JE=KY87@2V7X++8XY6OVT,LN50\YR*O%\-^@4['J.2
M^IQQP:OI06=@]X,@*D32LD(+"4H"ISID:I$SBL(@).DE_/L"#"5JM9"F#'KJ
M;HO\<(FE2?4B1%Z[B#TJZ"QE&(*G^"?FV99(??7Y*R('C<ESN4P2J&/DVJPC
MO4V9%C"RA96F=;D7)2EV$WL\Y;M/NGH+N!(7@[I-JB*-R^Z?"+0*C&>`;#=@
MN1K%VVHMP5R9:&S+O>7(,M=JR*8WU5JN>2+1J/XH?U:\M#!*<@0&_,!:*AE9
M_CU8OH;OM<C8>B%?Z4\66NT8!9])4%_0]Y<ZX.0OJN%A+3"7NH2F;A$H'N1&
MN4F9>3.V8)0;N5:I0+!8Q@SV<6[[.+<*6)J088)]))THHO8I=$86U?8W8X"\
M@[)4(3G'S%E%YB@Z+8=R!\I%=:WR\7$!/E0^*!Y`_SX$:-X#=_';8MG#3GYI
MM4<@EH2J[>%O8^7%7-#*RQFBF)IFDZ)X)$PUO*@\G.W,7:/AO^L<S[KS:/DV
MF(!'Z#WB97D7`<<-AS"DSS+)%-&\ZK+NVW%Z1TZR:R%)J`Z8Y!-FDM-[-%O=
M%ARA"4D.R9Z'&%74GHRXLBIW<)D'F#?\,2O)F9OXBA<@2O%9JFJN5)ZO*N2S
MV8LK>)AV/1>^7D!80>)<8.%4NSV7,U.)=!-84`SJ67+%(9UT,.PP3VX]65>U
M*R,C*0?U<+(Q-DY*LG&R=GTD>7&5T9$2A.[$-4;(:4E"3M=R_-1R0E*"4`GY
MJ>H0]"@,7`=TH1_@F9.5.R0.[\XO?7MRW`KE,^'3_:\F[TY_MQ?4JPC/VU]0
MWU]0?\L7U-=3!>,M$*3<=K';$TFWAO@'JW2X-)W*70UOL/I./->(A5RS:C5/
M#E?GN0FW&."ISDI-UK\&LO7&%SRMQ[)$EC<!1`,8(.5=.BD5%&Q.7<)VETK-
M`ZQ<+V\=%1='+F]^#%:_OJ99%]R<XC6G+NN[2U7U)C&E_][XUO(=;"2"+0A?
MP>9YN:0&O8*Z;(C@KM,%KKB7#2.BCM'L-8M>U_(\X%R^;-M2P?XFWK"Z7%<I
M'W5_LN(4//FCQ,)%<31IT,,.6W:<H/3/<HVIR^>N,M$X+'MSI@B'7T`0XJE\
M=_Z8#;60.P%YJ+O1#?!V9;DHCOC?C35&,RWDC"L-C3')UUU(^/T=/T+_;CM"
M?R.O'@31?'WK8P%L[+=/`9HSG-GZGJFNW30D.LW(6GK1AB7U%^CA9CPW?)G@
M<9)C;?4^O!UFUX0.J-LJDA/_5RG_Q`V^72$`^GX($)ZI&S2_O$=_7\9'UP#]
M//CMF-ZZZ_7<1]<!OB-AY$L^^OLR/;H&J*8G=P]27^[HK-X8<.7ZY!S?OX_W
M=W3?(1<.R4L#6._?$FQ!>4,H)@B5SXIW%P5W8:X@F@$W%-J_HJY/"C2K+IO5
M24>EN.R&9J&-#SRR6,L,CN$#=';<_.`UUD(Z!66BDMC0#B2>4,`$V/#>IV2!
M8^W.I2NWD"2*#%12Y";CB5\/O'RK\>HEP?1I+UM677HXD*EL2,ZIT_;4&ZK;
M0VTR4PTJL8^I8N:-DPWT5.:-\[*9-T[VF3?VF3?>;.:-L6?Y)&LV^_9ANI2B
M`;VY6*E<**%UWE6U[7)R;A+F:C1?Z8K?%RRG=R6#@<MRTVA,,+G630ZM^KZ-
MA<"S:=)'(;A.CH\_,B]U%&A!THM[*:8/2\M0]9!%X68(_5\CRW-G+G#PKR?+
MC']KB`06DQC1ZK=Y75X)6@I)0!W0%,CE]/TDSI*[S3[9)\Y25M<JS]$%^%`Y
M<=8UUN4\FO-(215K_'6(#!.'')@TM4M^%="U]2RD]F0Q6<D1!-2>@4E3>^GD
M!_L</45GWGV.GGV.GM9PI?),W]8</2L`FV3N['0PE-)M23O"A$]=?%>=;&0;
M!3OG"Z7T;4?2ZGI'E:?@4U4N>6U=^F2M!P(;N?'Q6@UGE8G6;SN2_+SZWPN0
MD9)F)2V--][$,0F_8;#R1[UAZV&+K.:94&EADV\$7)_CUV!&>8]YPR9$%U?-
MS<E=XT`2B3.VLC*D[NG7%WPC".`-FUP91:BY/M>]N''@Y.MB%5!(MR6Q^NJ;
M0A$YJ-N/4IDTY@L/O@!@`O2(C2Y?CB'T'T%`[)28<3"%H>4E?R?1]T,8_@'"
MUQC2Y$O$Z(;0R./5MZ,&U4#=CGV;9KB<V*\@6GU%RC%N-#>+XSLV3(8^:!8J
M^1VP;0]T5M[6:A.:9E`*OXVV2[H4"N)+;C>8H+(OY\ZTTP(S*"$/C6%UWT"[
M.\'YS;267Y8X-'H3R3`4NJFPP9NZG_"^T/T$J7<2RH[#&>8KG-@&:MQYL!^`
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M^MC[0[&T?)T?$\+5(L`$>"1@=VPADEQX.[E@OA`_;0LQ,0;ZU.AI8WTR[1MF
M3EK!?5+!?5+!-YM4,-&'7J9XT`LL.Q[*+E^2OW"VDPNTH79VA>+:4,TA3N+D
M'0?FE96TQUQ<[W3B%#_RW8TAI7>FJV>QT=0*L4,TCI#]@)T]_1Z!6.[?W/!A
M#)#O/D\3?LA@T&5F`2C5EJ3S5$;G@15(I.9`V8O`%59$VH>D]\3<XK(VQH4]
M$SIJ-7<?=7OYRA>\T"*S=!HW]Q4!(K65ITQ8"(%NU?R:\C(*L'P!">XGR3G7
M+[L56II]W%Z:7=Z8_:%AFEIW-.P:P^E$G_9'0]66:"E1R6Z_P%*-54=F_J=M
M6)RE&ZV\,DLX/C?;69Z8&FC'DBXCP^4+/\"864G:HHU#!X>[K-RJ.2%9^?`3
MN0G76)4D)<<34#VOHV4D5V[E5C5;*J_E*F54Y3@D,UHL/!>@#'Q>B`RGHJ2U
MG$B_@D7E4'3PC((0SDLPQZDH*\JL.'4B@E#'TK*'I+3W\=&PL!-4\JK=OE>>
M#&$Q:%2\;XH*=N)*7C599[]549$4@T;%AZ:H."U'Q>DFL+?=7*3DH"^NFF+C
MK!P;9[*SZ5;$1DH.*AN2WYR=XY%>`M]^F%OH6^&U[5;-UBYP<S6@6D!4%O<:
M=>'%4Z:F,NO=?"9X!.8K0OV5;V4,MFP-7`7+2J^&+0\$$_`(_`@,0<A=`^<5
M5V;]1.M=4%`&:F?<7_"L>FH3N*TI-TWJ_K:FNKI6>0[YGF]KOH47BDE^>=+V
M&#K&PR_^PKH'C`LJK%JW'4D!$+L?Q6:DH)&FE`LE[#RUAYE<X`)G!,V'HW3A
M?.Z&<0X)W7>PH*&+QP;?%KTN<'Z\'9/2'5U?]Z?7QG!J:OJP1T)3IOWA9V/8
MI5T>J/D2!%_$?,DZY22K71XSN@O`GQ&6QW@D0KWRQ*#I)',UY>;2-'Z]P<)H
MQI=8I"0UTF.&]M<Z]M<Z:C[53O4B?OP/M8+:%S8X<JIV9)T#EYNSC5Y%S@J3
MIW(N08KO=5;)D<HKTXIX5'G5N@6:']&34UQ6CCMNOV'RHWKL#H'K.JZ%7LAB
M8C2++Y?P9RA*%?7G**:LJIW7)6"2!(FC6>(R%W<H%*@K;]YBTY!=Y8II0;TI
MK%8"59_4JB6YT1N(ZY=ACO&PXN>^2((4VRHEZ[R-OY"B@:UZXXZC3=,-<Z_V
M)>'%9=JAR5>H.^RYK;XG?Y#D._B;?P-02P,$%`````@``X)E1X;E98Z]2@``
MM#`$`!4`'`!T>&UD+3(P,34P.3,P7VQA8BYX;6Q55`D``Q;'.U86QSM6=7@+
M``$$)0X```0Y`0``[7W[<^/(D>;O%W'_0]WLWKDG0IINJ>>Q/;9W@RU1,PRK
M)5I4]\R<?>&`@"*%'1#@X"&)_NNOJO`@@'J"CZIDCS?"Z[:8F?BRZJNL=]:?
M_NME&:$GG&9A$O_YB[.OWGR!<.PG01@O_OS%Q]GI:'8QF7R!LMR+`R]*8OSG
M+^+DB__ZS__Y/Q#YOS_]K]-3=!7B*/@>72;^Z22>)W]$-]X2?X]^P#%.O3Q)
M_X@^>5%!_Y)<A1%.T46R7$4XQ^2'\L/?HZ^_>O>`3D\-S'["<9"D'^\FC=G'
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MY^L587<64G)^4?WM,<5S,9@H35]3_=<Q7I`:#^B'WM$/G7U+/_1OU9^OO0<<
M?8&H).&LU*]W'5N5TFO;8*<X#9-@'&^'NJ_M"#YI.VF^@P-M?>LNW">Y%VT%
MOJUI'?8-WJ[$-WKV2YIT/7B[DFYI'@1VSD,>7+SB<HWH'Z_)OSH0\4M..E4<
MU""I"44$9E]@'4-EN[&>^!V[$8WF22KTG9F<>]D#LUMDIPO/6[VFO>9K'.59
M_9=3^I?3-V=5^/ZWZL__&/]6A*LEZ9T_X.4#;C[!_/OS%U*IUWW$5'Z4UK"]
MU-?X7DF\]A/2<ZWRTZ@LY5)]GB9+Q<>KHDFD(O^('AI;90F2STE`=\12G+%A
MS*`*;"-7EUN%:QD1.3HLQ/'IQ]D7_]E(H;^5<O_O3Z\WUMQQ8YHF*YSFZRE!
MFX_BH,'Y?GU/OCUZ"3.)WT::-CDTP)4VKPS4P'#-'&N??[7F"6*ZB,Q04*-]
M@J@V^AO5!\++JR*-P[Q(,?'R*GRA_\J4X4NE8).%>N!M\LFEP7!."[%/M4:!
MD:Q6`1;WQF2@D:PQGN6)_^OMBLZCU+VC7-YJ/ZF#W>DQ9<)@N*5#V*<6DT.E
M(#1&C9Z]--#TF3T9F\P1PFNSI2,`AB$B5'U6,!EX7=B',`Z7Q5(95GHR-@DA
MA-<F1$<`#"%$J/J$J&2`!8@[`E$5'%J_V^0!!ZO-@>9',/7?1]2O>_8[K#C@
MO>CC0%?&:AP0P>O$@;8`&!Z(4'%QH)396QR@VQ>G]68&JV.VH3'S8C^,PH0,
MD.ENC1>O?_+2E,RRQ#,60QT;'!@$GW+"2,$Y1X:@Y(:8E1J;O%2*J-8$UJ-<
M1%Z6W<XK=+?I7;AXS!4]C$+>9L31PFY''ZFP<Y:9(NPSC,FC9%ZS"B4I8CI[
MZK4&1ZFS;<+4&:`X=38X4)T=1Z0Z,PM5_\=;KOY8_X</6F=9CB9T`SF*Z&K?
M_J+88*:=;\.T<T!,.Q_,M//C8-KY#IWB.?DC#'Z]W89?;P'QZ^U@?KT]#GZ]
MW8%?;U.[_+I.XL4]3I<34HMQ'CYAB@C'&3MM0[=/Z-ZQG&F#U*UQ;@NG&O8-
MT(7!P^&`^XRD`HB:0=0.:@RAMB6VEP9L3D`AT7-QJIW;CHC5+5H!N,Y>;.MW
MYTQ2@.)V5RD/J,QAA_`W2?S7PHO">8@#\NLYVPYIJ$E!R*.2N:ZUD#34G28>
MF2HZI]`V:/E(=':.RHVO310"&'AFQ6H5A3B]2!C*E$7(NS#[5;GPJ=6R&9X,
M76A'+(V*<P8.P\F-RRHMU%%#5`\8^SB_M.>7E!I6E\/TT#L+8G)Q,&S38^06
MQ7B"[7%#5]*?7N(Y3E,<W.$G'!?8+'(-TK36EPYSI>E)S=2<\VHXUCZ_:F64
MEMH'7Z.@'?:4^/[H97BT2#&F4]>?POQQBM,X?&E?D[F^OE"L6VQGR-Y:QBZ.
M;M8WMK$"@Y:[0.?F$4P#M540T0'6U][AB-T`\=)\?9]Z9#+LLP-9[]?M7U0G
M'088L'H48K!CG;,2QMK.B;LU9.ZT12F&F!RH4Q=TG:;(<3I+YOFSE^))G!/@
MX4.$1UF&U5<A#'7M#A('N-,=+AHH@B'D$+1]+MY.QW<CE%6::$6(">ZZQ548
MASF^)E/XH.<::7,?O/].4K8[K(B=@RQ8/?@^W+7.27AS=3!L'8Z9.RO/+)PR
M$VAC`Y5&T,,:,3.H/#,`*;X2L&2P@O/+9.F%;'U4?3]#(6^3I5K8;4Y*A<$P
M4(>0GP8]X2@I+Z+Y248H-B?L\I-TE9")%$;/^"$CA#ST[.C')%TF,2['N>O+
MM%A<>'$0!@3"E(5MQ<DY<UUK<Z"A[C33'E-%YWS;!FV?>Y4ZRDM]%!`#R*\M
M5/UUAD[1%,<TI0:PKGL2!WB^<_<]V(K=X+B5B]V0.<B$<V+OAKM/\8V5TTC2
MI1]T0?-#$>7A*L)D+A?@I9?^FETEZ:<P]Y9AG+'%?+8XH8BN0RU8B[';N=9$
MVF'JSFFY/6;N#'QE!.6-%=;G/U5V7F<;0\`BKNG=3,=W,HWN8L*]@[G-W4M@
M1!G%>1B$44&WQF?8+](P#W$V?O&C(L#!%:FM<EV!;17<SL=>&I/Q13;%Z>S1
M2_'[M=B`ZB+G(;]H]5KHX8NN<\GT<)\#TZ`.[R-W`;:E@#8:H-8+JM.<RD#>
MD['9#H3PVLSM"(#AF@A5GQU[O[PD&7R.5JLT(8/>72;WPVU8&X!NZUXS!!UJ
MP#G)=D'-A:C*#*I7`2I#B%I"C2E4V0(VP)AY$<ZJ<P<WFLTCB:S5$:D*;F=4
M*A)TSCL3=/P-`B*+[O9\N.-@9]/>X]A_I).Q80?4>FJ.3ZD)G=`<5>OH@&&:
M(5"#0VN-&JC!UT61Y<ERZ-E<K995_IFYT*&?6@4.^XQP<N2KM`YY-E<RTI,"
M5MPDUNM8&\F9PF]&;CH%YTP:@E+*HY$SVBBN!>MUW--&=BE8IP"<-NHKP0UM
MWCNCC>*VKU['/6UD=WUU"L!IH[[IN^FUG-'FZRUH\S4<VGP]E#9?'P5MOC:C
MS>6A:5/OEXV")_K@`IE1)M%3&"\N4AR$^4V28_WFJ5[7^K:IJ3O<AJE.$0:M
M!J*5;I)6^J@Q@$H+B)I`KZ81X5&=F.!+8,L,]+9ZCM/E)7[(-7??Q*(VIW,J
ML.TYG$C..>4,P/491D5/J2RBP@`3;O^$:0HJ'(R><.HMQ$%.(VMUOT8%M[-O
M(Q($PR`5.FX?IY)%E?#!!U#),XXWF5R4M]3DLO8&3!JXFX&21-`Y*4S0\4N0
M1+R=-N>$71A[]3$.</J<AB3D9(?IJ#+L?[5(GEX'.*11YFOZ#\JBKUO!A?SI
M']=XX47C.`^%5\*$$C8XHX!&F2+XV3D_Y)BXWH9*H5+LX"E)1LLDS<-_DL%2
M_]2D,AN)7LUF(A)3)]HY2'0ZS@DS$&B?143S=*,J.LL*:OQ[A[,\#7W20[*C
M:A_C,,_N9A^5(QF-CMW+IP;PN_=-%0K.N3<$)7^KM-:I$M\P+6!T,SB8ZNY,
MJNXX*LB3J`:'4.NG/_`+3OTP(P0Y`T:+2YR&3QX]B?=^?>.Q=W/D\W"9L$VJ
MJ`&W22.6!$,?)3S^(EPM?$)O69;RAQTJE=Q5;)'V!*P-?X3`FH%.YU?GE2V%
MI(\4Y\`BQ:QXR/!O!8[S\9/N<4:)K-WD:`JXW91H`D'GQ#%!QZ<_JV41$X9-
M(,V:KU3:(8E4*[\24:A$TJS_<E0"MP!\^X33410E.;T*9C*XE<M;'>GJ8'>&
MO3)A,*S2(>2Z.2)_VBC`O)Y%N1\&H9>NZ2G=VSF;TVDBE43>=JQ2PNY'*Z$P
M&&;I$(I.5--72LH9^$%'QA^GM_)1<>M':R-B#E`S&FY^<5ZO0CC]2JRW`<(<
MQVA:/$2ACV[G<S+YV6-^!6D*Q'".H_9&A+R2Y;(6$QFJX;9R%8H%83!"@XZ_
MU4O%45O^T+SX(8F"I1?///]1P0B1E#4NR"$V+.!%8-2_%%>_YBM!Q"2M$N"V
MR$E/1!.X9D64RRZ%JD7M+8ZHP6Z62<1R,$BA!L>-*4MIM!'?_P-X$FI4WQG7
MBS:*U3*IJ#5J:,`VU)#(P:"&&ISD+C$:'V#]W9`2BLL"4E%GE)!=#9#(P:2$
M^B(`3XG]+;3*\K8G?D&GNZ,X*,\X3.)YDB[96>+10Y:GGI^+'#/3LY>S?8`;
MFXSM!DHP:#0`*;<[4ZDBHEL?8VEINSC&5**XPXN0(H]SFFNQY[5<S-:!)A7(
M^E232,8Y833`^ORH*+&198\ON:/%!;O*$-'T;R]_P6NI<YR<76)(8':9T1,"
M1`TQ,@DW*F'$I!$1=\&..H[1Q7Z!6]V?;7%!!*JF0/LW$#4O`"3M+*B,RUJ>
MXC1,2%\77'JYJKI[<K;K70BS3X".$"@FB)!)*5$*DR%$@*BX"W:,")"`@KF*
MO(7`K][OMM@@A%6SH/,CB-H7(>)R#-4RB`JYJ.N+(DTIQC#SO>@7[*7R8"`7
MM<4`'=B:##(Y$+S0@./OD3)Q5,HCJN`T.)2#E9]P%/TE3I[C&?:R),;!),L*
M;HG#0-[N<%(#NSNLE`B#()$)0LDPTT-4[?17JH=J151JNB/4IR0JXMQ+UU=A
MA%/1G1N)G%T"26!VB=,3`D08,3(I41IQQ.0=SE;+('B'5_1N1[R8Y5Y>R$DB
M$[<\=U6"[DUAA;*`F*,$*";0'VAVNTH<E?*H,N..28S(%Z3O7"2I?-6C)V67
M-T*(7;IT1`"Q1(1+$EV8**IEW1&B/&)R%25>?P%>(F.7#`)X72JT!``1@4<E
MH4%UPH=).NQ?DN4RB=FY,9;1.J,;RKG''G61AT2EDN6^QL"!7H^CT`!$)`.8
MLN54IED>!CQ!I3)J:;M<=RLG<^52SQ7YFV@HHY"UO?XFA=M?@^,$03!)ATZZ
M%E?-N:LE.:;BGC5T!<",,RU)-XSAH(KYTH@!9$L?FXXK;'UF[TS9Y44:,L)B
M)_/G5V'LQ7Y(6D"2A8J#!\-4[;Y;8^Y,]RD;O9YS[FT!EC\:6ZG24_"-,JJU
MT=]J?2#7+,JD#!H:]H6LOC4C!-AY'J8C`89$0EC<[L-L-KZ?0:)"M3Q@Q`A.
MUCXQ)'!Y?O0$@=%$C$ZV$5'J?`^#-A=>]BCQK?S):L+W%IA.5G?R=S!5W@+#
MU3#Y"4:UCGP_*>(\N\,^#I^\AXB^IE$14$9EI8K5V&``OA,B%/)@:&,`DNM>
M*A64-CHG*,9L<.)%4?+,\I;2EQV#I'C(YT6$O%J%B/S[NV]/WIU]RS+%_?LW
M[TZ^^^;M"3&5K;!/DV!$>UTSW.6177HY.DG7I#PD9=<5L?L\+@^N^_;MYG<P
M5!.`XE^MK41@<&":XI47!N.7%8XS/(J#6_IB=*=SE?AJI&F3,0-<:1/)0`T,
MO\RQ<M>,J"#RJX&0QS1@,-"$:PY9I>6/.Z;D2>Y%UZ9C9`DQ[JD1D,28ILD*
MI_EZ2O"R>PV_%>&*+A'(NRNUBMU@I`??C4)R>4#A1PNR3Z^K\`4'%:W8$`H&
MMUIQ4S-C%TI:S;DBA]K)ML*+@>&-')NXFP(U3^_VN3>DP@8,B]KB[L9"/&CY
M`&@C"X8^&H!]#E7B")?R,%C4SP5,(F;Y2'48+WY(DN`YC.23"A-5NW,S<V>Z
M<S:]'AC6#0#+S_&:Y,W@>KY+O*)[*EGEE"Z<R<7MIDU5@^XF3A7+@B&6!B"W
M,U8^,;]&0:D'@T:&]'%+&Q.Z.*6)X0Q.RY%R$I>PP1.D*5P)7^F;"T;(>0"Q
M]I5U#JFVKT/O(8S"/,09F1RRTVN/213@-*,3Q7RMF6F9JUM].VN@4YWWM`QU
MP71-`P%S+Z%,1N\GUY/[R7B&1C>7:'9_>_&7'V^O+\=WLS^@\5\_3NY_`4=5
MLXU[E8(C.AILX<NE(5)NV&9^2Q'(2D&]:SCUUG3'T&S3MR_L8KM7#%BTT=N5
M!$,B)3SIYNZJE(9!'K;RQ3<&U8J:2-KZRJ0<,K<ZR8N"(9`:GWHS+=JHP:#2
M)9YC`BVXPT\X+OKWX:52=B?T0HC=>7Q'!`Q5Q+CX)T]**9268C"881Q?7(<6
MLZCB.*!HYV_&`:6["0LNH+3\V"Q%F`^813J.R"2'+^$5KP`F$)F@%+Z,?$]?
M1@8_?"834/*7M,"!T%&SD:#6B,/AMJ&#BF&XQ@(8IFX%6S!LIRIH#&E;K^6`
MOI4ZBWJ:&`>VTU3VEN!Z27IK-V0OPV3L2>F89H_`L2_GAE+#ZO%_/?3.K0"Y
M.)B8H\?(O^[=:%1O?+=T8%!L\)HZE%7T8>OF1[!2/GAMO*WP!U2J`!EX3=-J
MLLHP?O(BZ9J!4-+RN289U-Z1IKX8&.;(L0D.,E6+"!E[%NH4K;P4/5$-].]O
MOGKSYNR/Z.S-R9LW[#\H*_-$>$7^F*3A/W'P1Q0G]5]#FB0M8'$M.4PBB=TZ
MSBI1AHI\O)CM+E($LM\OMF7`<$X"3-0#)K&";6^_V="-4NG\&R7]SK[[[N2[
M__CNY-WY=TS\[)MO3]Z\^^[DS=D["2$A7I,:!0&[@^Y%4R\,)O&%MPK)`+15
MIK)ICX&BU?FGL2.=.:=6"PS-C:%R<\M&$;&CHV&,_%(7!@7O<.Z%,0[&7AJ3
M5I*1N7"Q+"(OQ\$EGH=^*!O_F2C:I*"Y(VT*ZK7`4-`8JF!YHQ9$02D)@WO\
M2-=X2.QZCF$VMX"U_"'%)UX%R3K3"LP48/!&=Y9HRR-(L$Y_;7/J"Q;?#-%J
MU^#82`XN&T?UK?VK)+VL[NSSB0$T1W:&V;`ZM-O&O<XH;X@!,+WM-JBYCE>=
MSP$&?;N+!E,OO4U9QJR`3>>F.&5)(HU6'.3*[A9R=`[)UW9DFF`H.@BN9@7H
MI#4E?T7F*$$215Z:H15.R^GWEQ#96N8O'37K`D8%Q2NY8Z?,`3DK^QI`V2B!
MJ64AM]0#EW;L<8@AE*L57-.M"UQ'M5(:-,TZ$$TI5JX2PJ67/-FVL99KHDG2
M;1NJ@*:</N&VC'>0]T@&COZ,-!WMI`P9]QFH@2&C.5;5%LRQ#/>X1/?:L9Y2
MPQ$7349Y"G&(W#,<WW4Y!W1PQ[FE'-E)I9V22SZFDXC")95R-"<D%*2AW(!'
M4\Q4G-)*,X(#_5S*`)!&+`,W<)O$?K+$37I[S7D]J;3=]#Y*R-V,/D)1,+12
MX^/S]E!IM'F+`-JK`S,OPEEU\4R>!9&3LKH+*X;8V8+MBH`ABQA7GR25`*2<
M3A=)EM_.:5*J;)9$\C%13\INIR6$V.VG.B)@:"'&Q?=&&4L/OJ!R*".",+CQ
M0YIDV31-YM(S0AT)FYP00&OSH?4SK"US'EB?#$P"K9@(#!K<KG#JT>L,U?4I
M;=I3N;S5%`,ZV)TD`S)A,*%$AY!+-%#+U\DLH=S5G.$HHGD0<4P`1O1"7[`,
MXY`Z0X_N5N[)^EE#9:O#ED$.=48S1II@*#@(+G>)A8Z03M"B5#YA9WZ\CCX,
M>M[A#)/R?23N79+A6I2P+-5J5FIT[)Z2-8#?/2"K4`!#/1.4_&B[U&%4"S9:
M,'AVB5<I]D.//7!'FM*2/AG^3_8_)66@U+"<4E4'O9=5528.AE]ZC'R6EHU&
M&<Q:.C`HQ@T93(<6C@=J1@,T6.-Z&3Q)MM7^V`P87\K%K&LR$=&YVY9TPAD>
MJI`U&S&@O.$`RL?S$1$"0AB:S,QT5BB6M9YTSF@V*!($TU>IT(G3S87EXO2K
M*MI\"60FR,#=)''2;00JMT72UBDDA\R1B!>%12,IOCZ1/H293Z9_7HR3(JL(
M!8-%]%6\C.7>*!V8Q#DF9:5ZEE`L;ON)0A7H_G.%(EDP3-(`%#QQP7X&Q:+V
MB+]Y@CQ>T*5Y:1)ZI8K5*SP&X#LW=A3R=ECUKF15C!?T=)MJA&2`E7\XK!)"
M/I6"03`^TJK7E!3R-JFEA=WFE508UJ!;!U/U1$9_*`6#7)O9PQ6IO3+[5$&\
MJR8-29R]Q_,DQ:7<O?>"L_$+&3<F:4#:2KJ>Y'C)TN@135*&$2L833=ZP"_:
M/[%RT*+C3[T<Y'.P&MGA'>43E&89>F!&ZV::4[.0FBCQLXHU[W&,Y1OK4FG[
M34,*F:<U)PIM,*&&R=_P2)["C*[OTNN]\"AU@W/M2EU/QNK0002O,UQH"\"*
M7B)H?7H0&4!K<776F/J2R'LO"WVZ719&!6D5FM4Y8VV;!!KH4IM:AJI@IM##
M\`I[ON9JSPEZH-KEMF>I#V3!3^/E=F4#BI-;</%8.*B)@DK^P:#?3SA</-+6
M]$2&H`M\4RP?<'H[9\ZV[@R8L7);8S;)NIO#;0YO9PD,M7>"WV=\;0QYI344
M,W/T!*]?W2OA+I2`;1/-A87;^867/5Y%R;-N)T^M8C=MFQY\-X&;7!X,5PU`
M\@FBZULGA(-4"3$M<'=02%]!T;%Y58"#]^N/&0XF<;.U/:+)6\M\8FH*;F/(
M\M1G2T=[\Z.!5L"0>&OHW-V(T>Q'='5]^],,7=W=?D"WT_'=Z'YR\P,:7=Q/
M/K$'0U7DAC._/8=4.0)<L*>WH^"_BW*/,;M/[C"MGC#"'4_ND_T$E\-\RFZV
MYL,55C>_\_Z_`Z:5'-`Y/H=T\RF4)RBM/T:O"9:3*_)7^F^?]NUSUK<7Y%LT
MV?3F+*'7?`[(=+]]1%92R%T15X>81=QN_PZ&DP)0JG/),&C0W<&?Q&1*M`CI
M6U[L_7FC;7]>R=WQ"ID#\@,6?0TP=#*"R06KEA*=;X2-&O*8'@S6-9LW@ORN
MDN)0J]A-MJ8'W\VT)I<'PS8#D.H=.*`)=NO%4AQ<)$NZK:CJ\&3"5I=-E(`[
M"R9"23",4L(3OJ)%E^'(N,EOB<,@43<4UT]`7Q`'%])[.QH==UVD!+Z\A^PI
M@"&8"4I=_QC4:2+G$(\EDLE,BDF;N,3E?[>F+]43./JT0\8&+!]>&>A8[SR+
MH388K@Z&S"VU/9+_1;.M=2:5;$C']BTB<,\^\R[S&?R-2TNDZI:P<F?45.7U
M`)[#,L4L>.R("=)5DDH2*AGIO8B8?$W^BJ]&QRW]!/#5O&LIP"<<#Y:_IU)*
M`'F&1A#?Z8GTZH42Y6**F:KCWEGJC*9?YO3@<T^*67Q]LWK<'M3RBL2IS=KW
M%GSDE`$P4N*0`2=[FD?"2C%J,2]A\[$>*$R]]5;CP$8/QB"PYX;9"+!2LCI'
M><+I0Y+A[89_7<#2L=^J%(-*O7JAH,KW:5P*G)Y;ZDG<4%.OIP2?>F+`_+9:
MM8J3EF)0J=<>6K3>9]QJ:-+1!]`7R]TR'R*VE.%34PU</5ALK=9`Y2H)YVE!
M1BE;T%2DZKR?ECBC[:I[>H!7%*5@^1LI\0+E.%W2O3JJTF0AA4%&\_.)\C-T
MQ@9@GCR5G%@TU`9W76\8;M%A1\/#5:`)7*9BV<-1:J4A`(0V<-2`V`HK8*+P
MUM!U1ZDG-Y_&LP%'J2V>W?'6U;G+D?];$=(D`4:'Q@STK)[B,76C<Y1'IP1M
M(<D4,'>VAQ@FXU1`>^&<)Z3-D0X@7T\)\'P4!_19>Y9"V+0H%`:<$E'KF)*1
M4FWPU-0AYSA*0#V2D2\]Q[&J=-E>.*X583#7O(_8N9.!VOOOUNL?Q7!6CMMP
M.!O6!HYE.-MD<MMU.*LT!(#0!HX:$%MA!?IP5@]=-YR]FMR,;BY`#F?3Q,<X
M8(FPZ..7Q%%\.V\]6RCKOO1ZE@^EF[G1.YFN5@)#3%.D@C/J3`_1TD*9%^%V
M)H#RA4EZ=XO]$<Y8M^4M\^YVQ9*RC5]PZH>9-.V%@9XK3BK=D'%2J`22DRJD
M:D[B2II2,"D-P"/A3UZ:>O1)EQ*KXHZ.0L45]63@9:SKRX,DG`2D.=>>2P-`
MR&8^\-AYY`)U2+G;4/(HYDARW)HYTJHRA![6K9L:T.9)S&6<ADG0WYR3%)-*
MP>HCKEK@G?=<I=*P2*C%*7@FFOU,9^.4?(Y2EU#<LG*WG*ADQ8IOEGMIKBMI
M::H2^N,)>L"+,*89[-AJ'3,+L7C?.BC><:Q<)^W@$A<NC@.S8K7X?$RZ\.+J
MHMT%&=,F41C4#[A-25GA..^^&N!%3:(L[6M%^[%M]6F:?19'YR&;?1@&,\+=
MIS?<":R6[1/4L<YV#=KV:6MJOH`VGP"7M&VG`KL,,S]*LB+%]_@E?Q_)%[OV
M_YFC:7R*0MI;.Q1\X_-HDG+'N&<\?ARCB]L/T]'-+S!:%DTWFMW.JU/M9.`B
M*1^!G$UN2V&VR<D)@6&7#%F?'N]'L\D,W5ZAZ=UX-KZY']U/;F_0Z.82W8TO
MR/^^_@5-9K./XTLTNKBX_7C#3LY,[VYOR+\OQA^(!)#MAHVG4]*2?(.$=PH%
MJTDDM,`[&22DTF"HIX4HN>!"YS"U!KCQP"Q<Q.$\].D)"LX_72]OJFPU'<X@
MASKI<8PTP=!Q$%PN?<['#Q]&=[_0`#F;_'`SN9I<C&[N.['P]GIR`6;3M;F]
MO1D@:#.9*#1L/PZI@=Y_'U(B#H9Z>HS2V_=HHP(N%@K<TD5`M8ICFBFCG4H>
M,M%TD8V>@[ZYO[T#,BMHLDS1PP)5YI[PGYC.A%9>&)`Y$;OH59ZM-0YN.UNU
MFYMU+T703>>ZDTDP_-Z/']+;K<SL"6H9/D&5Z1.VA%5>,BS-0X[,?(H-[0*4
M2L/Z&^-JZ-P[XV)Q,*S58^264N]_'-^ABX]W=V,ZRIS-QE"FU](SY)H(;*!G
M^?B*F1N],RQJ)3",,T4J.,W"]$C8HYHLYC6ZX**<U$OS\>@P$R`8:CA>':(/
MG[?FX]FKR<]TD1)4R&0CB.K1U>X811LU353MTM+<F2X=]7J`:&@,EH^@3!55
MNORH<7]!-']9!HQS;]Z]?<,81__2`V^P!VFL98-G`UV@%#-4<<ZN83@Y8MV-
MIZ/))1K_/!W?S,8P0ML/21(\AU%$FDC_WJOQW'R@#9O!;BOWVE%OD`'G!-T%
M=9^NM0T6`#=6CF#N+'=9O[AIH&EWC=/8E>Y2IU8-#%?-L?(+G_>CFQ\F[Z_'
MH$:+;+#02C%D'$=-%*TOY!@YPJWG*+7`4,\8JCA564L3<CB4>VFTI*C3A,%(
M_1*C6NT(.#ELR?%Z,GH_N=[++6+)-.4&Y_01P?JY=4EP4XM:FY!HP#:S$(F<
M<WH8@!-=$*+BB,@CI@`C'HV]E-YR:-S012&%O,W8HX7=CCA28>=$,D7(L6E,
M8LKM;(:F),C,?AS=*2>PASSN1.\1/R91@-.,KB[F:_63Z3)IR_>$#!*H&F`5
M/@I6J?P!E4IHE.=I^%#D-,4T?7EUZJ40%_]Y=V^2')N/3@;H6SV.-]0M-5TE
MRF#BR%#$'(/O;R_^\N/M]>7X;D88_->/DWL@!UG*=Y+OO9<!)_`4&I;3^^J@
M][+ZRL3!\$R/47!7E6@@H@)Y=B;P2[]*I5)QS#/-NI1<'C+3]"M1%[<?QNA^
M]#.4X\-W.*+9!4G7GZ_O4R_.:":`)-9M5^K5;-++U(DVQ70Z8&AF"+1/M4H-
M,3W45@07VF0>FD>Z018@,-,P#@Y0!\]7\RAY-[X>W8\OT71T!R>YW5V8_9J-
MXN`CJ?,T]\+8($FC1L<J$4W@=ZBG4H!#-@.4'+VH#MNM[&B!"XL7M%;C/&5W
M@BEH\WAHIFHU+\X`9SJI1`STP+!Q`%CN5N['V>1F/)NAB]L;>@OWCEW+!1+[
M:'+(,"\S0\0!\9)>J,.Q/V33<J`-N]S<PKTN20<8`,36X:BYI#D;&RRB=JQ`
MGDX;.:\/L\.,@".U)O0.L7!<M-:%8S)-_S"Y9\D.6&H$$I7IW=_Q#9R+O[/B
M(<._%<3/\9-!IB>YN-5%;PWHSAJW1!8,TS0`N17L1AR5\N""8M\A[<Z*7-XE
MJ=0[)S)AL+329RQX/QO_]2,]S#'^!"<]RV2Y\L*4QN';E`3>59)YT>V</IAW
M'3[AH#S$Q[(RK+4+V5N9LKK`O8.SG87O+>R`(>X.X+F%\L84S1]'39PR&]6I
M8A@,OR(0/WE1@5L)NR8QB>@%&WV4GDK*RE#7)H<'N=,FK9$B&)8.0<M=.2.Z
MB"EWTQJV]&%0LWKD^0[[R2(.Z7*$6:0UT+.[?&[H1G?17*,$AHJF2/F]'::'
M6HI0:)=A4I:/9.)U23!&";O265V!4L9#(TV[U#-VI4L^K1H@^IEBY0E8:K(U
MGY9N?1D22!2<X05%=8=72=KD`%N;14)#7:OSG"'N=.8\)HI@:#D$+3<7*G51
MHPR$B/XC#HJ(##F:O$U5EI![>OA2RT5C=:MT'.A4AY&&NG!(.0PPQ\M*G0X;
M&P/0N"G(7C.,G7H#;OAIZIB8H3IM@!PUA*QB:<*NKOFE#>0!FG9+4X=LG0(&
M6N*7[=*]P".D,505$>?A"PY`$;#7SLH&=D/JN^H0AL5+A;K#:*EU2A$KI;I@
MB#D0L(J>JRH-#"YG/M`8VK\U3UIAG;!A\-#3V)*K4>A`5V4#4D,S`-D\%+N*
MV.$FE0?$X)O0U=LPQVQ;H._W59'3LRM+.@<LW]NH%B8&<7X_GW#1&/99.*)6
ML@_[X)K/'IU2M2OZ,OV2'<WW6M9@]1_M^4,KQX!1ZS'4=95I5NN.+.>L5!$,
MD8>@-9_Z11M+=A)$,+RRXTPF"JZ218B!RU)&=*6=D\@8HCY]!"KU8(2RS>!H
M%.=A$$9%3N+[#!-Z,TZ/7_RH"'!`7X*^2):KHGZ#:VCZB4-\R,U`>M\%)1YG
M[^LKSEO.P5U33C^3G`3IT(NB-:H_B;+FFT#:H/#NO^[`JD;)?:Z&8?E$VAIP
M.&L"TRB9"-6#=Z"U:9*L8;WW,GHQ<<WRHS][:<`\N5VQ^XGT6$_Y&F.6%<OR
M;P.72/;S$3=!?Y\%)`[X^_@"G(9S"+=4@=[;Z**"?(R^K$[&Z>A]Y/F_GA))
M@CA#'Y*`.$[$,_I]E)0*<!LC[0?)M)>53KO(1C[IR$A8V;H!#C7LNM%M5Q"Z
MAC;,*NC&M94KREGNJGRONM(_T-Q6<1M)/\\=H&QMSCO8H6;^:ZSIG(=;P55=
MC1QQ5R-A3I'+5<X/81PNB^4=@>Y%5:>6727I[0K3J\WQXAJ3%CET<+23;3?A
M>0_%(8[0.QAVWC@.X8UR_Y]91\O2/$J9?;2J/G"@L#T*GCQ"E)8;I9/B([-5
M'T3:M2B0;&_+6E#?U=TFQF]KR#FK]X&>>^6Z--=P%<V3M*9SVCY!';1.4'N-
M51B=0^N`1+6UH-I]Z`E:W^01`N5V=#I2SJFGA2;.*E]NRM?;-##(TGWSAN'<
MG*J1'A)3ZKA[\DH"7_[654\!#+%,4/8Y1J]<HARG2Y@'G)HSU#=8]QZE6-3)
M`]0"L,*'IUMRT')/*S!*7S8'1AEZRB,CXTMZ,JH_8-,).Z&-$+"0.!U),/%'
M"8^[8EO)D+B3!(4/I&-K7+CSGC]X)"Z&7J3E3E?6"75$<(7,:0O"(XX`'7<E
MT7M&RTH&!F>Z3Y@KQT!B47=/T<M'/"(Y,'Q1@).^!.]364=/5+0[4]V`P/(S
M%'F2>Y'I0$#Z[,3][?WH&DUN:%J:V[N=\_5+%FOXVTZJ1765M+4%%SWD9DE%
M+NJ\W9GA$T]?*PU0"5VJB=(DSHJ4KMRHYU,M,0>35`ZD8%[:R#AGB@:8[&WE
ML)8[[`O*XO4]1;\]5-GV>\KF#O6?5=9K.N?25G!E#).NPVK'!;O3[B(A]([H
MUHB>90)9VZ22PNUSB!,$11D9.AE#_$8>1B=U66!Z@K259C_$NNF%4L7J-,,`
M?&>ZH9!WSJH!(,5CH!3[.'QB)P%.T^J]CA5[K^,5.TYY]O9+&)QC<+O+R`:;
M01(%ZYM"2N#<YI!0&@S7M!#%3%LUP>S@O=HG'`=)>HE721;FP@UQB:#M_DP,
MM-^9=:6<\T`+3=:-/3%A,L0II1VM>'292T9M9KNV!FK0UD>&0!8OFW3?:=:_
M7'_0U4$20/R0';X4KPIN?H?W7JH0';\@N!&JT]C!Z'QG.1D8L*PI=*0@\;$O
M9/=VC`A@]S9,6\)Y$%7"XF^[5$+H;TP,RM66&M9U&.,)^:=L.THDZ(0='%`A
M0QHI>"SI0U,PA8HB)@N$+M)43#^D22:CCDX)1+*LC@-&B;*8!AAZ&<'D=\DW
M2;%.T()*PN#9R/>+9<&FLNT>E?P[PNP*5!RTDVA(G9<4UO[,V^3NO@NES?)]
MV;;3'MZ5[2'&"PI8-6C;LU_<V=R->3HG:NP[FQ=)X$MVAE7R\`;@1FC%DZ"K
MR<_C2X/)S^[K%A^\N)A[?EZD=&F8KI-(CZZ:J]E>TS!QHK_"H=)QWDL.!"I;
M_5BV56VL@M4;4_U=*2-.F2B[VE+4.R3;4I1K0HE76Z'>_\ZBM?6W(8?;6WZ#
M7FD3X!3W+-.[\70TN43CGZ?CF]G8486TQS!\_D;A@$^I`:_S-\3+#=`.D!Q/
MEG^L6#[@]'8^]6@N'>&6!2=B+\>8&-PFJUCW=Q@=MA@4ESF,2;$L1J4<C"FL
M(@ND_K:)J;+5A[T&.=1YV<M(TSGGMH(KNGB0X^J9N8TZJ`.*"@=5ZWAZ-2!T
ME*[EZ72.@8*J]3SV&[KPTG1-)RBD\RN@W.E4>-1:1&EWU\.+1FH(""\UCAHR
M56(%VLK;UAZHUMC:XN!YW5IT&]3#@.&K9-50K0%K5F>$592+%E+L'/F_%6&*
M`X4S/^%P\4C;$YE*>0O\,</S(KH.Y[*-_MU,VMWUV-WY[D[']O;`C`_VX$2?
M]+4\JA0ZL99F90Z3`$9SF,0!GLL=+Q/DDO%/_6:%]F;_MN;LWL7=S>GNA<#M
M;(&A_XX.\"D&:G.PYVU#W=Y3Z<$F^CX(#FVQ<TO\5J:#DM7/H9#YP?'V9JRM
MHN[@9+/2NH4-YW%W1^#0Q]?")1;S:&JF;#>&#G&H&SE--.'%RP&H=XZ2%BN.
MM)2MJDVD!V]/;Q!JZ$%DFU>_MM\%,C`)9!')V'G#)2:M/>>]Y1Z=Z)-^K'SU
MC64&I=G\U]A+OP??+`3NW^&E%Y)Q1GH[OPHSWXM^(9YLL<!L;!E((QE:%*9;
M!89FCZ')#/2EWW(H/=&KMVB9Q/EC!N1"]#!WJ7?WS\E>BJZQ!;<!]-S=GO*5
MH2,E>1>]@-;?'BV7R>=E^Q-;6P/.Y[;+.S*:FCIF3K?P"UC]W;&R^HJ4Z]X*
MJ30&F]-MAW>C-+5TQ(QNP1<0^C^.EM!$=G]EQ(P!)W3+X1T)362/F=`;^`)"
MOSO4HRF^GQ8XN""2(1G3W]-4O+HD>GH=>X^@&,+?/':B47!.H"$H!8>WJ!KR
M*SV44\7]7)W:VU5CBG#F15ZJ38$F$[9\#5@!N'>I5R#IG$]&\&1$6GEK8C@Z
M00])7&0X8_>B?/I(6I;1I3!XS)JFR1PS<%YTA0T9)E5RP#2-`P+&232@,4\-
M4\;`""](!*.T\WR?[C_072-0SYI42#]Y/NO1C0C'"3L@F@2P@&`]26C$$L.3
M]HWUFZ1T6?\APZ2XX$0P2O!LZJUISB*:+*'$?!UZ#V$4ZG.&#K)@F7)#7>OQ
MT%0=$CD'8I8\&5;QMHIYA[H"3\8%.+L,LQ+T'<Z+-*9OJ(ZB*'FFV;PS]@#,
MF6BT:JYK;5XPU)UF?F"JZ)QGVZ#E8F(MQO8RB9$5?:F<=K9I:>I0D\[ZNU=)
M^A-[!)WX0=P@TY6'@AB1#]R&J]N;B@YW:C,K-=>%0;SA@-7<>ZYMH&!C!,TQ
MH+Z91F'Z4*[1`*\CZ&!P)P`J&-BUI)S32@M--J"#\Y)F#3U9>Y'18$TL[8(N
M$L@BSO1$P1%'C$_*GEK<T1E$-L@S&P5+1*&E=M'!-$F<?#T9O9]<3^XGXYT3
MB.TI<VOS</HHSL,@C(H\?,(S[!<I<[(\28D#^J;`!9EA%GF5.V7LI7$8+[(I
M3F>/7HJ5^8#W_!&K&6,/4D"=;+-[_0*8L'40M[@LM]5':-Z6]F?0YCNH_A"B
M%8M:GZ)*]<?HU43$/@<KL_*.97>MR<>\/_-6._<]%TIG-+`GVV#:X9X=XL8;
M^VIUU]"R5.]8<.6M@L-42FW[B!I=MSCVV.)*PY]+<^MX(VIKITUCRZA\AG"G
MH>&Z9:U(RV(2R/<BGR8^`9/L9)8G_J^3+"/3E$N6`[5,"\#\SV[P,_M)_H*`
MF;+=5P6&.-1]:<!$$PRY!\&59]BKF!LR0R@H\^#2&R<K0/DAF%/3-)2^O-H6
ML,HV#EB'4<VO<%C3A\2-XEF<6E$)]"J,49!$D9>V8AB0BQ82^G_RH@)O&;?Z
MN@#"EM@=@ZC5581#OP%HMXY9)T_4'&B:EE&:_7B[HJ,!,BK!J1]F.-@FW$L,
M`2"P@:/&?;#0"G1JZZ'+>4X/P9%)6D:5>VPOF<ZVM<J?D](X&8)6UD'SGS7X
M/=!?90<`^_5NFH;RH^2^%GF?^DSA<V$^;?CO/8+GHCX-1E^G25/B,'L,[/UZ
M(S+UUO1/HV<O#:JR^H$(YMDD+HM2E<7W(%^R/HH^3%%QP_']?@9."SR8;^()
MP@.ULSGGR-82JW:X8*80F3OL9PHI.=_SDY>R#TDR;DADK)W4D<%KCN/T!9Q3
M286*2RU9B0%)2=&@CH,[FO,RNRWR+/=BFG9&TF#4*C:CGPGX=AA3R3LGT0"0
M,DZA9"-ZZ-A1H^NE5KU(8L;^PHO*C!0$BB#U[HZV[,>B+=WE8]9`0\YIN0_T
MLO2ZIUZ57M??Z*.T-H`B8@%&E+R(O"R[G5?%<)NR0JB'Y&Q-L/DQJW[ESF+O
M:,MF7-W)W7;`W<J0<\KO`SV7K*I2J]:'R43MN0[:AUDKEL3OCW&5+(L.=[-\
MXY[PC2:5M+48K(?<1%FYJ'-2F>'KTZ:E4-[F;#,'<&RL7ZO:[!U?>%&$@_?K
M?H,9TO:&6'4>+X<7@39RFIMT3O?]^J'=T%@1S(_>'E:P)&%3TA6LPI3-X+-+
M+Q=T!J(0L*TE:^%V-U>;4+R=&>>\W1T[W_/7>B@@>OL,X$/(^@EG]'+VCD35
M6'%+4B,7U015F@!,3A/<W)9!J>.4E5=>F+*MBQTXJ;3AEI$&[JGYJ#``F(UZ
MU-Q+D40#/=5[6+`&N&S9_D&_0?#0WR!HBF&49<6RWL=;83_'P3U.E[(5@D-^
MT/KFU$$+CMNC.LC7G+<T:RX*QBY,!N5$"%!KW&:[3E4&GQ)ZLC@*\_4=Z0SW
MO5$XY,M'L7D\O"CWLIEL_EE8+=:*K]SHKA%"9/8!9!U]K\5Q%V:_7J483V(2
MG<A8UE;3%7_W:!NNJA@/UFQ%'_T\&ZW"TWZ3I:)H3F0_UQ9;![#+\"D,<!S8
M[FR[WSW:%JLJQH-WM.V/?IXM5N%IO\76(F@=X@C(Z<EV_F+Z%DCLQ7X8+]A^
MTR@.FG14DJ(T5[=Z;7.@4YV;F8:Z8-@\$#!WO[+]&E*`YSA-Z;W*VLQ^LL(.
M6>3CMWNNDG2.PUR[&[@GFVX7`;=P7[TH.,"@<T[OTPOS74!ZQIV:LKK!0KH1
MUN8^X/PQ"7;99-%;<KS18NJJ9K-%9P8P>TVQB^YIE)%YR11=;;PTKX;YR2*F
MQTN&[(/V-9WO38M=T>Y%=]4`LTV&E8N(27SJ>]EC]WI!6JII3D<<</3&<HZ5
MKVOH$JAUI."]TJK`*,X/[)=2R&,ZCLK_B&\)@6/`(9WD*%3="V(Z1W\[[Q)G
M?AHRE_9=MAW31[&N(RB,O32EEEWG_=D!G.$68#82="2U(C\>>2MIID5L2C,J
MR"`Q%8S/#OB=HV@_NF+:2V.2?>3X6Y;&,^U,VVLTV'5R>L^<)@L_\K97ED9Y
M&[_NH?==\N)O'$6;4Q7/7MJ;Z`/'W]847ADFZCGR9E4-8UOW6'O7!SMWJ@XT
M[C;^^E$TQ>V*=)^3-<-/'W_SW<I?\4RN2;12W@*47/W+@.2)HT^`^/0A+G'1
M56M2LCTL0V6KFXB#'.IL(1II@N'Z(+C"+"6G@BPEH)[U&R]74;+&>(;3)]*4
MQ([>)/$3SFA+I0TYNZ=O([1_ISNJ-TG^"\XW*ZOMI$N2XK7T;9M-PVIQMEN6
ME0^#:9@VO>4>\J!V4!&GC1*B%X"6[*G%WV%#+P?B5TE:_8G*R6YDV`;Q631]
M90%;B0%"!)]_,%"YS9TYW42#YWY6%GT2,L!3(X=[5F_MOOB$4_L[5F\U.U8+
M4#M6JORR%[2!I1D[:O>1M)6M,O8+C`#(H:IQT#A[,&<!3`C="C8WX6FG2J6K
MV?C%K_*A-D=S3JJI.6A"LX/,._)99@,`G=7NF:8#/CHR*U%OQV5(6=Z;]]6T
MW50FZZ?,'NW;V;Z;]_KV5"SBI_IV-`ZGZ>S9(]4#?>WUL?8W4/LCZ&'=$:P^
MA-B78+W-M_7P\%KS*M\^#!_%9@Q7$'N98%R#>X-O;ZZHEIQE34K3HJ[-WMV#
M2!_8EW(_GP.8@UT6W<\]9?=SPTI<>U'W6/@&*WO#Y\TYC=/2'"P;^<^)<>XO
M,?\^V"9T6<JU`.#%YO%O!>&^Y-$*F9#5G10AP,Y.1T<"S,!."(OC!A-"?ZO%
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M8<%WCBE@2XMIGVV/^\CGU_)D+HJ>S\`!6WS`&Y5#/;NIN'*F?,;72,_><YH#
MW-@\G6F@Y'S,,!2I[$E,5.DV(V_$M(]_/`#U?JJ+L8/-";V1\_N;Z`,:5DA/
M>@G/M1_B2OH^$8`:BNR_:`<U_?U]WGF_X<[G?IL_KB1CNN*H/7;:O@>".*HF
MOE4![[65#T+P^33T;=R6O49]+*W=?*%M%`>MASH/V?@/BPE4++!1_`=:5!X.
MZ'@BA852Z`>.SVB!&NJ$U.[M8=N+V4:N_^Z6N,NUQ+*5EH\R)O1/;C.F[0KJ
MF+JP_53`/L/%;H@^OQBRE_*`M(9_AY=>&+-W?6*V,EQXT74X'[*<KS?A:F7?
MU#G9(K].W_D@;0?0VJ7_Q@YJ&4+4TJ&.7!^L?Q<5"7UP..MG6G*(P][Q;X?%
MO#E$[@`$C-;JT'.[^RMP6ODYD'HX_[Q;^3F$5FYW(Q52*S_NDUD/^K)ZT!^5
M,2PK68)%)TBL3U#=%#4W*[4+PWE8<.^[TVGG:+%(V=V!"<$6QEGHEU>$%=-,
MK8JUSM00?-/O:>2=<W$`2.Y9WUH+-6KH$Z!$7OOK=[O%<O@UZ?[WCFGA4EML
M!]K"Z'[L,S]#)W3V."['?1[T^KPO>$B<_3U/)[I%8F'6P'WP2"<'DH([T!R@
M]S6@K?20OMH9VN^G?5X6^(KP[@Y']";QE/2?(98E;Y3(VFP52KAM0@L%G0_U
M3=`)LO'C\(DR)CM%$1GM1VB.,4IQN'PHTHPQ%@:71KZ?%'&>D39#X7:]ZSWR
MW2L0,U6K#T,-<*;S+)2!'A@>#@#;IV6E@DX)$YD66A$U91HZ>TR\H/5+EUUH
MP*8I&E7IH&7"-MFF!MSFEU@2#*.4\+B3@VUA1*5AI4'FG+G6I#=6*3BE$P=<
M2:EK<&F&M1!-J'5ME@_8(;^F9'1(_N`MI-,;M8I3C@G`*UG6DH?+,QZDGFFN
MUG4\,D2\PT\X+O`-%@Y.>B(`TYQ*`/*#8B:R<W(WR?[(A;<*<R^ZQF0*>/L0
MA8ORD#S=OQ$MWBO%K>V+&(!N]D04LL[;HB%`+NM?$I_Z["H"&Y<F*TR;9+P@
M<R9B`^5$$T;49SZ-XN".QI5(_62N1-9FG%?";0<7H:!S-IF@XZ,+E4%C2&]>
MWM9\9HYD%&*%;U8\,(J7J+E3E-L8L,FOX8ZU26>N#8:)@R%+Z!G&?K($PL[6
M(8=-M+X*,]^+?L%>^L'+BS3,U_6;.9J$W5M;LSS^W<7EWM!X&U-@&+T;_CZ]
MKPIZ/Q$MPSA<%DN4EFQ?E0OQV0E:$Y/5'A>ZQ#YFR7[?GIW`:`F]UETZ\Z'T
MI=I,R,JS00%.;^>;4C*+%D/L.8SBP]U6!'5S8]"F,[LZTF\:E'/HU5NT)`WN
M,?OR>!A_6>!)?/^<4-]DBV=;V('&<*&;0YG=,7*,C!8Y(&#RM\=&7_)5O!\"
MMRS!I##GZG8D;LP<+XW[+@B(_-V1$?F*E.A>>-PR!)+&G*-;L;BQ<K0D[GL@
MX/!_'!6'=RL0D&S=@:)6>9DG=%EV=U9*J%@)5HNV]:3OL,_WS&=ASAUZ$@G8
M?JZG"ZS_3$_YJ_-%`"DDR;,\R1QE5,KR+EEYR\+WTP('%^3O(9EIW:>A%UTD
M62XZT&.D\(\@\:V5/OE609L#6UX1U8(A6CZ!4YJNZ6H*>P,>>1FMH_P1HP<O
MHALJ*'O$.$<!O6=2_9)LMF3H.B0U'Y`?TJ18/)+_]BII>N1Q51T4HB_/^Q4R
ME%-HR*?8OD(?,ZJ<(-)4(^SG[`-^B1BMDI3MJU;?C4+O@3YW&>(,O0H(V.<P
M?PS)SS$NUX7(1ZH_4?$X29?D.YN]('_M$RCA'$5)O,#IEU\Y86'P1(NU#H97
M25H&R3N<$1?\QU$<7.(G'"4K=O2T?-TL%`2";0T!8^UN7DC9["WIV3;*'*_\
M0M.=H*47E(2<EVN-:?4I1MA@\S'DL:_1<$4)^H`1+E?J`S?$B:+DF7I"RNBG
M1Z*1>1&^##/2FAX*TNE=8>'1Q*&ZP.@Q&+B[^/9<XT/!!B`]KOM[C'*K59H\
MX>!'@HX`OW\DZ%;KR[187-"+*K3\IN0_I#E^P/VG*;8R`(RVVZ'O<[=21Y4^
MH@908P%5)E!IPTD][^O8":C:TP/M5Q2I(,3F1NRD"7I%VF:U2E^W:C]9KKQX
M_8?.;:UJHK.)-V[J,/*R[';^DT<OP>2WZ1V]REYM2M]A/UG$X3^[;^0-4`-6
MLT,P\SOO<YRRH4!,HK7O98^L5NL[1/7H@'4PS^47,E`56J=[O21QH_DYJW[G
M!YC;F3F."C?RH4\`*LP:<UV[M"M.F0;R4C8\#.E0@;3^BXM??CG]\.'T\I(.
M#99>#H<(S9OPVU)`8>`(*E^/7M[NYT2W&D>VVOB&!7`JN5F2P3X]?4'&DE7R
MY_?K[2I]@,$C(,%P;X2D8'T!,\6"?D8OCF:TP5-3*&!/KK*`45Y-A4,/V@!8
MB7W`^6,2;!L)M&:.@`JF/LBCPE-M`2V9">BQ@=Y()L3<912@-'$,E6Z`?VCO
M_U3:!-3[)\\X'L7LHCN9>EQ?7TCFVC)!8!6I1BEOGSY59*LUU20,19%/VJJ[
M27.1Y<D2I]Q]HS-9!6D4@%64&5I!A=&EL:SN,*N;5^6"6UI=^4'5JE?9H2):
MJ&QAC#3%94(:81:2*=P\]$G[1'Z%@RB5LS:\L7-"%P(#/`]C,EY_6#.;Y'MA
MOCY!64'7@K-J0M_56J5)4/@YBNAMPLV?,[Q@*\;U7[ZB2S8D.&2_LF^3?Y,@
M@.FV1[2F"]($%/G>?,[\3>A27<;^VQ,Z`(NDYT-)>GY4)#W_%TD_`Y*^'4K2
MMT=%TK?_(NEG0-*OAY+TZZ,BZ=?_(NGQD/22#I=3'%1WJ[G*E%#53`T680=A
MYF:!E3*JM)$@UX3#_;BM]UN/<Y_UL]]?G<0L:H4YO@Z?<#`A91$OPH<(C[(,
MY]GXQ8\*NI/X0Y($SV$4]5(_;&L#5BUO[P!W"I%$]];)(*9^@G!M`)&O>+%/
M3Z>5O[%5@T5E]@1%GO\K%5L]KC-VDBTK'NA>KE\>!GGTGMC1(]IM_#=[D@J%
M#?2Z#R/??<`Q^:.;1:'K)%[0C>P)BUJD.-MI$*>DL(BU=Y(8,4`7%H&&`^\3
MAUI`U`1J;*"V$42M(&K&9;3X4$1YN"+MHCSR1KJH)**4O"`=5IC?)#F6U*RI
M(JQJ'8B:.VU>J:-*'S4&4&D!41,0ZO,^]0*\]-)?Z3;5IS#WEF&<S8H5^6FI
MZ-.'J<.LVT'8I36\L8*(&53;02U#+NOY)HG_6G@1F0C@X/S-V?DL3_Q?FT!#
M0XNDADT58=7M0-2"7#^HT4?4`&(66J&916.'%3I-\<H+`S(WR"@%24B2',R5
M"<*J,`U*W2%LW9G;(B:":4Z/7I6W`N@?_>9C])\L9009JCT_AF2V3D=C]#RV
M_^BE"YI<>>&1UIPC[*4TM7Z&R&S,>R!S[^2);M)O%A#"N++@;Y)6T"GZ(L7$
M3+$BS,IP^A3Z.&L^0D]RA@$._EBN%)26LNJPC^APKOQ4[LGF6.Y7Z*)[_-<E
M3ZL3<-EEF/E1DA4IOL<O^?N(-"H98Q4J(+FKQ\O-]!M)2L=5::8YY.>RNCYX
M<3&GY$W9"T.DP9"0Z*LCC$H'9(49`#Y(W%FVO_N9AIY-24*(/N*K/LJ;><::
M(*EM#/L@!)=>=_H\N0ZHFZWKO5_I^NBMUP1-="WLWR?18YJT%``]6=Y=.MQA
MSP'<8=+WQ1D)3LWENXRNK(J>CC94A$7.@:CES^YYM0*;K(3E\;]D_CUZ%7Z)
MZ$7`C-X$+#^#%F1>&O?W'L.X6GD^00]%3@A!MQJ78<XN"YY0_A$V-1=7Z9)U
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M'8``1BMW)2"_;L%NP2'V?F+W?K2WP44'>FVY:HB+/`J.3.>Y=TW1<X4/>25`
M,H:K$+;G7NSZO9NU60=U<0ZA29S_[IO$^;^:A*1)T%W9*:GB1_KZ1CW9^RG,
M'Z<XC<.7\M@=+O+0S^2WT[:R`HR4.[C`C0G85G=M##76$#6'2GNH;1`1BR['
M"A\W:W-L\6]SX9*K:KDHK/K4XI2'`GZETLNRQ`_9(YITE=MMZI#:#_I6#KO:
MV@N"K=C7Q,/K<(ZYJMS6$*R*WM$+/DU0F*$PQ\MZ$;B\+%`'\M,ZD+?#]R:H
M1\2P\]PRU<K^)QP'27J)5TD6"AJR4`I6U:H@]NMM0I<,5W0_(68-EAWQ+<\#
M/#%]%%0&7!T?&Y5!A="D?SI:?G),IP.KOLP!B\Z+;5311A>5RNAOI;KR7="#
MU5V5B:2Z:\#74_=W8'4B!"=/_;NJ+E2T1K$NRKP<ZLN6VSN_PBIO$;1^:9<R
MZ*Q*<.!DQ#>]E91M\PNL<NW#ZI<I^=UA<<YRTO%''^D&W'-*1@^I=$U4(@BK
ML#4H^?D.%4=M>1>5\$,2!4LOGGG^HZSX>1%8!2_%UR_R2A`Q22<!FO0/9'1<
MG3<F8UU9J!;+P2IV-4@N?)?2]?%G(NYP&CA^P:D?9CB0]942.5@5H`;9KX!*
M&C7BZ`Q"#<BVFB5RL&M`O:W,U\"YRY&YR3,<H$I;!`W6<QSU:S'E_$MPR%<H
M8/G!^@[NJGS5N+B38M7]XDK.:2&+SYC*9,`5M0":K+0WHDX+7%[,X`I74Z2.
MBO%Z\PZ"(D+P4H"*5P&.NV"^$74=,%I0-"4.LZA-RMA1T;+-NT<RO2*SV/%O
M19BO127,2P$J:`4XX59E)?H'5`JC45X^C<*>3<D3-/5@4'T4!V:UH],!5%?&
M4!4MA9VX+L4=5=(/]#CW-$WFH;`':/T,J.A%J+AU%G9.O11R5+;->XWU_5A1
M"7-"@,I9CHU?&*\OB=6BKLM\$OO)$E\3$BA+?2,&L=P%Z.0E7PJC5U1<^8#]
M(8?GY58@FS[?SJ_*C$_5%6/AH%TA#ZA"C&!R`_R6$ET,:-00TW-40V0&EW3I
M5;584?5(A0'5C1ZC8,\ZX5I-I>2JX6Q:^A7Y.SWZ$L8%P5<U[R3.WN-YDN)2
M[MY[P=GX)4^])`T(K=+U),=+-I&GIUN2*"KW\3$I;&&_?L#/`:*&#2^YXRSM
M*%Q>F=M\&&V^C![8IVO^L8^?H,[G$?M^N>BR08!J"$Z92O!6+>9]F7!/SC).
M%!Q#Y`@EM4L4ZH$.>E7I.(P<*7WI[A*7_SV)1WY]^];'X1.="THJ1ZL'JZ;,
MX0JJC2FA5[7ZE_3J:FT!;4R`J<1)_$2F[DDJ62A2*H"N-A%.P_IJJ8*IIUMZ
MC;M:4Y0O3IOH@:XU!5S#RF,6FHPA3E>_)>XU4ZG!]=C3A%^3,L"#ZG(S]016
MFW5<GY8/2`_K_2HET'4HPSJTWZOTP51<+WN\6<7UE$!7G`RK8<7U$^2#J;AV
M]Z#9XC)6!EV1.LQ;=8KN]]!N<'[A98_3*HW2^_7'C.:$WW07?AX^2:O67!M0
MW6X!6I3YGMI`M1%ZW_05M4/J^,MV/]G8<E2_U:7<[#X9^;\5(5WZZ%[V$%6K
M5@E0;9IC[5=BK4GW32M=_CH+E&HC1".DRM<T%W,^B@.ZA\CRKQG5GU0;<D7J
M09O4:&WEA*6QSD^:'5AF"E;4I=/=;.NH*]`&5+U;@!X8=1M3[J.NQ-EF0VBK
M^A5HPZ]?%>B!];O93G->O\Q3EO^O/U`4U:=<&E#]&8#D\XIFCR>H5$*"\:ZS
MR4JY:+@F?!H]9.SNMWA>PLL!JA`E/'ZV40F?(-J*_E8KV+Z%V^R?^WZQ+"*:
MA^&2WO6F*1G"A,R&5Q%F*63BH+U;/FATLR_;@.IZ[RYQ1Q,V'T#M+YR@YAML
M8-3^R@FLL9.UW,]OG=-B2\#<<-C4@J,@<25_A:[%US8E1>%@N!5`#7\'\/W:
M+DV=,EO\//8$M4-`VR"\RN\]NVBF<1R5V@8ZM`*)KK,1U;`G(\6CK6$V`-7G
MUM#Y45IM2%;+]%A:_7QF;<[=.+KK)SM@;5C7)IJ@:G@08+Y>N<9:GD8'5)M[
M3.587G<55?S>/P)@,'9XW[B;/M3,:9FXLO,LZJB;X+(M5WT0L2^>H.J;Y!^;
MKY(>I'"0=65?Y5==8*?;UX<C(/<10$'J<+X=DH"MKQXY`3_AC([%8_;Z'7V/
M^CZA?Y+GN*U3+DSI4QV'8.MNB#XC:N^I(`[9#DJ(Y0I*!9)N4]$_]Z)T#155
M6)O4'8BA/=+6TW*1#)?2,,Y"_Y,7B<_\'.QCG^=X0N*CM7%%\WW$`+ADZ(.^
M0!_T_6.W0,^D%#W(UZ#%Y<,Z:6WL`8.DS=&@:[I%EET5>9'B#V$<+HME?7RA
M3'X<T*Q#5V'F>]$OV!..=K<V!HABN_L@OR!;FCQ!I5%46:WI0GYH#)?7-:EI
M1&T#)L=E09K2_7-"8:IO.IL:.3(RB+'O0(++\ED[8I+5O?.+[%K?'U.,]U#]
MC9FC)`"/?@\4H$:/@P17I-AWYT!CY1@IP(/?G0'4YC$08(=:/[ZJWKU^:?4*
M*K3]IVOR+_+G^D_D_]&Q)?G+_P=02P,$%`````@``X)E1[3I.G`P+P``UR4#
M`!4`'`!T>&UD+3(P,34P.3,P7W!R92YX;6Q55`D``Q;'.U86QSM6=7@+``$$
M)0X```0Y`0``[7WK;R.WLN?W!?9_T)V+Q3T+[#SLF4G.S#W9"UF2)\*1)462
M)\DB0-"6*+GOM+J5?MC6^>N7[);D?O!1[(=8TC@?$L<FV57U*Y+%8E7Q'__U
MM'9:#\0/;,_]Z=7%FW>O6L2=>PO;7?WTZG;ZNCWM]/NO6D%HN0O+\5SRTRO7
M>_5?__=__H\6_><?__;Z=>O:)L[B<ZOKS5_WW:7WGZVAM2:?6U^(2WPK]/S_
M;'VUG(C]QKNV'>*W.MYZXY"0T#\D'_[<^O#FTUWK]6O`L%^)N_#\VTG_,.Q]
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MX,VM,-9$Y6=:PA;L_U[OF[UFOWI]<?GZ_<6;IV#Q:B_\6(*^YY`)6;;8?ZE&
M';X:I@!?+Z@NK=^R)F\I3-&:JD3;7?3<T`ZW##-_'9-,V8C'O/?)\J=73"M>
M[W6$??C?(7W#[8;.K\!FT^-5ZVTE6CN>&WB.O:#:N+BR'";IZ3TA8:`B5-GQ
M*%2.+9\*ZY[0#I93FF3N*$W1SR8M81`'H^5HP]8^"JV6N.4C'(/NCA7<7SO>
M8VFR"P/42_5Z8[E;-6V99G52<&4%-N5R[).`\AOC0R?TA,SI_SG;?A!$9-&>
MS[V(3G%W-?8]E_XX3X2C(KN.L>OD=1JMUY:_'2VG]LJUEW0*T=7K^?L4_;E-
ME%SIC5(G_7WW@8K&\Y7Z4FA8)Q4C]H=.Y+.%J!T$@`58W*-.NJ[M)ZI.\?!#
M$JIHXK>NDQZJ]AO+7O2>-L2-C0@I/?S6]6H/M4Y6]IU#8*B)VC>E2P/;NK,=
M.P1,046W.BFDRC'P@F!,_.D]W7M5E`F:U[J*A=[\V[WG+.A1H_=71`TOY8HE
M[%&O?M$?R<QZ4N/':5HG)1/BL%V<VDH09>*WKG6/C0+;)4%`30RV]0'M*'FO
MFJV0M1W&VR[=G^GWV$9&#\T`X0&ZUKN#WP7DKXA^KO<`L4!$[8]O5=1K71S%
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M904\I(&ZRRC>I"YH!_07F2[D*23N@BSV`S&::XDKH;]F(^WB@"Y:KUO[7ND?
M+7?12H9HI<?8T;_GP/'F&:(=%G;C^2K9Q:%.,EK;=P&=C//#_:!CW1$G'OY/
MUA?6]6T98G<"C@.!`C)_L_(>WBZ(_9;2_X']P!CY\/K=Q2X,Z-_IK_Y,:)B0
ME<T^[88L](I#.6W*;YDG-*T7;7_>\GRZ!U#$]F-:_CRC#<7(I5V+MYLX;.7U
M_-YV#HJT]+VUKBAW8O,4C*2E2TDX.@2=>`UW^G3>//V3;&48%)H"0;C`AX*`
M:Q,P[/F8T6'YTL^V``K]$I/0>3R:E#4]EMD>Y6#!XD7E0L\U!4K_/4;I<[DV
M`4.;4K-@%%T[UHHO_EP3H-@_8!([ETL3XMZY2Z[M8&XYOQ/+ERJ^N#40A(^8
M0%#Q;F[C_94XSC]=[]&=$BOP7+*(@PQ]V08L[`)$Y@=,R("D8`Z>KYX340GZ
MVSAM(I#!4F@*A.-'?'`(N#9HGB;S=T(VGL^.N$ERAM1*%?0`@O)W?*#(96`.
MFUA'.G0Q7:7"=WF0Y!H"D?B$#PDNQ^8`&$=WCCV_=CR+=^H_4)UI!CZSX9,^
MAUV#"Y.W7GMN['".;WB"413&B7IT@DJ7)VD_*#H8C]0`@9@\\R4F8'(&NJ:_
M$VPBDN90<%`>O87LF\>$F>5@1%*-H7B@/(P+6.>@\8^W!>X&]!<-N\75F8@9
MG_AEZW7KD(I&?^Z,AM/1H-]MSWK=UE5[T!YV>JWIS[W>;-KZVZUK10N;#OR_
M2SG'TQJWM(*[&+TH>+VRK`U3NX]OB1,&^]_$;O24_NU^_>>!VM'RVG8I?S:=
M'EY@*WSIN^ZPWI4G5'GVDD`.-2/Y=J8<ZUIRS<XJ`2?U+V]5T=@'T@%!*30W
MYF^O"QR!`'!@Q+)GQ9`D?S7F?`>)T>-0C$G"NX#<@*75V@\LPGA(PATSDLD@
M[67,(5\"$0C_.)`Z!"6G$DZ+R&1;&?/1ET""QQ\.R6<C<*EQ&4<\9G@3`P+J
M;,R-7P(G#6G@@`\(5#E(ZO??U[RQ<["@K"P)_>-BD`A!2'!,;>B%EA.W-#P)
MO0WQP^W8L9(#WE^1O6'RD2Z'\E[&+@6J8PP1!X[IEUH>U%8VM[&Q:X+J,$F8
MQX%.=C4?>NY<;T-+]S!VB0`0MFP/*W*-`YM\"@B=VKVGN1,Q]^T7SUL\VHXC
MQ@G6V]S=@S9H.N+``6"7;-@R$>SH!4PN<0]SUQ#:0*G8Q@$.')3R8#3F=("#
M`0#A).W!;%4A$6@F;R3J,N3/!;%4;B`U6(MY06KK$#X"%/7&/!\54->5$X[E
M-$4UV*<NZP-%L#&?B#8,0A11N]CW#M"QM67>3[#K-]\>BE=C#A.`P/FN7S[G
M.-")]_DB9XH#-*\#%)_&G!W:^"AXQP%0=[<13\@#<2->_/;!*,XUA`+2F%M#
M&Q`!KSB`T)DD5>9'8]Z+VO>;,[0;GX\Q6L8%KQOXVA@_WF*IX)B:N8V6<DM_
MXT=4"WD\@$T/Y3A0B!MSF<`PDEHE0&'A`)I33%<Z+^$0->9(J6\6GLMR"ZC)
MR@G%D76"@MR8"Z8BR.`JM:;G7QF?2@U>E,O&O"@5@3L5W\EXOT[$!,>/W$CO
MWXJ-H4@UYBW1QD;",PY04LD3"D2*+:%P-!@]4F*-XW&+`XOV8A%[3BUG;-F+
MOMNQ-C;=+%-$2ZQ&0%\H7@U&@FCB!9<(#@0GK*Z02Q8]RW?I[AE0HS9:1W&Y
MK2Y9VG-;LD5!^D(1;#!(1!-!N$1P("A^!@)B5,`1:LS!4H/Y<"XVOLJN*G\%
MIQ']C=1HA,JF5AU`EE#&?R<NDUWVOEQV6>MOF;%?LLV:LYD<QWMDD%Y[?M>+
M[L)EY!2S'=3W?7K#G'"N6AEYX=B:LV<I.L%&?BR(16S*YU^34ATIQ?U/.-E-
M3T0884TR^-M1>._Y]K^>5WH5G,5^IC/F:H-1)!*\\"6O5NI!M^]C.JVN9MBR
MHL`+F;R(B(3!,E5$,,:C`86"`\&4`T1_'P1U-IVK5P%)#>&@0Q.^_4D[G7!:
M'T`82%%3[7K"#B><H*<0`E*D0)M=+?6R,&;KE:R79=YYDWYQ?K0A^<=>,XZ;
M#S+'S71&_W/3&\ZFK=%U:S3N3=JS/FV`I$!0\O+O@7JUET;8P:0CW7)(L(NA
ME"8O%QH:=JXHI)_WGO/9Q++P!71]8%F#P=1SI%M3KJ%I'X@>"`(^<8#PQ6?/
M<?G>4G;YEVEDVG.A)WP.?Z=^<;3;7-S5+G4:DM(O[F+:HZ$'IY)W'+-J2AR'
M9403EY+KL/C1Q=IVXP=.V(L^.^(ENPZPOVF/AAH.KQ1?F+"<4)%2&NXIM5VZ
MDSI>7.)#":&BFVD/ABYR("G@`*Q+J##IB2,6)56Q-2L/_J_,PU7<I']Q)],.
M"UVP`!+``56!,8TMS+QG0A<6(;=G8Y$DFSE[X14`9+JQ:8=%:2B+')\\F,S9
MH6%:\IN;KD.D:5;*>$:R5#(2AY[K935/`0RO`XYR0]"))F<;!S:L;&80)Z<D
MU/7=D%"A*DJ$\GO@J#$$1$?%.`YXTO;/P2'MKIA?1E:\1MH+1_4A($P0`>AO
M6Y^2;<LE*^;^-K]Q%5<)Y2%-TL5XS2(=@)6LG[I1\FQF75,Y)>E_$67V^:+E
MBBP]GR3M9M83"7I/5&(4):KM_K9/S8`X99?VI'PYL9S4BW2#'S5>'4EOG6]<
M_.>AH93UG4BOB$ND3G5A!^-5E_0U0\CV&>PJ)(2<:G/-C%=BTMH]>"R>^GS<
MIW3M@ZJNK,">,^^E[414L=0'6_``QHL(Z6"M*18<!KR"Z-(8(J@XI(N'%IJX
M4/R5V*M[QM,#-1I69!BM[X@_6L:$IX)\P."6'<]XU:%JF%<3(_K0*?8\S[7C
M/0HBIS["(Z<Z[>G/K>O!Z%<LD5.IJ+@#EUI);IQ>9BTC1M#8]QYLBO[5]C8@
MB[Y[<(VWYZ']D.1P*IDL,Q:>-#<AFD5#JZ3$<*S@S=K"30%50>IZ=K+1XAS_
M'26.V&#F30@]9\_M^!FM9X)G7FVSM9FOF0XLJTU/F@0#A[JE`PQ@,17F`\T:
M144<?X$+N.Q-0/XU#^AE2+&?Z4"T(X(+$R$.N&-N`THH)Y]>#+:\E^G(M2-"
M#1$?#J#WYTBRZ'AKY@A2+,VB]J8CW8X(KEQD.&#-KC7[VM\=2OE*%BNGZ&8Z
M;L[88BT0(`ZL*?,^H>K8)<E_4^SN"LN!4JW`8Y@.N3NB%NB+%JM*%(OAZ"@#
MKS>"0#U=;%3@BH5T^M>116[W;S9+:T,KNAD/"6Q`"SAR.4?XX\N__=LABE,<
MK+?Q",0&E$$LI;/5B>=MLIQ6%/H;#WEL2B\$DCI'S<B];%'&>#AT-1XAV:#I
MD)-/Z6"8!^+?>0'!J`K@5[,`78T',S:@"NJ7MLY&%=*[(^C]&(TAC$<S-FQ-
MU/GZ#&(5*3Z`I+EW%'H;#Y%L9OL02`F'0P%^Q5E'J`:"!R_KO/O7E-RI!]`*
M.$Y2ONH)[Y&.93PTL[X`'X#,<*P/U.S=.63;\[\BFR5T0&^(`5V-!UY6@,?3
M9?9<SI`%5JGTZ*(7;L>.Y89M=\%>9(B+@6CHAF0,XP]&-J<D2LF=OK;`A5?'
M9H'@[<K:M$5?<F=J8!S2DVLP,*1C&7]9L3X#`R`S)`:&[\T)6<1II*P8+WOK
M@W(/>4,.T-7X"XP5X"E$'L'DA`_6F+S1)LX*[CT1?VX'\M<6E%V-O^38"*Q2
M.>&#]5?+]RU6\2VA5!X^*.EE_)G'1L`420<'CG"6Z]AA$3P$61O&^I([=:LL
M9I?XMK?(NS?%NB'K@^#)26TK2RV#<T!9CB>"1R1+(E<9HTT,/?VZ'YX"4G]>
MPK$ZQK-P.E@QVFM!J^?FO1^FTIK7&\M]?J`TD[S\0^MUJVL'<\<+(I_0_YG]
MW&MU1C?C]O!W@WG)(W]EN;L@Z>>T[*1V[#@EH=1C'L\9VX`*D?4,;[+V8A4.
MG@&?48VZ<J2'W/J_9#A+NE;=RM>&;`@6-#426`V'8+1,\T)98V'-;NALD\>,
M=A%+U!:E1JI+?YPG_/%7H!_S*]!5>]J/JR6,)[UI;SB+GYIIM8?=UJ37H?\_
M^+W5GTYO>]U6N],9W0YG_>$7VG8TI#]WDEH++RL7WI5KIT'/2B)FEM/TC-<.
MH6#03/YIM%Y;_G:TG-HKUU[:<W9I]#S9J3#FZ6-G9IK_/3_-I[<W-^W)[VRB
M3_M?AOWK?J<]G&7F]&C0[_1[)F=SD3M`*0))'Y/YF#+,`'8`M+_A&:I&+)]T
MJ247-'-QGTLBL.L_Y:=;?_B5[HRCB4FK_D#S,V60!$)))\,5MG-T`6:1O)?Q
ME]R4^'"J;:N$@&;*2#)NTG/GXEU^[HSHH7C2ZMQ.)CVV0TVG/:,FYB%GF!7+
MWL6%LN=>J0&RL>P%-45B3A,6=:9:Y8%-/T:0`1=RMI5U,CP9:T*9]WB!7$QH
MYNNU_40/DS&1Z9<B,W/U(C]7K_N_L9-A/$?_3VO8FQF<J,+H*O54!'0U>PO+
MITYK+]0;Q?!T!&-9O)+5%A6:&;A;:_*5^S,S\#(_`\>3WKC=[[9ZOXU[PVG/
MZ/Q+DY]=,2%3$-*[U"P,G]:+F.AWG]Z_BTEFO\G1"W33LIZ0CL;G#QR+_12"
MLH9LU@@CKS/SYGWQA#9K#[_TKP8]\R8F>QKXT7;8>YAY;G0,2LUAC)[F1.2!
M#G6`SH;G7RE$"Z<]L)#03$958F1F3GZ0G_P&_?95?]"?F?5)QARE6-&9D)"^
MI@]Q7/*@ASE59]/W!V#L>.<VF&303#UZ:&,EL_8UY?E3[F-^RM$C6VLPFDY;
M8SKSIC^W)^4L2(&)E:-),F-8<V%K1"]/`&:&I(NI^2"5+G<&*/E&H_=Q&/6]
MYU#)!>RX%_)]]!>%V)OI;-3YY\^C0;<WF?Y'J_?+;7]FTEU?Y`/R-("XC\G+
MKP)90R\D6MN+QA#&GP%0X9:_`M.5#IJIEGK=C3_'"M$E_6%G=--KS=J_&37B
M#H3K785).F%X:$[SU"3K9?PJ3(F/Z-FY4Y@W$^*P[-RQY8L/0X6(C4EO$+]I
M,VY/#!^!4N1O9[[E!A06EK2DGD+JG@;GD8@XK6FE-8CA60;%,3?52L@)S<R[
MB@+;)4'0\5P6,[E[JY0_`PM!'%>WT_ZP1\]&G=&0A4).XMA(HS/1#KX%;7=Q
M2[GQ0\MV8<G1BFXFDQO2N#`RM28?K+?I60?!+)\9H2$6-'.-)2?;23UORF[R
M1O"*N,(@Q<M"Y`>U%6_ZL^3]-A:!3.<="TWL#0W')4HXTS$H-8<Q.BT!E((F
MJ-XXAJ=J*9P+4[>,Z-!,XFET%Y"_(CIH[T&817!9B`.9WEY->[_<,K=][ZOA
MG(`\"P`WBK"'22=*CBB(TT3<Q;231(%)WD6BXAW1?($$Z4N#]2\+,1WP8/W6
MW_9#FWS7](SB]OOKC67[<1ZK3S'9>('EC)8#SUT-[(=]?%Q,\1;B="DUVJG%
M]%>1&8[Z&->4_J^6$Y%4)E'?I4Q'\4:>T"Z&&=C=]#NHVL!JB04'DKMBW>PY
M(;H>,\F")RN@J^D72K41!(L#"WH!H33<LV?+*>6.%\=N[J+15+,0U-GX(Z3Z
M"()%@@/#*5DQ"B=DPUY>V_&Y!<]"8'?C[XUJ)[[IB`6->7O(.)JQUS`$]BLG
MMG*7_=;Z6]+/I'%Z5FEPT_D]640.8>_.[BC<1=O%@H;,+_`(QN\$==/C=(6#
M9I9QTH0DTTT1-IE$,V.8>2^9<](9+$!=:PZKQSC+O#I](:*9Z]DT.]D\+\1J
M%I+M,$SR[R_KKDJN'9Z)67N&'=XIETUJDDVY0HQH+KL.QX1#FF;7R/ZX6RD]
M=[ZSY+1W1\D(QJ>@?I*>-H_(YF(^J4DV&SG1I+F</0SS\;M+WDL?L[*$4MKW
M;)0YCH('.X/DO@I"1.+FVS'@L:L!.R3Q54^>E^LH9*)8,Y=74L8MO0EKJ$<]
M7S%]`5.GXM0I=S2[@R!]5+9)%.*FA4FD&#:+<\\F%6"G61Q(TOVD,TJATD$S
M'W,Y@[)Y6(B>+F:65IN`L!33Y`MZB:;Y/@AVU=&R[8;VPG8H)`]D2JA='^M+
M[VGN1!1%]N0(JS0>[0N@ELA3;>);QG98`*P*.ZQN@:.9Q,5\0\D\?E\(RN:E
MR6+82OEIE&5R9K/]4,S^6*6NK("EW<2/2+8?+7^1?C&*Q>4DTRH(HG7R._U#
M5SW?,1U<"M($X<2O4]:XSF9IWMCB14\`,1MIWG8/&&VKZ([NV*;/8;4I3#FA
MHMD9)+D*LBVB$/TOS=MIQ.I34JZP`#7ZHYC'R8'^AI[XU]%ZPK3`V;\N?.WY
MAT?H!^R)JA+;0*7A318UT=8#X:2N0<)HYC4L*:%+0LMV@B%[N9`9O?S)7BDY
M8?>)UN$;WWV6@F`]:R\>V`NO*8U+])$?_2E]KI&-5WZXD\D]J,8F)FMMQW-`
MV6#+"B6:_L:/R"+E)WJ^VE/J*G@<TU:8=@AM.4'A`#EU3=M1`<EK>W*9!V*&
M<0"2O7R/J85,,D6WDTLO`(D!C6'S'!.<&!9\DT46C[[K^!*07C<S0P*(^..W
M/KE`<QG3J;FB]XSI`_'OO("8?W#VP!V[8`[H^8A=6TL>!A>U-VU?2%$2`,IE
M&<>&=:!Q8CW>6"'Q;<N!H))M;MJ.*`,*CV$<F&2CVU6V`[^U:9-!`Q$9NS@`
M23,#VX;,IQ*6F1+I%WK*;CB\E^C-A_WLPJ%D]ATP`0J!J7=F&5`"YU41/H7W
M7=;AO/*55-QB6CMW+/9=RA!SJRD/P:F61N,^``+F'GH+G%;%0?[0$-\KJ3`=
M4H_R0/H;,^_T<-#DZACHL/>E(X=Y3D!@<)H;,^1*RU[(,XX%J1L1%G:5K9ZL
MMK*EO8P9>Z46*H@$<&`5LY9U)L+\W((^0)P^XL!)S7VSB]=7:G-[?I=LO,`.
M19>"@K9`2?^`9]GB<XMC'LAR^I03`M09B->/.&:&ACS.X"";3>Z'!5A`TOQ1
MQ5&<;<8_75%\,K=C?9`=O=.MC*<0E\OBY[%:\\T%HAG(GWB%9'_QQ'N9;@TP
M-J6XD[AR!(OF$'.1;Z>:<@5M1C7S\MP</"/O<(!!IR'ITQ\E5TN\MCA`X:N4
M"($4^0>_B%D4A$IUM9W1;[>?;`DLH,XGA!.(GY1C$2-NC-"NM[9LB4$!ZHP#
M-PW]!)<-2C'Y;"R9?/%S3]D-6=\17XQ;H:'I@`<-+<R_]LGG&<>1^CKR73NN
M9^`NJ'G'?@I4V,CZF`Z!*`^36A(X$!-R^,7W@C([V*Z?\3Q#D8T$7>PR_./`
MJCV?1^LH]B^G#X7T9X?$<G47Z3HB0M;$J-;W!=,++%@!ZA:J_M'\4W(<=LF*
M$6$^J%#(HC101][+]$)>?3VH(XP'D_<EZ^V5>E\*Q=T*I191^%Z0UEJ47P?=
M6&ZTI(-'/KO:95?ITM2&U-6*O*=Q9Z=^O40P;\>XIMO'.N0#':#H0/J;WB,K
M@@07T>D'VF=%I9]]5`+V!@\UI6N9JL1P!O>"A6I_H)O!0FD[3OU35#>#WUTI
MU+017ZSD*3D2*?J=08%3F&A,+N*B@G(1<ZB,EF-JW+O"8)I"*]/[;B7,N!P)
M+2)4:RA_Z2Q4(Y0LG2\KYLNE[S$+^+Y<`+]<``OO.L0UG:^V-]9_>W['L8)`
M?A&L-<@)X:;%%XZ+80G)SP0/K;7RDEA[(!RXEM!G..A\QE%<(B>E8HD_]9;A
M(Q54CG35]26PNVF;LZ1VYQ#6DA6.2S-*(O%=$B9\,0Z5-]*2+J9]-_7`J)1)
M0[[5]F;C>Y3TGSU_[;ED%A\?MET_6G4L=V$OZ,:R.](((8IKB6D/8SIQOR)L
MY9AN%,HA%5SB-K#=58$G&7J@GM#ELK%,_QH0TQ`1EJ5R099U6+7:`^&P@$"6
MK39OJ2T!+[9Z%FZIP7!@7%+']92@$6M7L!!7W$MKWT,;K+U26H/3JS*2_?.&
M)7-O'#+SK0596_XW5A+UJQU::]L-IM&&_FFM!$]W$&.9NO5"6$YV./98B5T!
M*LL'[7\J\9=Z\D"/H2)J5MT3L9]`7?,**ACT,*:"0M.7HZ6`%8Z%V)=0"6J%
M\$X_0%8NN+)K-VHO126%:*H"GI$0_+\BF](LX?978J_NF>X_4`MS16X#LHR<
M@;V4W*!6&]6T85Y);>H0*([M1&'<)J_3V>[J<#$-*,%<=D1CA6)TS;^J0CM-
MZ.N#W&"-F;H0K*80B*/3=%GAVPYLJ%(C`17C[]@5H[0`<*T0G..0UKH`ZP\^
M/F)'79-O\XM`,WI"%;F"EO![0W6DP6K_C>J(3&9GD;HG"*^].#"9CJ_]4'@E
M6!)?>_$28(O#CY`\CI9VG^S3=:IXB`&CGD$Z0QUBQ6$UR)QL11XFA%V8+%AB
MP#65E>7\3BQ9W8TZ!D?LKH9C#?=L:@K]%+6(T3][].K2F\-PB+W=Q]&4G&!/
M5C?HYR6NS-(#(G9^'U$_TL(]50VY]J+:MIWG\1![N8^G'VG1GJQZI)*H:U&/
M>#S3H2TXU".=GXXE&31=ASSU^J\L)_3#A?S9J$&_?=4?]&?IA\M-GEQC%M.\
M:1Q7(7UKC<%/WF'NT)8V-5=G[*D^P,,VZFZ&3XYP##)1]4!IX%AL=]1.+<?R
M(>^KB-J;/K7I8Z5@""%(8]];DB"@$K6<:P('2]C/]`&J*F@*@:`"[ZLUC^4*
M!:W0WO1IIBI8`@&@`8F]G!Z,K2U+U&`5&A.J4PQ#D(,/8OKP405.75$U%/!.
MU^R$[IB>":$VL1LP>AS'>V0O^P7Q0\X7`OL#WMWT2:"<(:(KGJ8R-/>?N_;\
M7^\ISP&EBY(5^O9=1`>1[V2Q1:4S@NDXI9)&H[Z0T"R<;.Y/*&'0G2W3UG2L
M4=5=C<,X+F"\K>5`=R]^!]-1/Y4A$H@`!TYY[F#O)E:P*#ZAPTDA@C.H`#DD
MX<`+@C'QI_=4E%)'U67>4<6>HAJ,IM/6N#=I37]N3W!41^Y9OFN[JP-3:K^4
MN(?)RE?S>[*('#):MMW07MA.Q.IH3LD\\F-E3.)^R(*]Q)K4*MD5-<QSHRII
M5O-W<.0^JY0@7WNK9B$@J9Y6D9F!NN9:?5_`H3?-S+K\_E^;T)#4AZO(T-66
M/X"\\D:C'WW1QGKDB*/>'9]"2/D/=4\<FG*$&0A2&W0E[Z:A-_\VVC"V5;70
M.$U-WQY!%;=02E3`-(ZCY:^L*KSZ);M<,].70B6QX#*+`X>*BT9[S1RXC6W0
M^^$-7[;7;4/7N_MF,4`3"!,O0/>>0Y$)V+-2X1;TML2']WD?PW0VZOSSY]&@
MVYM,_Z/5^^6V/_L=V?,2"7\`+T.N'8:JVB=9[IPO\)=ZYD<\EZ"H9QZ0^9N5
M]_!V06P&P`?V`Y/[AY3<Z:_^')"5Y?3H.DN5AG^BI*T*C4Y!TCRZZSQQ026<
M?%]XEJ)-LBT,RY8GMH)@LQ0W4]!P&MI+XMRRG)I'NO'3S5):`T_<W)AM7!`4
MY[I?P61#U_L=[Y&P%TV9^62YV\&@(Y6MN+FQ(`N`;%5,-B3;+]2R6UONU)K?
MRS66U]#8M2U`GF+&<)S8NL2W'V*+]VH[M.)8>ZF/5-3^%#8W!0LX:@T_4P?Q
M)O);XP!#KEI"4-`Y_&"^OG)NOL:"'F5JE`]*:,"M)UCFDT]=2%?X7!NH)!L+
M281(DD,WID5^O`\FB;THL9LG:$?AO>?;_WKVPW"?897V.Y4ZN3#^,6(UMOR1
M'_.Y^&HY$=E[Z:"8B?N;OH@H"9Y*(#A`I-;SVG,U9YNTD^F["C!<`-:18M0/
M@D@+GWT'T_DJY;')LHP4EU$4!B%[9L!=:8"3Z64Z!:4\0ASF<<`4TYCH3S?R
M*7ET);:]14+UD#S&?Y+ZHF']36>D@*'3$P@2$!EQ8]^>RZYL4FU,IYS`P2@P
MAD3@?"6)39GRDR;?W72J2=4YPQ<':@23:9X*DPEZ3\2?VX',HB@SEND<E7K6
M0ZF@4`,=ZV8].,N&,IWB4LL4/@64XV!%B]+%;CR(&^PD[%ON*N;_:OO<9&QM
MV:_:CY:_<_<$7U@H5M!W$ZX5+]@T\C'C58OU-N5F9'U"<4J"2K,?2@8JF2T[
M^Q*J]!*J]!*J)$%@@"ZU9L)66_DE;ZK)"<D\136.))&8(-6]8:81#FD7-(0G
MZ#W)**YH!YZ["HF_[I*[<$8_)E=O?FL<L@=I.I\!'/$+>=I4$0RB]CC@D"F6
M`I1F`_WVS[BV%P^LF,J$/'C.`SU]=7RRL,.A%XH7GO0KL.KNIB^>Y/K$>]D6
M*A(<!]#XR=[1<I?4,_(G[+TV^?HEZ8)CUH`6,0D7J0LS;,BHEC-I)QSH*#4.
M`E3#8<QT`MN.[3T'HNZ^K@AG5G8S?8$!T*EL83.8'!HK.R?ZO#R$"]#/M!N[
M-B!J#OC21N*R)!*7N@%VC>WPM4%Q:1B*]R6A>*\+16->_]J@>'^<<-(H#.P%
MZ7AN0&T_60)X'*`I:@TU<1N+A=,4NX+M.NW:EXPX24;<AY>,./P9<?L527)'
MP=H5FZ$/;N:3C>EL>Z#.7<1+&BR43][+6-RR5-S<"AU2OAO:$@N?SCT`3S>-
MF/+(<I+7URA)Z>?@1=-">SAC?B,(3M58PS3%N*;#/M8B#H`[_#'8_95;)EQF
MB:B',Q8!K3$I*TFJH=EZZUK)8T0L)"((G\GC65"LAZR#L2!GZ(Q3<XMX3@TC
M9F./EL\E=3J6XY#%U3:O-)JS2V=@8\'05>>9OO2:2N+GKP(;VX^%&'2IU55<
M!P2SL>Q@QKR0T)E:34K'A.XK"4*Z,5>'33&0L9#J2I"!I'-,N*XMVX]#0ZN!
M)1W&F&NY$E0`R>#8'>,0S3MU%.==/HKSP&$["*+U/BIX0^;4YIX1?RTQ2YO\
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MAO,M\&&XUL'DI<#'D21]8[OV.EJK9)UK9KIV+$<_<I+F\H5C&;FQGD`BSS8S
MG6`-$#F/+QPB?ZD%\5(+XJ46!#^CZ5`_5%YZ0-CZU-+<%6PWFSYV^*J\NH"P
MM;G[_WJ$77,E`</7(ET2S'T[=MHW<`^2&1U]TFRMW)Z%=ASB)<`/U33P*=,.
MFN851R7F$]>B]'LR^RO!!C2(_QG3->J:UQZ9>$]<<W:WR:D4^5PB=B9'M[F+
M?#`!IOV61ZNWK@D)#CUL._'@9,'G?A>[)%8C:/^3>5)*3R`X0.RM-XZW)61*
M_`>J87S*AY[[0`*FE$QG@YD76D[Z[RR0=^B%OY/P.5(M_2*%),3A.)\W[9X$
MJ]!1X3AS#4SV[FO/W_V*M9-D/AZ;#M/^6_,Z*04(AW)^-P&2"%XH0Q@D&1(?
M19BN[(&O#IMY?A"GUMS2253V)4C..*9+Q];S`II00$B6&,FS7M6Q%0US%J^>
MZ2"++++Y0&DFGOD'K7CFEQAFO8DVOR>+R"$[SZ!LJPE$>XTJ_+F^3^"XM81%
M3M?'-9:@Z[*V2&$UJ]'*&Z`+ZJY[0M5E$0[0Q8\GO"K?2\HU^SY@SC&-(_J\
M/*O/[+@+:`Q[,U_#H3Y<U=>=Z:7X1Q%/>?">/#O@5(%^DB[&;V\;G!8BMY-(
M<#B.;R<9`][PBOX2/OX2/MY$^'AC%[TOX>-'OU4]Z?#QERIV3886UG;X1E#X
M[GLK#')^Y4&_:RT'EQ0]93W__DHL-Q>?V:A6O]1E_CZJE387T'E2BZZBPND9
MUGMZGHR9:]$?]<H\77PW%Z.BAU.C]=KRMZ-E>QY2'0JWMQ0BG]6U:+MQ>07F
M@%.]TZ<[B.%3@_RFL@Q#]6P+HMH?29)*,N$52`C:FK9@U1*7,GGB^VTQ<C_A
MMKGP/LZGC#[])T>WL02)K)A+[X>;)$(LM/P0R3'D>P@S;:8,^3$U\7BU./'$
M(B9QE.D4@D/^=LE@4\%81A]6U-*BTH+25Y)/B9*X9,5RBQ`H2<49M"L2'[$T
MR^;R5V4?,_JXXS$7*XFH7\ROJI_Z\]+P^Y)&#;`_+VLRP7KN&:QINV6>Q40T
MK8><3QE],O.86B@4LUD=%)7XD:1R*X[\L*ZFDSC4'@`=$9S=CG0>U16:>B!1
M1S.P5%LX9Q>#,-*/>_!M2+?K),+P8XP-ZG?]4)W(VJMB?,^;:375I,/P(XX&
M-;448">BK/"S>=M=])XVMA^/T+3N-DN6X?<HS1D5M<!Y'II]*B:PA@.GJ:<W
MT1O!+VZ>M-"^)B5NXOF=1)!Y[%?&%;XJ78:?+C4W"^H!]!2\3Q/"<NWB5Y?=
M6**1Y0SLI:8C2CV*N3<]RSJEH))I*!*HN86<QQ@+>0UXP<EQA)014@P_X5E2
M&3S38CLWI;S$HY0:=F']OO7354J>J6C:V"N3,E"\;`)*H(FDCRK$@,,#,2JQ
M2<$UNK:V5RL_CN7IT\_:;F#/DP0`N2&F[`4%N['<'[7A!>0<T?)1SP*:9?<H
M?H_\)Z':T8Q?#@I\8RX./@+?R<W>"2FJADONLAF7'#)5/4/_6SV;>59,Q[&\
M"M^$JFHS?K,*JMHH!K5KJIDLQ0EQ6,#UF"[R-@EVR85#]GX9>Y/XP&PF4_'O
M^4S%26_0GO6ZK7%[,NOWIL])BH>!3"8KIEC<SJ@"!%1M>&%\G&))RIY&TQAX
M+V'R4A2R[9`4?0*"4DA)R#*#I92JL-"S!(\!NE*GD+=5>>0CJ3\JTJFK;?HO
MBC)V&F.<$&HZ;.&H39JF2U59E-<6!SCZ*BD!KMF'<>.$KG'DS^^I3=2F1E>L
M5+_:X?V8^*[]-$M9$(-!1_J2:\FQ3"=[BW4NXW2N(B@<;I]N1*XI\UGC3SR_
M!,U-EU"#OJX@Y18'(.WYW(O<,*!'$;:*9TGM1#X3AQ@?6&_3LPO^Q)R&,-`\
M@G$5!92M@#W$,B?,U1ZO\[`#U:?\@>KJ=MH?]J;35F<T[/2&LTE[UA\-T1VL
M[.`;BP.\I1S[E"Z7X0,X5<F[&9R%&>P8F8JCE:@]$ML#`D]NZHDX0G+.*I`'
M.&_)^N``2JYV*H3PG<,*)%YMU:]"2#N=`TYI?G`<L8K\T"^JSEK23DAQ*NJ?
M<ME+,86BY/@TVFP<F_@%2E45L94=39N%`"W,NZ!@LL!AV7>B(/36)8!3=C1=
M9U(?.*`L&@I)$7[]0NK+4'<S_?JH!A`PALS`<%D.ADM-&!I[R+,N&"[-PO"^
M'`SO=?<3#!L*C",S.'PHA\,'71P:"Y6K"X</*+?UHHUY1=SY_=KROVD?='(]
MD5K1FJ>='%,XWD@JTKFG4OO<4^B)%#:!8BH!S+.'XQAD.228D`?B1F1(0N7A
MA]\<G>4LT,+\N4?&/(YE\10?BM-:Z(JOOKU_>?7MY=6W%.'E7GVK/WB2)T>N
MI!&_^E:8FF/BLU]8*UDPK+R7X5MK]16&:F?FR``'6KG]";PM(_1!JD`1L'H6
M#Y=TO/7:#N/"1FUWP?+&;+J$N'-H?/#'=_GK[,[HYJ8_N^D-9]-6>]AEM]JS
M_O!+;]C!%RTLX_[`D_J26W.86CT*UL8.+6=`K(",[AQ[E80BL*P_D3-!UL/X
M>ED"CXQ?02T.',MG3"'E<<*DZ[!:'6X@"3X0-#>_E%;`2\X:)K!&&\+6*G<5
MTQHP2G=T3B-Z>J"_2XCGEJ'8#:(SANDW[^J`55]F:**[U'LB?RN\*+<5OFR`
MQSUD[#/CG_>':TJCY?Q.+/_&"B/?#K?[]^0AK)<<\)2WVJJ\(U[<KR-6\7!W
M3-XE"P9)806*QVCYS!YXK=<9TOR.7@U2Z2:@+]O3?X`((H)N1/KN[-%CG$N<
MJ26&,F])'%N=N++\GM2(?I74IDBIP1#<HQA1I8(\OR-ENO8BORY=2HUE[%$T
MLZI4D.9WHTF5U<?\U8H1G:FL**''O&$8',WTU!^0OR+F!GB(N3MXER7.Y<O"
M,]FW5]/>+[?T1-WJ?8W/U6F'LG%_<IY)]?%1W`-#A8.3K#:A`N&ERL01L3CQ
M*A,Y75)G-@D[G!(>(AYP9#)QR%/%\TFZ(,%%KF=J@'`%[F7I4V<M<9N;=H4I
M]4R."L80&T:BO;`M?\MB&D;+N+J%>D$3=$$R=:!+FH`+'+'**;*&UIK^F"H@
MHUS=`'V18*72/T[DC8JS9@KD[-Z`78ZI<E$;4A!+46B%ODH*E^IZEBB%)*=V
MR"T[DZ9HU\;XRJ\EQ@QC6I?8N[^P?[':E/0W_Q]02P,$%`````@``X)E1W=(
MZ*59#@``P)$``!$`'`!T>&UD+3(P,34P.3,P+GAS9%54"0`#%L<[5A;'.U9U
M>`L``00E#@``!#D!``#M76USXC@2_GQ7=?_!EZJKFZL[0B"3V4UV9J^,<1+7
M$F`QF9F]FJHM80M0C9%8R4Y@?_VU_,*+;63#3&Z\!_MA%J1N2<_35DO=%LK;
M?R]FGO:$N2",OCMKG%^<:9@ZS"5T\N[LT:[IMF%99]J_?_S+GS7X[^U?:S7M
MEF#/O=':S*E9=,Q^T+IHAF^T.TPQ1S[C/VCOD1?($G9+/,PU@\WF'O8Q5$0]
MW6BOSZ]'6JU6HMGWF+J,/PZL5;-3WY_?U.O/S\_GE#VA9\8_BW.'E6O.9@%W
M\*JM_LTGLWVG#\COF'\R/(*I+SX-IP!DC@.?..*A_>EC:]#YU+QH7%U<7UY\
M\A<S]U?YJ7%UOA@#V#;RH2%9_[=FN]&`?RZNAHWO;AI7-XTW_RDY*A_Y@5B-
MZF)Q$?]73OV!"&>E_,\W8O[\W6)`/DX#^GU@C&CCP48_=9:C_O7SE?O[$GLM
M?W:]O'?I3_=+_?.LC;K#Y>]VH_WQ[N?W#]VHR[?"F>(9TN#YH.+=V0;GSY?G
MC$_JS8N+1OWC0\<.Y<XBP9N%1^CG//'&]?5U/:Q-1#.2BQ'WDJ8OZ[)ZA`1>
MM0RU1"%/J/`1=;;D77^EL"E\58\JMT1)KNB;2)0DHBY.R0GLG$_84QTJ0+[Q
MNG;1J%TV$O%`U"8(S5<J8R1&8=-QA52YRJAPYF&1JQ/6Y"A11FDPRV?']7G=
M7\YQ'81J((4Y<59ZQ4K;"C`&69P_NK`F9W1RRJP4_(W)-7-AWL[JR=P"W^/A
M&4S!6\9G;3Q&@0<&_"U`'AD3[)YI/N(3[,MG7LR1@TNUF4P?1"F#60;>)RZ1
M9?,Y@6D$!7]Z*Y^W&\GO$%!H\@/X'%4/4J0.,S&0(]:I:U*?^$LY+?DL[.=,
M(P!;*2%[AG&$?;MX3"@)!QA/_H96TQ+US8^(NEK4EK;1V-MZNIF-Q@.!W1[]
M,?P\YUA`,Z%2!PIBQ5ADAY*#/"?P]M-9#R57)2Y(./\"*QB,"N81%SRQVT*>
M=`/V%&-?1";87:WFOPFD2\^,8P,8O:[=ZUAM?6BVM9;>T;N&J=GWICFTM5>/
M%`4N@1[^<3)$END^XH!TBD$!>056V995F^CR,!-IK[8Z.9DL,L.*2=$;]^9R
M-P?]YTRB'7)J4[U6F<H>PO\>S"Z8J7>K]?KF0!]:('":5THC&4A,;SWV7&"C
MM9C:1%?E363H]KUVV^E].)DH,=%LCN@R,43T14WW&[FHP];=8R+@&+X,[TW@
M_*&O=W\Y8B9;2!!X:/L;P&#S-,`.?/.6EA`!=G7'80%L@>BDSQF%CT[TK$?T
M?U$+:IM]E[992[>M<$;T!Z8-LR/T6YK>;6L#TX#OG5\TR[8?80+IAM%[[`ZM
M[AW(]KKPV8CFTQ';V@YF,\27O;%-)A1V^0Z"G?+:,N#,'()CJY:45=OO^[3]
M[,>'!WWPB[2@;=UUK5O+T+O#+6.!"S0L\YC-9-$G`,1X[-[67]5D7Z?)MKKO
MX8'O#8[9O?5DA1%PN?_4A5A%*3GE2G8;%VEV>[!^##3C<3`PY1-LV^91^Y9;
ML@`W'S+9Q7Y$<JI,37`C3?"M]5'Z\9#8?VE=<WC$[,+B.D?$-1=S3&663K*;
M*E.SVTRS"PMH7[?:FOFQ;W9M\XBYM0`-G9"1AS<=1*94S>]EUOD.]>Z=U>J8
M)]^PZ6P[!(V(![WB'$^\6:GF^[7:'7<LO65UK.%Q;R3`Z7:8$'W,[2GBL=M(
M%ZIYODKS#'Y8Z_1L6^L#W?:]/CAFUV'[S/D\99Z+N3!_"X@?;]ERRM4T9X)3
M>]@S?KKO==KFP/Z[9O[\:`V/>1MG4?B(AVB!5^YY7:"F-A-#6EV(^DUMJ'\\
M:N<PP)[,7/417_OB5)F:V$QP-S`[8>ZJKP^.W/&V`D$H%L)@5&9!ME*[.^K4
M7&=BN]:C;75-<,-&KRL3'W$&]X@Y-]AL1OPPJZ13%]B5>0I,UQD-E8"2_68F
M]@,'\F`-H_2L3#Z!$63RPNP>>>;"#D8"_Q8`*/-IG2#,E*K9S@2"]F/+AA50
M[NO,]Z<47HFTW"&IO'(IO68FD"R?TM->)7T<\ZN+53IOB""X%*D<7URHMD%.
ML!EG^K1740/'3'`VM;?)],Y:->4%\684XI_83^<!-YG/K5&SGHD^,SG!$^7I
MY.`FY;DU:LHSD6@J47@B/)LQW/;DN75JTG-BU%3V\$3[SC3B+N^>%5$;(1//
M[DPIGHR1R2UN&B&_2DU^)L#-YAE/K.<E'#>)WUFKY/XR$][F)1]/["M3#)MF
M*!93VR,3`"O3#2?#E(V*V]A'Q!-=Q&72[0GO$QUG=-4F_*(H.>Y+6W5VS*9=
M1<8Q*ZEX.2E5FT,5,,<M'#/'V9AXB^S=U6K62\;,)P.D@N9\/U4@HS9%F4#Z
MY':*+*(P1`'_F:AZ-__'S/IVOF*+]?PJ->N9L#J3RSAQGDEFY'N?0BFU)3*Q
M=4Z"X^1_BJVB-$:!#7+.!^^TP8GZ#+L-)?<--?FO,S&V@OS&,;._(X.W<T.:
M(Z.V1":Z5J3Y3LM#.L^W98<==6K^,Z%Q7J;O1'Q.JF]'_J)83FV03'"<G_X[
M+<][&:=1UCI%*T<FBBYIGN->1HIY;Y8U4+/`0)G8NJR!FB<#Y?!>8)8"8Y0Z
M2'U:7U0&*/)<10XK$W6KY\-1NZGM`]?Y"WR!C-H818>T3^MZB8/;^78I*:NV
M3]F#W2<[E7T3FV^L?124%KO:[S#XR6Y[VJVLN0JLM.\[]-.&('-X?STOMMZ6
MJX745LEY+9XZVK\U7_[?IHO\1]ZR.,!C+;R=\49>XO?N3!!Y9>=97#;E>/SN
M3%[C5TONU?L5H)TO9EXB(IM6W,X8FC/-1MQQT@3B3J:5S.V1T`B;XW#?44\&
MGS3@$U^J;U[[HLE^8`;7OP9D#XWVA0PJV'M!K!W9_E<%"4_?OB!3#^P+0376
MO7Q5P#!U]@6\/=M>"&][U<DFW/CFROKZZLKX>_IZR[<`G'%?HYG;,E5WIT:W
MOG:8$S:E4)'?:HE>31;5&LW:9>-\(=SU2/<9Q)J&_0:1Z!TPB/Q+84MVGRC(
M?J_VZG'7G;$[.L[5D1]J:^6R_2LOH%7UGZM8QYXODI+:NJE#1I.]//;PX81M
M'3">$O?FEGDX-C6[D:)\2*[EP]EX\X6#.6P@1:.(+]X--U3A#=<?9&P0[74'
M9#+UQ0<L_X==_0GV:A,L-\`<.7Z`O`&,`SP5G73(&&:O1/+N[`OTB>?)XZ,P
M$!Y(IR@O?KX!9TF8.PQ]NAM$D>V9%OGX2"(IM7P\DW)`$>P,P9D&LO2.LV">
MB!(048$W/"1$;QQCZ/$0@;F8DR2B1CY>58NX7B30#]8^%#BT]U*@WV,AXYP#
M`!=I5A#L+2(\O$1]3ZAJO4*@T2KJ)U6CZ"Y<(`"/B+^-?L8HQ")\^5(,@+<:
M8=X;V]@)>/@&^Y;Q,29^:[D7(_NU<^"C(.0;7O%B3SX8-.ST`?M3YN[[])?0
M/A2VSV%>O:"7DZ?9!MAA$TI^E[>NJ[U:1GH/6/_3!_X1<,!**T=I,.&OL:PL
MJ92H*JSX%**\^C?PI,>-3Z$DH!3U%?5,\8@'$,5#+#5MXR?LL;F4":W29=3)
MA5A*H:*8;>1A(?-0\D<>8H#]@%.Y=](]CSW+`8@[QESY(BR"O(?\P8@=CMT7
MA+P:*BP-'Z80,0O`!)#`O8T"G_%;C$7J6=Y/I;+`'0<&Y!H0N,K+YX><("]\
M4--HB^6J"M%`<^(CKX,A+N^-/#*)=KY#S&>K]40I\NUC`-U]DE3UT3+,^<,3
M=QO`+,.)EX')MN%H=,<G3_$5@K'U#M>OJ(^R:)SWPAWRA-WTL5-SX7B!_,-1
MTO,\`X;PTM6(C,-4*\I#:KG9-F3>1-Y'H:*8DPU]'\*OC1U3MKC\^#='2JB/
M)YA_C854!@4M\"FNO(,?-J>A/]#E-FX2BK:6:Y%X<NK/B+N]>>A_>H$OQR<?
MQE3&8I6FV$A=2&^UL2A_F[Z_O:_\!L";WY#T9B5(C[U*]/?QVGC.!%E/S%V5
M%74O\7`?$`W&DF@>LJ[:[!>(5A3G*B\"@ADGFA1^:Q>Z_;LVL7X[/L0+O^4Q
MYW/*%FK)O6=*],?L;ORDC:\27E&'>(2%)S?"/\V21/8/6)*_#JN*Y!",0/J"
M!,[!\%PFO<N+8FN4!=?X(Z)KED77_".BNRR+[K*ZZ#J,3N2":86G$6'CO[E"
M]\'ARM=1VSCW4JD>8EB#?D[^7&7SHM$,3RROL,CQ;\,M+U\]K&T\QK#<0ECS
MA&F`M\Z<#HCXO(VTK'3U<(8VZ0<0N,$.4I]P'-9_(/ZTCSDEB\V_%MSI&*EY
M>YAR]5BX9USN@Z+Q+ML\F!ARTRQ?Q\7!WS;P\O+5P_H@$^5S#P\Y<B$&X)]E
M]N8]\=$,=EYV,)]'"BG$^VI5#[<^GW/VA-U];;V_7O6P&X'PV0SSC&-*;:**
MY?Y`V)HEL55X![5SS)<EL55X_[1SS*]+8GM=76R)MXS3Y+`M8-Z3#.7#%Q-=
MYN-\[UHL7SVL!GO&=+USSVP2=M=7#POL6/7H);D\A)#*XV<VM\6BU4,8Y053
M;C]56+U1/_9[VR/>**C>:&V?C+'W2%W,GSD(\W0>9F=]];#<,<^=(6HC9YI"
MD5=3O?'+!#AQ<7Q`!%$_]>3OJJX>DC@E8BXP=XC`;FH.[ZRN/I*F&DF%]V=M
MY@3A*Q?JFA1:6%IT#&%"])(F'NTJ1U!*]LLQ?N5S=*D[9]*H=E97'4ATB6\!
MG+10Y4`57GV<!KB'0N7`9N]%3:-3250.SNI'!"D0V?+*#7UUAW-\LF<9;F9D
M]AH>*IGJE<G=#+!]M2H'.WZ7&;U:S[B._,K*@4B=`TB6V3XG3L:[EY.M.L2\
MHP[RUS@%:(O5*@=<GTPXGL@?D5#9I"!.^,N---!"L6\([&T]^NT7?/PO4$L!
M`AX#%`````@``X)E1ZH7<7<<F@``OS8(`!$`&````````0```*2!`````'1X
M;60M,C`Q-3`Y,S`N>&UL550%``,6QSM6=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@``X)E1_DM-VF-$0``S^0``!4`&````````0```*2!9YH``'1X;60M
M,C`Q-3`Y,S!?8V%L+GAM;%54!0`#%L<[5G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(``."94<][#A;<QD``#*4`0`5`!@```````$```"D@4.L``!T>&UD
M+3(P,34P.3,P7V1E9BYX;6Q55`4``Q;'.U9U>`L``00E#@``!#D!``!02P$"
M'@,4````"``#@F5'AN5ECKU*``"T,`0`%0`8```````!````I($%Q@``='AM
M9"TR,#$U,#DS,%]L86(N>&UL550%``,6QSM6=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@``X)E1[3I.G`P+P``UR4#`!4`&````````0```*2!$1$!`'1X
M;60M,C`Q-3`Y,S!?<')E+GAM;%54!0`#%L<[5G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(``."94=W2.BE60X``,"1```1`!@```````$```"D@9!``0!T
M>&UD+3(P,34P.3,P+GAS9%54!0`#%L<[5G5X"P`!!"4.```$.0$``%!+!08`
1````!@`&`!H"```T3P$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760185698256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">30,136,673<span></span>
</td>
<td class="nump">30,779,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">17,414,242<span></span>
</td>
<td class="nump">16,851,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">12,722,431<span></span>
</td>
<td class="nump">13,927,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191670480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsNoncurrent', window );">Prepaid manufacturing costs</a></td>
<td class="nump">$ 978,704<span></span>
</td>
<td class="nump">$ 963,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">193,347<span></span>
</td>
<td class="nump">463,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">TOTAL PREPAID EXPENSE</a></td>
<td class="nump">$ 1,172,051<span></span>
</td>
<td class="nump">$ 1,427,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760118091312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narative)<br></strong></div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfPatents', window );">Number of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfPatents', window );">Number of patents</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSites', window );">Number of sites</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patents outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of sites</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187244640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,792,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(472,867)<span></span>
</td>
<td class="num">(793,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">17,414,242<span></span>
</td>
<td class="nump">17,414,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable</a></td>
<td class="nump">13,848,923<span></span>
</td>
<td class="nump">13,848,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 27 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,996,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
<td class="nump">$ 64,265,785<span></span>
</td>
<td class="nump">64,265,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">$ 59,095,453<span></span>
</td>
<td class="nump">$ 59,095,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760362509456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
4 &#150; INVENTORY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Finished product</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">787,232</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">874,294</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Raw material</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">82,827</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">155,341</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Deferred costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152,478</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">870,059</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182,113</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a, b, c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760116639344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2015</div></th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th"><div>Feb. 17, 2015</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Aug. 04, 2014</div></th>
<th class="th"><div>Jul. 29, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,787,927<span></span>
</td>
<td class="nump">177,787,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,787,927<span></span>
</td>
<td class="nump">177,787,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">472,867<span></span>
</td>
<td class="nump">793,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,478<span></span>
</td>
<td class="nump">$ 589,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based compensation options grants in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember', window );">Options exercised 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=txmd_Option1Member', window );">Options exercised 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_StifelUnderwritersMember', window );">Stifel Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="nump">4,423,077<span></span>
</td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617,282<span></span>
</td>
<td class="nump">13,580,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember', window );">Goldman Sachs Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,850,106<span></span>
</td>
<td class="nump">8,565,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=txmd_Option1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=txmd_Option1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_StifelUnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_StifelUnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_GoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191312560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetLossPerShareTablesAbstract', window );"><strong>Net Loss Per Share Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss
per share allocable to common stockholders if they were not antidilutive for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">As of September 30,</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Stock options</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">17,414,242</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,851,943</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,722,431</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,136,673</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,779,859</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetLossPerShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetLossPerShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117696512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,528,061</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,706,542</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">930,913</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">814,205</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">615,946</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">276,470</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">490,170</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">442,430</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">388,268</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,965</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">208,361</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">90,446</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">96,440</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">160,503</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">86,998</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,368</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,620</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72,710</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,386,777</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,840,639</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760115542352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>May. 11, 2013</div></th>
<th class="th"><div>May. 31, 2013</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,772,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,772,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">Sancilio and Company Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnamortizedCostsOfWarrants', window );">Unamortized costs of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Number of shares purchased forfeit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member', window );">Sancilio &amp;amp;amp; Company Warrants 1st Installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">45.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights', window );">Valuation method of warrants</a></td>
<td class="text">Black-Scholes Model<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recognised</a></td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member', window );">Sancilio and Company Warrants 2nd Installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">45.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,517<span></span>
</td>
<td class="nump">$ 38,517<span></span>
</td>
<td class="nump">115,551<span></span>
</td>
<td class="nump">$ 115,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member', window );">Sancilio and Company Warrants 3rd Installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember', window );">Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember', window );">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 260,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to non cash compensation expenses of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to fair value of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refer to numbers of shares forfeit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to valuation method of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnamortizedCostsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to unamortized costs associated with warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnamortizedCostsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117981952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and
2014 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Nine Months Ended September 30,</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.47-1.54</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.68-1.77</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.77-62.94</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">%</font></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">69.15-70.93</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Dividend yield</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares Underlying Stock Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.88</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.92</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,996,311</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,231,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.38</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(472,867</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Expired/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(136,334</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.01</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2015</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,414,242</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.21</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.09</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,265,785</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: 10pt; font: 10pt Times New Roman, Times, Serif">
<p style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at September 30, 2015</p>
</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">13,848,923</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.59</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.49</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">59,095,453</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191338800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2015, future minimum rental payments are as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"></font></p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Years Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 43%; vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015 (3 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif">121,698</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2016</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">493,790</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">388,976</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,511,551</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191329280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
3 &#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment
of Long-Lived Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes
in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets
during the three and nine months ended September 30, 2015 and 2014.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of
accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of
such instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements. </i> The fair value hierarchy gives the highest priority to quoted prices in
active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and
liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1in; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable
inputs (Level 3) in connection with any required impairment test.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is
fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support
team utilizing similar marketing techniques.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We</font><font style="font-size: 10pt"> include outbound
shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold.
A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three
banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC
sales, net of estimated returns, sales discounts, and eCommerce fees.</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue
from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following
product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January
1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve
as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return
no longer existed.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">We
maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we
send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages,
which is reviewed, and adjusted if necessary, on a quarterly basis.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was
included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance
sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of
which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying
consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other
activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants
that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff
with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing
experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside
legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters.
These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical
trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We
make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable
advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or
when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study
expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided
by</font><font style="font-size: 10pt"> CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study
costs as long term Accrued Expenses related to the costs that will be paid at the completion of one of our clinical trials. Estimated
accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in
which the facts that give rise to the revision become known.</font>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187255904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities', window );">Advance payments for future research and development activities</a></td>
<td class="nump">$ 948,499<span></span>
</td>
<td class="nump">$ 1,175,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued Expense</a></td>
<td class="nump">1,213,874<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets current</a></td>
<td class="nump">755,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Long term prepaid expense</a></td>
<td class="nump">$ 193,347<span></span>
</td>
<td class="nump">$ 463,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of advance payments made for future research and development activiites to be expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187474448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense for the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2015 (3 months)</a></td>
<td class="nump">$ 8,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2016</a></td>
<td class="nump">34,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2017</a></td>
<td class="nump">34,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2018</a></td>
<td class="nump">34,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2019</a></td>
<td class="nump">$ 34,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117615152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 81,123,988<span></span>
</td>
<td class="nump">$ 51,361,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $96,916 and $59,753, respectively</a></td>
<td class="nump">3,666,586<span></span>
</td>
<td class="nump">2,154,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">870,059<span></span>
</td>
<td class="nump">1,182,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,120,805<span></span>
</td>
<td class="nump">1,537,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">87,781,438<span></span>
</td>
<td class="nump">56,235,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">56,748<span></span>
</td>
<td class="nump">63,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">1,172,051<span></span>
</td>
<td class="nump">1,427,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,324,284<span></span>
</td>
<td class="nump">1,228,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">2,621,335<span></span>
</td>
<td class="nump">2,780,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">90,459,521<span></span>
</td>
<td class="nump">59,079,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,301,625<span></span>
</td>
<td class="nump">6,327,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 6,386,777<span></span>
</td>
<td class="nump">3,840,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">522,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 11,688,402<span></span>
</td>
<td class="nump">$ 10,690,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued Expense</a></td>
<td class="nump">1,213,874<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 12,902,276<span></span>
</td>
<td class="nump">$ 10,690,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,787,927 and 156,097,019 issued and outstanding, respectively</a></td>
<td class="nump">$ 177,788<span></span>
</td>
<td class="nump">$ 156,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">279,723,640<span></span>
</td>
<td class="nump">182,982,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(202,344,183)<span></span>
</td>
<td class="num">(134,749,836)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">77,557,245<span></span>
</td>
<td class="nump">48,389,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 90,459,521<span></span>
</td>
<td class="nump">$ 59,079,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187404848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,626,862<span></span>
</td>
<td class="nump">$ 1,047,493<span></span>
</td>
<td class="nump">$ 4,328,964<span></span>
</td>
<td class="nump">$ 3,341,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
<td class="nump">$ 5,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued for excercised warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued for excercised warrants, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised1Member', window );">Warrant Exercised 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued for excercised warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued for excercised warrants, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised2Member', window );">Warrant Exercised 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="nump">232,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued for excercised warrants, shares</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,445,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,968,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantExercised2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191315248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
1 &#150; THE COMPANY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed, BocaGreenMD, Inc., a Nevada corporation, or BocaGreen, and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#34;our company,&#34; &#34;we,&#34; &#34;our,&#34; or &#34;us.&#34;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Nature
of Business</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are a women&#146;s health care product company focused on creating and commercializing products targeted exclusively for women.
As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary
for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used
in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related
hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug
candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical
efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates
are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone
or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter,
or OTC, vitamins.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 272<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760324178992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 7,856<span></span>
</td>
<td class="nump">$ 7,122<span></span>
</td>
<td class="nump">$ 22,104<span></span>
</td>
<td class="nump">$ 22,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760184738448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment
of Long-Lived Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes
in circumstances indicate that their carrying values may not be recoverable. There was no impairment of any long-lived assets
during the three and nine months ended September 30, 2015 and 2014.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of
accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of
such instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements. </i> The fair value hierarchy gives the highest priority to quoted prices in
active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and
liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1in; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2015 and December 31, 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable
inputs (Level 3) in connection with any required impairment test.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is
fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support
team utilizing similar marketing techniques.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We</font><font style="font-size: 10pt"> include outbound
shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold.
A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three
banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC
sales, net of estimated returns, sales discounts, and eCommerce fees.</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue
from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following
product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January
1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve
as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return
no longer existed.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">We
maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we
send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages,
which is reviewed, and adjusted if necessary, on a quarterly basis.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities were $948,499 at September 30, 2015, of which $755,152 was
included in Other current assets and $193,347 was included in long term Prepaid expense on the accompanying consolidated balance
sheets. Advance payments to be expensed in future research and development activities were $1,175,082 at December 31, 2014, of
which $711,362 was included in Other current assets and $463,720 was included in long term Prepaid expense on the accompanying
consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other
activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants
that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff
with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing
experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside
legal counsel also provided professional research and advice regarding research and development, patents and regulatory matters.
These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical
trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We
make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable
advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or
when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study
expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided
by</font><font style="font-size: 10pt"> CROs. As of September 30, 2015, we classified $1,213,874 of the accrued clinical study
costs as long term Accrued Expenses related to the costs that will be paid at the completion of one of our clinical trials. Estimated
accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in
which the facts that give rise to the revision become known.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section CC<br><br><br><br> -Subsection 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191703200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 201,604<span></span>
</td>
<td class="nump">$ 186,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(144,856)<span></span>
</td>
<td class="num">(122,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">56,748<span></span>
</td>
<td class="nump">63,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">132,150<span></span>
</td>
<td class="nump">132,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 69,454<span></span>
</td>
<td class="nump">$ 53,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760365048928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">870,949</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">394,878</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">381,813</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">373,339</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">411,864</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other receivables-related party (Note 13)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">219,086</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,637</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,120,805</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,537,407</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White"><b>&#160;</b></font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191316688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &#150; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Interim
Financial Statements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2014. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance </font><font style="font: 10pt Times New Roman, Times, Serif">with accounting
principles generally accepted in the United States of America, or GAAP<font style="color: #252525">, for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying
unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete
financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting
of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for
the interim periods presented. Interim results are not necessarily indicative of results for a full year, or any other interim
period.</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, the Financial Accounting Standards Board, or FASB, issued final guidance that requires entities to measure
inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance
applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail
inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does
not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM
guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable
costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate
other measures of &#147;market.&#148; The guidance is effective for public business entities for fiscal years beginning after
December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating
the impact of this guidance on our consolidated financial statements and disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-10, Technical Corrections and Improvements, to correct
differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references
and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for
fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The other amendments are effective
immediately. We do not expect the adoption of ASU 2015-10 to have a material effect on our consolidated financial statements and
disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #252525">In
August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure
of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether
there are conditions and events that raise substantial doubt about </font><font style="font: 10pt Times New Roman, Times, Serif">the
entity&#146;s ability to continue as a going concern within one year after the financial statements are issued (or available
to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December
15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or
interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of
ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with
Customers (Topic 606). The standard&#146;s core principle is that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous
guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration
to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,
the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after
December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,
2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements
and disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently
issued, but not yet effective, accounting standards been adopted in the current period.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760182114720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 96,916<span></span>
</td>
<td class="nump">$ 59,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">177,787,927<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">177,787,927<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760184723696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
12 &#150; INCOME TAXES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of (i) the losses recorded
during the nine months ended September 30, 2015, (ii) additional losses expected for the remainder of 2015, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#34;more likely than not&#34; that some component or all of the benefits of deferred tax assets will not be
realized. As of September 30, 2015, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760118105744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 02, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,848,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760325492720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
13 &#150; RELATED PARTIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was
elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course
of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent
directors of our company.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015 and 2014, we did not engage in any transactions with Pernix. At September 30, 2015 and
December 31, 2014, there were amounts due Pernix of approximately $46,000.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Additionally,
there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and
supply agreement in the amounts of approximately $250,000 at both September 30, 2015 and December 31, 2014.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph b<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760118109120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
<td class="nump">$ 5,190,175<span></span>
</td>
<td class="nump">$ 4,186,261<span></span>
</td>
<td class="nump">$ 14,513,158<span></span>
</td>
<td class="nump">$ 10,768,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">1,193,965<span></span>
</td>
<td class="nump">1,068,605<span></span>
</td>
<td class="nump">3,270,695<span></span>
</td>
<td class="nump">2,792,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,996,210<span></span>
</td>
<td class="nump">3,117,656<span></span>
</td>
<td class="nump">11,242,463<span></span>
</td>
<td class="nump">7,976,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">7,060,944<span></span>
</td>
<td class="nump">6,043,354<span></span>
</td>
<td class="nump">20,089,998<span></span>
</td>
<td class="nump">16,610,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">16,421,753<span></span>
</td>
<td class="nump">14,909,430<span></span>
</td>
<td class="nump">58,789,302<span></span>
</td>
<td class="nump">29,052,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,548<span></span>
</td>
<td class="nump">12,747<span></span>
</td>
<td class="nump">44,400<span></span>
</td>
<td class="nump">39,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">23,499,245<span></span>
</td>
<td class="nump">20,965,531<span></span>
</td>
<td class="nump">78,923,700<span></span>
</td>
<td class="nump">45,702,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(19,503,035)<span></span>
</td>
<td class="num">(17,847,875)<span></span>
</td>
<td class="num">(67,681,237)<span></span>
</td>
<td class="num">(37,725,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">27,630<span></span>
</td>
<td class="nump">6,260<span></span>
</td>
<td class="nump">71,728<span></span>
</td>
<td class="nump">43,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="nump">9,364<span></span>
</td>
<td class="nump">15,162<span></span>
</td>
<td class="nump">27,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,027)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">30,390<span></span>
</td>
<td class="nump">15,624<span></span>
</td>
<td class="nump">86,890<span></span>
</td>
<td class="num">(188,860)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(19,472,645)<span></span>
</td>
<td class="num">(17,832,251)<span></span>
</td>
<td class="num">(67,594,347)<span></span>
</td>
<td class="num">(37,914,629)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,472,645)<span></span>
</td>
<td class="num">$ (17,832,251)<span></span>
</td>
<td class="num">$ (67,594,347)<span></span>
</td>
<td class="num">$ (37,914,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">177,206,168<span></span>
</td>
<td class="nump">152,200,455<span></span>
</td>
<td class="nump">171,589,595<span></span>
</td>
<td class="nump">147,594,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760187515248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpensesDisclosureTextBlock', window );">PREPAID EXPENSE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
7 &#150; PREPAID EXPENSE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid
expense (long-term) consists of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">978,704</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">963,543</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">193,347</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,720</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,172,051</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,263</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191368496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
6 &#150; FIXED ASSETS, NET</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,895</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">201,604</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(144,856</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">56,748</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,293</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended September 30, 2015 and 2014 was $7,856 and $7,122, respectively, and $22,104 and $22,713 for
the nine months ended September 30, 2015 and 2014, respectively.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13-14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760184719488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Finished product</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">787,232</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">874,294</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Raw material</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">82,827</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">155,341</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Deferred costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152,478</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">870,059</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182,113</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191336880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
14 - BUSINESS CONCENTRATIONS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
purchase our products from several suppliers with approximately 54% and 77% of our purchases supplied from one vendor for the
nine months ended September 30, 2015 and 2014, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain
drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated
from four major customers accounted for approximately 90% and 95% of our recognized revenue for the nine months ended September
30, 2015 and 2014, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Customers
that generated more than 10% of our sales are designated as customers &#147;A&#148;, &#147;B&#148;, &#147;C&#148; and &#147;D&#148;.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015, two customers generated more than 10% of revenues and during the nine months ended September
30, 2014, four customers generated more than 10% of revenues. During the nine months ended September 30, 2015, customer A generated
approximately $6,930,000 in revenues and customer B generated approximately $3,005,000 in revenues. During the nine months ended
September 30, 2014, customers A, B, C and D generated approximately $3,930,000, $1,846,000, $1,590,000 and $1,555,000 in sales,
respectively.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6442-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191392240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetLossPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
10 &#150; NET LOSS PER SHARE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of
common stock, par value $0.001 per share, or Common Stock outstanding during the period, less any shares subject to repurchase
or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three and nine
months ended September 30, 2015 and 2014.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since
we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as
warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.</font></p>

<p style="font: 10pt/14.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss
per share allocable to common stockholders if they were not antidilutive for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">As of September 30,</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Stock options</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">17,414,242</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,851,943</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,722,431</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,136,673</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,779,859</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760362501600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 8 &#150; INTANGIBLE ASSETS, NET</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2015</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Gross Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;Net</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Amortization Period (yrs.)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;OPERA<sup>&#174; </sup>software patent</font></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(3,994</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,957</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Development costs of</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Approved hormone</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">605,502</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(40,199</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">565,303</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Hormone therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">585,241</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">585,241</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Multiple trademarks for</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">145,783</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">145,783</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">indefinite</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,460,220</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(135,936</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,324,284</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&#160;&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;December 31, 2014</font></p>
</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Gross Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;Net</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Amortization Period (yrs.)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;OPERA<sup>&#174; </sup>software patent</font></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(2,496</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">29,455</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Development costs of</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Approved hormone</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">439,184</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,401</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">419,783</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">18</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Hormone therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Multiple trademarks for</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,342,228</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(113,640</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,228,588</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">Trademarks are perpetual and are not amortized. As of September 30, 2015, the remaining life related to OPERA&#174; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years. During the three and nine months ended September 30, 2015 and 2014, there was no impairment recognized.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">In addition to numerous pending patent applications, as of September 30, 2015, we had </font><font style="font: 10pt Times New Roman, Times, Serif">13 issued patents,<font style="background-color: white"> including:</font></font></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#183;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">one method patent that relates to our OPERA&#174; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#160;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#183;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">twelve utility patents that relate to our combination progesterone and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Israel, Mexico, Brazil, Japan, Russia, South Africa and South Korea.</td>
</tr>
</table>
<p style="margin: 0 0 0 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Amortization expense was $8,692 and $5,625 for the three months ended September 30, 2015 and 2014, respectively and $22,296 and $17,196 for the nine months ended September 30, 2015 and 2014, respectively. Estimated amortization expense for the next five years is as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amortization</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015 (3 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif">8,692</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2016</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2019</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117828000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
9 &#150; OTHER CURRENT LIABILITIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,528,061</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,706,542</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">930,913</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">814,205</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">615,946</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">276,470</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">490,170</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">442,430</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">388,268</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,965</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">208,361</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">90,446</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">96,440</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">160,503</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">86,998</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,368</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,620</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72,710</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,386,777</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,840,639</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20,24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191344240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 11 &#150; STOCKHOLDERS&#146; EQUITY</u></b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Preferred Stock</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">At September 30, 2015, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Common Stock</u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">At September 30, 2015, we had 350,000,000 shares of Common Stock authorized, of which 177,787,927 shares of Common Stock were issued and outstanding.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On July&#160;9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#160;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#160;15, 2015 and we issued 4,423,077 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &#38; Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Exercises During 2015</u></i></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2015, certain individuals exercised stock options to purchase 95,000 shares of Common Stock for $98,478 in cash. During the nine months ended September 30, 2015, certain individuals exercised stock options to purchase 472,867 shares of Common Stock for $589,829 in cash.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Exercises During 2014</u></i></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2014, certain individuals exercised stock options to purchase 793,800 shares of Common Stock. Stock options to purchase shares of Common Stock were exercised as follows: (i) 674,193 options for $315,546 in cash and (ii) <font style="letter-spacing: -0.15pt">119,607 options, pursuant to the stock options&#146; cashless provision, wherein 113,837 shares of Common Stock were issued. Also during the nine months ended September 30, 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.</font></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Warrants to Purchase Common Stock </u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2015, we had warrants outstanding to purchase an aggregate of 12,772,431 shares of Common Stock with a weighted-average contractual remaining life of 1.92 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In January 2013, we granted warrants to purchase 1,250,000 shares of Common Stock in connection with the issuance of a Revolving Credit Note to Plato and Associates, LLC, or the Plato Warrant. The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the nine months ended September 30, 2015 and 2014, $0 and $260,027, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In May 2013, we entered into a consulting agreement with Sancilio &#38; Company, Inc., or SCI, to develop drug technology to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
<td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. &#160;The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. &#160;We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
<td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares vested on June 30, 2013.&#160;&#160;The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%.&#160;&#160;As of September 30, 2015, we recorded $115,543 in other current assets in the accompanying consolidated financial statements with respect to such shares.&#160;&#160;During the three and nine month periods ended September 30, 2015 and 2014, we recorded $38,517 and $115,551, respectively, as non-cash compensation in the accompanying consolidated financial statements with respect to such shares; and</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
<td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. &#160;It is anticipated that this event will not occur before December 2016.</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $567,000 and will be recognized over a period of 1.75 years.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant
at an exercise price of $6.35 and the expiration date of April 6, 2020. The total non-cash compensation expense related to this
warrant was $42,266 and $86,008, respectively, for the three and nine months ended September 30, 2015.</font></p>

<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Warrant exercises</u></i></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 310,000 shares of Common Stock<font style="letter-spacing: -0.15pt"> pursuant to the warrants&#146; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.</font> During the nine months ended September 30, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000<font style="letter-spacing: -0.15pt"> shares of Common Stock were exercised pursuant to the warrants&#146; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued. </font></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Options to Purchase Common Stock </u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. During the nine months ended September 30, 2015, we granted 1,231,000 non-qualified stock options under the 2009 Plan. As of September 30, 2015, there were non-qualified stock options to purchase 15,445,768 shares of Common Stock outstanding under the 2009 Plan.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of September 30, 2015, there were non-qualified stock options to purchase 1,968,474 shares of Common Stock outstanding under the 2012 Plan.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including estimated volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the nine months ended September 30, 2015 and 2014 are set forth in the table below.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September 30,</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.47-1.54</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.68-1.77</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Volatility</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.77-62.94</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">%</font></td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">69.15-70.93</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Term (in years)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif">Dividend yield</td>
<td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;<font style="background-color: white">&#160;</font></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares Underlying Stock Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</font></p>
</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.88</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.92</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,996,311</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,231,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.38</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(472,867</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Expired/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(136,334</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.01</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2015</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,414,242</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.21</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.09</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,265,785</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: 10pt; font: 10pt Times New Roman, Times, Serif">
<p style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at September 30, 2015</p>
</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">13,848,923</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.59</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.49</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">59,095,453</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">At September 30, 2015, our outstanding stock options had exercise prices ranging from $0.10 to $7.72 per share.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">Share-based compensation expense for options recognized in our results of operations (based on vested awards) for the three and nine months ended September 30, 2015 were $1,626,862 and $4,328,964, respectively, and $1,047,493 and $3,341,604, respectively, for the same periods in 2014. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At September 30, 2015, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $5,593,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.3 years. No tax benefit was realized due to a continued pattern of operating losses.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white; font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191177536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 870,949<span></span>
</td>
<td class="nump">$ 394,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">381,813<span></span>
</td>
<td class="nump">299,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
<td class="nump">373,339<span></span>
</td>
<td class="nump">411,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Other receivables-related party (Note 13)</a></td>
<td class="nump">249,981<span></span>
</td>
<td class="nump">249,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">219,086<span></span>
</td>
<td class="nump">181,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidVendorDeposits', window );">Prepaid vendor deposits</a></td>
<td class="nump">25,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 2,120,805<span></span>
</td>
<td class="nump">$ 1,537,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidVendorDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a prepaid vendor deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidVendorDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5865-108316<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117808672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2015 (3 months)</a></td>
<td class="nump">$ 121,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
<td class="nump">493,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
<td class="nump">507,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
<td class="nump">388,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments</a></td>
<td class="nump">$ 1,511,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117730368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
16 &#150; SUBSEQUENT EVENTS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
October 2015, we completed enrollment in the REPLENISH trial, a phase 3 study of TX-001HR in postmenopausal women with an intact
uterus. The trial was designed to enroll approximately 1,750 patients at approximately 100 sites.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191326832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of prepaid expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid
expense (long-term) consists of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">2014</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">978,704</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">963,543</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">193,347</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,720</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,172,051</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,263</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760185121216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 5,190,175<span></span>
</td>
<td class="nump">$ 4,186,261<span></span>
</td>
<td class="nump">$ 14,513,158<span></span>
</td>
<td class="nump">$ 10,768,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member', window );">Customer A [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,930,000<span></span>
</td>
<td class="nump">$ 3,930,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer B [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005,000<span></span>
</td>
<td class="nump">1,846,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer C [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer D [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,555,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760185727264">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,528,061<span></span>
</td>
<td class="nump">$ 1,706,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">930,913<span></span>
</td>
<td class="nump">814,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">615,946<span></span>
</td>
<td class="nump">276,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">490,170<span></span>
</td>
<td class="nump">442,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">388,268<span></span>
</td>
<td class="nump">185,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">208,361<span></span>
</td>
<td class="nump">90,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96,440<span></span>
</td>
<td class="nump">160,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,998<span></span>
</td>
<td class="nump">91,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,620<span></span>
</td>
<td class="nump">72,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,386,777<span></span>
</td>
<td class="nump">$ 3,840,639<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 710<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760119818240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,594,347)<span></span>
</td>
<td class="num">$ (37,914,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">22,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">22,296<span></span>
</td>
<td class="nump">17,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">37,163<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">4,740,906<span></span>
</td>
<td class="nump">3,934,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,549,532)<span></span>
</td>
<td class="num">(460,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">312,054<span></span>
</td>
<td class="nump">31,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(621,923)<span></span>
</td>
<td class="nump">197,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(15,162)<span></span>
</td>
<td class="num">(17,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,025,504)<span></span>
</td>
<td class="nump">3,534,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(522,613)<span></span>
</td>
<td class="num">(754,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">2,546,138<span></span>
</td>
<td class="nump">909,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Long term accrued expenses</a></td>
<td class="nump">1,213,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(62,434,546)<span></span>
</td>
<td class="num">(30,235,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(117,992)<span></span>
</td>
<td class="num">(193,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(15,559)<span></span>
</td>
<td class="num">(30,962)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(133,551)<span></span>
</td>
<td class="num">(224,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">91,374,649<span></span>
</td>
<td class="nump">42,771,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">589,829<span></span>
</td>
<td class="nump">315,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">92,330,478<span></span>
</td>
<td class="nump">43,267,899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase in cash</a></td>
<td class="nump">29,762,381<span></span>
</td>
<td class="nump">12,807,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">51,361,607<span></span>
</td>
<td class="nump">54,191,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">$ 81,123,988<span></span>
</td>
<td class="nump">$ 66,999,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760325492720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
5 &#150; OTHER CURRENT ASSETS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">870,949</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">394,878</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">381,813</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">373,339</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">411,864</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other receivables-related party (Note 13)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">219,086</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,637</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,120,805</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,537,407</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760117920320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2015</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Gross Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;Net</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Amortization Period (yrs.)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;OPERA<sup>&#174; </sup>software patent</font></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(3,994</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,957</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Development costs of</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Approved hormone</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">605,502</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(40,199</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">565,303</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Hormone therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">585,241</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">585,241</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Multiple trademarks for</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">145,783</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">145,783</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">indefinite</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,460,220</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(135,936</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,324,284</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">&#160;</font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;December 31, 2014</font></p>
</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Gross Carrying Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;Net</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Amount</font></p>
</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Amortization Period (yrs.)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;OPERA<sup>&#174; </sup>software patent</font></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(2,496</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">29,455</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Development costs of</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Approved hormone</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">439,184</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,401</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">419,783</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">18</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Hormone therapy drug</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;&#160;&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Multiple trademarks for</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;&#160;&#160;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,342,228</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(113,640</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,228,588</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Estimated amortization expense for the next five years is as
follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Year Ending December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Estimated Amortization</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015 (3 months)</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif">8,692</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2016</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2017</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2018</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">34,768</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpense</Role>
      <ShortName>PREPAID EXPENSE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - PREPAID EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseTables</Role>
      <ShortName>PREPAID EXPENSE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpense</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - FIXED ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetails</Role>
      <ShortName>FIXED ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - PREPAID EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseDetails</Role>
      <ShortName>PREPAID EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpenseTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INTANGIBLE ASSETS (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONSOLIDATED BALANCE SHEETS (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>txmd-20150930.xml</File>
    <File>txmd-20150930_cal.xml</File>
    <File>txmd-20150930_def.xml</File>
    <File>txmd-20150930_lab.xml</File>
    <File>txmd-20150930_pre.xml</File>
    <File>txmd-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760191701360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 8,692<span></span>
</td>
<td class="nump">$ 5,625<span></span>
</td>
<td class="nump">$ 22,296<span></span>
</td>
<td class="nump">$ 17,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfPatents', window );">Number of patents</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patents outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139760325064768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 15 &#150; COMMITMENTS AND CONTINGENCIES</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. On February 18, 2015, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The straight line rental expense related to our current lease totaled approximately $119,000 and $90,000 for the three months ended September 30, 2015 and 2014, respectively, and approximately $328,000 and $271,000 for the nine months ended September 30, 2015 and 2014, respectively. The 2014 amounts were partially offset by the rent income of approximately $6,000 and $42,000, respectively, for sublet space. We did not sublet any space during the nine months ended September 30, 2015.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2015, future minimum rental payments are as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: yellow; font: 10pt Times New Roman, Times, Serif"></font></p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Years Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 43%; vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015 (3 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif">121,698</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2016</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">493,790</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">388,976</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,511,551</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
